{"c1853bbf302dfb1c66154cb4a208aaa63d19dda4": [["Practice of novel method of bedside postpyloric tube placement in patients with coronavirus disease 2019", [["tube", "ANATOMY", 48, 52], ["coronavirus disease", "DISEASE", 80, 99], ["postpyloric tube", "MULTI-TISSUE_STRUCTURE", 36, 52], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["novel method", "TREATMENT", 12, 24], ["bedside postpyloric tube placement", "TREATMENT", 28, 62], ["coronavirus disease", "PROBLEM", 80, 99]]]], "9ac42667792ed9fcaac8fa8aa0ac6c493f39f3b5": [["IntroductionSpline regression is one of the most used tools for nonparametric and semiparametric regression and has been extensively developed along the last decades.", [["IntroductionSpline regression", "PROBLEM", 0, 29], ["nonparametric and semiparametric regression", "PROBLEM", 64, 107], ["semiparametric regression", "OBSERVATION", 82, 107]]], ["The main ideia is to select some knots on the function domain to define a partition and then fit a fixed degree polynomial on each segment in such a way that these polynomials smoothly match at the internal knots through continuity conditions imposed on their derivatives.IntroductionThe result is typically a smooth curve fitting, which accurately estimates a large variety of smooth functions.IntroductionFurther, spline regression offers a great flexibility in curve estimation problems according to convenient choices of degree and internal knots and, as generally occurs in nonparametric regression by basis expansion, the infinite estimation problem becomes a finite parametric estimation problem, once the spline function is determined by the estimation of its coefficients.", [["a fixed degree polynomial on each segment", "PROBLEM", 97, 138], ["continuity conditions", "PROBLEM", 221, 242], ["their derivatives", "TREATMENT", 254, 271], ["a great flexibility in curve estimation problems", "PROBLEM", 441, 489], ["the infinite estimation problem", "PROBLEM", 624, 655], ["a finite parametric estimation problem", "PROBLEM", 664, 702], ["the spline function", "TEST", 709, 728], ["main", "OBSERVATION_MODIFIER", 4, 8], ["internal knots", "OBSERVATION", 198, 212], ["large", "OBSERVATION_MODIFIER", 361, 366], ["variety", "OBSERVATION_MODIFIER", 367, 374], ["smooth functions", "OBSERVATION", 378, 394], ["internal knots", "OBSERVATION", 536, 550]]], ["For more details about spline based methods, their theory and applications in Statistics, see Wahba (1990) , Ramsay (2004) , Friedman et al. (2001) , and James et al. (2013) .IntroductionOne of the main issues in spline regression is the selection of the number and positions of the knots.", [["main", "OBSERVATION_MODIFIER", 198, 202], ["spline regression", "OBSERVATION", 213, 230], ["knots", "OBSERVATION_MODIFIER", 283, 288]]], ["In some data analyses, wrong specification of the knots can cause a high impact on the spline regression performance.IntroductionExcessive number of knots may lead the spline regression to overfit the dataset while a not enough number of knots can lead to underfitting.", [["some data analyses", "TEST", 3, 21], ["a high impact", "PROBLEM", 66, 79], ["the spline regression", "PROBLEM", 164, 185], ["underfitting", "PROBLEM", 256, 268]]], ["Moreover, the positions of the knots should be well determined, since high concentration of knots on a specific interval of the domain overfits the data on this region and underfits the data outside it.", [["knots", "OBSERVATION", 31, 36]]], ["Then, a good procedure for knots selection should provide optimal number and locations of knots, in order to have a well performed spline curve fitting.IntroductionIn practice, the selection of knots is done by hand and few studies in the literature provide some systematic method to overcome this difficulty.", [["hand", "ANATOMY", 211, 215], ["hand", "ORGANISM_SUBDIVISION", 211, 215], ["a good procedure", "TREATMENT", 6, 22], ["knots selection", "TREATMENT", 27, 42], ["a well performed spline curve fitting", "TREATMENT", 114, 151], ["IntroductionIn practice", "TREATMENT", 152, 175], ["few studies", "TEST", 220, 231]]], ["Osborne et al. (1998) proposed an algorithm based on the LASSO estimator to estimate the locations of knots.", [["an algorithm", "TEST", 31, 43], ["the LASSO estimator", "TREATMENT", 53, 72], ["knots", "OBSERVATION", 102, 107]]], ["Ruppert (2002) presented two algorithms for selection of a fixed number of knots on penalized spline regression, called P-splines.", [["P-splines", "DNA", 120, 129], ["penalized spline regression", "PROBLEM", 84, 111], ["P-splines", "TREATMENT", 120, 129]]], ["The first one is based on the minimization of the generalized cross validation statistic and the second one is based on the Demmler-Reinsch type diagonalization and\u00dclker and Arslan (2009) proposed an artificial immune system to perform knots selection in curve and surface B-splines estimation by considering the knots locations candidates as antibodies.", [["antibodies", "PROTEIN", 343, 353], ["Reinsch type diagonalization", "TREATMENT", 132, 160], ["an artificial immune system", "TREATMENT", 197, 224], ["knots selection in curve", "TEST", 236, 260], ["surface B-splines estimation", "TREATMENT", 265, 293]]], ["Bayesian methods are proposed by Denison et al. (1998) who proposed a joint prior distribution for the number and locations of knots, and Biller (2000) , who gave an adaptive bayesian approach for knot selection based on reversible jump Markov chain Monte Carlo in semiparametric generalized linear models.IntroductionAlthough the methods described above have been well succeeded, they work with a fixed number of knots and/or require some prior information regarding possible regions where the knots should be set, which can be seen as a limitation in some cases.", [["an adaptive bayesian approach", "TREATMENT", 163, 192], ["knot selection", "TREATMENT", 197, 211], ["reversible jump Markov chain", "TREATMENT", 221, 249], ["joint", "ANATOMY", 70, 75]]], ["We test the performance of the method on simulated data and we also apply it to daily reported cases of covid-19 on several countries to obtain a fit on the epidemiological curve.", [["covid", "TEST", 104, 109], ["the epidemiological curve", "TEST", 153, 178]]], ["This paper is organized as follows: Section 2 is addressed to the description of the spline model and the proposed method of automatic knots selection.", [["automatic knots selection", "TREATMENT", 125, 150]]], ["Simulation studies about the performance of the method are shown in Section 3.", [["Simulation studies", "TEST", 0, 18]]], ["Applications to real datasets involving daily reported cases of Covid-19 are done in Section 4.", [["Covid", "TEST", 64, 69]]], ["Section 5 provides conclusion and suggestions of future works.Spline regression model with variable number of knotsWe start with a nonparametric regression problem of the formSpline regression model with variable number of knotswhere x i are scalars, f is an unknown smooth function with domain [a, b] such that f (x i ) = E(y i |x i ) andSpline regression model with variable number of knots{ i } n i=1 are zero mean independent random variables with unknown variance \u03c3 2 .", [["Spline regression model", "TREATMENT", 62, 85], ["a nonparametric regression problem", "TREATMENT", 129, 163], ["the formSpline regression model", "TREATMENT", 167, 198], ["Spline regression model", "TEST", 339, 362], ["knots", "OBSERVATION_MODIFIER", 110, 115]]], ["To estimate f , we define a sequence of knots a = t 0 < t 1 < ... < t K < t K+1 = b that defines a partition of [a, b] in intervals [a, t 1 ), [t 1 , t 2 ), ..., [t K , b] and use a m\u2212th order spline regression model, m = p + 1, defined bySpline regression model with variable number of knotswhere p, K \u2208 Z + , \u03b2 = [\u03b2 0 , ..., \u03b2 p+K ] is the vector of coefficients, (u) p + = u p I(u \u2265 0) and t 1 < ... < t K are fixed internal knots which, from the now on, will be referred to as just knots.", [["Z", "PROTEIN", 305, 306], ["knots", "TEST", 40, 45], ["K", "TEST", 70, 71], ["K+1", "TEST", 76, 79], ["a partition", "TEST", 97, 108], ["t", "TEST", 150, 151], ["K", "TEST", 165, 166], ["a m\u2212th", "TEST", 180, 186], ["spline regression", "TEST", 193, 210], ["model", "TEST", 211, 216], ["m", "TEST", 218, 219], ["p", "TEST", 222, 223], ["regression model", "TEST", 246, 262], ["knotswhere", "TEST", 287, 297], ["K", "TEST", 301, 302], ["Z", "TEST", 305, 306], ["\u03b2", "TEST", 311, 312], ["\u03b2", "TEST", 316, 317], ["p", "TEST", 329, 330], ["K", "TEST", 331, 332], ["the vector", "TEST", 338, 348], ["coefficients", "TEST", 352, 364], ["u", "TEST", 367, 368], ["u \u2265", "TEST", 382, 385], ["t", "TEST", 393, 394], ["t K", "TEST", 405, 408], ["fixed internal knots", "PROBLEM", 413, 433], ["internal knots", "OBSERVATION", 419, 433]]], ["In general, a spline regression model is a p degree polynomial on each interval of two consecutive knots and has p \u2212 1 continuous derivatives everywhere (supposing that the knots have no multiplicity).", [["a spline regression model", "PROBLEM", 12, 37], ["1 continuous derivatives", "TREATMENT", 117, 141]]], ["In this work we adopt a set of knots sufficiently spaced, i.e, we assume |t k+1 \u2212 t k | > \u03b4 for some \u03b4 > 0, k = 0, ..., K. Thus, the problem of estimating f becomes a finite parametric estimation problem, whose parameters are the vector of coefficients \u03b2, the number of interna knots K and their locations t k , k = 1, ..., K. Let us denote by \u03b8 the vector of parameters to be estimated, i.e, \u03b8 = [\u03b2, K, t 1 , ..., t K ] .", [["k", "TEST", 76, 77], ["k", "TEST", 84, 85], ["some \u03b4", "TEST", 96, 102], ["k", "TEST", 108, 109], ["a finite parametric estimation problem", "PROBLEM", 165, 203], ["their locations t k", "TEST", 290, 309], ["k", "TEST", 312, 313], ["K", "TEST", 401, 402], ["t", "TEST", 404, 405]]], ["We assume a fixed value for p, the degree of the spline function.Spline regression model with variable number of knotsThe estimation of the parameters should consider its performance regarding a loss function, such as in our case, the the residual sum of squares and also some degree of smoothness for f .", [["a fixed value", "TEST", 10, 23], ["Spline regression model", "TREATMENT", 65, 88], ["a loss function", "PROBLEM", 193, 208], ["spline function", "OBSERVATION", 49, 64], ["knots", "OBSERVATION_MODIFIER", 113, 118], ["some degree", "OBSERVATION_MODIFIER", 272, 283]]], ["We propose to control the smoothness with a roughness penalty defined in terms of the number of intervals established by the knots, i.e, the K knots define K + 1 intervals on the domain of f .", [["K", "CHEMICAL", 156, 157], ["a roughness penalty", "PROBLEM", 42, 61], ["the K knots", "TEST", 137, 148], ["K", "TEST", 156, 157]]], ["Thus, we define the penalized sum of squaresSpline regression model with variable number of knotswhere y = [y 1 , ..., y n ] , \u03bb > 0 is a tuning parameter previously chosen and f is the spline function (2.1).", [["Spline regression model", "TREATMENT", 44, 67], ["\u03bb", "TEST", 127, 128], ["a tuning parameter", "TEST", 136, 154], ["the spline function", "TEST", 182, 201]]], ["Thus, the estimator\u03b8 is obtained by\u03b8Spline regression model with variable number of knotsConsidering the definition above, we search for a curve estimate that has good fitting properties with low residual sum of squares and which is also smooth enough according to a reasonable number of knots that is controlled by the penalty on the number of segments of the domain.", [["Spline regression model", "TREATMENT", 36, 59], ["a curve estimate", "TEST", 137, 153], ["low residual sum of squares", "PROBLEM", 192, 219], ["knots", "OBSERVATION_MODIFIER", 84, 89], ["smooth", "OBSERVATION_MODIFIER", 238, 244], ["knots", "OBSERVATION", 288, 293]]], ["The tuning parameter \u03bb attributes a weight on the roughness penalty term.", [["The tuning parameter", "TREATMENT", 0, 20]]], ["High \u03bb values increase the importance of the penalization, i.e, a preference for smoothness is given against accuracy.", [["High \u03bb values", "PROBLEM", 0, 13], ["accuracy", "TEST", 109, 117]]], ["On the other hand, low \u03bb value favors models with high number of parameters, which can lead to overfitting.", [["overfitting", "PROBLEM", 95, 106], ["high number", "OBSERVATION_MODIFIER", 50, 61]]], ["The specification of a good value for \u03bb is an issue inherent to any regularized estimator and, as in other similar approaches, could be chosen by a standard cross validation procedure.B-splines and natural splines modelsOur proposed method for automatic knots selection can be applied to other spline basis structures.", [["a standard cross validation procedure", "TREATMENT", 146, 183], ["B-splines", "TREATMENT", 184, 193], ["natural splines models", "TREATMENT", 198, 220], ["automatic knots selection", "TREATMENT", 244, 269]]], ["A well known spline basis is the B-splines, proposed by De Boor et al. (1978) , which are more adapted for computational implementation due to its compact support.", [["computational implementation", "TREATMENT", 107, 135]]], ["The i-th B-spline of order m and knots a = t 0 <B-splines and natural splines modelsis a spline of order m defined on the same knots such that is nonzero over at most m consecutive subintervals, i.e, over [t i , t i+m ] and zero outside it and can be defined recursively byB-splines and natural splines models.", [["byB", "PROTEIN", 271, 274], ["The i-th B-spline", "TREATMENT", 0, 17], ["B-splines", "TREATMENT", 48, 57], ["natural splines", "TREATMENT", 62, 77], ["natural splines", "OBSERVATION", 287, 302]]], ["Then, f is expanded in the B-splines basis instead of (2.1) as Another commonly used spline basis structure is the natural spline.", [["expanded", "OBSERVATION", 11, 19], ["natural spline", "OBSERVATION", 115, 129]]], ["This approach imposes the function f to be linear on its extremes, i.e, in regions lesser than t 1 and greater than t K .", [["linear", "OBSERVATION_MODIFIER", 43, 49], ["regions", "ANATOMY_MODIFIER", 75, 82], ["lesser", "OBSERVATION_MODIFIER", 83, 89]]], ["Such constraint guarantees stable estimation on the boundaries of the function, see James et al. (2013) .", [["stable", "OBSERVATION_MODIFIER", 27, 33]]], ["For more about spline basis structures, see De Boor (2001) .B-splines and natural splines modelsTo illustrate the role of the penalization on the curve estimation, we generate data from an underlying function defined by cubic B-splines basis on [0, 100] with three not equally spaced knots at t 1 = 20, t 2 = 45, and t 3 = 80 and signal to noise ratio SNR=3.", [["natural splines models", "TREATMENT", 74, 96], ["the curve estimation", "TEST", 142, 162], ["SNR", "TEST", 352, 355]]], ["Figure 2 .2(a) shows the underlying function, its knots locations and the generated data.", [["Figure", "TEST", 0, 6]]], ["After data generation, we estimate the underlying function using cubic B-splines expansion considering eleven knots with prespecified locations fixed at [t 1 , t 2 , \u00b7 \u00b7 \u00b7 , t 11 ] = [6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26] .", [["cubic B-splines expansion", "TREATMENT", 65, 90], ["t", "TEST", 160, 161], ["t", "TEST", 174, 175]]], ["The estimated curve is the pink line in the knots at [t 1 , t 2 , \u00b7 \u00b7 \u00b7 , t 11 ] = [6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26] (pink) characterizing locally overfitting around the higher peak and undefitting on remaining domain and estimated curve by the proposed method (blue) with optimal number and locations of knots.Simulation studiesThe proposed method was applied in simulated data to evaluate its performance in several scenarios.", [["The estimated curve", "TEST", 0, 19], ["the knots", "TEST", 40, 49], ["t", "TEST", 60, 61], ["t", "TEST", 74, 75], ["locally overfitting", "PROBLEM", 148, 167], ["Simulation studies", "TEST", 320, 338], ["The proposed method", "TREATMENT", 338, 357], ["curve", "OBSERVATION_MODIFIER", 14, 19], ["pink line", "OBSERVATION", 27, 36], ["higher peak", "OBSERVATION", 179, 190], ["knots", "OBSERVATION_MODIFIER", 314, 319]]], ["We considered the cubic B-splines with one knot at t 1 = 50, two knots at t 1 = 25 and t 2 = 75 and three knots at t 1 = 25, t 2 = 50 and t 3 = 75 as underlying functions.", [["cubic B-splines", "DNA", 18, 33], ["the cubic B-splines", "TREATMENT", 14, 33]]], ["Table 3 .3: Simulation results of the proposed method for data generated from a cubic B-splines with three knots at t 1 = 25, t 2 = 50 and t 3 = 75.Analysis of covid-19 time seriesThe counts of daily new cases of the novel coronavirus disease (covid-19) varies considerably throughout the affected countries and regions, mainly due to testing criteria used, delays in notification, and population and authorities response to the outbreak, among others.", [["coronavirus disease", "DISEASE", 223, 242], ["coronavirus", "ORGANISM", 223, 234], ["coronavirus", "SPECIES", 223, 234], ["a cubic B-splines", "TREATMENT", 78, 95], ["Analysis", "TEST", 148, 156], ["covid", "TEST", 160, 165], ["the novel coronavirus disease", "PROBLEM", 213, 242], ["covid", "TEST", 244, 249], ["testing criteria", "TEST", 335, 351], ["coronavirus disease", "OBSERVATION", 223, 242]]], ["Even though, the analysis of the disease's daily new infected cases is important to understand at what stage of the epidemic each country is in.", [["the disease", "PROBLEM", 29, 40], ["new infected cases", "PROBLEM", 49, 67]]], ["Therefore, we can use the method presented above to estimate the dates at which the trend of new cases counts had changed.Analysis of covid-19 time seriesThis may be helpful not only to define public policy such as when safely relax social distance measures but also to verify the effectiveness of mitigations measures taken.", [["new cases counts", "TEST", 93, 109], ["Analysis", "TEST", 122, 130], ["covid", "TEST", 134, 139], ["social distance measures", "TREATMENT", 233, 257], ["mitigations measures", "TREATMENT", 298, 318], ["new", "OBSERVATION_MODIFIER", 93, 96]]], ["Here we perform estimation and prediction for Covid-19 data using our proposed method, the data is publicly available at https://opendata.ecdc.Analysis of covid-19 time serieseuropa.eu/covid19/.Analysis of covid-19 time seriesIn general, during an epidemic the daily number of new infected cases shows several trends that are not related to the disease spreading itself, but to other causes, such as delay in test processing time or lack of testing.", [["estimation", "TEST", 16, 26], ["Covid", "TEST", 46, 51], ["covid", "TEST", 155, 160], ["covid", "TEST", 206, 211], ["new infected cases", "PROBLEM", 277, 295], ["the disease spreading itself", "PROBLEM", 341, 369], ["testing", "TEST", 441, 448], ["new", "OBSERVATION_MODIFIER", 277, 280], ["infected", "OBSERVATION", 281, 289], ["not related to", "UNCERTAINTY", 326, 340], ["disease", "OBSERVATION", 345, 352]]], ["For this reason, we considered the 7-days moving average smoother on the time series before applying our method.", [["our method", "TREATMENT", 101, 111]]], ["Further, to avoid knots estimation in the beginning of the time series, we remove the 10% initial dates as possible knots locations.Analysis of covid-19 time seriesConsidering data available until May 30th, In the European countries considered here, we note that mean daily new cases present a decreasing pattern as the peak occurred in late March, period in which our method selects some knots, indicating a change in trend.", [["knots estimation", "TEST", 18, 34], ["Analysis", "TEST", 132, 140], ["covid", "TEST", 144, 149], ["a change in trend", "PROBLEM", 407, 424], ["decreasing", "OBSERVATION_MODIFIER", 294, 304], ["peak", "OBSERVATION_MODIFIER", 320, 324], ["change", "OBSERVATION_MODIFIER", 409, 415]]], ["Moreover, the first change point in late March indicates a decrease in the slope of the fitted curve, the remaining knots are located near the date the country reaches its peak so far.", [["decrease", "OBSERVATION_MODIFIER", 59, 67], ["peak", "OBSERVATION_MODIFIER", 172, 176]]], ["In Brazil, the data suggest the country have not reached its peak of infection yet, change points merely reveal small changes in the increasing pattern.", [["infection", "DISEASE", 69, 78], ["infection", "PROBLEM", 69, 78], ["small changes", "PROBLEM", 112, 125], ["infection", "OBSERVATION", 69, 78], ["small", "OBSERVATION_MODIFIER", 112, 117], ["changes", "OBSERVATION", 118, 125], ["increasing", "OBSERVATION_MODIFIER", 133, 143], ["pattern", "OBSERVATION_MODIFIER", 144, 151]]], ["Finally, Iran and South Korea both show oscillations during the observed period, however at latest dates the new cases are apparently increasing, suggesting a new wave of reported cases.", [["a new wave of reported cases", "PROBLEM", 157, 185], ["oscillations", "OBSERVATION", 40, 52], ["new", "OBSERVATION_MODIFIER", 109, 112], ["increasing", "OBSERVATION_MODIFIER", 134, 144], ["new", "OBSERVATION_MODIFIER", 159, 162]]], ["We also perform similar analysis for several other countries and for Brazilian states and municipalities, that are updated daily, and the results and coded algorithms in R can be accessed at the webpage https://www.ime.usp.br/~gpeca/covid-19.Analysis of covid-19 time seriesWe mention that the principal aim of this section is solely to show a descriptive analysis of the Covid-19 situation in the countries based on public available datasets and the proposed automatic method of knots estimation as a tool to do so.", [["similar analysis", "TEST", 16, 32], ["the Covid", "TEST", 368, 377]]], ["For a public policy guide to deal with this sad pandemic context, several social and biological factors beyond the scope of our study should be considered on a deeper analysis.DiscussionIn this paper we introduced a method to estimate the number and position of the knots of a spline regression function.", [["our study", "TEST", 124, 133], ["a deeper analysis", "TEST", 158, 175], ["a method", "TREATMENT", 214, 222], ["a spline regression function", "TREATMENT", 275, 303]]], ["The method is based on the minimization of the sum of squared residuals plus a penalty that depends on the number of knots.", [["The method", "TREATMENT", 0, 10], ["squared residuals", "PROBLEM", 54, 71]]], ["We evaluate the performance of the criterion on simulated data, and we showed that our proposed method has a great performance in the simulation studies, even with low SNR values.", [["the simulation studies", "TEST", 130, 152]]], ["We also applied the method to perform a descriptive data analysis on covid-19 daily reported cases in several countries.", [["a descriptive data analysis", "TEST", 38, 65]]], ["In this analysis we show that the penalized least squares estimation guaranteed quite smooth curve fittings that estimated accurately underlying smooth functions automatically, i.e, without requiring to specify the number of internal knots and their locations, which is necessary in most spline based curve fitting methods available in the literature.DiscussionThe penalizing constant \u03bb used in our data analyses was set to a fixed value.", [["this analysis", "TEST", 3, 16], ["smooth curve fittings", "PROBLEM", 86, 107], ["our data analyses", "TEST", 395, 412], ["smooth functions", "OBSERVATION", 145, 161]]], ["However as in many other similar approaches, it could be chosen by a cross validation procedure.", [["a cross validation procedure", "TREATMENT", 67, 95]]]], "0d5f06bc0ca113fb12ebc20fafe05c803462a4b9": [["In science fiction, to 'mutate' is to undergo a significant transformation.", [["a significant transformation", "PROBLEM", 46, 74], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["transformation", "OBSERVATION", 60, 74]]], ["Characters in Marvel Comics, for example, possess incredible new abilities due to mutation.", [["incredible new abilities", "PROBLEM", 50, 74], ["mutation", "PROBLEM", 82, 90]]], ["In the entertainment industry, the dramatization of evolution to portray disease outbreaks is a common trope.", [["portray disease outbreaks", "PROBLEM", 65, 90]]], ["In Michael Crichton's The Andromeda Strain, an extraterrestrial microorganism continuously 'mutates' to acquire new biological properties, including the ability to degrade plastic and escape containment.", [["The Andromeda Strain", "PROBLEM", 22, 42], ["an extraterrestrial microorganism", "PROBLEM", 44, 77], ["escape containment", "OBSERVATION", 184, 202]]], ["The exaggerated book The Hot Zone inspired the 1995 thriller film Outbreak, in which a fictional Ebola-like virus rapidly mutates into a highly infectious strain capable of aerosolized transmission.", [["Ebola", "DISEASE", 97, 102], ["Ebola-like virus", "ORGANISM", 97, 113], ["a fictional Ebola-like virus", "PROBLEM", 85, 113], ["highly", "OBSERVATION_MODIFIER", 137, 143], ["infectious", "OBSERVATION", 144, 154], ["aerosolized", "OBSERVATION", 173, 184]]], ["Given the accessibility and mass appeal of these works, it is unsurprising that, during a reallife outbreak, journalists and scientists are sometimes predisposed to draw upon these fictional views.", [["mass", "PROBLEM", 28, 32], ["mass", "OBSERVATION", 28, 32]]]], "931bb5ac1463ece127fcf68bca8576d8942ea58b": [["IntroductionThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection shows fast contagiousness and a high rate of morbidity and mortality [1] [2] [3] [4] .", [["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["infection", "DISEASE", 77, 86], ["contagiousness", "DISEASE", 98, 112], ["SARS-CoV-2", "ORGANISM", 65, 75], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 156, 171], ["severe acute respiratory syndrome coronavirus", "SPECIES", 16, 61], ["SARS-CoV-2", "SPECIES", 65, 75], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 61], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["infection", "PROBLEM", 77, 86], ["fast contagiousness", "PROBLEM", 93, 112], ["a high rate of morbidity", "PROBLEM", 117, 141], ["mortality", "TEST", 146, 155], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49]]], ["Italian public healthcare systems have been overwhelmed by infected people, forcing clinicians to tough decisions for rationing medical care [5, 6] .", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["rationing medical care", "TREATMENT", 118, 140]]], ["Assessing the severity of coronavirus disease 2019 (COVID-19) is crucial for a correct triage and prioritization.", [["coronavirus disease", "DISEASE", 26, 45], ["coronavirus", "ORGANISM", 26, 37], ["coronavirus disease", "PROBLEM", 26, 45], ["COVID", "TEST", 52, 57], ["coronavirus disease", "OBSERVATION", 26, 45]]], ["From published experiences, the patients at greatest risk of serious illness of COVID-19 and death are elderly comorbid patients, particularly those with cardiovascular diseases [7] [8] [9] [10] .", [["cardiovascular", "ANATOMY", 154, 168], ["COVID", "DISEASE", 80, 85], ["death", "DISEASE", 93, 98], ["cardiovascular diseases", "DISEASE", 154, 177], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 120, 128], ["[7] [8] [9", "SIMPLE_CHEMICAL", 178, 188], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 120, 128], ["COVID", "TEST", 80, 85], ["cardiovascular diseases", "PROBLEM", 154, 177]]], ["Cardiac injury, demonstrated by the rise of high-sensitivity cardiac troponins is a common finding in patients with severe COVID-19 and previous reports pointed it as a strong predictor of adverse outcome [9] [10] [11] [12] .IntroductionSuch observations may justify considering other pathogenetic mechanisms of myocardial damage, beyond the direct viral infection of the myocardium by SARS-CoV-2.", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 61, 68], ["myocardial", "ANATOMY", 312, 322], ["myocardium", "ANATOMY", 372, 382], ["Cardiac injury", "DISEASE", 0, 14], ["myocardial damage", "DISEASE", 312, 329], ["infection", "DISEASE", 355, 364], ["Cardiac", "ORGAN", 0, 7], ["cardiac", "ORGAN", 61, 68], ["patients", "ORGANISM", 102, 110], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 205, 223], ["myocardial", "MULTI-TISSUE_STRUCTURE", 312, 322], ["myocardium", "ORGAN", 372, 382], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 386, 396], ["high-sensitivity cardiac troponins", "PROTEIN", 44, 78], ["patients", "SPECIES", 102, 110], ["Cardiac injury", "PROBLEM", 0, 14], ["high-sensitivity cardiac troponins", "PROBLEM", 44, 78], ["severe COVID", "PROBLEM", 116, 128], ["adverse outcome", "PROBLEM", 189, 204], ["myocardial damage", "PROBLEM", 312, 329], ["the direct viral infection of the myocardium", "PROBLEM", 338, 382], ["CoV", "TEST", 391, 394], ["injury", "OBSERVATION", 8, 14], ["myocardial", "ANATOMY", 312, 322], ["damage", "OBSERVATION", 323, 329], ["viral", "OBSERVATION_MODIFIER", 349, 354], ["infection", "OBSERVATION", 355, 364], ["myocardium", "ANATOMY", 372, 382]]], ["Either the concomitant presence of the cytokines storm and the pneumonia-related hypoxia could also determine myocardial ischemia, by altering the myocardial oxygen supply-demand balance.", [["myocardial", "ANATOMY", 110, 120], ["myocardial", "ANATOMY", 147, 157], ["pneumonia", "DISEASE", 63, 72], ["hypoxia", "DISEASE", 81, 88], ["myocardial ischemia", "DISEASE", 110, 129], ["oxygen", "CHEMICAL", 158, 164], ["oxygen", "CHEMICAL", 158, 164], ["myocardial", "MULTI-TISSUE_STRUCTURE", 110, 120], ["myocardial", "MULTI-TISSUE_STRUCTURE", 147, 157], ["oxygen", "SIMPLE_CHEMICAL", 158, 164], ["cytokines", "PROTEIN", 39, 48], ["the cytokines storm", "PROBLEM", 35, 54], ["the pneumonia", "PROBLEM", 59, 72], ["hypoxia", "PROBLEM", 81, 88], ["myocardial ischemia", "PROBLEM", 110, 129], ["the myocardial oxygen supply", "TREATMENT", 143, 171], ["cytokines storm", "OBSERVATION", 39, 54], ["pneumonia", "OBSERVATION", 63, 72], ["ischemia", "OBSERVATION", 121, 129], ["myocardial", "ANATOMY", 147, 157], ["oxygen supply", "OBSERVATION", 158, 171]]], ["The concerted negative effects of these events, along with underlying coronary artery disease (CAD), can explain the cardiac troponins elevation.", [["coronary artery", "ANATOMY", 70, 85], ["cardiac", "ANATOMY", 117, 124], ["coronary artery disease", "DISEASE", 70, 93], ["CAD", "DISEASE", 95, 98], ["cardiac troponins", "DISEASE", 117, 134], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 70, 85], ["cardiac", "ORGAN", 117, 124], ["troponins", "PROTEIN", 125, 134], ["these events", "PROBLEM", 34, 46], ["underlying coronary artery disease", "PROBLEM", 59, 93], ["CAD", "PROBLEM", 95, 98], ["the cardiac troponins elevation", "PROBLEM", 113, 144], ["negative", "OBSERVATION", 14, 22], ["coronary artery", "ANATOMY", 70, 85], ["disease", "OBSERVATION", 86, 93], ["cardiac", "ANATOMY", 117, 124], ["troponins elevation", "OBSERVATION", 125, 144]]], ["However, little is known about the clinical significance of cardiac injury in non-critically ill COVID-19 patients.", [["cardiac", "ANATOMY", 60, 67], ["cardiac injury", "DISEASE", 60, 74], ["COVID", "DISEASE", 97, 102], ["cardiac", "ORGAN", 60, 67], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["cardiac injury", "PROBLEM", 60, 74], ["cardiac", "ANATOMY", 60, 67], ["injury", "OBSERVATION", 68, 74]]], ["Furthermore, the link between cardiac injury and mortality is unclear: specifically, it is not known whether there is a direct effect of cardiac injury on mortality or whether this effect is mediated by the underlying comorbid conditions.", [["cardiac", "ANATOMY", 30, 37], ["cardiac", "ANATOMY", 137, 144], ["cardiac injury", "DISEASE", 30, 44], ["cardiac injury", "DISEASE", 137, 151], ["cardiac", "ORGAN", 30, 37], ["cardiac", "ORGAN", 137, 144], ["cardiac injury", "PROBLEM", 30, 44], ["cardiac injury", "PROBLEM", 137, 151], ["the underlying comorbid conditions", "PROBLEM", 203, 237], ["cardiac", "ANATOMY", 30, 37], ["injury", "OBSERVATION", 38, 44], ["cardiac", "ANATOMY", 137, 144], ["injury", "OBSERVATION", 145, 151]]], ["Therefore, the aims of the present study are (1) to describe the clinical characteristics, the incidence of cardiac injury and outcomes of a cohort of Italian COVID-19 patients, admitted to our medical non-intensive COVID-19 Unit, (2) to perform a post-hoc exploratory mediation analysis to identify the extent to which the cardiac injury mediates in-hospital mortality.MethodsThe data, analytic methods, and study materials will be available to other researchers for purposes of reproducing the results or replicating the procedure on reasonable request.MethodsThis was a single-center, observational study enrolled all consecutive patients with laboratory-confirmed SARS-CoV-2 infection and clinical and radiological signs of COVID-19, referred from the Emergency Department to our medical, non-intensive COVID-19 Unit of Azienda Ospedaliera Padova (Italy), between February 26th and March 31st 2020.", [["cardiac", "ANATOMY", 108, 115], ["cardiac", "ANATOMY", 324, 331], ["cardiac injury", "DISEASE", 108, 122], ["cardiac injury", "DISEASE", 324, 338], ["SARS-CoV-2 infection", "DISEASE", 668, 688], ["cardiac", "ORGAN", 108, 115], ["patients", "ORGANISM", 168, 176], ["cardiac", "ORGAN", 324, 331], ["patients", "ORGANISM", 633, 641], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 633, 641], ["the present study", "TEST", 23, 40], ["cardiac injury", "PROBLEM", 108, 122], ["a post-hoc exploratory mediation analysis", "TEST", 246, 287], ["the cardiac injury", "PROBLEM", 320, 338], ["analytic methods", "TEST", 387, 403], ["study materials", "TEST", 409, 424], ["the procedure", "TREATMENT", 519, 532], ["observational study", "TEST", 588, 607], ["laboratory", "TEST", 647, 657], ["SARS", "PROBLEM", 668, 672], ["CoV", "TEST", 673, 676], ["2 infection", "PROBLEM", 677, 688], ["COVID", "TEST", 728, 733], ["cardiac", "ANATOMY", 108, 115], ["injury", "OBSERVATION", 116, 122], ["cardiac", "ANATOMY", 324, 331], ["injury", "OBSERVATION", 332, 338], ["infection", "OBSERVATION", 679, 688]]], ["Criteria for referral to our Unit was the no-need, or no-eligibility for age or comorbidities, of mechanical or non-invasive ventilation.", [["comorbidities", "PROBLEM", 80, 93], ["mechanical or non-invasive ventilation", "TREATMENT", 98, 136]]], ["Patients without laboratory cardiac troponins evaluation were excluded from the study.MethodsAccording to the WHO guidance (13), laboratory confirmation for SARS-CoV-2 was defined as a positive result of real-time reverse transcriptase-polymerase chain reaction assay of nasal and pharyngeal swabs.MethodsStudy data and clinical information were collected and managed by medical staff using REDCap electronic data capture tools hosted at University of Padova [14, 15] .MethodsAll clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki (2001).", [["cardiac", "ANATOMY", 28, 35], ["nasal", "ANATOMY", 271, 276], ["pharyngeal swabs", "ANATOMY", 281, 297], ["SARS", "DISEASE", 157, 161], ["Patients", "ORGANISM", 0, 8], ["nasal", "ORGANISM_SUBDIVISION", 271, 276], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 281, 297], ["reverse transcriptase", "PROTEIN", 214, 235], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 157, 165], ["laboratory cardiac troponins evaluation", "TEST", 17, 56], ["the study", "TEST", 76, 85], ["laboratory confirmation", "TEST", 129, 152], ["SARS", "PROBLEM", 157, 161], ["CoV", "TEST", 162, 165], ["nasal and pharyngeal swabs", "PROBLEM", 271, 297], ["MethodsStudy data", "TEST", 298, 315], ["All clinical investigations", "TEST", 476, 503], ["nasal", "ANATOMY", 271, 276], ["pharyngeal swabs", "ANATOMY", 281, 297]]], ["Verbal consent from patients for management of personal data was obtained.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["personal data", "TEST", 47, 60]]], ["The study protocol was approved by the cardiovascular section inhouse Ethics Committee on Human Research of the Padova Province.Data collectionClinical patient data reported in this study included the following: age, sex, body mass index (BMI), clinical parameters on admission in the Emergency Room, comorbidities including hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, chronic CAD, chronic heart failure, cerebrovascular disease, peripheral atheromasia, chronic pulmonary-kidney-liver disease, solid malignancy, leukemia, lymphoma, dementia, connective tissue disease and acquired immunodeficiency disease.", [["cardiovascular", "ANATOMY", 39, 53], ["body", "ANATOMY", 222, 226], ["atrial", "ANATOMY", 339, 345], ["heart", "ANATOMY", 414, 419], ["cerebrovascular", "ANATOMY", 429, 444], ["pulmonary", "ANATOMY", 486, 495], ["kidney", "ANATOMY", 496, 502], ["liver", "ANATOMY", 503, 508], ["solid malignancy", "ANATOMY", 518, 534], ["leukemia", "ANATOMY", 536, 544], ["lymphoma", "ANATOMY", 546, 554], ["connective tissue", "ANATOMY", 566, 583], ["hypertension", "DISEASE", 325, 337], ["atrial fibrillation", "DISEASE", 339, 358], ["diabetes mellitus", "DISEASE", 360, 377], ["dyslipidemia", "DISEASE", 379, 391], ["chronic CAD", "DISEASE", 393, 404], ["chronic heart failure", "DISEASE", 406, 427], ["cerebrovascular disease", "DISEASE", 429, 452], ["peripheral atheromasia", "DISEASE", 454, 476], ["chronic pulmonary-kidney-liver disease", "DISEASE", 478, 516], ["malignancy", "DISEASE", 524, 534], ["leukemia, lymphoma", "DISEASE", 536, 554], ["dementia", "DISEASE", 556, 564], ["connective tissue disease", "DISEASE", 566, 591], ["acquired immunodeficiency disease", "DISEASE", 596, 629], ["Human", "ORGANISM", 90, 95], ["patient", "ORGANISM", 152, 159], ["body", "ORGANISM_SUBDIVISION", 222, 226], ["heart", "ORGAN", 414, 419], ["pulmonary", "ORGAN", 486, 495], ["kidney", "ORGAN", 496, 502], ["liver", "ORGAN", 503, 508], ["solid malignancy", "CANCER", 518, 534], ["leukemia", "CANCER", 536, 544], ["lymphoma", "CANCER", 546, 554], ["connective tissue", "TISSUE", 566, 583], ["Human", "SPECIES", 90, 95], ["patient", "SPECIES", 152, 159], ["The study protocol", "TEST", 0, 18], ["this study", "TEST", 177, 187], ["body mass index", "PROBLEM", 222, 237], ["comorbidities", "PROBLEM", 301, 314], ["hypertension", "PROBLEM", 325, 337], ["atrial fibrillation", "PROBLEM", 339, 358], ["diabetes mellitus", "PROBLEM", 360, 377], ["dyslipidemia", "PROBLEM", 379, 391], ["chronic CAD", "PROBLEM", 393, 404], ["chronic heart failure", "PROBLEM", 406, 427], ["cerebrovascular disease", "PROBLEM", 429, 452], ["peripheral atheromasia", "PROBLEM", 454, 476], ["chronic pulmonary-kidney-liver disease", "PROBLEM", 478, 516], ["solid malignancy", "PROBLEM", 518, 534], ["leukemia", "PROBLEM", 536, 544], ["lymphoma", "PROBLEM", 546, 554], ["dementia", "PROBLEM", 556, 564], ["connective tissue disease", "PROBLEM", 566, 591], ["acquired immunodeficiency disease", "PROBLEM", 596, 629], ["hypertension", "OBSERVATION", 325, 337], ["atrial", "ANATOMY", 339, 345], ["fibrillation", "OBSERVATION", 346, 358], ["diabetes mellitus", "OBSERVATION", 360, 377], ["dyslipidemia", "OBSERVATION", 379, 391], ["chronic", "OBSERVATION_MODIFIER", 393, 400], ["CAD", "OBSERVATION", 401, 404], ["chronic", "OBSERVATION_MODIFIER", 406, 413], ["heart", "ANATOMY", 414, 419], ["failure", "OBSERVATION", 420, 427], ["cerebrovascular disease", "OBSERVATION", 429, 452], ["peripheral", "ANATOMY_MODIFIER", 454, 464], ["atheromasia", "OBSERVATION", 465, 476], ["chronic", "OBSERVATION_MODIFIER", 478, 485], ["pulmonary", "ANATOMY", 486, 495], ["kidney", "ANATOMY", 496, 502], ["liver", "ANATOMY", 503, 508], ["disease", "OBSERVATION", 509, 516], ["solid", "OBSERVATION_MODIFIER", 518, 523], ["malignancy", "OBSERVATION", 524, 534], ["leukemia", "OBSERVATION", 536, 544], ["lymphoma", "OBSERVATION", 546, 554], ["dementia", "OBSERVATION", 556, 564], ["connective tissue disease", "OBSERVATION", 566, 591], ["immunodeficiency disease", "OBSERVATION", 605, 629]]], ["Charlson Comorbidity Index, a score widely used in epidemiological studies to predict length of hospitalization, health-resources use, and 1-year mortality, was calculated [16] .", [["Charlson Comorbidity Index", "TEST", 0, 26], ["epidemiological studies", "TEST", 51, 74]]], ["Laboratory examinations on admission and the maximum value during the hospitalization were reported.", [["Laboratory examinations", "TEST", 0, 23], ["the maximum value", "TEST", 41, 58]]], ["In particular, the high-sensitivity cardiac troponin I (Hs-cTnI) assay was based on the immunometric method with chemiluminescence detection and patients were considered to have acute cardiac injury if serum levels Hs-cTnI were above the 99th percentile upper reference limit (32 ng/L for males, 16 ng/L for females).", [["cardiac", "ANATOMY", 184, 191], ["serum", "ANATOMY", 202, 207], ["cardiac injury", "DISEASE", 184, 198], ["troponin I", "GENE_OR_GENE_PRODUCT", 44, 54], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 56, 63], ["patients", "ORGANISM", 145, 153], ["cardiac", "ORGAN", 184, 191], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 215, 222], ["cardiac troponin I", "PROTEIN", 36, 54], ["Hs", "PROTEIN", 56, 58], ["cTnI", "PROTEIN", 59, 63], ["cTnI", "PROTEIN", 218, 222], ["patients", "SPECIES", 145, 153], ["Hs-cTnI) assay", "TEST", 56, 70], ["the immunometric method", "TEST", 84, 107], ["chemiluminescence detection", "TEST", 113, 140], ["acute cardiac injury", "PROBLEM", 178, 198], ["serum levels Hs", "TEST", 202, 217], ["cTnI", "TEST", 218, 222], ["males", "TEST", 289, 294], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["cardiac", "ANATOMY", 184, 191], ["injury", "OBSERVATION", 192, 198]]], ["Electrocardiography and echocardiography data were not object of analysis in this work.", [["Electrocardiography", "TEST", 0, 19], ["echocardiography data", "TEST", 24, 45], ["analysis", "TEST", 65, 73]]], ["Cardiac imaging diagnostic techniques requiring the transportation of COVID-19 patients in other areas of the hospital and all cardiac catheterization laboratory procedures were discouraged to minimize the risk of dissemination and staff exposure, and performed only if considered decisive for the patient management or lifesaving, according to scientific consensus statements [17, 18] .OutcomeThe endpoint was incidence of COVID-19 associated inhospital mortality.", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 127, 134], ["patients", "ORGANISM", 79, 87], ["patient", "ORGANISM", 298, 305], ["patients", "SPECIES", 79, 87], ["patient", "SPECIES", 298, 305], ["Cardiac imaging", "TEST", 0, 15], ["COVID", "TEST", 70, 75], ["all cardiac catheterization", "TEST", 123, 150], ["the patient management", "TREATMENT", 294, 316], ["lifesaving", "TREATMENT", 320, 330], ["COVID", "TEST", 424, 429], ["cardiac", "ANATOMY", 127, 134], ["catheterization", "OBSERVATION", 135, 150], ["dissemination", "OBSERVATION", 214, 227]]], ["The number of patients discharged, and referred to intensive care unit (ICU), and still admitted on April the 1st 2020, was also determined.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Discharge criteria were: (1) relieved clinical symptoms, (2) normal body temperature, (3) complete weaning from oxygen therapy maintained for 48 h, (4) resolution of inflammation as shown by chest radiography and blood tests, (5) no evidence of arterial oxygen desaturation on six-minute walk test.Statistical analysisDescriptive statistics were carried out for all clinical variables.", [["body", "ANATOMY", 68, 72], ["chest", "ANATOMY", 191, 196], ["blood", "ANATOMY", 213, 218], ["arterial", "ANATOMY", 245, 253], ["oxygen", "CHEMICAL", 112, 118], ["inflammation", "DISEASE", 166, 178], ["oxygen", "CHEMICAL", 254, 260], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 254, 260], ["body", "ORGANISM_SUBDIVISION", 68, 72], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["chest", "ORGANISM_SUBDIVISION", 191, 196], ["blood", "ORGANISM_SUBSTANCE", 213, 218], ["arterial", "MULTI-TISSUE_STRUCTURE", 245, 253], ["oxygen", "SIMPLE_CHEMICAL", 254, 260], ["clinical symptoms", "PROBLEM", 38, 55], ["oxygen therapy", "TREATMENT", 112, 126], ["inflammation", "PROBLEM", 166, 178], ["chest radiography", "TEST", 191, 208], ["blood tests", "TEST", 213, 224], ["arterial oxygen desaturation", "PROBLEM", 245, 273], ["six-minute walk test", "TEST", 277, 297], ["Statistical analysisDescriptive statistics", "TEST", 298, 340], ["inflammation", "OBSERVATION", 166, 178], ["chest", "ANATOMY", 191, 196], ["no evidence of", "UNCERTAINTY", 230, 244], ["arterial", "ANATOMY", 245, 253], ["oxygen desaturation", "OBSERVATION", 254, 273]]], ["Data are presented as median (interquartile range [IQR]) for continuous variables and as percentages (absolute numbers) for categorical variables.", [["continuous variables", "TEST", 61, 81], ["categorical variables", "TEST", 124, 145]]], ["To compare differences between survivors and non-survivors, we used the Mann-Whitney U test, Chi-square test, or Fisher's exact test, as appropriate.Statistical analysisA two-sided p of less than 0.05 was considered statistically significant.Statistical analysisCardiac injury effect on in-hospital mortality was evaluated using a Generalized Additive Model with logit link and restricted cubic splines to allow for non-linearities [19] .", [["Chi-square test", "TEST", 93, 108], ["Fisher's exact test", "TEST", 113, 132], ["Statistical analysisA", "TEST", 149, 170], ["Statistical analysisCardiac injury effect", "PROBLEM", 242, 283], ["a Generalized Additive Model with logit link", "TREATMENT", 329, 373], ["restricted cubic splines", "TREATMENT", 378, 402], ["injury", "OBSERVATION", 270, 276]]], ["Potential mediators of the link between cardiac injury and mortality were explored using a mediation analysis [20] .", [["cardiac", "ANATOMY", 40, 47], ["cardiac injury", "DISEASE", 40, 54], ["cardiac", "ORGAN", 40, 47], ["cardiac injury", "PROBLEM", 40, 54], ["a mediation analysis", "TEST", 89, 109], ["cardiac", "ANATOMY", 40, 47], ["injury", "OBSERVATION", 48, 54]]], ["Both mediation and outcome models were built using an exhaustive search approach among all variables considered in the dataset using the Bayesian Information Criterion [21] .", [["an exhaustive search approach", "TREATMENT", 51, 80]]], ["All confidence intervals (CIs) have been computed using bias-adjusted bootstrap with 10,000 runs.", [["bias-adjusted bootstrap", "TREATMENT", 56, 79]]], ["We used the Somer's Dxy as a measure of goodness of fit (the closer to 1 the better) to present results of the multivariable model for outcome.", [["the Somer's Dxy", "TREATMENT", 8, 23]]], ["Analyses were conducted using the R System [22] , with mediation [23] and glmulti [24] libraries.Baseline characteristicsDuring the study period, 136 patients were admitted to our Medical Unit for COVID-19.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["COVID", "TEST", 197, 202]]], ["Patients with missing Hs-cTnI results (n = 27) were excluded.", [["Patients", "ORGANISM", 0, 8], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 22, 29], ["cTnI", "PROTEIN", 25, 29], ["Patients", "SPECIES", 0, 8], ["cTnI results", "TEST", 25, 37]]], ["The study population included 109 patients (female n = 36, 33%), with a median age was 71 years (IQR 60-81), and a BMI 28 kg/ m 2 [24] [25] [26] [27] [28] [29] [30] .", [["patients", "ORGANISM", 34, 42], ["[25] [26] [27] [28", "SIMPLE_CHEMICAL", 135, 153], ["patients", "SPECIES", 34, 42], ["The study population", "TEST", 0, 20], ["IQR", "TEST", 97, 100], ["a BMI", "TEST", 113, 118]]], ["During the observation period, 20 (18%) patients died, 83 (76%) patients were discharged, 6 (5.5%) were still hospitalized.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 64, 72]]], ["The median length of stay was 11 days (IQR 6-16).Baseline characteristicsHypertension (68 patients, 62%), dyslipidemia (39, 36%) and diabetes mellitus (27, 25%) were the most common cardiovascular risk factors.", [["cardiovascular", "ANATOMY", 182, 196], ["Hypertension", "DISEASE", 73, 85], ["dyslipidemia", "DISEASE", 106, 118], ["diabetes mellitus", "DISEASE", 133, 150], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["Hypertension", "PROBLEM", 73, 85], ["dyslipidemia", "PROBLEM", 106, 118], ["diabetes mellitus", "PROBLEM", 133, 150], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["Hypertension", "OBSERVATION", 73, 85], ["dyslipidemia", "OBSERVATION", 106, 118]]], ["No current smokers were identified, past smokers were 26 (24%).", [["smokers", "ORGANISM", 11, 18], ["smokers", "OBSERVATION", 11, 18]]], ["Chronic CAD, chronic heart failure, cerebrovascular disease, and chronic kidney disease were known in 18 patients (17%), 16 (15%), 17 (16%), and 13 (12%), respectively.", [["heart", "ANATOMY", 21, 26], ["cerebrovascular", "ANATOMY", 36, 51], ["kidney", "ANATOMY", 73, 79], ["CAD", "DISEASE", 8, 11], ["chronic heart failure", "DISEASE", 13, 34], ["cerebrovascular disease", "DISEASE", 36, 59], ["chronic kidney disease", "DISEASE", 65, 87], ["heart", "ORGAN", 21, 26], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 36, 51], ["kidney", "ORGAN", 73, 79], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["Chronic CAD", "PROBLEM", 0, 11], ["chronic heart failure", "PROBLEM", 13, 34], ["cerebrovascular disease", "PROBLEM", 36, 59], ["chronic kidney disease", "PROBLEM", 65, 87], ["CAD", "OBSERVATION", 8, 11], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["heart", "ANATOMY", 21, 26], ["failure", "OBSERVATION", 27, 34], ["cerebrovascular disease", "OBSERVATION", 36, 59], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["kidney", "ANATOMY", 73, 79], ["disease", "OBSERVATION", 80, 87]]], ["Charlson Comorbidity Index was 0 in 36 (33%), 1-2 in 39 (36%), > 3 in 34 (16%).", [["Charlson Comorbidity Index", "TEST", 0, 26]]], ["Other comorbidities, as well as admission parameters, symptoms, home therapy and clinical management are reported in Supplemental Files.Baseline characteristicsCompared with the survivors, non-survivors were significantly older (86 vs 69 years, p < 0.001), more likely to have hypertension (80% vs 58%, p = 0.050), dyslipidemia (55% vs 32%, p = 0.047), chronic kidney disease (30% vs 8%, p = 0.014), chronic CAD (45% vs 9%, p = 0.001) and higher Charlson Comorbidity Index values (Table 1) .Laboratory valueOn admission, abnormal median values of hemoglobin, lymphocytes, C-reactive protein (CRP), d-Dimer and lactate dehydrogenase (LDH) were recorded.", [["kidney", "ANATOMY", 361, 367], ["lymphocytes", "ANATOMY", 559, 570], ["hypertension", "DISEASE", 277, 289], ["dyslipidemia", "DISEASE", 315, 327], ["chronic kidney disease", "DISEASE", 353, 375], ["chronic CAD", "DISEASE", 400, 411], ["lactate", "CHEMICAL", 610, 617], ["lactate", "CHEMICAL", 610, 617], ["kidney", "ORGAN", 361, 367], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 547, 557], ["lymphocytes", "CELL", 559, 570], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 572, 590], ["CRP", "GENE_OR_GENE_PRODUCT", 592, 595], ["d-Dimer", "SIMPLE_CHEMICAL", 598, 605], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 610, 631], ["LDH", "GENE_OR_GENE_PRODUCT", 633, 636], ["hemoglobin", "PROTEIN", 547, 557], ["lymphocytes", "CELL_TYPE", 559, 570], ["C-reactive protein", "PROTEIN", 572, 590], ["CRP", "PROTEIN", 592, 595], ["d-Dimer", "PROTEIN", 598, 605], ["lactate dehydrogenase", "PROTEIN", 610, 631], ["LDH", "PROTEIN", 633, 636], ["Other comorbidities", "PROBLEM", 0, 19], ["admission parameters", "TEST", 32, 52], ["symptoms", "PROBLEM", 54, 62], ["home therapy", "TREATMENT", 64, 76], ["clinical management", "TREATMENT", 81, 100], ["hypertension", "PROBLEM", 277, 289], ["p", "TEST", 303, 304], ["dyslipidemia", "PROBLEM", 315, 327], ["p", "TEST", 341, 342], ["chronic kidney disease", "PROBLEM", 353, 375], ["p", "TEST", 388, 389], ["chronic CAD", "PROBLEM", 400, 411], ["p", "TEST", 424, 425], ["higher Charlson Comorbidity Index values", "PROBLEM", 439, 479], ["abnormal median values", "PROBLEM", 521, 543], ["hemoglobin", "TEST", 547, 557], ["lymphocytes", "TEST", 559, 570], ["C", "TEST", 572, 573], ["reactive protein", "TEST", 574, 590], ["CRP", "TEST", 592, 595], ["d-Dimer", "TEST", 598, 605], ["lactate dehydrogenase (LDH)", "PROBLEM", 610, 637], ["comorbidities", "OBSERVATION", 6, 19], ["hypertension", "OBSERVATION", 277, 289], ["dyslipidemia", "OBSERVATION", 315, 327], ["chronic", "OBSERVATION_MODIFIER", 353, 360], ["kidney", "ANATOMY", 361, 367], ["disease", "OBSERVATION", 368, 375], ["chronic", "OBSERVATION_MODIFIER", 400, 407], ["CAD", "OBSERVATION", 408, 411], ["lymphocytes", "ANATOMY", 559, 570], ["reactive protein", "OBSERVATION", 574, 590]]], ["Hs-cTnI levels were out of normality ranges in 41 (38%).", [["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 0, 7], ["cTnI", "PROTEIN", 3, 7], ["Hs", "TEST", 0, 2], ["cTnI levels", "TEST", 3, 14]]], ["Compared with survivors, non-survivors presented with higher median levels of Hs-cTnI (64 vs 6 ng/L, p < 0.001; abnormal in 90% vs 30%, p < 0.001) (Fig. 1a) , CRP (101 vs 58 mg/L, p = 0.006), d-Dimer (773 vs 230 \u00b5g/L, p = 0.003) and LDH (405 vs 304 U/L, p = 0.008).", [["d-Dimer", "CHEMICAL", 192, 199], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 78, 85], ["CRP", "GENE_OR_GENE_PRODUCT", 159, 162], ["d-Dimer", "SIMPLE_CHEMICAL", 192, 199], ["LDH", "GENE_OR_GENE_PRODUCT", 233, 236], ["cTnI", "PROTEIN", 81, 85], ["CRP", "PROTEIN", 159, 162], ["Hs", "TEST", 78, 80], ["cTnI", "TEST", 81, 85], ["p", "TEST", 136, 137], ["CRP", "TEST", 159, 162], ["vs", "TEST", 168, 170], ["p", "TEST", 180, 181], ["d-Dimer", "TEST", 192, 199], ["vs", "TEST", 205, 207], ["\u00b5g", "TEST", 212, 214], ["p", "TEST", 218, 219], ["LDH", "TEST", 233, 236], ["U/L", "TEST", 249, 252], ["p", "TEST", 254, 255], ["LDH", "ANATOMY", 233, 236]]], ["During the hospitalization, almost the same trend was observed, with non-survivors showing higher levels of peak Hs-cTnI (279 vs 16 ng/L, p < 0.001; abnormal in 90% vs 32%, p < 0.001) (Fig. 1b) Table 2 reports the relative effect of each predictor as a mediator on in-hospital mortality as evaluated at multivariate mediation analysis: as it can be seen the strongest mediator of in-hospital mortality was peak Hs-cTnI, followed by chronic kidney disease, and chronic CAD.", [["kidney", "ANATOMY", 440, 446], ["chronic kidney disease", "DISEASE", 432, 454], ["chronic CAD", "DISEASE", 460, 471], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 113, 120], ["kidney", "ORGAN", 440, 446], ["non-survivors", "TEST", 69, 82], ["peak Hs", "TEST", 108, 115], ["cTnI", "TEST", 116, 120], ["vs", "TEST", 126, 128], ["ng", "TEST", 132, 134], ["p", "TEST", 138, 139], ["p", "TEST", 173, 174], ["cTnI", "TEST", 414, 418], ["chronic kidney disease", "PROBLEM", 432, 454], ["chronic CAD", "PROBLEM", 460, 471], ["chronic", "OBSERVATION_MODIFIER", 432, 439], ["kidney", "ANATOMY", 440, 446], ["disease", "OBSERVATION", 447, 454], ["chronic", "OBSERVATION_MODIFIER", 460, 467], ["CAD", "OBSERVATION", 468, 471]]], ["The addition of LDH increased the proportion mediated to 89%.", [["LDH", "CHEMICAL", 16, 19], ["LDH", "GENE_OR_GENE_PRODUCT", 16, 19], ["LDH", "PROTEIN", 16, 19], ["LDH", "TEST", 16, 19]]], ["The independent predictive effect of Hs-cTnI is further supported by the multivariate model for mortality with an OR of 32.58 (Table 3) .", [["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 37, 44], ["Hs", "DNA", 37, 39], ["cTnI", "PROTEIN", 40, 44], ["cTnI", "TEST", 40, 44]]], ["We then performed an additional analysis to assess whether the peak of Hs-cTnI was either mediated or direct.", [["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 71, 78], ["Hs", "DNA", 71, 73], ["cTnI", "PROTEIN", 74, 78], ["an additional analysis", "TEST", 18, 40], ["cTnI", "TEST", 74, 78]]], ["Figure 3 shows that a statistically significant effect of the average direct effect: this testifies a direct effect of peak Hs-cTnI on mortality, with no significant interaction with other confounders.DiscussionCardiac injury is a powerful predictor of mortality in patients with severe COVID-19 infection.", [["Cardiac", "ANATOMY", 211, 218], ["Cardiac injury", "DISEASE", 211, 225], ["infection", "DISEASE", 296, 305], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 124, 131], ["Cardiac", "ORGAN", 211, 218], ["patients", "ORGANISM", 266, 274], ["cTnI", "PROTEIN", 127, 131], ["patients", "SPECIES", 266, 274], ["peak Hs", "TEST", 119, 126], ["Cardiac injury", "PROBLEM", 211, 225], ["severe COVID-19 infection", "PROBLEM", 280, 305], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["effect", "OBSERVATION_MODIFIER", 48, 54], ["no", "UNCERTAINTY", 151, 153], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["interaction", "OBSERVATION", 166, 177], ["injury", "OBSERVATION", 219, 225], ["infection", "OBSERVATION", 296, 305]]], ["However, little is known in non-critically ill COVID-19 patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Furthermore, it is unclear the relative predictive role of cardiac injury in the context of other comorbidities.DiscussionIn the present study, we show that: (1) COVID-19 nonsurvivors show higher Hs-cTnI, both on admission and peak levels.", [["cardiac", "ANATOMY", 59, 66], ["cardiac injury", "DISEASE", 59, 73], ["cardiac", "ORGAN", 59, 66], ["cTnI", "PROTEIN", 199, 203], ["cardiac injury", "PROBLEM", 59, 73], ["other comorbidities", "PROBLEM", 92, 111], ["the present study", "TEST", 125, 142], ["COVID", "TEST", 162, 167], ["higher Hs", "PROBLEM", 189, 198], ["cTnI", "TEST", 199, 203], ["peak levels", "TEST", 227, 238], ["cardiac", "ANATOMY", 59, 66], ["injury", "OBSERVATION", 67, 73]]], ["(2) There is a dose-response relationship between Hs-cTnI levels and mortality up to 200 ng/L; (3) Hs-cTnI is the most powerful mediator of in-hospital mortality; (4) This mediation is independent of other underlying confounding variables.DiscussionSince the first Chinese observational studies, cardiac injury demonstrated by elevation of cardiac troponins has been reported in 10-30% in-patients with COVID-19 and associated with severe COVID-19 illness, a higher need for intensive care and higher odds of in-hospital mortality [3, 4, 8, 9] .", [["cardiac", "ANATOMY", 296, 303], ["cardiac", "ANATOMY", 340, 347], ["cardiac injury", "DISEASE", 296, 310], ["elevation of cardiac troponins", "DISEASE", 327, 357], ["illness", "DISEASE", 448, 455], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 50, 57], ["cardiac", "ORGAN", 296, 303], ["cardiac", "ORGAN", 340, 347], ["patients", "ORGANISM", 389, 397], ["cTnI", "PROTEIN", 53, 57], ["cardiac troponins", "PROTEIN", 340, 357], ["patients", "SPECIES", 389, 397], ["Hs", "TEST", 50, 52], ["cTnI levels", "TEST", 53, 64], ["Chinese observational studies", "TEST", 265, 294], ["cardiac injury", "PROBLEM", 296, 310], ["elevation of cardiac troponins", "PROBLEM", 327, 357], ["COVID", "TEST", 403, 408], ["severe COVID-19 illness", "PROBLEM", 432, 455], ["intensive care", "TREATMENT", 475, 489], ["cardiac", "ANATOMY", 296, 303], ["injury", "OBSERVATION", 304, 310], ["elevation", "OBSERVATION", 327, 336], ["cardiac", "ANATOMY", 340, 347]]], ["Our data confirmed this observation, yet reporting a higher rate of cardiac injury (38% on admission, 46% during hospitalization) and mortality (18%), which may be explained by the characteristics of our population, represented by older and comorbid patients.", [["cardiac", "ANATOMY", 68, 75], ["cardiac injury", "DISEASE", 68, 82], ["cardiac", "ORGAN", 68, 75], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["Our data", "TEST", 0, 8], ["this observation", "TEST", 19, 35], ["cardiac injury", "PROBLEM", 68, 82], ["mortality", "TEST", 134, 143], ["cardiac", "ANATOMY", 68, 75], ["injury", "OBSERVATION", 76, 82], ["may be explained", "UNCERTAINTY", 157, 173]]], ["Indeed, median age of our patients (71 years) was notably higher than [3, 4, 8, 9] .", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["Along with the age, also comorbidities were more prevalent, with a Charlson comorbidity index \u2265 3 in about one third of patients, and in keeping with previous reports [4, 8, 25, 26] , patients with hypertension, diabetes, chronic kidney disease and chronic CAD were associated with poor outcome.DiscussionCardiac injury in patients with COVID-19 has been also demonstrated to be predictive of in-hospital mortality [7, 12, 27, 28] .", [["kidney", "ANATOMY", 230, 236], ["hypertension", "DISEASE", 198, 210], ["diabetes", "DISEASE", 212, 220], ["chronic kidney disease", "DISEASE", 222, 244], ["CAD", "DISEASE", 257, 260], ["DiscussionCardiac injury", "DISEASE", 295, 319], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 184, 192], ["kidney", "ORGAN", 230, 236], ["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 323, 331], ["a Charlson comorbidity index", "TEST", 65, 93], ["hypertension", "PROBLEM", 198, 210], ["diabetes", "PROBLEM", 212, 220], ["chronic kidney disease", "PROBLEM", 222, 244], ["chronic CAD", "PROBLEM", 249, 260], ["poor outcome", "PROBLEM", 282, 294], ["DiscussionCardiac injury", "PROBLEM", 295, 319], ["hypertension", "OBSERVATION", 198, 210], ["diabetes", "OBSERVATION", 212, 220], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["kidney", "ANATOMY", 230, 236], ["disease", "OBSERVATION", 237, 244], ["chronic", "OBSERVATION_MODIFIER", 249, 256], ["CAD", "OBSERVATION", 257, 260], ["injury", "OBSERVATION", 313, 319]]], ["In a metanalysis exploring the risk factors for COVID-19 patients to develop critical disease or death, a Hs-cTnI > 28 pg/mL was associated with an OR of 43.24 (95% CI 9.92-188.49) to deterioration of the patient's condition [27] .", [["death", "DISEASE", 97, 102], ["patients", "ORGANISM", 57, 65], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 106, 113], ["patient", "ORGANISM", 205, 212], ["cTnI", "PROTEIN", 109, 113], ["patients", "SPECIES", 57, 65], ["patient", "SPECIES", 205, 212], ["COVID", "TEST", 48, 53], ["critical disease", "PROBLEM", 77, 93], ["death", "PROBLEM", 97, 102], ["a Hs", "TEST", 104, 108], ["cTnI", "TEST", 109, 113], ["CI", "TEST", 165, 167]]], ["We also found that the risk for mortality increases exponentially with low levels of Hs-cTnI, reaching a plateau at a concentration of about 200 ng/L. These Hs-cTnI levels are uncommonly observed in type-1 acute myocardial infarction or acute myocarditis, and seem likely to be related to myocardial inflammation and supply/demand discrepancy (ischemia).DiscussionIn the context of elderly and comorbid patients affected by viral pneumonia and systemic inflammation, it can however be problematic to extrapolate the clinical predictive value of cardiac injury, beyond other factors like hypoxemia, hypercoagulation, and systemic inflammation.", [["myocardial", "ANATOMY", 212, 222], ["myocardial", "ANATOMY", 289, 299], ["cardiac", "ANATOMY", 545, 552], ["myocardial infarction", "DISEASE", 212, 233], ["myocarditis", "DISEASE", 243, 254], ["myocardial inflammation", "DISEASE", 289, 312], ["ischemia", "DISEASE", 344, 352], ["pneumonia", "DISEASE", 430, 439], ["systemic inflammation", "DISEASE", 444, 465], ["cardiac injury", "DISEASE", 545, 559], ["hypoxemia", "DISEASE", 587, 596], ["hypercoagulation", "DISEASE", 598, 614], ["inflammation", "DISEASE", 629, 641], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 85, 92], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 157, 164], ["myocardial", "MULTI-TISSUE_STRUCTURE", 212, 222], ["myocardial", "MULTI-TISSUE_STRUCTURE", 289, 299], ["patients", "ORGANISM", 403, 411], ["cardiac", "ORGAN", 545, 552], ["cTnI", "PROTEIN", 88, 92], ["cTnI", "PROTEIN", 160, 164], ["patients", "SPECIES", 403, 411], ["type-1", "SPECIES", 199, 205], ["mortality", "PROBLEM", 32, 41], ["cTnI", "PROBLEM", 88, 92], ["These Hs", "TEST", 151, 159], ["cTnI levels", "TEST", 160, 171], ["type-1 acute myocardial infarction", "PROBLEM", 199, 233], ["acute myocarditis", "PROBLEM", 237, 254], ["myocardial inflammation", "PROBLEM", 289, 312], ["demand discrepancy", "PROBLEM", 324, 342], ["ischemia", "PROBLEM", 344, 352], ["viral pneumonia", "PROBLEM", 424, 439], ["systemic inflammation", "PROBLEM", 444, 465], ["cardiac injury", "PROBLEM", 545, 559], ["hypoxemia", "PROBLEM", 587, 596], ["hypercoagulation", "PROBLEM", 598, 614], ["systemic inflammation", "PROBLEM", 620, 641], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["myocardial", "ANATOMY", 212, 222], ["infarction", "OBSERVATION", 223, 233], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["myocarditis", "OBSERVATION", 243, 254], ["seem likely to be related to", "UNCERTAINTY", 260, 288], ["myocardial", "ANATOMY", 289, 299], ["inflammation", "OBSERVATION", 300, 312], ["ischemia", "OBSERVATION", 344, 352], ["viral", "OBSERVATION_MODIFIER", 424, 429], ["pneumonia", "OBSERVATION", 430, 439], ["systemic", "OBSERVATION_MODIFIER", 444, 452], ["inflammation", "OBSERVATION", 453, 465], ["cardiac", "ANATOMY", 545, 552], ["injury", "OBSERVATION", 553, 559], ["hypoxemia", "OBSERVATION", 587, 596], ["hypercoagulation", "OBSERVATION", 598, 614], ["systemic", "OBSERVATION_MODIFIER", 620, 628], ["inflammation", "OBSERVATION", 629, 641]]], ["This is clinically important since experts' consensus endorse the use of Hs-cTnI after hospitalization as a tool to identify COVID-19 patients with cardiac injury, predict the progression of the disease and set up early treatment approach [29, 30] .", [["cardiac", "ANATOMY", 148, 155], ["cardiac injury", "DISEASE", 148, 162], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 73, 80], ["patients", "ORGANISM", 134, 142], ["cardiac", "ORGAN", 148, 155], ["cTnI", "PROTEIN", 76, 80], ["patients", "SPECIES", 134, 142], ["cardiac injury", "PROBLEM", 148, 162], ["the disease", "PROBLEM", 191, 202], ["cardiac", "ANATOMY", 148, 155], ["injury", "OBSERVATION", 156, 162], ["disease", "OBSERVATION", 195, 202]]], ["Our mediation analysis highlights the central role of cardiac injury in the prediction of mortality, since the peak of Hs-cTnI was the variable with the largest impact on the odds for in-hospital mortality.DiscussionThe present study has the limitations inherent of singlecenter, retrospective, observational studies, with a relatively small sample size.", [["cardiac", "ANATOMY", 54, 61], ["cardiac injury", "DISEASE", 54, 68], ["cardiac", "ORGAN", 54, 61], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 119, 126], ["cTnI", "PROTEIN", 122, 126], ["Our mediation analysis", "TEST", 0, 22], ["cardiac injury", "PROBLEM", 54, 68], ["The present study", "TEST", 216, 233], ["observational studies", "TEST", 295, 316], ["a relatively small sample size", "PROBLEM", 323, 353], ["central", "OBSERVATION_MODIFIER", 38, 45], ["cardiac", "ANATOMY", 54, 61], ["injury", "OBSERVATION", 62, 68], ["largest", "OBSERVATION_MODIFIER", 153, 160], ["small", "OBSERVATION_MODIFIER", 336, 341], ["sample", "OBSERVATION_MODIFIER", 342, 348], ["size", "OBSERVATION_MODIFIER", 349, 353]]], ["Nevertheless, the available sample allows to estimate, assuming a baseline event rate of 20%, a range of OR between approximately 0.3 and 1.8 with a power of 0.80 and the observed effects are all well above the upper limit.", [["upper limit", "OBSERVATION_MODIFIER", 211, 222]]], ["We included all patients admitted to our medical COVID-19 Unit for a COVID illness, who did not need any Direct effects of each predictor on mortality as evaluated at mediation analysis.", [["COVID illness", "DISEASE", 69, 82], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["mediation analysis", "TEST", 167, 185]]], ["No mediated effect was observed as statistically significant.", [["mediated effect", "PROBLEM", 3, 18], ["effect", "OBSERVATION", 12, 18], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["Effect is the increase (decrease) in probability of the outcome between risk factor's levels.", [["risk factor's levels", "TEST", 72, 92], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["ME is the size (%) of the average causal mediation effects relative to the total effect Hs-cTnI high-sensitivity cardiac troponin I, CAD coronary artery disease, LDH lactate dehydrogenase, BNP brain natriuretic peptide In conclusion, the risk stratification is of crucial importance in patients suffering from COVID-19: the use of Hs-cTnI is now considered an important tool to predict outcome.", [["coronary artery", "ANATOMY", 137, 152], ["CAD coronary artery disease", "DISEASE", 133, 160], ["lactate", "CHEMICAL", 166, 173], ["lactate", "CHEMICAL", 166, 173], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 88, 95], ["troponin I", "GENE_OR_GENE_PRODUCT", 121, 131], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 137, 152], ["LDH", "GENE_OR_GENE_PRODUCT", 162, 165], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 166, 187], ["BNP brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 189, 218], ["patients", "ORGANISM", 286, 294], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 331, 338], ["cTnI", "PROTEIN", 91, 95], ["cardiac troponin I", "PROTEIN", 113, 131], ["LDH lactate dehydrogenase", "PROTEIN", 162, 187], ["BNP", "PROTEIN", 189, 192], ["Hs", "DNA", 331, 333], ["cTnI", "PROTEIN", 334, 338], ["patients", "SPECIES", 286, 294], ["Hs", "TEST", 88, 90], ["cTnI", "TEST", 91, 95], ["high-sensitivity cardiac troponin I", "PROBLEM", 96, 131], ["CAD coronary artery disease", "PROBLEM", 133, 160], ["LDH lactate dehydrogenase", "TEST", 162, 187], ["BNP brain natriuretic peptide", "PROBLEM", 189, 218], ["COVID", "TEST", 310, 315], ["cTnI", "PROBLEM", 334, 338], ["size", "OBSERVATION_MODIFIER", 10, 14], ["coronary artery", "ANATOMY", 137, 152]]], ["In this study, we not only confirmed that Hs-cTnI is a predictor of in-hospital mortality also in noncritically ill patients with COVID-19, but also that it is the most important mediator independent from any other confounder.", [["noncritically ill", "DISEASE", 98, 115], ["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 42, 49], ["patients", "ORGANISM", 116, 124], ["cTnI", "PROTEIN", 45, 49], ["patients", "SPECIES", 116, 124], ["this study", "TEST", 3, 13]]], ["Cardiac damage plays a central role in the prognosis of patients with COVID-19 infection.Statement of human and animal rightsAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Statement of human and animal rightsInformed consent Verbal consent from patients for management of personal data was obtained.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac damage", "DISEASE", 0, 14], ["COVID-19", "CHEMICAL", 70, 78], ["infection", "DISEASE", 79, 88], ["Cardiac", "ORGAN", 0, 7], ["patients", "ORGANISM", 56, 64], ["human", "ORGANISM", 102, 107], ["human", "ORGANISM", 171, 176], ["human", "ORGANISM", 397, 402], ["patients", "ORGANISM", 457, 465], ["patients", "SPECIES", 56, 64], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 171, 176], ["participants", "SPECIES", 177, 189], ["human", "SPECIES", 397, 402], ["patients", "SPECIES", 457, 465], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 397, 402], ["Cardiac damage", "PROBLEM", 0, 14], ["COVID-19 infection", "PROBLEM", 70, 88], ["All procedures", "TREATMENT", 125, 139], ["personal data", "TEST", 484, 497], ["damage", "OBSERVATION", 8, 14], ["central", "OBSERVATION_MODIFIER", 23, 30], ["infection", "OBSERVATION", 79, 88]]], ["Fig. 3 Mediation analysis of an abnormal Hs-cTnI.", [["Hs-cTnI", "GENE_OR_GENE_PRODUCT", 41, 48], ["cTnI", "PROTEIN", 44, 48], ["an abnormal Hs", "PROBLEM", 29, 43]]], ["Effects are the increase (decrease) in probability of the outcome between risk factor's levels Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["increase", "OBSERVATION_MODIFIER", 16, 24], ["decrease", "OBSERVATION_MODIFIER", 26, 34]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]], ["To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.", [["licen", "ORGANISM", 68, 73]]]], "PMC7443812": [["BackgroundCOVID-19, a mild to severe respiratory syndrome that follows infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China in December 2019 and rapidly became a pandemic that affected millions of people, causing substantial mortality around the world.", [["BackgroundCOVID-19", "CHEMICAL", 0, 18], ["respiratory syndrome", "DISEASE", 37, 57], ["infection", "DISEASE", 71, 80], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 93, 131], ["SARS-CoV-2", "ORGANISM", 135, 145], ["people", "ORGANISM", 258, 264], ["people", "SPECIES", 258, 264], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 86, 145], ["BackgroundCOVID", "TEST", 0, 15], ["a mild to severe respiratory syndrome", "PROBLEM", 20, 57], ["infection", "PROBLEM", 71, 80], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 86, 131], ["SARS-CoV", "TEST", 135, 143], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["respiratory syndrome", "OBSERVATION", 37, 57], ["Severe", "OBSERVATION_MODIFIER", 86, 92], ["Acute", "OBSERVATION_MODIFIER", 93, 98], ["Respiratory Syndrome", "OBSERVATION", 99, 119], ["substantial", "OBSERVATION_MODIFIER", 274, 285], ["mortality", "OBSERVATION", 286, 295]]], ["Most individuals infected with SARS-CoV-2 develop a flu-like, mild clinical syndrome (non-pneumonia or a mild atypical pneumonia), and a sizeable proportion (~ 20%) require hospitalization (dyspnea, low oxygen saturation), with a substantial proportion leading to a critical illness (respiratory failure, septic shock, and/or multiple organ dysfunction) and death [1, 2].BackgroundWhile the mechanism by which only some individuals develop severe respiratory pathology is still not fully clarified, a number of studies have shown that patients who are ill enough to require hospitalization tend to be older persons affected by multimorbidity, including hypertension, diabetes, and/or obesity [3].", [["respiratory", "ANATOMY", 284, 295], ["organ", "ANATOMY", 335, 340], ["respiratory", "ANATOMY", 447, 458], ["SARS", "DISEASE", 31, 35], ["flu", "DISEASE", 52, 55], ["non-pneumonia", "DISEASE", 86, 99], ["pneumonia", "DISEASE", 119, 128], ["dyspnea", "DISEASE", 190, 197], ["oxygen", "CHEMICAL", 203, 209], ["respiratory failure", "DISEASE", 284, 303], ["septic shock", "DISEASE", 305, 317], ["organ dysfunction", "DISEASE", 335, 352], ["death", "DISEASE", 358, 363], ["multimorbidity", "DISEASE", 627, 641], ["hypertension", "DISEASE", 653, 665], ["diabetes", "DISEASE", 667, 675], ["obesity", "DISEASE", 684, 691], ["oxygen", "CHEMICAL", 203, 209], ["SARS-CoV-2", "ORGANISM", 31, 41], ["oxygen", "SIMPLE_CHEMICAL", 203, 209], ["organ", "ORGAN", 335, 340], ["patients", "ORGANISM", 535, 543], ["CoV-", "SPECIES", 36, 40], ["patients", "SPECIES", 535, 543], ["persons", "SPECIES", 607, 614], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["a flu", "PROBLEM", 50, 55], ["mild clinical syndrome", "PROBLEM", 62, 84], ["non-pneumonia", "PROBLEM", 86, 99], ["a mild atypical pneumonia", "PROBLEM", 103, 128], ["dyspnea", "PROBLEM", 190, 197], ["low oxygen saturation", "PROBLEM", 199, 220], ["a critical illness", "PROBLEM", 264, 282], ["respiratory failure", "PROBLEM", 284, 303], ["septic shock", "PROBLEM", 305, 317], ["multiple organ dysfunction", "PROBLEM", 326, 352], ["death", "PROBLEM", 358, 363], ["severe respiratory pathology", "PROBLEM", 440, 468], ["multimorbidity", "PROBLEM", 627, 641], ["hypertension", "PROBLEM", 653, 665], ["diabetes", "PROBLEM", 667, 675], ["obesity", "PROBLEM", 684, 691], ["infected", "OBSERVATION", 17, 25], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["atypical", "OBSERVATION_MODIFIER", 110, 118], ["pneumonia", "OBSERVATION", 119, 128], ["sizeable", "OBSERVATION_MODIFIER", 137, 145], ["proportion", "OBSERVATION_MODIFIER", 146, 156], ["respiratory failure", "OBSERVATION", 284, 303], ["septic shock", "OBSERVATION", 305, 317], ["organ", "ANATOMY", 335, 340], ["dysfunction", "OBSERVATION", 341, 352], ["hypertension", "OBSERVATION", 653, 665], ["diabetes", "OBSERVATION", 667, 675], ["obesity", "OBSERVATION", 684, 691]]], ["Disease severity in hospitalized patients is characterized by severe pneumonia associated with overt inflammatory reaction characterized by high C-reactive protein (CRP) and interleukin-6 (IL-6), low albumin, high sedimentation rate, low eosinophils, and lymphopenia.", [["eosinophils", "ANATOMY", 238, 249], ["pneumonia", "DISEASE", 69, 78], ["lymphopenia", "DISEASE", 255, 266], ["patients", "ORGANISM", 33, 41], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 145, 163], ["CRP", "GENE_OR_GENE_PRODUCT", 165, 168], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 174, 187], ["IL-6", "GENE_OR_GENE_PRODUCT", 189, 193], ["albumin", "GENE_OR_GENE_PRODUCT", 200, 207], ["eosinophils", "CELL", 238, 249], ["C-reactive protein", "PROTEIN", 145, 163], ["CRP", "PROTEIN", 165, 168], ["interleukin-6", "PROTEIN", 174, 187], ["IL", "PROTEIN", 189, 191], ["eosinophils", "CELL_TYPE", 238, 249], ["patients", "SPECIES", 33, 41], ["Disease severity", "PROBLEM", 0, 16], ["severe pneumonia", "PROBLEM", 62, 78], ["overt inflammatory reaction", "PROBLEM", 95, 122], ["high C-reactive protein", "PROBLEM", 140, 163], ["CRP", "TEST", 165, 168], ["interleukin", "TEST", 174, 185], ["IL", "TEST", 189, 191], ["low albumin", "PROBLEM", 196, 207], ["high sedimentation rate", "PROBLEM", 209, 232], ["low eosinophils", "PROBLEM", 234, 249], ["lymphopenia", "PROBLEM", 255, 266], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["pneumonia", "OBSERVATION", 69, 78], ["overt", "OBSERVATION_MODIFIER", 95, 100], ["inflammatory", "OBSERVATION", 101, 113], ["high", "OBSERVATION_MODIFIER", 140, 144], ["reactive", "OBSERVATION_MODIFIER", 147, 155], ["low albumin", "OBSERVATION_MODIFIER", 196, 207], ["high sedimentation", "OBSERVATION_MODIFIER", 209, 227], ["low eosinophils", "OBSERVATION", 234, 249], ["lymphopenia", "OBSERVATION", 255, 266]]], ["Hospitalized individuals also have increased lactate dehydrogenase (LDH), a marker of cellular death, often associated with altered coagulation [4, 5].", [["cellular", "ANATOMY", 86, 94], ["lactate", "CHEMICAL", 45, 52], ["death", "DISEASE", 95, 100], ["lactate", "CHEMICAL", 45, 52], ["individuals", "ORGANISM", 13, 24], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 45, 66], ["LDH", "GENE_OR_GENE_PRODUCT", 68, 71], ["cellular", "CELL", 86, 94], ["lactate dehydrogenase", "PROTEIN", 45, 66], ["LDH", "PROTEIN", 68, 71], ["increased lactate dehydrogenase (LDH)", "PROBLEM", 35, 72], ["cellular death", "PROBLEM", 86, 100], ["altered coagulation", "PROBLEM", 124, 143], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["lactate dehydrogenase", "OBSERVATION", 45, 66], ["cellular death", "OBSERVATION", 86, 100]]], ["High LDH, low lymphocyte count and high levels of high-sensitivity CRP predict mortality of individual patients more than 10 days in advance with greater than 90% accuracy [6].", [["lymphocyte", "ANATOMY", 14, 24], ["LDH", "GENE_OR_GENE_PRODUCT", 5, 8], ["lymphocyte", "CELL", 14, 24], ["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["patients", "ORGANISM", 103, 111], ["LDH", "PROTEIN", 5, 8], ["CRP", "PROTEIN", 67, 70], ["patients", "SPECIES", 103, 111], ["High LDH", "PROBLEM", 0, 8], ["low lymphocyte count", "PROBLEM", 10, 30], ["high levels", "PROBLEM", 35, 46], ["CRP", "TEST", 67, 70], ["LDH", "ANATOMY", 5, 8], ["low lymphocyte count", "OBSERVATION", 10, 30]]], ["Several meta-analyses also associated IL-6 levels with the severity of COVID-19 syndrome [7\u20139].BackgroundThus, an extraordinary proliferation of studies published over the last few months suggests that SARS-CoV-2 infection unleashes a powerful, and apparently uncontrolled inflammatory response that most likely adds to the tissue damage already caused by the viral infection toward the COVID-19 underlying pathology.", [["tissue", "ANATOMY", 324, 330], ["SARS", "DISEASE", 202, 206], ["infection", "DISEASE", 213, 222], ["tissue damage", "DISEASE", 324, 337], ["viral infection", "DISEASE", 360, 375], ["COVID-19", "CHEMICAL", 71, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 38, 42], ["SARS-CoV-2", "ORGANISM", 202, 212], ["tissue", "TISSUE", 324, 330], ["IL-6", "PROTEIN", 38, 42], ["SARS-CoV-2", "SPECIES", 202, 212], ["Several meta-analyses", "TEST", 0, 21], ["IL", "TEST", 38, 40], ["COVID", "TEST", 71, 76], ["syndrome", "PROBLEM", 80, 88], ["an extraordinary proliferation of studies", "PROBLEM", 111, 152], ["SARS", "PROBLEM", 202, 206], ["CoV", "PROBLEM", 207, 210], ["2 infection", "PROBLEM", 211, 222], ["uncontrolled inflammatory response", "PROBLEM", 260, 294], ["the tissue damage", "PROBLEM", 320, 337], ["the viral infection", "PROBLEM", 356, 375], ["the COVID", "TEST", 383, 392], ["underlying pathology", "PROBLEM", 396, 416], ["extraordinary", "OBSERVATION_MODIFIER", 114, 127], ["proliferation", "OBSERVATION", 128, 141], ["SARS", "OBSERVATION", 202, 206], ["uncontrolled", "OBSERVATION_MODIFIER", 260, 272], ["inflammatory", "OBSERVATION", 273, 285], ["tissue", "ANATOMY", 324, 330], ["damage", "OBSERVATION", 331, 337], ["viral", "OBSERVATION_MODIFIER", 360, 365], ["infection", "OBSERVATION", 366, 375]]], ["The high concentration of pro-inflammatory mediators, which has been named \u2018the cytokine storm,\u2019 damages the cardiac, hepatic, and renal systems leading to tumor necrosis factor (TNF)-mediated multi-organ system failure and/or death [10].", [["cardiac", "ANATOMY", 109, 116], ["hepatic", "ANATOMY", 118, 125], ["renal systems", "ANATOMY", 131, 144], ["multi-organ system", "ANATOMY", 193, 211], ["tumor", "DISEASE", 156, 161], ["necrosis", "DISEASE", 162, 170], ["multi-organ system failure", "DISEASE", 193, 219], ["death", "DISEASE", 227, 232], ["cardiac", "ORGAN", 109, 116], ["hepatic", "MULTI-TISSUE_STRUCTURE", 118, 125], ["renal", "ORGAN", 131, 136], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 156, 177], ["TNF", "GENE_OR_GENE_PRODUCT", 179, 182], ["pro-inflammatory mediators", "PROTEIN", 26, 52], ["cytokine", "PROTEIN", 80, 88], ["tumor necrosis factor", "PROTEIN", 156, 177], ["TNF", "PROTEIN", 179, 182], ["the cardiac, hepatic, and renal systems", "PROBLEM", 105, 144], ["tumor necrosis factor", "PROBLEM", 156, 177], ["multi-organ system failure", "PROBLEM", 193, 219], ["death", "PROBLEM", 227, 232], ["high concentration", "OBSERVATION_MODIFIER", 4, 22], ["pro-inflammatory mediators", "OBSERVATION", 26, 52], ["cardiac", "ANATOMY", 109, 116], ["hepatic", "ANATOMY", 118, 125], ["renal", "ANATOMY", 131, 136], ["tumor", "OBSERVATION_MODIFIER", 156, 161], ["necrosis", "OBSERVATION", 162, 170], ["multi-organ system", "ANATOMY", 193, 211], ["failure", "OBSERVATION", 212, 219]]], ["SARS-CoV-2 mostly affects levels of pro-inflammatory cytokines/chemokines typical of T helper 1 (TH1) cell response such as IL-6, IFN\u03b3, IP-10, and MCP1 [11, 12], that attract monocytes and T cells to the infected site [13, 14], which probably contributes to the lymphopenia and increased neutrophil\u2013lymphocyte ratio seen in ~ 80% of patients [15, 16].", [["T helper 1 (TH1) cell", "ANATOMY", 85, 106], ["monocytes", "ANATOMY", 175, 184], ["T cells", "ANATOMY", 189, 196], ["site", "ANATOMY", 213, 217], ["neutrophil\u2013lymphocyte", "ANATOMY", 288, 309], ["SARS", "DISEASE", 0, 4], ["lymphopenia", "DISEASE", 262, 273], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["T helper 1", "GENE_OR_GENE_PRODUCT", 85, 95], ["TH1", "GENE_OR_GENE_PRODUCT", 97, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 124, 128], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 130, 134], ["IP-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["MCP1", "GENE_OR_GENE_PRODUCT", 147, 151], ["monocytes", "CELL", 175, 184], ["T cells", "CELL", 189, 196], ["neutrophil\u2013lymphocyte", "CELL", 288, 309], ["patients", "ORGANISM", 333, 341], ["pro-inflammatory cytokines", "PROTEIN", 36, 62], ["chemokines", "PROTEIN", 63, 73], ["IL-6", "PROTEIN", 124, 128], ["IFN\u03b3", "PROTEIN", 130, 134], ["MCP1", "PROTEIN", 147, 151], ["monocytes", "CELL_TYPE", 175, 184], ["T cells", "CELL_TYPE", 189, 196], ["patients", "SPECIES", 333, 341], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["pro-inflammatory cytokines", "TEST", 36, 62], ["cell response", "TEST", 102, 115], ["IL", "TEST", 124, 126], ["IP", "TEST", 136, 138], ["MCP1", "TEST", 147, 151], ["the lymphopenia", "PROBLEM", 258, 273], ["increased neutrophil\u2013lymphocyte ratio", "PROBLEM", 278, 315], ["attract monocytes", "ANATOMY", 167, 184], ["infected", "OBSERVATION_MODIFIER", 204, 212], ["probably contributes to", "UNCERTAINTY", 234, 257], ["lymphopenia", "OBSERVATION", 262, 273], ["increased", "OBSERVATION_MODIFIER", 278, 287], ["neutrophil\u2013lymphocyte ratio", "OBSERVATION", 288, 315]]], ["Noteworthy, while severe COVID-19 affects disproportionally older people, systemic inflammation from SARS-CoV-2 is detected in patients of all age groups, including a severe multisystem inflammatory syndrome with features of Kawasaki disease recently identified in children [17, 18].COVID-19 and inflammagingInflammation is a physiological response essential to oppose infections and contribute to tissue repair.", [["tissue", "ANATOMY", 398, 404], ["inflammation", "DISEASE", 83, 95], ["SARS", "DISEASE", 101, 105], ["multisystem inflammatory syndrome", "DISEASE", 174, 207], ["Kawasaki disease", "DISEASE", 225, 241], ["Inflammation", "DISEASE", 308, 320], ["infections", "DISEASE", 369, 379], ["people", "ORGANISM", 66, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 101, 111], ["patients", "ORGANISM", 127, 135], ["children", "ORGANISM", 265, 273], ["tissue", "TISSUE", 398, 404], ["people", "SPECIES", 66, 72], ["patients", "SPECIES", 127, 135], ["children", "SPECIES", 265, 273], ["SARS-CoV", "SPECIES", 101, 109], ["severe COVID", "PROBLEM", 18, 30], ["systemic inflammation", "PROBLEM", 74, 95], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["a severe multisystem inflammatory syndrome", "PROBLEM", 165, 207], ["Kawasaki disease", "PROBLEM", 225, 241], ["COVID", "TEST", 283, 288], ["inflammagingInflammation", "PROBLEM", 296, 320], ["oppose infections", "PROBLEM", 362, 379], ["tissue repair", "TREATMENT", 398, 411], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["inflammation", "OBSERVATION", 83, 95], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["multisystem", "OBSERVATION_MODIFIER", 174, 185], ["inflammatory syndrome", "OBSERVATION", 186, 207], ["Kawasaki disease", "OBSERVATION", 225, 241], ["Inflammation", "OBSERVATION", 308, 320], ["infections", "OBSERVATION", 369, 379], ["tissue", "ANATOMY", 398, 404], ["repair", "OBSERVATION", 405, 411]]], ["Systemic, sustained chronic inflammation due to persistent tissue damage, environmental stressors, unhealthy lifestyle, and social and psychological stress is associated with the risk of developing many chronic diseases (Fig. 1) including metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease (CVD), sarcopenia, osteoporosis, immunosenescence, autoimmune disorders, cancer, chronic kidney disease, neurodegenerative disorders, depression, and possibly accelerated cognitive decline and dementia [19].", [["tissue", "ANATOMY", 59, 65], ["non-alcoholic fatty liver", "ANATOMY", 276, 301], ["cardiovascular", "ANATOMY", 311, 325], ["cancer", "ANATOMY", 407, 413], ["kidney", "ANATOMY", 423, 429], ["inflammation", "DISEASE", 28, 40], ["tissue damage", "DISEASE", 59, 72], ["chronic diseases", "DISEASE", 203, 219], ["metabolic syndrome", "DISEASE", 239, 257], ["type 2 diabetes", "DISEASE", 259, 274], ["non-alcoholic fatty liver disease", "DISEASE", 276, 309], ["cardiovascular disease", "DISEASE", 311, 333], ["CVD", "DISEASE", 335, 338], ["sarcopenia", "DISEASE", 341, 351], ["osteoporosis", "DISEASE", 353, 365], ["immunosenescence", "DISEASE", 367, 383], ["autoimmune disorders", "DISEASE", 385, 405], ["cancer", "DISEASE", 407, 413], ["chronic kidney disease", "DISEASE", 415, 437], ["neurodegenerative disorders", "DISEASE", 439, 466], ["depression", "DISEASE", 468, 478], ["cognitive decline", "DISEASE", 505, 522], ["dementia", "DISEASE", 527, 535], ["tissue", "TISSUE", 59, 65], ["liver", "ORGAN", 296, 301], ["cardiovascular", "ANATOMICAL_SYSTEM", 311, 325], ["cancer", "CANCER", 407, 413], ["kidney", "ORGAN", 423, 429], ["sustained chronic inflammation", "PROBLEM", 10, 40], ["persistent tissue damage", "PROBLEM", 48, 72], ["psychological stress", "PROBLEM", 135, 155], ["many chronic diseases", "PROBLEM", 198, 219], ["metabolic syndrome", "PROBLEM", 239, 257], ["type 2 diabetes", "PROBLEM", 259, 274], ["non-alcoholic fatty liver disease", "PROBLEM", 276, 309], ["cardiovascular disease (CVD)", "PROBLEM", 311, 339], ["sarcopenia", "PROBLEM", 341, 351], ["osteoporosis", "PROBLEM", 353, 365], ["immunosenescence", "PROBLEM", 367, 383], ["autoimmune disorders", "PROBLEM", 385, 405], ["cancer", "PROBLEM", 407, 413], ["chronic kidney disease", "PROBLEM", 415, 437], ["neurodegenerative disorders", "PROBLEM", 439, 466], ["depression", "PROBLEM", 468, 478], ["accelerated cognitive decline", "PROBLEM", 493, 522], ["dementia", "PROBLEM", 527, 535], ["sustained", "OBSERVATION_MODIFIER", 10, 19], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["inflammation", "OBSERVATION", 28, 40], ["persistent tissue", "OBSERVATION_MODIFIER", 48, 65], ["damage", "OBSERVATION", 66, 72], ["many", "OBSERVATION_MODIFIER", 198, 202], ["chronic", "OBSERVATION_MODIFIER", 203, 210], ["diseases", "OBSERVATION", 211, 219], ["metabolic syndrome", "OBSERVATION", 239, 257], ["diabetes", "OBSERVATION", 266, 274], ["non-alcoholic", "OBSERVATION_MODIFIER", 276, 289], ["fatty liver disease", "OBSERVATION", 290, 309], ["cardiovascular", "ANATOMY", 311, 325], ["disease", "OBSERVATION", 326, 333], ["sarcopenia", "OBSERVATION", 341, 351], ["osteoporosis", "OBSERVATION", 353, 365], ["autoimmune disorders", "OBSERVATION", 385, 405], ["cancer", "OBSERVATION", 407, 413], ["chronic", "OBSERVATION_MODIFIER", 415, 422], ["kidney", "ANATOMY", 423, 429], ["disease", "OBSERVATION", 430, 437], ["neurodegenerative", "OBSERVATION_MODIFIER", 439, 456], ["disorders", "OBSERVATION", 457, 466], ["depression", "OBSERVATION", 468, 478], ["possibly", "UNCERTAINTY", 484, 492], ["accelerated", "OBSERVATION_MODIFIER", 493, 504], ["cognitive decline", "OBSERVATION", 505, 522]]], ["The mechanisms by which cellular damage and dysfunction cause ailments such as atherosclerosis, chronic ischemia, central obesity or degenerative diseases have been described and are relatively clear.", [["cellular", "ANATOMY", 24, 32], ["cellular damage", "DISEASE", 24, 39], ["atherosclerosis", "DISEASE", 79, 94], ["chronic ischemia", "DISEASE", 96, 112], ["obesity", "DISEASE", 122, 129], ["degenerative diseases", "DISEASE", 133, 154], ["cellular", "CELL", 24, 32], ["cellular damage", "PROBLEM", 24, 39], ["dysfunction cause ailments", "PROBLEM", 44, 70], ["atherosclerosis", "PROBLEM", 79, 94], ["chronic ischemia", "PROBLEM", 96, 112], ["central obesity", "PROBLEM", 114, 129], ["degenerative diseases", "PROBLEM", 133, 154], ["cellular damage", "OBSERVATION", 24, 39], ["atherosclerosis", "OBSERVATION", 79, 94], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["ischemia", "OBSERVATION", 104, 112], ["central", "OBSERVATION_MODIFIER", 114, 121], ["obesity", "OBSERVATION", 122, 129], ["degenerative", "OBSERVATION_MODIFIER", 133, 145], ["diseases", "OBSERVATION", 146, 154], ["relatively", "OBSERVATION_MODIFIER", 183, 193], ["clear", "OBSERVATION", 194, 199]]], ["However, in older individuals these \u201cdirect\u201d mechanisms only explain a relatively small portion of the pro-inflammatory state that is observed progressively more frequently as people age.", [["people", "ORGANISM", 176, 182], ["people", "SPECIES", 176, 182], ["small", "OBSERVATION_MODIFIER", 82, 87], ["pro-inflammatory state", "OBSERVATION", 103, 125]]], ["Other conditions associated with a chronic inflammatory response are more \u201ccomplex\u201d and still not well understood.", [["a chronic inflammatory response", "PROBLEM", 33, 64], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["inflammatory", "OBSERVATION", 43, 55]]], ["Mechanisms include isolation, mental health problems, chronic stress, disturbed sleep, poor diet, dysbiosis, obesity, physical inactivity, and xenobiotics [19].", [["dysbiosis", "DISEASE", 98, 107], ["obesity", "DISEASE", 109, 116], ["physical inactivity", "DISEASE", 118, 137], ["mental health problems", "PROBLEM", 30, 52], ["chronic stress", "PROBLEM", 54, 68], ["disturbed sleep", "PROBLEM", 70, 85], ["dysbiosis", "PROBLEM", 98, 107], ["obesity", "PROBLEM", 109, 116], ["physical inactivity", "PROBLEM", 118, 137], ["obesity", "OBSERVATION", 109, 116]]], ["One of the stress-response mechanisms recently implicated in the pathogenesis of sustained chronic inflammation is the accumulation of cellular senescence.", [["cellular", "ANATOMY", 135, 143], ["inflammation", "DISEASE", 99, 111], ["cellular", "CELL", 135, 143], ["sustained chronic inflammation", "PROBLEM", 81, 111], ["cellular senescence", "PROBLEM", 135, 154], ["sustained", "OBSERVATION_MODIFIER", 81, 90], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["inflammation", "OBSERVATION", 99, 111], ["accumulation", "OBSERVATION_MODIFIER", 119, 131], ["cellular senescence", "OBSERVATION", 135, 154]]], ["Cells become senescent in response to many stresses, including genomic instability, oxidative stress, energetic crisis, metabolic derangement, altered proteostasis, and many others.", [["Cells", "ANATOMY", 0, 5], ["genomic instability", "DISEASE", 63, 82], ["metabolic derangement", "DISEASE", 120, 141], ["Cells", "CELL", 0, 5], ["senescent", "PROBLEM", 13, 22], ["many stresses", "PROBLEM", 38, 51], ["genomic instability", "PROBLEM", 63, 82], ["oxidative stress", "PROBLEM", 84, 100], ["energetic crisis", "PROBLEM", 102, 118], ["metabolic derangement", "PROBLEM", 120, 141], ["altered proteostasis", "PROBLEM", 143, 163], ["genomic instability", "OBSERVATION", 63, 82], ["energetic crisis", "OBSERVATION", 102, 118], ["metabolic derangement", "OBSERVATION", 120, 141], ["altered", "OBSERVATION_MODIFIER", 143, 150], ["proteostasis", "OBSERVATION", 151, 163]]], ["The hallmarks of cellular senescence are an irreversible arrest in cell proliferative capacity, resistance to apoptosis and the massive secretion of senescence-associated secretory phenotype (SASP) molecules that include cytokines, chemokines and chemokines among other molecular species.", [["cellular", "ANATOMY", 17, 25], ["cell", "ANATOMY", 67, 71], ["cellular", "CELL", 17, 25], ["cell", "CELL", 67, 71], ["senescence-associated secretory phenotype (SASP) molecules", "PROTEIN", 149, 207], ["cytokines", "PROTEIN", 221, 230], ["chemokines", "PROTEIN", 232, 242], ["chemokines", "PROTEIN", 247, 257], ["cellular senescence", "PROBLEM", 17, 36], ["an irreversible arrest in cell proliferative capacity", "PROBLEM", 41, 94], ["apoptosis", "PROBLEM", 110, 119], ["the massive secretion of senescence", "PROBLEM", 124, 159], ["secretory phenotype (SASP) molecules", "PROBLEM", 171, 207], ["cytokines", "TREATMENT", 221, 230], ["chemokines", "TREATMENT", 232, 242], ["chemokines", "TREATMENT", 247, 257], ["other molecular species", "PROBLEM", 264, 287], ["cellular senescence", "OBSERVATION", 17, 36], ["irreversible", "OBSERVATION_MODIFIER", 44, 56], ["arrest", "OBSERVATION", 57, 63], ["cell proliferative capacity", "OBSERVATION", 67, 94], ["apoptosis", "OBSERVATION_MODIFIER", 110, 119], ["massive", "OBSERVATION_MODIFIER", 128, 135], ["secretion", "OBSERVATION_MODIFIER", 136, 145], ["secretory phenotype", "OBSERVATION", 171, 190], ["molecular species", "OBSERVATION", 270, 287]]], ["Research in animal models and some initial data in humans suggest the hypothesis that the typical pro-inflammatory state of aging is in large part sustained by the accumulation of senescent cells and the spilling in the blood of SASP pro-inflammatory factors.", [["cells", "ANATOMY", 190, 195], ["blood", "ANATOMY", 220, 225], ["humans", "ORGANISM", 51, 57], ["cells", "CELL", 190, 195], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["SASP pro-inflammatory factors", "GENE_OR_GENE_PRODUCT", 229, 258], ["senescent cells", "CELL_TYPE", 180, 195], ["SASP pro-inflammatory factors", "PROTEIN", 229, 258], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57], ["senescent cells", "PROBLEM", 180, 195], ["the spilling", "PROBLEM", 200, 212], ["SASP pro-inflammatory factors", "PROBLEM", 229, 258], ["pro-inflammatory", "OBSERVATION_MODIFIER", 98, 114], ["large", "OBSERVATION_MODIFIER", 136, 141], ["accumulation of", "OBSERVATION", 164, 179], ["senescent cells", "OBSERVATION", 180, 195], ["spilling", "OBSERVATION_MODIFIER", 204, 212], ["SASP pro-inflammatory factors", "OBSERVATION", 229, 258]]], ["This hypothesis may explain why chronic inflammation has been associated with many age-related chronic conditions such as insulin resistance, CVD, osteoarthritis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary arterial hypertension, Alzheimer\u2019s, Parkinson\u2019s, and macular degeneration, which are all characterized by the accumulation of senescent cells [19\u201323].", [["pulmonary", "ANATOMY", 183, 192], ["pulmonary arterial", "ANATOMY", 220, 238], ["macular", "ANATOMY", 283, 290], ["cells", "ANATOMY", 366, 371], ["inflammation", "DISEASE", 40, 52], ["CVD", "DISEASE", 142, 145], ["osteoarthritis", "DISEASE", 147, 161], ["chronic obstructive pulmonary disease", "DISEASE", 163, 200], ["COPD", "DISEASE", 202, 206], ["emphysema", "DISEASE", 209, 218], ["pulmonary arterial hypertension", "DISEASE", 220, 251], ["Alzheimer\u2019s, Parkinson\u2019s, and macular degeneration", "DISEASE", 253, 303], ["insulin", "GENE_OR_GENE_PRODUCT", 122, 129], ["pulmonary", "ORGAN", 183, 192], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 220, 238], ["macular", "TISSUE", 283, 290], ["cells", "CELL", 366, 371], ["senescent cells", "CELL_TYPE", 356, 371], ["chronic inflammation", "PROBLEM", 32, 52], ["chronic conditions", "PROBLEM", 95, 113], ["insulin resistance", "PROBLEM", 122, 140], ["CVD", "PROBLEM", 142, 145], ["osteoarthritis", "PROBLEM", 147, 161], ["chronic obstructive pulmonary disease", "PROBLEM", 163, 200], ["COPD)", "PROBLEM", 202, 207], ["emphysema", "PROBLEM", 209, 218], ["pulmonary arterial hypertension", "PROBLEM", 220, 251], ["Alzheimer\u2019s", "PROBLEM", 253, 264], ["Parkinson\u2019s", "PROBLEM", 266, 277], ["macular degeneration", "PROBLEM", 283, 303], ["senescent cells", "PROBLEM", 356, 371], ["may explain why", "UNCERTAINTY", 16, 31], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["inflammation", "OBSERVATION", 40, 52], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["conditions", "OBSERVATION", 103, 113], ["insulin resistance", "OBSERVATION", 122, 140], ["osteoarthritis", "OBSERVATION", 147, 161], ["chronic", "OBSERVATION_MODIFIER", 163, 170], ["obstructive", "OBSERVATION_MODIFIER", 171, 182], ["pulmonary", "ANATOMY", 183, 192], ["disease", "OBSERVATION", 193, 200], ["COPD", "OBSERVATION", 202, 206], ["emphysema", "OBSERVATION", 209, 218], ["pulmonary arterial", "ANATOMY", 220, 238], ["hypertension", "OBSERVATION", 239, 251], ["Alzheimer", "OBSERVATION", 253, 262], ["Parkinson\u2019s", "OBSERVATION", 266, 277], ["macular degeneration", "OBSERVATION", 283, 303], ["accumulation", "OBSERVATION_MODIFIER", 340, 352], ["senescent cells", "OBSERVATION", 356, 371]]], ["Importantly, there is strong evidence from model organisms, and more recently from human studies, that dysfunction in many of the mechanisms of aging biology, the so-called hallmarks of aging, all converge into a pro-inflammatory response.", [["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["model organisms", "PROBLEM", 43, 58], ["human studies", "TEST", 83, 96], ["dysfunction", "PROBLEM", 103, 114], ["strong evidence from", "UNCERTAINTY", 22, 42], ["model", "OBSERVATION_MODIFIER", 43, 48], ["organisms", "OBSERVATION", 49, 58]]], ["Relevant for the discussion here, exogenous compounds such as bacteria or viral fragments including elements of microbiota (pathogen-associated molecular patterns, or PAMPs) or endogenously produced chemical compounds that structurally mimic exogenous compounds, such as uric acid crystals or mitochondrial fragments (damage-associated molecular patterns or DAMPs) interact with sensors, referred to as pattern recognition receptors (PPRs), expressed on the cell surface and in the cytoplasm (e.g. Toll-like receptor, NOD-like receptor, cyclic GMP-AMP synthase, aryl hydrocarbon receptor) to trigger inflammatory responses (e.g. IL-1\u03b2, IL-18, NF-\u03baB activation, pro-inflammatory cytokine secretion [e.g. TNF, IL-1, IL-6, and IL-8], and type 1 interferon) that contribute to the state of chronic subclinical systemic inflammation seen in aging (termed inflammaging) [24].", [["mitochondrial fragments", "ANATOMY", 293, 316], ["cell surface", "ANATOMY", 458, 470], ["cytoplasm", "ANATOMY", 482, 491], ["uric acid", "CHEMICAL", 271, 280], ["GMP", "CHEMICAL", 544, 547], ["AMP", "CHEMICAL", 548, 551], ["inflammation", "DISEASE", 815, 827], ["uric acid", "CHEMICAL", 271, 280], ["cyclic GMP-AMP", "CHEMICAL", 537, 551], ["aryl hydrocarbon", "CHEMICAL", 562, 578], ["PAMPs", "GENE_OR_GENE_PRODUCT", 167, 172], ["uric acid", "SIMPLE_CHEMICAL", 271, 280], ["mitochondrial", "CELLULAR_COMPONENT", 293, 306], ["DAMPs", "GENE_OR_GENE_PRODUCT", 358, 363], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 403, 432], ["PPRs", "GENE_OR_GENE_PRODUCT", 434, 438], ["cell surface", "CELLULAR_COMPONENT", 458, 470], ["cytoplasm", "ORGANISM_SUBSTANCE", 482, 491], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 498, 516], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 518, 535], ["cyclic GMP-AMP synthase", "GENE_OR_GENE_PRODUCT", 537, 560], ["aryl hydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 562, 587], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 629, 634], ["IL-18", "GENE_OR_GENE_PRODUCT", 636, 641], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 643, 648], ["TNF", "GENE_OR_GENE_PRODUCT", 703, 706], ["IL-1", "GENE_OR_GENE_PRODUCT", 708, 712], ["IL-6", "GENE_OR_GENE_PRODUCT", 714, 718], ["IL-8", "GENE_OR_GENE_PRODUCT", 724, 728], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 735, 752], ["PAMPs", "PROTEIN", 167, 172], ["mitochondrial fragments", "PROTEIN", 293, 316], ["DAMPs", "PROTEIN", 358, 363], ["pattern recognition receptors", "PROTEIN", 403, 432], ["PPRs", "PROTEIN", 434, 438], ["Toll-like receptor", "PROTEIN", 498, 516], ["NOD-like receptor", "PROTEIN", 518, 535], ["cyclic GMP-AMP synthase", "PROTEIN", 537, 560], ["aryl hydrocarbon receptor", "PROTEIN", 562, 587], ["NF-\u03baB", "PROTEIN", 643, 648], ["pro-inflammatory cytokine", "PROTEIN", 661, 686], ["TNF", "PROTEIN", 703, 706], ["IL-8", "PROTEIN", 724, 728], ["type 1 interferon", "PROTEIN", 735, 752], ["exogenous compounds", "PROBLEM", 34, 53], ["bacteria", "PROBLEM", 62, 70], ["viral fragments", "PROBLEM", 74, 89], ["microbiota (pathogen", "PROBLEM", 112, 132], ["PAMPs", "PROBLEM", 167, 172], ["endogenously produced chemical compounds", "PROBLEM", 177, 217], ["structurally mimic exogenous compounds", "PROBLEM", 223, 261], ["uric acid crystals", "PROBLEM", 271, 289], ["mitochondrial fragments", "PROBLEM", 293, 316], ["cyclic GMP", "TREATMENT", 537, 547], ["AMP synthase", "TREATMENT", 548, 560], ["aryl hydrocarbon receptor", "TREATMENT", 562, 587], ["inflammatory responses", "PROBLEM", 600, 622], ["IL", "TEST", 629, 631], ["IL", "TEST", 636, 638], ["NF", "TEST", 643, 645], ["pro-inflammatory cytokine secretion", "TEST", 661, 696], ["TNF", "TEST", 703, 706], ["IL", "TEST", 708, 710], ["IL", "TEST", 714, 716], ["IL", "TEST", 724, 726], ["type 1 interferon", "TREATMENT", 735, 752], ["chronic subclinical systemic inflammation", "PROBLEM", 786, 827], ["viral fragments", "OBSERVATION", 74, 89], ["exogenous compounds", "OBSERVATION", 242, 261], ["mitochondrial fragments", "OBSERVATION", 293, 316], ["chronic", "OBSERVATION_MODIFIER", 786, 793], ["subclinical", "OBSERVATION_MODIFIER", 794, 805], ["systemic", "OBSERVATION_MODIFIER", 806, 814], ["inflammation", "OBSERVATION", 815, 827]]], ["Indeed, inflammaging, which results in an increased incidence and worsening of age-related conditions [25\u201327], is characterized clinically by higher levels of several inflammatory blood biomarkers, including CRP, IL-6, IL-18, and TNF [28].", [["blood", "ANATOMY", 180, 185], ["inflammaging", "DISEASE", 8, 20], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["CRP", "GENE_OR_GENE_PRODUCT", 208, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 213, 217], ["IL-18", "GENE_OR_GENE_PRODUCT", 219, 224], ["TNF", "GENE_OR_GENE_PRODUCT", 230, 233], ["CRP", "PROTEIN", 208, 211], ["IL", "PROTEIN", 219, 221], ["TNF", "PROTEIN", 230, 233], ["an increased incidence", "PROBLEM", 39, 61], ["age-related conditions", "PROBLEM", 79, 101], ["several inflammatory blood biomarkers", "TEST", 159, 196], ["CRP", "TEST", 208, 211], ["IL", "TEST", 213, 215], ["IL", "TEST", 219, 221], ["TNF", "TEST", 230, 233], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["incidence", "OBSERVATION_MODIFIER", 52, 61], ["worsening", "OBSERVATION_MODIFIER", 66, 75], ["several", "OBSERVATION_MODIFIER", 159, 166], ["inflammatory", "OBSERVATION", 167, 179]]], ["IL-6 serum levels also predict incident disability and frailty [29], with high IL-6 scores being related to lower walking speeds [30], and the risk of developing mobility disability increasing linearly for IL-6 levels higher than 2.5 pg/ml [31].", [["serum", "ANATOMY", 5, 10], ["disability", "DISEASE", 40, 50], ["frailty", "DISEASE", 55, 62], ["mobility disability", "DISEASE", 162, 181], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 206, 210], ["IL-6", "PROTEIN", 0, 4], ["IL", "PROTEIN", 79, 81], ["IL", "PROTEIN", 206, 208], ["IL", "TEST", 0, 2], ["serum levels", "TEST", 5, 17], ["frailty", "TEST", 55, 62], ["high IL", "PROBLEM", 74, 81], ["developing mobility disability", "PROBLEM", 151, 181], ["IL", "TEST", 206, 208], ["mobility", "OBSERVATION", 162, 170]]]], "20f1d4a18b2f757fe76adc91cfb61d07d444fabb": [["Apoptosis is initiated in a receptor-mediated manner through the extrinsic pathway, or through altered mitochondrial permeability via the intrinsic pathway.", [["mitochondrial", "ANATOMY", 103, 116], ["mitochondrial", "CELLULAR_COMPONENT", 103, 116], ["Apoptosis", "PROBLEM", 0, 9], ["the extrinsic pathway", "TEST", 61, 82], ["altered mitochondrial permeability", "PROBLEM", 95, 129], ["mitochondrial permeability", "OBSERVATION", 103, 129]]], ["Activation of either results in the assembly of macromolecular complexes that lead to initiator caspase activation, and, in turn, to the activation of effector caspases such as caspase-3.", [["caspase", "GENE_OR_GENE_PRODUCT", 96, 103], ["caspases", "GENE_OR_GENE_PRODUCT", 160, 168], ["caspase-3", "GENE_OR_GENE_PRODUCT", 177, 186], ["macromolecular complexes", "PROTEIN", 48, 72], ["caspase", "PROTEIN", 96, 103], ["effector caspases", "PROTEIN", 151, 168], ["caspase-3", "PROTEIN", 177, 186], ["macromolecular complexes", "PROBLEM", 48, 72], ["initiator caspase activation", "TREATMENT", 86, 114], ["effector caspases", "TREATMENT", 151, 168], ["caspase", "TREATMENT", 177, 184]]], ["This process can be inhibited by intracellular inhibitor of apoptosis proteins, and the action of these, in turn, can be blocked by proteins such as Smac/DIABLO.", [["intracellular", "ANATOMY", 33, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["Smac", "GENE_OR_GENE_PRODUCT", 149, 153], ["DIABLO", "GENE_OR_GENE_PRODUCT", 154, 160], ["apoptosis proteins", "PROTEIN", 60, 78], ["Smac", "PROTEIN", 149, 153], ["DIABLO", "PROTEIN", 154, 160], ["apoptosis proteins", "PROBLEM", 60, 78], ["Smac/DIABLO", "TREATMENT", 149, 160]]]], "PMC7019278": [], "ca131fc20061badfba15710f705222291325920c": [["IntroductionCoronavirus HKU1 is a newly identified human coronavirus.", [["Coronavirus", "ORGANISM", 12, 23], ["HKU1", "GENE_OR_GENE_PRODUCT", 24, 28], ["human", "ORGANISM", 51, 56], ["coronavirus", "ORGANISM", 57, 68], ["Coronavirus HKU1", "PROTEIN", 12, 28], ["human", "SPECIES", 51, 56], ["coronavirus", "SPECIES", 57, 68], ["human coronavirus", "SPECIES", 51, 68], ["a newly identified human coronavirus", "PROBLEM", 32, 68]]], ["7, 20 It has a global distribution and was first reported in Hong Kong, USA, Australia and Europe.", [["global", "OBSERVATION_MODIFIER", 15, 21], ["distribution", "OBSERVATION_MODIFIER", 22, 34]]], ["4, 13, 21, 23, 38 The reported incidences varied from 0 to 4.4% of patients hospitalized for acute pulmonary and extrapulmonary symptoms.", [["pulmonary", "ANATOMY", 99, 108], ["extrapulmonary", "ANATOMY", 113, 127], ["acute pulmonary and extrapulmonary symptoms", "DISEASE", 93, 136], ["patients", "ORGANISM", 67, 75], ["pulmonary", "ORGAN", 99, 108], ["patients", "SPECIES", 67, 75], ["acute pulmonary and extrapulmonary symptoms", "PROBLEM", 93, 136], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["pulmonary", "ANATOMY", 99, 108], ["extrapulmonary", "ANATOMY", 113, 127], ["symptoms", "OBSERVATION", 128, 136]]], ["Laboratory detection is mostly achieved by RT-PCR.", [["Laboratory detection", "TEST", 0, 20], ["RT", "TEST", 43, 45], ["PCR", "TEST", 46, 49]]], ["5, 6, 29 Because the nucleocapsid protein is highly conserved, this has been successfully cloned and used to detect antibody response by enzyme immunoassay (EIA) and Western blot analysis of sera from infected human.", [["sera", "ANATOMY", 191, 195], ["sera", "ORGANISM_SUBSTANCE", 191, 195], ["human", "ORGANISM", 210, 215], ["nucleocapsid protein", "PROTEIN", 21, 41], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["the nucleocapsid protein", "TEST", 17, 41], ["antibody response", "TEST", 116, 133], ["enzyme immunoassay", "TEST", 137, 155], ["EIA", "TEST", 157, 160], ["Western blot analysis", "TEST", 166, 187], ["sera from infected human", "PROBLEM", 191, 215]]], ["35, 40 Ideal antibody test for a viral infection is the presence of neutralizing antibody.IntroductionNeutralizing antibodies were shown to be the long lasting protective immune responses to many viral infections including coronavirus.", [["viral infection", "DISEASE", 33, 48], ["viral infections", "DISEASE", 196, 212], ["coronavirus", "DISEASE", 223, 234], ["coronavirus", "ORGANISM", 223, 234], ["neutralizing antibody", "PROTEIN", 68, 89], ["Neutralizing antibodies", "PROTEIN", 102, 125], ["Ideal antibody test", "TEST", 7, 26], ["a viral infection", "PROBLEM", 31, 48], ["neutralizing antibody", "PROBLEM", 68, 89], ["IntroductionNeutralizing antibodies", "TREATMENT", 90, 125], ["many viral infections", "PROBLEM", 191, 212], ["coronavirus", "PROBLEM", 223, 234], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["infection", "OBSERVATION", 39, 48], ["neutralizing antibody", "OBSERVATION", 68, 89], ["viral infections", "OBSERVATION", 196, 212]]], ["1, 2, 8, 28, 33, 39, 42 The utility of assay based on neutralizing antibodies response against pseudotyped human coronaviruses had been successfully reported.", [["pseudotyped", "ORGANISM", 95, 106], ["human", "ORGANISM", 107, 112], ["coronaviruses", "ORGANISM", 113, 126], ["neutralizing antibodies", "PROTEIN", 54, 77], ["pseudotyped", "SPECIES", 95, 106], ["human", "SPECIES", 107, 112], ["human coronaviruses", "SPECIES", 107, 126], ["assay", "TEST", 39, 44], ["neutralizing antibodies", "TEST", 54, 77], ["pseudotyped human coronaviruses", "PROBLEM", 95, 126]]], ["12, 16, 28, 35 As HCoV-HKU1 had not been successfully propagated in culture, it was not possible to determine and measure the neutralizing antibody response to the virus.", [["HCoV", "GENE_OR_GENE_PRODUCT", 18, 22], ["HKU1", "GENE_OR_GENE_PRODUCT", 23, 27], ["HCoV", "PROTEIN", 18, 22], ["HKU1", "PROTEIN", 23, 27], ["HCoV", "TEST", 18, 22], ["culture", "TEST", 68, 75], ["the neutralizing antibody response", "PROBLEM", 122, 156], ["the virus", "PROBLEM", 160, 169]]], ["This is the first report that examined the seroepidemiology of HCoV-HKU1 by making use of HCoV-HKU1 pseudotyped virus to confirm the presence of neutralizing antibodies from serologically positive serum for evaluation of the prevalence of HCoV-HKU1 as a cause of respiratory tract infection in various age groups in our local population.IntroductionWe analyzed 297 serum samples assayed concurrently with the HKU1 recombinant protein nucleocapsid and spike based ELISA.", [["serum", "ANATOMY", 197, 202], ["respiratory tract", "ANATOMY", 263, 280], ["serum samples", "ANATOMY", 365, 378], ["respiratory tract infection", "DISEASE", 263, 290], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 63, 72], ["HCoV-HKU1 pseudotyped virus", "ORGANISM", 90, 117], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["HCoV", "GENE_OR_GENE_PRODUCT", 239, 243], ["HKU1", "GENE_OR_GENE_PRODUCT", 244, 248], ["respiratory tract", "ORGANISM_SUBDIVISION", 263, 280], ["serum samples", "ORGANISM_SUBSTANCE", 365, 378], ["HKU1", "DNA", 68, 72], ["neutralizing antibodies", "PROTEIN", 145, 168], ["HKU1 recombinant protein nucleocapsid", "PROTEIN", 409, 446], ["HCoV", "SPECIES", 63, 67], ["HCoV-HKU1 pseudotyped virus", "SPECIES", 90, 117], ["HCoV", "SPECIES", 239, 243], ["HCoV", "TEST", 90, 94], ["HKU1 pseudotyped virus", "PROBLEM", 95, 117], ["neutralizing antibodies", "PROBLEM", 145, 168], ["serologically positive serum", "PROBLEM", 174, 202], ["evaluation", "TEST", 207, 217], ["HCoV", "PROBLEM", 239, 243], ["HKU1", "PROBLEM", 244, 248], ["respiratory tract infection", "PROBLEM", 263, 290], ["serum samples", "TEST", 365, 378], ["the HKU1 recombinant protein nucleocapsid", "PROBLEM", 405, 446], ["spike based ELISA", "PROBLEM", 451, 468], ["respiratory tract", "ANATOMY", 263, 280], ["infection", "OBSERVATION", 281, 290]]], ["After establishment of the baseline value by confirmation with Western blot, immunofluorescent microscopy, flow cytometry and the presence of neutralization antibodies to HCoV-HKU1 pseudotyped virus, we screened another 709 serum samples in various age groups and found that >10% of the studied population from age 21 to 70 has been associated with HCoV-HKU1 infection which implicated that this recently identified virus has already been endemic in our community.Expression and purification of nucleocapsid (N) antigens and HCoV-HKU1 spike (S)Recombinant 6xHis tagged N protein was expressed as reported.", [["serum samples", "ANATOMY", 224, 237], ["infection", "DISEASE", 359, 368], ["HCoV-HKU1 pseudotyped virus", "ORGANISM", 171, 198], ["serum samples", "ORGANISM_SUBSTANCE", 224, 237], ["HCoV", "GENE_OR_GENE_PRODUCT", 349, 353], ["HKU1", "GENE_OR_GENE_PRODUCT", 354, 358], ["nucleocapsid (N) antigens", "GENE_OR_GENE_PRODUCT", 495, 520], ["HCoV", "GENE_OR_GENE_PRODUCT", 525, 529], ["neutralization antibodies", "PROTEIN", 142, 167], ["nucleocapsid (N) antigens", "PROTEIN", 495, 520], ["HCoV", "PROTEIN", 525, 529], ["HKU1 spike (S)Recombinant 6xHis tagged N protein", "PROTEIN", 530, 578], ["HCoV-HKU1 pseudotyped virus", "SPECIES", 171, 198], ["HCoV", "SPECIES", 349, 353], ["Western blot", "TEST", 63, 75], ["immunofluorescent microscopy", "TEST", 77, 105], ["flow cytometry", "TEST", 107, 121], ["neutralization antibodies", "PROBLEM", 142, 167], ["HCoV", "TEST", 171, 175], ["HKU1 pseudotyped virus", "PROBLEM", 176, 198], ["serum samples", "TEST", 224, 237], ["HCoV", "PROBLEM", 349, 353], ["HKU1 infection", "PROBLEM", 354, 368], ["virus", "PROBLEM", 416, 421], ["nucleocapsid (N) antigens", "TEST", 495, 520], ["HCoV", "TEST", 525, 529], ["HKU1 spike", "PROBLEM", 530, 540], ["Recombinant 6xHis tagged N protein", "TREATMENT", 544, 578], ["infection", "OBSERVATION", 359, 368]]], ["38 Briefly, expressed N protein was bound to nickel hitrap column (Amersham Biosciences), purified protein was eluted using the AKTA explorer system (Amersham Biosciences) The human codon optimized cDNA coding for HCoV-HKU1-S (genotype A) was synthesized 5 and served as a template for spike fragment amplifications covering amino acid residues 14-367 and cloned into bacterial expression vector pGEX-5X3 (Amersham Biosciences) with N-terminal fused to glutathione S-transferase (GST) gene.", [["nickel", "CHEMICAL", 45, 51], ["amino acid residues 14-367", "CHEMICAL", 325, 351], ["glutathione", "CHEMICAL", 453, 464], ["nickel", "CHEMICAL", 45, 51], ["amino acid", "CHEMICAL", 325, 335], ["N", "CHEMICAL", 433, 434], ["glutathione", "CHEMICAL", 453, 464], ["S", "CHEMICAL", 465, 466], ["human", "ORGANISM", 176, 181], ["HCoV-HKU1-S", "GENE_OR_GENE_PRODUCT", 214, 225], ["amino acid", "AMINO_ACID", 325, 335], ["pGEX-5X3", "GENE_OR_GENE_PRODUCT", 396, 404], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 453, 478], ["GST", "GENE_OR_GENE_PRODUCT", 480, 483], ["N protein", "PROTEIN", 22, 31], ["purified protein", "PROTEIN", 90, 106], ["HCoV", "PROTEIN", 214, 218], ["HKU1", "DNA", 219, 223], ["S", "DNA", 224, 225], ["bacterial expression vector pGEX-5X3", "DNA", 368, 404], ["Amersham Biosciences", "DNA", 406, 426], ["N-terminal", "DNA", 433, 443], ["glutathione S-transferase (GST) gene", "DNA", 453, 489], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["The human codon", "TREATMENT", 172, 187], ["HCoV", "TEST", 214, 218], ["HKU1", "TEST", 219, 223], ["a template", "TREATMENT", 271, 281], ["spike fragment amplifications", "PROBLEM", 286, 315], ["amino acid residues", "TEST", 325, 344], ["glutathione S", "TEST", 453, 466]]], ["Recombinant protein was expressed in Escherichia coli BL21-Gold(DE3) cells.", [["DE3) cells", "ANATOMY", 64, 74], ["Escherichia coli", "ORGANISM", 37, 53], ["Gold", "GENE_OR_GENE_PRODUCT", 59, 63], ["DE3) cells", "CELL", 64, 74], ["Escherichia coli BL21-Gold(DE3) cells", "CELL_LINE", 37, 74], ["Escherichia coli BL21", "SPECIES", 37, 58], ["Escherichia coli", "SPECIES", 37, 53], ["Recombinant protein", "TEST", 0, 19], ["Escherichia coli BL21", "TEST", 37, 58], ["Gold(DE3) cells", "TREATMENT", 59, 74], ["Escherichia coli BL21", "OBSERVATION", 37, 58]]], ["Cloning primer sequences were listed in Table 1 .Serum samplesIndex serum controls were obtained from our previously reported cases of HCoV-HKU1 infection.", [["Serum samples", "ANATOMY", 49, 62], ["serum", "ANATOMY", 68, 73], ["infection", "DISEASE", 145, 154], ["Serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["HCoV", "GENE_OR_GENE_PRODUCT", 135, 139], ["primer sequences", "DNA", 8, 24], ["HCoV", "SPECIES", 135, 139], ["Cloning primer sequences", "TREATMENT", 0, 24], ["Serum samples", "TEST", 49, 62], ["Index serum controls", "TEST", 62, 82], ["HCoV", "PROBLEM", 135, 139], ["HKU1 infection", "PROBLEM", 140, 154], ["infection", "OBSERVATION", 145, 154]]], ["38 Negative controls were obtained from left-over sera from infants 3-6 months of age.", [["sera", "ANATOMY", 50, 54], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["infants", "ORGANISM", 60, 67], ["infants", "SPECIES", 60, 67], ["left", "ANATOMY_MODIFIER", 40, 44]]], ["These control sera were used to calibrate our ELISA assays.", [["sera", "ANATOMY", 14, 18], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["our ELISA assays", "TEST", 42, 58]]], ["A total of 1006 random samples from patients hospitalized for acute respiratory illness were used in this evaluation.ELISAAn ELISA-based IgG antibody detection assay was designed and standardized as previously reported.", [["samples", "ANATOMY", 23, 30], ["respiratory", "ANATOMY", 68, 79], ["acute respiratory illness", "DISEASE", 62, 87], ["patients", "ORGANISM", 36, 44], ["IgG antibody", "PROTEIN", 137, 149], ["patients", "SPECIES", 36, 44], ["random samples", "TEST", 16, 30], ["acute respiratory illness", "PROBLEM", 62, 87], ["this evaluation", "TEST", 101, 116], ["ELISAAn ELISA", "TEST", 117, 130], ["based IgG antibody detection assay", "TEST", 131, 165], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory illness", "OBSERVATION", 68, 87]]], ["38 Briefly, recombinant S and N antigens (0.25 and 0.2 g/ml, respectively) were coated onto 96-well immunoplate (Maxisorb, Nunc).", [["recombinant S and N antigens", "PROTEIN", 12, 40]]], ["100 l test serum diluted 1:200 was tested in duplicate.Confirmation of ELISA result by Western blot analysis100-ng of purified GST-tagged spike S and His6-tagged nucleocapsid N were loaded into SDS-polyacrylamide gel, separated and transferred to polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences).", [["serum", "ANATOMY", 11, 16], ["SDS-polyacrylamide", "CHEMICAL", 194, 212], ["polyacrylamide", "CHEMICAL", 198, 212], ["polyvinylidene difluoride", "CHEMICAL", 247, 272], ["PVDF", "CHEMICAL", 274, 278], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["GST", "GENE_OR_GENE_PRODUCT", 127, 130], ["His6", "GENE_OR_GENE_PRODUCT", 150, 154], ["nucleocapsid N", "SIMPLE_CHEMICAL", 162, 176], ["SDS-polyacrylamide", "SIMPLE_CHEMICAL", 194, 212], ["GST", "PROTEIN", 127, 130], ["tagged spike S", "PROTEIN", 131, 145], ["His6", "PROTEIN", 150, 154], ["nucleocapsid N", "PROTEIN", 162, 176], ["l test serum", "TEST", 4, 16], ["blot analysis", "TEST", 95, 108], ["purified GST", "TEST", 118, 130], ["tagged spike S", "PROBLEM", 131, 145], ["His6-tagged nucleocapsid N", "TREATMENT", 150, 176], ["polyacrylamide gel", "TREATMENT", 198, 216], ["polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences", "TREATMENT", 247, 310]]], ["Results were revealed using ECL system (Amersham Biosciences).Production of HCoV-HKU1 spike bearing pseudotyped virusThe full length, human codon optimized HCoV-HKU1 spike gene, with which AT-rich codons of the wild-type sequence replaced with the synonymous GC-rich codons that corresponded to the most frequently used human codons, was cloned into pcDNA 3.1(+), cotransfected with lentiviral vector containing reporter gene, GFP was used for pseudotype virus production.", [["HCoV", "GENE_OR_GENE_PRODUCT", 76, 80], ["HKU1", "GENE_OR_GENE_PRODUCT", 81, 85], ["pseudotyped virus", "ORGANISM", 100, 117], ["human", "ORGANISM", 134, 139], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 156, 165], ["human", "ORGANISM", 320, 325], ["pcDNA", "GENE_OR_GENE_PRODUCT", 350, 355], ["lentiviral", "ORGANISM", 383, 393], ["GFP", "GENE_OR_GENE_PRODUCT", 427, 430], ["pseudotype virus", "ORGANISM", 444, 460], ["HCoV", "PROTEIN", 76, 80], ["HKU1", "PROTEIN", 81, 85], ["human codon optimized HCoV-HKU1 spike gene", "DNA", 134, 176], ["AT-rich codons", "DNA", 189, 203], ["wild-type sequence", "DNA", 211, 229], ["synonymous GC-rich codons", "DNA", 248, 273], ["human codons", "DNA", 320, 332], ["pcDNA 3.1", "DNA", 350, 359], ["lentiviral vector", "DNA", 383, 400], ["reporter gene", "DNA", 412, 425], ["GFP", "DNA", 427, 430], ["pseudotyped virus", "SPECIES", 100, 117], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 320, 325], ["pseudotyped virus", "SPECIES", 100, 117], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 320, 325], ["Production of HCoV", "PROBLEM", 62, 80], ["HKU1 spike bearing pseudotyped virus", "PROBLEM", 81, 117], ["The full length", "TEST", 117, 132], ["human codon optimized HCoV", "TEST", 134, 160], ["HKU1 spike gene", "PROBLEM", 161, 176], ["human codons", "TREATMENT", 320, 332], ["pcDNA", "TEST", 350, 355], ["lentiviral vector", "TREATMENT", 383, 400], ["GFP", "TEST", 427, 430], ["pseudotype virus production", "PROBLEM", 444, 471]]], ["5Neutralization assay with pseudotyped virusThe neutralization assay based on the HCoV-HKU1-S pseudotyped virus was performed by measuring the infection of A549 cells (carcinomic human alveolar basal epithelial cells) as indicated by the expression of the green fluorescent protein (GFP).", [["A549 cells", "ANATOMY", 156, 166], ["alveolar basal epithelial cells", "ANATOMY", 185, 216], ["infection", "DISEASE", 143, 152], ["pseudotyped virus", "ORGANISM", 27, 44], ["HCoV-HKU1-S pseudotyped virus", "ORGANISM", 82, 111], ["A549 cells", "CELL", 156, 166], ["human", "ORGANISM", 179, 184], ["alveolar basal epithelial cells", "CELL", 185, 216], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 256, 281], ["GFP", "GENE_OR_GENE_PRODUCT", 283, 286], ["A549 cells", "CELL_LINE", 156, 166], ["carcinomic human alveolar basal epithelial cells", "CELL_TYPE", 168, 216], ["green fluorescent protein", "PROTEIN", 256, 281], ["GFP", "PROTEIN", 283, 286], ["S pseudotyped virus", "SPECIES", 92, 111], ["human", "SPECIES", 179, 184], ["pseudotyped virus", "SPECIES", 27, 44], ["HCoV-HKU1-S pseudotyped virus", "SPECIES", 82, 111], ["human", "SPECIES", 179, 184], ["5Neutralization assay", "TEST", 0, 21], ["pseudotyped virus", "PROBLEM", 27, 44], ["The neutralization assay", "TEST", 44, 68], ["the HCoV", "TEST", 78, 86], ["S pseudotyped virus", "PROBLEM", 92, 111], ["the infection of A549 cells", "PROBLEM", 139, 166], ["carcinomic human alveolar basal epithelial cells", "PROBLEM", 168, 216], ["pseudotyped virus", "OBSERVATION", 27, 44], ["A549 cells", "OBSERVATION", 156, 166], ["alveolar", "ANATOMY_MODIFIER", 185, 193], ["epithelial cells", "OBSERVATION", 200, 216]]], ["5 Pre-heat inactivated serum samples were twofold serially diluted from 1:25 to 1:800, and were mixed with 40 ng pseudotyped virus.", [["serum samples", "ANATOMY", 23, 36], ["serum samples", "ORGANISM_SUBSTANCE", 23, 36], ["pseudotyped", "ORGANISM", 113, 124], ["Pre-heat inactivated serum samples", "TEST", 2, 36], ["40 ng pseudotyped virus", "PROBLEM", 107, 130], ["pseudotyped virus", "OBSERVATION", 113, 130]]], ["Pseudotyped virus was quantitated using p24 ELISA kit (bioM\u00e9rieux).", [["p24", "GENE_OR_GENE_PRODUCT", 40, 43], ["p24", "PROTEIN", 40, 43], ["Pseudotyped virus", "PROBLEM", 0, 17], ["p24 ELISA kit", "TEST", 40, 53]]], ["Virus infectivity was determined 72 h post-infection by measuring the mean fluorescence level expressed in infected cells by flow cytometry (Beckton Dickinson, FACSCalibur).", [["cells", "ANATOMY", 116, 121], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 116, 121], ["infected cells", "CELL_TYPE", 107, 121], ["Virus infectivity", "PROBLEM", 0, 17], ["infection", "PROBLEM", 43, 52], ["the mean fluorescence level", "TEST", 66, 93], ["infected cells", "PROBLEM", 107, 121], ["flow cytometry", "TEST", 125, 139], ["infection", "OBSERVATION", 43, 52], ["infected cells", "OBSERVATION", 107, 121], ["flow cytometry", "OBSERVATION", 125, 139]]], ["Neutralization antibody titers were determined as the percentage of inhibition of virus infectivity (mean fluorescence) at the final dilution of patient serum inhibiting 50% pseudotyped virus infection (ID 50 ), compared to viral infectivity without treatment with serum.Production of Semliki Forest Viral (SFV) particles carrying HCoV-HKU1 S: development of cell-based assay for detection of S-specific antibodyThe human codon optimized cDNA coding for HCoV-HKU1-S was subcloned with the C-terminal fused in-frame with FLAG sequence (-DYKDDDDK-), into Bam HI site of pSFV1 Semliki Forest Viral expression vector, 32 resulting in the plasmid pSFV1-S-FLAG.", [["serum", "ANATOMY", 153, 158], ["serum", "ANATOMY", 265, 270], ["cell", "ANATOMY", 359, 363], ["plasmid", "ANATOMY", 634, 641], ["infection", "DISEASE", 192, 201], ["C", "CHEMICAL", 489, 490], ["patient", "ORGANISM", 145, 152], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["pseudotyped virus", "ORGANISM", 174, 191], ["serum", "ORGANISM_SUBSTANCE", 265, 270], ["Semliki Forest Viral", "ORGANISM", 285, 305], ["SFV", "ORGANISM", 307, 310], ["cell", "CELL", 359, 363], ["S-specific antibody", "GENE_OR_GENE_PRODUCT", 393, 412], ["human", "ORGANISM", 416, 421], ["HCoV-HKU1-S", "GENE_OR_GENE_PRODUCT", 454, 465], ["FLAG", "GENE_OR_GENE_PRODUCT", 520, 524], ["Bam HI", "GENE_OR_GENE_PRODUCT", 553, 559], ["pSFV1 Semliki", "ORGANISM", 568, 581], ["pSFV1-S-FLAG", "GENE_OR_GENE_PRODUCT", 642, 654], ["HCoV", "PROTEIN", 331, 335], ["S-specific antibody", "PROTEIN", 393, 412], ["HCoV", "DNA", 454, 458], ["HKU1", "DNA", 459, 463], ["S", "DNA", 464, 465], ["C-terminal fused in-frame", "DNA", 489, 514], ["FLAG sequence", "DNA", 520, 533], ["DYKDDDDK", "DNA", 536, 544], ["Bam HI site", "DNA", 553, 564], ["pSFV1 Semliki Forest Viral expression vector", "DNA", 568, 612], ["pSFV1", "DNA", 642, 647], ["S-FLAG", "DNA", 648, 654], ["patient", "SPECIES", 145, 152], ["Semliki", "SPECIES", 285, 292], ["human", "SPECIES", 416, 421], ["SFV", "SPECIES", 307, 310], ["human", "SPECIES", 416, 421], ["Neutralization antibody titers", "TEST", 0, 30], ["virus infectivity", "PROBLEM", 82, 99], ["mean fluorescence", "TEST", 101, 118], ["patient serum", "TEST", 145, 158], ["50% pseudotyped virus infection", "PROBLEM", 170, 201], ["viral infectivity", "PROBLEM", 224, 241], ["serum", "TEST", 265, 270], ["Semliki Forest Viral (SFV) particles", "PROBLEM", 285, 321], ["S-specific antibody", "PROBLEM", 393, 412], ["The human codon", "TREATMENT", 412, 427], ["HCoV", "TEST", 454, 458], ["HKU1", "TEST", 459, 463], ["the C", "TEST", 485, 490], ["FLAG sequence", "TEST", 520, 533], ["DYKDDDDK", "TEST", 536, 544], ["the plasmid pSFV1", "TEST", 630, 647], ["viral infectivity", "OBSERVATION", 224, 241], ["Semliki Forest", "OBSERVATION", 285, 299], ["Semliki Forest", "OBSERVATION", 574, 588]]], ["Table 2 Comparison of results between ELISA using HKU1 spike and nucleocapsid, and confirmation by Western blot.", [["HKU1", "GENE_OR_GENE_PRODUCT", 50, 54], ["HKU1", "PROTEIN", 50, 54], ["ELISA", "TEST", 38, 43], ["HKU1 spike", "PROBLEM", 50, 60], ["nucleocapsid", "PROBLEM", 65, 77]]], ["True positive samples against protein spike were tested for presence of antibodies against HKU1-pseudotyped virus with spike envelope. were compared to image analysis by fluorescence microscopy (Eclipse 80i Nikon).Screening for serum antibody against recombinant HCoV-HKU1 nucleocapsid (N) and spike (S)-based ELISATo establish the baseline for the ELISA tests, the cutoff was determined as mean optical density value plus three standard deviations at 450/620 nm observed.", [["samples", "ANATOMY", 14, 21], ["serum", "ANATOMY", 228, 233], ["HKU1", "GENE_OR_GENE_PRODUCT", 91, 95], ["pseudotyped virus", "ORGANISM", 96, 113], ["serum", "ORGANISM_SUBSTANCE", 228, 233], ["HCoV-HKU1 nucleocapsid", "GENE_OR_GENE_PRODUCT", 263, 285], ["antibodies", "PROTEIN", 72, 82], ["HKU1", "PROTEIN", 91, 95], ["serum antibody", "PROTEIN", 228, 242], ["HCoV", "PROTEIN", 263, 267], ["HKU1 nucleocapsid", "PROTEIN", 268, 285], ["HKU1-pseudotyped virus", "SPECIES", 91, 113], ["HCoV", "SPECIES", 263, 267], ["True positive samples", "PROBLEM", 0, 21], ["protein spike", "PROBLEM", 30, 43], ["antibodies", "TEST", 72, 82], ["HKU1", "TEST", 91, 95], ["pseudotyped virus", "PROBLEM", 96, 113], ["spike envelope", "PROBLEM", 119, 133], ["image analysis", "TEST", 152, 166], ["fluorescence microscopy", "TEST", 170, 193], ["Screening", "TEST", 214, 223], ["serum antibody", "TEST", 228, 242], ["recombinant HCoV", "TEST", 251, 267], ["HKU1 nucleocapsid", "PROBLEM", 268, 285], ["the ELISA tests", "TEST", 345, 360], ["the cutoff", "TEST", 362, 372], ["pseudotyped virus", "OBSERVATION", 96, 113]]], ["As the result, the mean ELISA OD for S and N-based test was 0.177 and 0.183 with standard deviation 0.106 and 0.117, respectively.", [["the mean ELISA", "TEST", 15, 29], ["S and N-based test", "TEST", 37, 55]]], ["Absorbance values of 0.495 and 0.534 were selected as the cutoff values for S and N-based ELISA tests, respec- are S-based-ELISA negative samples.", [["samples", "ANATOMY", 138, 145], ["Absorbance values", "TEST", 0, 17], ["the cutoff values", "TEST", 54, 71], ["S and N", "TEST", 76, 83], ["ELISA tests", "TEST", 90, 101], ["respec", "TEST", 103, 109]]], ["Serum C (S0) was taken from a patient who had recovered from HKU1 infection.", [["Serum", "ANATOMY", 0, 5], ["infection", "DISEASE", 66, 75], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 6, 7], ["patient", "ORGANISM", 30, 37], ["HKU1", "GENE_OR_GENE_PRODUCT", 61, 65], ["patient", "SPECIES", 30, 37], ["Serum C (S0)", "TEST", 0, 12], ["HKU1 infection", "PROBLEM", 61, 75], ["infection", "OBSERVATION", 66, 75]]], ["Sera D-N (S1-S11) are samples which were S based-ELISA positive with OD \u2265 0.6 and O-R (S12-S15) with OD between 0.495 and <0.6. tively (Fig. 1) .", [["samples", "ANATOMY", 22, 29], ["O-R", "SIMPLE_CHEMICAL", 82, 85], ["S12", "PROTEIN", 87, 90], ["Sera D", "TEST", 0, 6], ["samples", "TEST", 22, 29], ["S", "TEST", 41, 42], ["ELISA", "TEST", 49, 54], ["OD", "TEST", 69, 71], ["\u2265", "TEST", 72, 73], ["OD", "TEST", 101, 103]]], ["With reference to this standard, we found that 5% (15/297) samples were positive for both S and N, and 2% (6/297) were positive only against N but negative in S-based ELISA ( Table 2) .", [["samples", "ANATOMY", 59, 66], ["samples", "CANCER", 59, 66], ["samples", "TEST", 59, 66], ["both S and N", "TEST", 85, 97]]], ["No samples were found to be positive only against the S but negative to N antigen.Confirmation of ELISA test with Western blotA confirmatory Western blot was done against 21 ELISA seropositive samples.", [["samples", "ANATOMY", 3, 10], ["samples", "ANATOMY", 193, 200], ["N antigen", "GENE_OR_GENE_PRODUCT", 72, 81], ["N antigen", "PROTEIN", 72, 81], ["the S", "TEST", 50, 55], ["ELISA test", "TEST", 98, 108], ["21 ELISA seropositive samples", "PROBLEM", 171, 200]]], ["All 15 samples (S1-S15) tested positive by both S and N-based ELISA were also positive by Western blot of their respective antigens ( Table 2 and Fig. 2 ).", [["samples", "ANATOMY", 7, 14], ["antigens", "PROTEIN", 123, 131], ["All 15 samples (S1-S15)", "TEST", 0, 23], ["N-based ELISA", "TEST", 54, 67]]], ["The other 6 (2%) positive N-based ELISA samples were found to produce weakly positive protein band to N (50 kDa) but none to S (66 kDa) by Western blot.", [["samples", "ANATOMY", 40, 47], ["N", "PROTEIN", 102, 103], ["S", "PROTEIN", 125, 126], ["66 kDa", "PROTEIN", 128, 134], ["based ELISA samples", "TEST", 28, 47], ["weakly positive protein band", "PROBLEM", 70, 98], ["kDa", "TEST", 131, 134], ["Western blot", "TEST", 139, 151]]], ["Seronegative samples all remained negative in Western blot.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["Seronegative samples", "TEST", 0, 20]]], ["There is no discrepancy in of results between our ELISA system and the Western blot assay.Index patient serum specifically neutralized HCoV-HKU1 S-pseudotyped virus infectionTo achieve an assay for detection neutralizing antibodies (Nab) to unculturable HCoV-HKU1.", [["serum", "ANATOMY", 104, 109], ["patient", "ORGANISM", 96, 103], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["HCoV", "GENE_OR_GENE_PRODUCT", 135, 139], ["Nab", "GENE_OR_GENE_PRODUCT", 233, 236], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 254, 263], ["neutralizing antibodies", "PROTEIN", 208, 231], ["Nab", "PROTEIN", 233, 236], ["HCoV", "PROTEIN", 254, 258], ["HKU1", "PROTEIN", 259, 263], ["patient", "SPECIES", 96, 103], ["HCoV", "SPECIES", 135, 139], ["HCoV", "SPECIES", 254, 258], ["our ELISA system", "TEST", 46, 62], ["the Western blot assay", "TEST", 67, 89], ["Index patient serum", "TEST", 90, 109], ["neutralized", "TEST", 123, 134], ["HCoV", "TEST", 135, 139], ["HKU1", "PROBLEM", 140, 144], ["pseudotyped virus infectionTo", "PROBLEM", 147, 176], ["an assay", "TEST", 185, 193], ["detection neutralizing antibodies", "TEST", 198, 231], ["HCoV", "TEST", 254, 258], ["no", "UNCERTAINTY", 9, 11], ["discrepancy", "OBSERVATION_MODIFIER", 12, 23]]], ["It was shown that the infection could be blocked by convalescent patients serum recovering from HCoV-HKU1 infection.", [["serum", "ANATOMY", 74, 79], ["infection", "DISEASE", 22, 31], ["infection", "DISEASE", 106, 115], ["patients", "ORGANISM", 65, 73], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["HCoV", "GENE_OR_GENE_PRODUCT", 96, 100], ["HKU1", "GENE_OR_GENE_PRODUCT", 101, 105], ["patients", "SPECIES", 65, 73], ["HCoV", "SPECIES", 96, 100], ["the infection", "PROBLEM", 18, 31], ["convalescent patients serum", "TEST", 52, 79], ["HCoV", "PROBLEM", 96, 100], ["HKU1 infection", "PROBLEM", 101, 115], ["infection", "OBSERVATION", 22, 31], ["infection", "OBSERVATION", 106, 115]]], ["The inhibition appeared to be specific to the HCoV-HKU1 as the same serum did not neutralize VSV-G enveloped pseudotyped retroviral particles (Fig. 3A) .", [["serum", "ANATOMY", 68, 73], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 46, 55], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["VSV-G", "ORGANISM", 93, 98], ["pseudotyped", "ORGANISM", 109, 120], ["retroviral", "ORGANISM", 121, 131], ["HCoV", "DNA", 46, 50], ["HKU1", "DNA", 51, 55], ["the HCoV", "TEST", 42, 50], ["VSV", "TEST", 93, 96], ["pseudotyped retroviral particles", "OBSERVATION", 109, 141]]], ["Serum from other patients recovering from other coronavirus infections, such as SARS and non-SARS human coronavirus, 229E and OC-43, did not block the HCoV-HKU1-psuedotyped virus infection (Fig. 3B-D) and no cross-reactivity with HKU1-S antigen shown by Western blot (Fig. 3E ).", [["Serum", "ANATOMY", 0, 5], ["coronavirus infections", "DISEASE", 48, 70], ["SARS", "DISEASE", 80, 84], ["229E and OC-43", "CHEMICAL", 117, 131], ["infection", "DISEASE", 179, 188], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 17, 25], ["coronavirus", "ORGANISM", 48, 59], ["human", "ORGANISM", 98, 103], ["OC-43", "GENE_OR_GENE_PRODUCT", 126, 131], ["HCoV-HKU1-psuedotyped virus", "ORGANISM", 151, 178], ["HKU1-S antigen", "GENE_OR_GENE_PRODUCT", 230, 244], ["HKU1", "PROTEIN", 156, 160], ["HKU1", "PROTEIN", 230, 234], ["S antigen", "PROTEIN", 235, 244], ["patients", "SPECIES", 17, 25], ["human", "SPECIES", 98, 103], ["coronavirus", "SPECIES", 104, 115], ["human coronavirus", "SPECIES", 98, 115], ["HCoV-HKU1-psuedotyped virus", "SPECIES", 151, 178], ["Serum", "TEST", 0, 5], ["other coronavirus infections", "PROBLEM", 42, 70], ["SARS", "PROBLEM", 80, 84], ["non-SARS human coronavirus", "PROBLEM", 89, 115], ["OC", "TEST", 126, 128], ["the HCoV", "TEST", 147, 155], ["HKU1", "PROBLEM", 156, 160], ["psuedotyped virus infection", "PROBLEM", 161, 188], ["cross-reactivity", "TEST", 208, 224], ["HKU1-S antigen", "TEST", 230, 244], ["coronavirus infections", "OBSERVATION", 48, 70], ["no", "UNCERTAINTY", 205, 207]]], ["This demonstrated that our HCoV-HKU1-pseudotyped virus can serve as a surrogate tool to detect neutralizing antibodies to HCoV-HKU1.Correlation of neutralization assay with different serological testsTo assess the correlation between the presence of neutralization antibodies and ELISA baseline, we analyzed 15 S-based ELISA positive sera (S1-S15).", [["sera", "ANATOMY", 334, 338], ["HCoV", "GENE_OR_GENE_PRODUCT", 27, 31], ["HKU1", "GENE_OR_GENE_PRODUCT", 32, 36], ["pseudotyped", "ORGANISM", 37, 48], ["virus", "ORGANISM", 49, 54], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 122, 131], ["sera", "ORGANISM_SUBSTANCE", 334, 338], ["neutralizing antibodies", "PROTEIN", 95, 118], ["HCoV", "PROTEIN", 122, 126], ["HKU1", "PROTEIN", 127, 131], ["neutralization antibodies", "PROTEIN", 250, 275], ["S1", "PROTEIN", 340, 342], ["HCoV-HKU1-pseudotyped virus", "SPECIES", 27, 54], ["HCoV", "SPECIES", 122, 126], ["our HCoV", "TEST", 23, 31], ["HKU1", "PROBLEM", 32, 36], ["pseudotyped virus", "PROBLEM", 37, 54], ["a surrogate tool", "TEST", 68, 84], ["neutralizing antibodies", "TEST", 95, 118], ["HCoV", "TEST", 122, 126], ["neutralization assay", "TEST", 147, 167], ["different serological tests", "TEST", 173, 200], ["neutralization antibodies", "PROBLEM", 250, 275], ["ELISA baseline", "TEST", 280, 294]]], ["Two randomly selected negative samples along with the index patient serum (S0) as positive control for the neutralization assay.", [["samples", "ANATOMY", 31, 38], ["serum", "ANATOMY", 68, 73], ["patient", "ORGANISM", 60, 67], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["patient", "SPECIES", 60, 67], ["the index patient serum", "TEST", 50, 73], ["the neutralization assay", "TEST", 103, 127]]], ["Neutralizing antibodies were detected in 11 serum samples (S1-11) with S-based ELISA absorbance values score >0.", [["serum samples", "ANATOMY", 44, 57], ["serum samples", "ORGANISM_SUBSTANCE", 44, 57], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["Neutralizing antibodies", "TEST", 0, 23], ["serum samples", "TEST", 44, 57], ["S1", "TEST", 59, 61], ["S-based ELISA absorbance values score", "TEST", 71, 108]]], ["6 gave results corresponding to neutralizing antibodies titers (ID 50 ) between 1:55 and 1:292 while no detectable neutralization activities (corresponding to titers of <1:25) were found in samples scored <0.6 (S12-S15).", [["samples", "ANATOMY", 190, 197], ["neutralizing antibodies titers", "TEST", 32, 62], ["detectable neutralization activities", "PROBLEM", 104, 140], ["titers", "TEST", 159, 165], ["neutralization activities", "OBSERVATION", 115, 140]]], ["Detection of antibodies against native HCoV-HKU1 S protein expressed in BHK-21 cells by indirect immunofluorescent microscopy.", [["BHK-21 cells", "ANATOMY", 72, 84], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 39, 50], ["BHK-21 cells", "CELL", 72, 84], ["antibodies", "PROTEIN", 13, 23], ["HCoV", "PROTEIN", 39, 43], ["HKU1 S protein", "PROTEIN", 44, 58], ["BHK-21 cells", "CELL_LINE", 72, 84], ["HCoV", "SPECIES", 39, 43], ["BHK-21", "SPECIES", 72, 78], ["Detection of antibodies", "TEST", 0, 23], ["native HCoV", "TEST", 32, 43], ["HKU1 S protein", "TEST", 44, 58], ["BHK", "TEST", 72, 75], ["indirect immunofluorescent microscopy", "TEST", 88, 125]]], ["Sera A and B (C1-2) are S-based ELISA negative samples.", [["samples", "ANATOMY", 47, 54], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["B", "CELL", 11, 12], ["C1-2", "GENE_OR_GENE_PRODUCT", 14, 18], ["Sera A and B (C1", "TEST", 0, 16]]], ["Serum C (S0) was taken from a patient who had recovered from HKU1 infection.", [["Serum", "ANATOMY", 0, 5], ["infection", "DISEASE", 66, 75], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 6, 7], ["patient", "ORGANISM", 30, 37], ["HKU1", "GENE_OR_GENE_PRODUCT", 61, 65], ["patient", "SPECIES", 30, 37], ["Serum C (S0)", "TEST", 0, 12], ["HKU1 infection", "PROBLEM", 61, 75], ["infection", "OBSERVATION", 66, 75]]], ["Sera D-N are samples (S1-S11) which were S-based ELISA positive with OD \u2265 0.6 and O-R (S12-S15) with OD between 0.495 and <0.6.Correlation of neutralization assay with different serological testsTwo different binding assays were applied to detect Sspecific antibodies from the seropositive samples (S1-S15), using flow cytometry and immunofluorescent microscope analysis (IF), against S-expressed BHK-21 cells 5 (Figs.", [["samples", "ANATOMY", 13, 20], ["samples", "ANATOMY", 290, 297], ["BHK-21 cells", "ANATOMY", 397, 409], ["O-R", "SIMPLE_CHEMICAL", 82, 85], ["Sspecific antibodies", "GENE_OR_GENE_PRODUCT", 247, 267], ["BHK-21 cells", "CELL", 397, 409], ["S12", "PROTEIN", 87, 90], ["Sspecific antibodies", "PROTEIN", 247, 267], ["S15", "PROTEIN", 302, 305], ["S-expressed BHK-21 cells", "CELL_LINE", 385, 409], ["Sera D", "TEST", 0, 6], ["samples", "TEST", 13, 20], ["S", "TEST", 41, 42], ["ELISA", "TEST", 49, 54], ["OD", "TEST", 69, 71], ["\u2265", "TEST", 72, 73], ["OD", "TEST", 101, 103], ["neutralization assay", "TEST", 142, 162], ["different serological tests", "TEST", 168, 195], ["Two different binding assays", "TEST", 195, 223], ["Sspecific antibodies", "TEST", 247, 267], ["the seropositive samples", "TEST", 273, 297], ["flow cytometry", "TEST", 314, 328], ["immunofluorescent microscope analysis", "TEST", 333, 370], ["BHK", "TEST", 397, 400]]], ["4 and 5) in order to correlate the results between ELISA and neutralization assays ( Table 3 ).", [["ELISA", "TEST", 51, 56], ["neutralization assays", "TEST", 61, 82]]], ["Distinctive antibody signals by both IF and flow cytometry were detected in those samples, scored absorbance values >0.6 (Figs.", [["samples", "ANATOMY", 82, 89], ["IF", "PROTEIN", 37, 39], ["Distinctive antibody signals", "TEST", 0, 28], ["flow cytometry", "TEST", 44, 58], ["absorbance values", "TEST", 98, 115]]], ["4 and 5D-N, sera S1-S11) with net geometric mean fluorescence intensity (MFI) of 53.8 \u00b1 5.2 although weaker signal was observed in samples with lower absorbance values <0.6 with net MFI of 37.35 \u00b1 3.0 (Figs.", [["sera", "ANATOMY", 12, 16], ["samples", "ANATOMY", 131, 138], ["S1", "PROTEIN", 17, 19], ["S11", "PROTEIN", 20, 23], ["net geometric mean fluorescence intensity", "TEST", 30, 71], ["MFI", "TEST", 73, 76], ["weaker signal", "PROBLEM", 101, 114], ["lower absorbance values", "TEST", 144, 167], ["net MFI", "TEST", 178, 185]]], ["4 and 5O-R; samples S12-S15).", [["5O-R", "GENE_OR_GENE_PRODUCT", 6, 10], ["S12-S15", "GENE_OR_GENE_PRODUCT", 20, 27], ["5O", "PROTEIN", 6, 8], ["S12", "PROTEIN", 20, 23], ["S15", "PROTEIN", 24, 27]]], ["Very good positive correlations with the neutralization assay were shown with ELISA and flow cytometry which suggested our S protein-targeted serological assay is a reliable indicator to predict the presence of neutralization antibodies in S-based seropositive samples with ELISA absorbance scored above 0.6.Determination of seroprevalence from different age groups in local community709 blood samples were collected from patients who had attended Queen Mary Hospital and were found to be clinically free of active respiratory infections.", [["samples", "ANATOMY", 261, 268], ["blood samples", "ANATOMY", 388, 401], ["respiratory", "ANATOMY", 515, 526], ["respiratory infections", "DISEASE", 515, 537], ["blood samples", "ORGANISM_SUBSTANCE", 388, 401], ["patients", "ORGANISM", 422, 430], ["S protein", "PROTEIN", 123, 132], ["neutralization antibodies", "PROTEIN", 211, 236], ["patients", "SPECIES", 422, 430], ["the neutralization assay", "TEST", 37, 61], ["ELISA", "TEST", 78, 83], ["flow cytometry", "TEST", 88, 102], ["our S protein", "TEST", 119, 132], ["targeted serological assay", "TEST", 133, 159], ["neutralization antibodies", "PROBLEM", 211, 236], ["seropositive samples", "TEST", 248, 268], ["ELISA absorbance", "TEST", 274, 290], ["blood samples", "TEST", 388, 401], ["active respiratory infections", "PROBLEM", 508, 537], ["good", "OBSERVATION_MODIFIER", 5, 9], ["positive", "OBSERVATION", 10, 18], ["neutralization", "OBSERVATION", 211, 225], ["active", "OBSERVATION_MODIFIER", 508, 514], ["respiratory", "ANATOMY", 515, 526], ["infections", "OBSERVATION", 527, 537]]], ["These were categorized into different age groups and analyzed for IgG level against HCoV-HKU1 spike protein by ELISA method as described above (Fig. 6) .", [["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 84, 93], ["IgG", "PROTEIN", 66, 69], ["HCoV", "PROTEIN", 84, 88], ["HKU1 spike protein", "PROTEIN", 89, 107], ["HCoV", "SPECIES", 84, 88], ["IgG level", "TEST", 66, 75], ["HCoV", "TEST", 84, 88], ["HKU1 spike protein", "PROBLEM", 89, 107], ["ELISA method", "TEST", 111, 123]]], ["With reference to cutoff standard determined in previous tests, the mean absorbances and percentage of population predicted with neutralizing antibodies against S protein in each group are shown in Fig. 6 .", [["antibodies against S protein", "GENE_OR_GENE_PRODUCT", 142, 170], ["neutralizing antibodies", "PROTEIN", 129, 152], ["S protein", "PROTEIN", 161, 170], ["previous tests", "TEST", 48, 62], ["the mean absorbances", "TEST", 64, 84], ["neutralizing antibodies", "TREATMENT", 129, 152]]], ["ANOVA analysis showed that there are no significant differences in sample means among age groups of 31-40, 41-50, 51-60 and 61-70.DiscussionHCoV-HKU1, a newly identified human coronavirus, had been consistently detected in the respiratory specimens of patients suffering from respiratory tract infections, in a multitude of studies around the world.", [["respiratory specimens", "ANATOMY", 227, 248], ["respiratory tract", "ANATOMY", 276, 293], ["respiratory tract infections", "DISEASE", 276, 304], ["DiscussionHCoV", "GENE_OR_GENE_PRODUCT", 130, 144], ["HKU1", "GENE_OR_GENE_PRODUCT", 145, 149], ["human", "ORGANISM", 170, 175], ["patients", "ORGANISM", 252, 260], ["tract", "ORGANISM_SUBDIVISION", 288, 293], ["HKU1", "DNA", 145, 149], ["human", "SPECIES", 170, 175], ["coronavirus", "SPECIES", 176, 187], ["patients", "SPECIES", 252, 260], ["human coronavirus", "SPECIES", 170, 187], ["ANOVA analysis", "TEST", 0, 14], ["sample means", "TEST", 67, 79], ["a newly identified human coronavirus", "PROBLEM", 151, 187], ["respiratory tract infections", "PROBLEM", 276, 304], ["no", "UNCERTAINTY", 37, 39], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["differences", "OBSERVATION_MODIFIER", 52, 63], ["human coronavirus", "OBSERVATION", 170, 187], ["respiratory tract", "ANATOMY", 276, 293], ["infections", "OBSERVATION", 294, 304]]], ["4, 9, 13, 31, 37, 39 Its prevalence was found to be generally comparable to the other non-SARS human coronaviruses, such as 229E, OC43 and NL63 in our local population particularly in winter season.", [["human", "ORGANISM", 95, 100], ["coronaviruses", "ORGANISM", 101, 114], ["OC43", "GENE_OR_GENE_PRODUCT", 130, 134], ["human", "SPECIES", 95, 100], ["human coronaviruses", "SPECIES", 95, 114], ["OC43", "TEST", 130, 134]]], ["17, 23 Any individual may probably experience coronavirus infections and carry antibodies.", [["coronavirus infections", "DISEASE", 46, 68], ["coronavirus", "ORGANISM", 46, 57], ["antibodies", "PROTEIN", 79, 89], ["coronavirus infections", "PROBLEM", 46, 68], ["carry antibodies", "PROBLEM", 73, 89], ["may probably", "UNCERTAINTY", 22, 34], ["coronavirus", "OBSERVATION", 46, 57]]], ["This is the first report that examined seroepidemiology and seroprevalence of HCoV-HKU1 including neutralization test as one of the determination parameters.DiscussionIn the first publication on HCoV-HKU1 an ELISA based antibody test was made against nucleocapsid (N) proteins and seroconversion was observed in index patient.", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 78, 87], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 195, 204], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 251, 267], ["patient", "ORGANISM", 318, 325], ["HCoV", "PROTEIN", 195, 199], ["HKU1", "DNA", 200, 204], ["nucleocapsid (N) proteins", "PROTEIN", 251, 276], ["patient", "SPECIES", 318, 325], ["HCoV", "SPECIES", 78, 82], ["HCoV", "SPECIES", 195, 199], ["HCoV", "TEST", 78, 82], ["neutralization test", "TEST", 98, 117], ["the determination parameters", "TEST", 128, 156], ["HCoV", "TEST", 195, 199], ["an ELISA based antibody test", "TEST", 205, 233], ["nucleocapsid (N) proteins", "PROBLEM", 251, 276], ["seroconversion", "PROBLEM", 281, 295]]], ["25, 27, 38, 40 Its high percentage in sequence conservation results false-positivity renders it not an ideal single marker for serodiagnosis despite its antigenicity.", [["serodiagnosis", "PROBLEM", 127, 140]]], ["25, 27, 40 In regard to minimize cross-reactivity, we incorporated spike (S) protein as an additional marker which exhibits least exhibition of sequence conservation among coronavirus proteins.", [["coronavirus", "ORGANISM", 172, 183], ["spike (S) protein", "PROTEIN", 67, 84], ["coronavirus proteins", "PROTEIN", 172, 192], ["spike (S) protein", "PROBLEM", 67, 84], ["an additional marker", "TEST", 88, 108], ["sequence conservation", "TREATMENT", 144, 165], ["coronavirus proteins", "PROBLEM", 172, 192]]], ["3, 39 The results of WB analysis support the specificities of both the N and S-based ELISA.", [["3, 39", "CHEMICAL", 0, 5], ["WB analysis", "TEST", 21, 32], ["the specificities", "TEST", 41, 58]]], ["No seropositive serum, above the cutoff values, were failed by WB tested by its target antigen.", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["seropositive serum", "TEST", 3, 21], ["the cutoff values", "TEST", 29, 46], ["seropositive", "OBSERVATION_MODIFIER", 3, 15], ["serum", "OBSERVATION_MODIFIER", 16, 21]]], ["As expected, 28.5% (6/21) of N-based seropositive samples were tested negative by S-based assay which further indicates the inclusion of double markers is critical in curtailing the false-positive rates and non-specificities.DiscussionOur neutralizing results are in general, consistent (73.3%, samples S1-S15) with those obtained by ELISA with scores above the cutoff (0.495).", [["samples", "ANATOMY", 50, 57], ["N-based seropositive samples", "TEST", 29, 57], ["double markers", "TEST", 137, 151], ["non-specificities", "PROBLEM", 207, 224], ["ELISA", "TEST", 334, 339], ["positive rates", "OBSERVATION", 188, 202]]], ["For the 4 neutralization-negative, S-based positive samples (S12-S15), were detected containing low level of S-protein-specific antibodies by binding assays immunofluorescent microscopy and flow cytometry using S-expressed BHK-21 cells (Figs.", [["samples", "ANATOMY", 52, 59], ["BHK-21 cells", "ANATOMY", 223, 235], ["S12-S15", "GENE_OR_GENE_PRODUCT", 61, 68], ["S-protein", "SIMPLE_CHEMICAL", 109, 118], ["BHK-21 cells", "CELL", 223, 235], ["S12", "PROTEIN", 61, 64], ["S15", "PROTEIN", 65, 68], ["S-protein-specific antibodies", "PROTEIN", 109, 138], ["S-expressed BHK-21 cells", "CELL_LINE", 211, 235], ["the 4 neutralization", "TEST", 4, 24], ["S-protein", "TEST", 109, 118], ["immunofluorescent microscopy", "TEST", 157, 185], ["flow cytometry", "TEST", 190, 204], ["BHK", "TEST", 223, 226]]], ["100% consistency of the results in the binding assays and our pseudovirus neutralization tests can be achieved if ELISA cutoff was raised to 0.6, as in samples S1-S11.", [["samples", "ANATOMY", 152, 159], ["pseudovirus", "ORGANISM", 62, 73], ["pseudovirus", "SPECIES", 62, 73], ["the binding assays", "TEST", 35, 53], ["our pseudovirus neutralization tests", "TEST", 58, 94], ["ELISA cutoff", "TEST", 114, 126]]], ["It is justifiable to set the cutoff to a high level to insure as a reliable index in determination the seroprevalence and excludes the false-positivities posed by the presence of other human coronavirus antibodies.", [["human", "ORGANISM", 185, 190], ["human coronavirus antibodies", "PROTEIN", 185, 213], ["human", "SPECIES", 185, 190], ["human coronavirus", "SPECIES", 185, 202], ["other human coronavirus antibodies", "PROBLEM", 179, 213], ["coronavirus antibodies", "OBSERVATION", 191, 213]]], ["23, 40 Based on the standard we determined, our results show a rising trend of seroprevalence from age group 11-20, peaks in group from 31-50 (\u223c12%) and declines to 5.3% in age group 61-70, while with no seropositive cases identified in the age group <10 (Fig. 6 ).", [["seropositive cases", "PROBLEM", 204, 222]]], ["This pattern is within our expectations, as the incidence of HCoV-HKU1 infections were found to be relatively low (0.3%) in Hong Kong 23, 39 while other reports were mostly targeted to patients with respiratory symptoms and used RT-PCR for viral detection, which would only identify cases with active disease.", [["respiratory", "ANATOMY", 199, 210], ["infections", "DISEASE", 71, 81], ["respiratory symptoms", "DISEASE", 199, 219], ["HCoV-HKU1", "ORGANISM", 61, 70], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["HCoV", "SPECIES", 61, 65], ["HCoV", "TEST", 61, 65], ["HKU1 infections", "PROBLEM", 66, 81], ["respiratory symptoms", "PROBLEM", 199, 219], ["RT-PCR", "TEST", 229, 235], ["viral detection", "TEST", 240, 255], ["active disease", "PROBLEM", 294, 308], ["infections", "OBSERVATION", 71, 81], ["low", "OBSERVATION_MODIFIER", 110, 113], ["active", "OBSERVATION_MODIFIER", 294, 300], ["disease", "OBSERVATION", 301, 308]]], ["9, 10, 11, 14, 19, 21, 22, 29, 31, 34, 37 In contrast, our study excluded sera from patients with respiratory symptoms, and the detection of specific IgG antibodies would allow a better estimation of the incidence in the wider population.", [["sera", "ANATOMY", 74, 78], ["respiratory", "ANATOMY", 98, 109], ["respiratory symptoms", "DISEASE", 98, 118], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["patients", "ORGANISM", 84, 92], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 150, 164], ["IgG antibodies", "PROTEIN", 150, 164], ["patients", "SPECIES", 84, 92], ["our study", "TEST", 55, 64], ["respiratory symptoms", "PROBLEM", 98, 118], ["the detection", "TEST", 124, 137], ["specific IgG antibodies", "PROBLEM", 141, 164]]], ["Our study is not truly population-based, especially not including extrarespiratory disease 9,37 the present results still demonstrates that a substantial adult population has no demonstrable immunity to HCoV-HKU1.DiscussionOne limitation of the newly developed assay is that we have utilized the S protein from HCoV-HKU1 genotype A only.", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 203, 212], ["HCoV", "GENE_OR_GENE_PRODUCT", 311, 315], ["HCoV", "PROTEIN", 203, 207], ["HKU1", "DNA", 208, 212], ["S protein", "PROTEIN", 296, 305], ["HCoV", "SPECIES", 203, 207], ["Our study", "TEST", 0, 9], ["extrarespiratory disease", "PROBLEM", 66, 90], ["a substantial adult population", "PROBLEM", 140, 170], ["HCoV", "TEST", 203, 207], ["the S protein", "TEST", 292, 305], ["HCoV", "TEST", 311, 315], ["not truly", "UNCERTAINTY", 13, 22], ["substantial", "OBSERVATION_MODIFIER", 142, 153], ["adult", "OBSERVATION_MODIFIER", 154, 159], ["population", "OBSERVATION", 160, 170], ["no demonstrable", "UNCERTAINTY", 175, 190]]], ["There are currently three known genotypes (A, B and C) of HCoV-HKU1 in circulation, with the S proteins of genotypes A and B sharing about 84% amino acid similarity.", [["amino acid", "CHEMICAL", 143, 153], ["amino acid", "CHEMICAL", 143, 153], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 58, 67], ["B", "GENE_OR_GENE_PRODUCT", 123, 124], ["amino acid", "AMINO_ACID", 143, 153], ["HCoV", "PROTEIN", 58, 62], ["HKU1", "PROTEIN", 63, 67], ["S proteins", "PROTEIN", 93, 103], ["HCoV", "TEST", 58, 62], ["HKU1 in circulation", "PROBLEM", 63, 82], ["the S proteins", "TEST", 89, 103], ["amino acid similarity", "TEST", 143, 164], ["circulation", "ANATOMY", 71, 82]]], ["The S protein of genotype C, arising from the recombination of genotypes A and B, is identical to that of genotype B. It is likely that there will be an appreciable degree of cross-reactivity between the two closely related S proteins and hence the test may pick up some of the patients infected with HCoV-HKU1 genotype B. The incorporation of the S protein of genotype B will be an important area of improvement in the future development of the assay.DiscussionThe development of a vaccine is possibly the best strategy to protect against HCoV-HKU1 infections in the predominantly nonimmune population and reduce the risk of a major outbreak.", [["infections", "DISEASE", 550, 560], ["genotype C", "GENE_OR_GENE_PRODUCT", 17, 27], ["B", "GENE_OR_GENE_PRODUCT", 79, 80], ["patients", "ORGANISM", 278, 286], ["HCoV-HKU1 genotype B.", "ORGANISM", 301, 322], ["HCoV-HKU1", "ORGANISM", 540, 549], ["S protein", "PROTEIN", 4, 13], ["S proteins", "PROTEIN", 224, 234], ["S protein", "PROTEIN", 348, 357], ["patients", "SPECIES", 278, 286], ["HCoV", "SPECIES", 301, 305], ["HCoV", "SPECIES", 540, 544], ["The S protein", "TEST", 0, 13], ["genotype C", "PROBLEM", 17, 27], ["genotype B.", "PROBLEM", 106, 117], ["an appreciable degree of cross-reactivity", "PROBLEM", 150, 191], ["the two closely related S proteins", "PROBLEM", 200, 234], ["the test", "TEST", 245, 253], ["HCoV", "TREATMENT", 301, 305], ["HKU1 genotype B.", "TREATMENT", 306, 322], ["the S protein of genotype B", "TREATMENT", 344, 371], ["the assay", "TEST", 442, 451], ["a vaccine", "TREATMENT", 481, 490], ["HCoV", "PROBLEM", 540, 544], ["HKU1 infections", "PROBLEM", 545, 560], ["a major outbreak", "PROBLEM", 626, 642], ["cross-reactivity", "OBSERVATION", 175, 191], ["infections", "OBSERVATION", 550, 560], ["predominantly", "OBSERVATION_MODIFIER", 568, 581], ["nonimmune", "OBSERVATION", 582, 591], ["major", "OBSERVATION_MODIFIER", 628, 633], ["outbreak", "OBSERVATION", 634, 642]]], ["Recent success in producing infectious full length cDNA clones would pave way for the development of genetically engineered live attenuated protective vaccines.", [["cDNA clones", "DNA", 51, 62], ["infectious full length cDNA clones", "TREATMENT", 28, 62], ["attenuated protective vaccines", "TREATMENT", 129, 159], ["infectious", "OBSERVATION_MODIFIER", 28, 38]]], ["34, 36 The assays developed in the present work would be valuable for studying the humoral immune response to HCoV-HKU1 and in guiding further drug and vaccine design.", [["HCoV-HKU1", "CHEMICAL", 110, 119], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 110, 119], ["HCoV", "SPECIES", 110, 114], ["The assays", "TEST", 7, 17], ["HCoV", "TEST", 110, 114], ["HKU1", "TREATMENT", 115, 119], ["further drug and vaccine design", "TREATMENT", 135, 166]]]], "496a324afb57a1ca28b7556eede524254cb83ce3": [["IntroductionOne of the main issues that threats our health around the glop are infectious diseases.", [["infectious diseases", "DISEASE", 79, 98], ["glop", "CANCER", 70, 74], ["infectious diseases", "PROBLEM", 79, 98], ["main", "OBSERVATION_MODIFIER", 23, 27], ["infectious", "OBSERVATION", 79, 89]]], ["Nowadays, the outbreak of 2019 virus disease (COVID-19) is a global pandemic [4, 5] .", [["COVID-19", "CHEMICAL", 46, 54], ["2019 virus", "ORGANISM", 26, 36], ["2019 virus disease", "PROBLEM", 26, 44], ["COVID", "TEST", 46, 51], ["a global pandemic", "PROBLEM", 59, 76]]], ["The first case of this virus was recognized and reported on 31-12-2019 in the city of Wuhan, the capital of Hubei in China [6] .", [["this virus", "PROBLEM", 18, 28]]], ["Then, the virus has spread rapidly around the world and affected more than 200 countries [7] .IntroductionThe number of cases and deaths of this virus are globally considered as serious problems.", [["deaths", "DISEASE", 130, 136], ["the virus", "PROBLEM", 6, 15], ["this virus", "PROBLEM", 140, 150], ["virus", "OBSERVATION", 10, 15], ["spread", "OBSERVATION_MODIFIER", 20, 26], ["rapidly", "OBSERVATION_MODIFIER", 27, 34]]], ["The number of confirmed cases were more than 4 million and around 200 thousand deaths by 12-05-2020.", [["deaths", "DISEASE", 79, 85]]], ["Although the outbreak seems to have decreased in China, the virus and its impacts are still going global, and those numbers are increasing.", [["the virus", "PROBLEM", 56, 65], ["decreased", "OBSERVATION_MODIFIER", 36, 45], ["virus", "OBSERVATION", 60, 65], ["impacts", "OBSERVATION_MODIFIER", 74, 81], ["increasing", "OBSERVATION_MODIFIER", 128, 138]]], ["This leads to our concerns about variation in the affected cases and the mortality rate of the COVID-19 pandemic.", [["the affected cases", "PROBLEM", 46, 64], ["the mortality rate", "TEST", 69, 87], ["the COVID", "TEST", 91, 100], ["pandemic", "PROBLEM", 104, 112]]], ["Furthermore, there are a lot of concerns about economic global impact of this crises.", [["this crises", "PROBLEM", 73, 84]]], ["It is now understood that the devastating influence of the virus on economy and world health is incomparable [8] .IntroductionThe primary objective of this manuscript is construction of a reliable, robust and interpretable model describing, decomposing, forecasting the number of confirmed cases, and predict the peak of this pandemic in Saudi Arabia.", [["the virus", "PROBLEM", 55, 64], ["devastating", "OBSERVATION_MODIFIER", 30, 41]]], ["The rate of mortality in Saudi Arabia is low, less than 1% till writing this paper.", [["mortality", "OBSERVATION_MODIFIER", 12, 21], ["low", "OBSERVATION_MODIFIER", 41, 44]]], ["Thus, we are only interested in the new daily cases affected by the virus and try to detect its peak.", [["the virus", "PROBLEM", 64, 73]]], ["However, since our aim is to analyse the daily data series of COVID-19, we seek to use a promising, reliable, and capable method for analysing time series.", [["COVID", "TEST", 62, 67]]], ["There is a number of various methods for analysing time series, but several of these methods requiring, for example, linearity or non linearity of a particular form as they are parametric methods.IntroductionAn alternative method uses non-parametric approaches that are neutral with respect to problematic areas of specification, such as linearity, stationarity and normality [13] .", [["analysing time series", "TEST", 41, 62], ["IntroductionAn alternative method", "TREATMENT", 196, 229], ["non-parametric approaches", "TREATMENT", 235, 260], ["non linearity", "OBSERVATION_MODIFIER", 130, 143]]], ["Thus, such approaches can show a reliable and better means of decomposing time series data.", [["decomposing time series data", "TEST", 62, 90]]], ["Singular Spectrum Analysis (SSA) is a relatively new non-parametric technique that has shown and proved its capabible use in several applications of time series in different disciplines, such as genetics and biology [14, 15] , medicine [16, 17] , engineering [18, 19] , economics and finance [20, 21] , and other areas.", [["Singular Spectrum Analysis", "TEST", 0, 26]]], ["A comprehensive review of the method and description of its extensions and modifications can be found in [26] .IntroductionAlthough the signals can be affected by an internal or external noise, which often have unknown characteristics, they can be identified if the signal and noise subspaces are accurately separated.", [["the method", "TEST", 26, 36], ["an internal or external noise", "PROBLEM", 163, 192], ["the signal and noise subspaces", "PROBLEM", 262, 292], ["internal", "OBSERVATION_MODIFIER", 166, 174], ["external noise", "OBSERVATION", 178, 192]]], ["It is known that removing noises from any signal is necessary for analysing any kind of time series, and is helpful in decomposing the signal in a proper manner [27] .IntroductionThe main idea of SSA is to analyse the main series into different components, then reconstruct the noise free series for further analysis.", [["removing noises", "PROBLEM", 17, 32], ["further analysis", "TEST", 300, 316], ["main", "OBSERVATION_MODIFIER", 183, 187]]], ["It depends upon two main choices; namely, the window length L and the number of required eigenvalues, denoted by r, for reconstruction.", [["reconstruction", "TREATMENT", 120, 134], ["main", "OBSERVATION_MODIFIER", 20, 24]]], ["Thus, an appropriate selection of L and r leads to a perfect analysis and separability between the time series components.", [["a perfect analysis", "TEST", 51, 69], ["L", "ANATOMY_MODIFIER", 34, 35]]], ["It was discussed in [28] that for a series of length N , selecting L = N/4 is common practice.It also should be mentioned that L should be large enough, but not larger than half of the series [24] .", [["large", "OBSERVATION", 139, 144], ["larger", "OBSERVATION_MODIFIER", 161, 167]]], ["In [29] , it was shown that for a series of length N and the optimal selection of the number of eigenvalues r for reconstructing the signal, the appropriate value of the window length is median{1, . . . , N }.", [["N", "CHEMICAL", 205, 206]]], ["Despite various attempts that have been applied, there is no universal rule for obtaining optimal selections of L and r.IntroductionWe have proposed an approach in [2, 3] for the selection of the value of r for noise reduction, filtering, and signal extraction in SSA.", [["an approach", "TREATMENT", 149, 160], ["noise reduction", "TREATMENT", 211, 226], ["signal extraction", "TREATMENT", 243, 260], ["SSA", "PROBLEM", 264, 267], ["no universal", "UNCERTAINTY", 58, 70], ["SSA", "OBSERVATION_MODIFIER", 264, 267]]], ["This has also been applied to the distinction of noise from chaos in time series analysis [30] , and for the correction of noise in gene expression data [31] .", [["series analysis", "TEST", 74, 89]]], ["In [3] , we have developed the approach and introduced new criteria to the discrimination between epileptic seizure and normal EEG signals, the filtering of the EEG signal segments, and elimination of the noise included in the signal.", [["epileptic seizure", "DISEASE", 98, 115], ["EEG signal segments", "PROTEIN", 161, 180], ["epileptic seizure", "PROBLEM", 98, 115], ["the noise", "PROBLEM", 201, 210], ["segments", "OBSERVATION_MODIFIER", 172, 180]]], ["The approach is mainly used to identify the required number of eigen-values/singular values corresponding to the signal component, which depends on the distribution of the eigenvalues of a scaled Hankel matrix.", [["matrix", "CELLULAR_COMPONENT", 203, 209], ["the signal component", "PROBLEM", 109, 129], ["a scaled Hankel matrix", "PROBLEM", 187, 209], ["signal", "OBSERVATION_MODIFIER", 113, 119], ["component", "OBSERVATION_MODIFIER", 120, 129], ["scaled", "OBSERVATION_MODIFIER", 189, 195], ["Hankel matrix", "OBSERVATION", 196, 209]]], ["The correlation between eigenvalues, the coefficients of skewness, kurtosis and variation of the eigenvalues distributions were proposed and proved to be new criteria for the separability between signal and noise components as they can split the eigenvalues into two groups [2] .", [["kurtosis", "PROBLEM", 67, 75], ["the separability between signal and noise components", "PROBLEM", 171, 223]]], ["Different simulated and real signals were used considering different signal to noise ratio in [2, 3] , and evaluated to show the ability of the approach in the selection of r.IntroductionThe remainder of this paper is structured as follows: the following section gives a short description of the modified SSA approach and its algorithm.", [["noise ratio", "TEST", 79, 90]]], ["In Section 3, we show that this approach can decompose a synthetic data into two main distinct subspaces.", [["a synthetic data", "TEST", 55, 71], ["main", "OBSERVATION_MODIFIER", 81, 85], ["distinct", "OBSERVATION_MODIFIER", 86, 94], ["subspaces", "OBSERVATION_MODIFIER", 95, 104]]], ["Section 4 presents the implementation of the approach in decomposing and reconstructing COVID-19 daily cases series.", [["the approach", "TREATMENT", 41, 53], ["reconstructing COVID", "TEST", 73, 93]]], ["The section also presents the prediction of COVID-19 in Saudi Arabia using Vector SSA for the extracted signal by the modified SSA.", [["COVID", "TEST", 44, 49], ["Vector SSA", "TREATMENT", 75, 85]]], ["A time series is decomposed by the SSA technique into a sum of components, allowing the identification of each one as either a main or noise component.", [["the SSA technique", "TEST", 31, 48], ["main", "OBSERVATION_MODIFIER", 127, 131]]], ["The goal here is to consider the signal as a whole so that we can identify the appropriate value of r related to the whole signal component.", [["the whole signal component", "PROBLEM", 113, 139]]], ["Therefore, the modified SSA focuses on the selection of r to identify the signal subspace.ReviewConsider a one-dimensional series Y N = (y 1 , . . . , y N ) of length N .", [["signal subspace", "OBSERVATION", 74, 89]]], ["Transferring this series into a multi-dimensional series X 1 , . . . , X K where X i = (y i , . . . , y i+L\u22121 ) T \u2208 R L provides X = (x i,j ) L,K i,j=1 , where L is an integer (2 L N/2) and K = N \u2212 L + 1.", [["\u2208", "TEST", 114, 115], ["K i", "TEST", 144, 147], ["j", "TEST", 148, 149], ["L", "TEST", 160, 161], ["an integer", "TEST", 165, 175], ["K", "TEST", 190, 191]]], ["A matrix X is a Hankel matrix, all the elements along the diagonal i + j = const are equal.", [["matrix X", "DNA", 2, 10], ["a Hankel matrix", "TREATMENT", 14, 29], ["diagonal", "ANATOMY_MODIFIER", 58, 66], ["equal", "OBSERVATION", 85, 90]]], ["Set B = XX T and denote by \u03bb i (i = 1, . . . , L) the eigenvalues of B taken in decreasing order of magnitude ( \u03bb 1 \u2265 . . . \u2265 \u03bb L \u2265 0) and by U 1 , . . . , U L the orthonormal system of the eigenvectors of matrix B corresponding to these eigenvalues.ReviewThe SVD of matrix X can be written as follows:ReviewwhereReviewThe elementary matrices X i having rank 1, U i and V i are the left and right eigenvectors of matrix X. Note that the collection (Reviewcalled the ith eigentriple of the SVD.", [["left", "ANATOMY", 382, 386], ["matrix B", "GENE_OR_GENE_PRODUCT", 206, 214], ["matrix B", "PROTEIN", 206, 214], ["magnitude", "TEST", 100, 109], ["U", "TEST", 142, 143], ["matrix B", "PROBLEM", 206, 214], ["the collection", "PROBLEM", 433, 447], ["eigenvectors", "ANATOMY_MODIFIER", 190, 202], ["left", "ANATOMY_MODIFIER", 382, 386], ["right", "ANATOMY_MODIFIER", 391, 396], ["SVD", "OBSERVATION", 489, 492]]], ["Note also that ||X|| 2Reviewwhere || || F denotes the Frobenius norm.", [["|| || F", "GENE_OR_GENE_PRODUCT", 34, 41]]], ["Fundamental to the question of the eigenvalues behaviour, \u03bb i , is that if the series size increases, there is a corresponding increase in the eigenvalues.", [["a corresponding increase in the eigenvalues", "PROBLEM", 111, 154], ["size", "OBSERVATION_MODIFIER", 86, 90], ["increase", "OBSERVATION_MODIFIER", 127, 135]]], ["Let \u03b6 1 , . . . , \u03b6 L denote the matrix A eigenvalues in decreasing order of magnitude (1 \u2265 \u03b6 1 \u2265 . . . \u2265 \u03b6 L \u2265 0).", [["Let \u03b6 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["the matrix A eigenvalues", "PROBLEM", 29, 53], ["magnitude", "TEST", 77, 86], ["matrix", "OBSERVATION_MODIFIER", 33, 39], ["eigenvalues", "OBSERVATION", 42, 53], ["decreasing", "OBSERVATION_MODIFIER", 57, 67]]], ["The simulation technique is performed to obtain the distribution of \u03b6 i and to understand the behaviour of each eigenvalue.", [["The simulation technique", "TEST", 0, 24]]], ["This helps to identify the value of r.", [["r.", "SPECIES", 36, 38]]], ["Here, the goal is to establish the distribution and related forms of \u03b6 i , which will be used to select the appropriate value of r for removing noise from COVID-19 series.ReviewIt was proved in our work [2] that the largest eigenvalue has a positive skewed distribution for a white noise process.", [["COVID", "TEST", 155, 160], ["a white noise process", "PROBLEM", 274, 295], ["largest", "OBSERVATION_MODIFIER", 216, 223], ["positive skewed", "OBSERVATION_MODIFIER", 241, 256]]], ["Therefore, if skew(\u03b6 c ) (c \u2208 {1, . . . , L}) is the maximum, and the pattern for skew(\u03b6 c ) to skew(\u03b6 L ) has the same pattern, the same as emerged for the white noise, then the first r = c\u22121 eigenvalues correspond to the signal and the rest to the noise.", [["skew(\u03b6 c ) (c \u2208 {1", "PROBLEM", 14, 32], ["the white noise", "PROBLEM", 153, 168]]], ["A similar procedure can be done using the the coefficients of kurtosis and variation of \u03b6 i .", [["A similar procedure", "TREATMENT", 0, 19]]], ["Furthermore, if \u03c1 s (\u03b6 c\u22121 , \u03b6 c ) is the minimum, and the pattern for the set {\u03c1 s (\u03b6 i , \u03b6 i+1 )} L\u22121 i=c is similar to what was observed for the white noise, then we select the first r = c \u2212 1 eigenvalues for the signal and the rest for the noise component (for more information see [2] ).ReviewIn this research, we use the third and fourth central measures moments of the distribution, which are the skewness (Skew) and kurtosis (Kurt).", [["\u03b6 c", "GENE_OR_GENE_PRODUCT", 29, 32], ["L\u22121 i=c", "GENE_OR_GENE_PRODUCT", 100, 107], ["\u03b6 c", "PROTEIN", 29, 32], ["Furthermore", "TEST", 0, 11], ["s", "TEST", 18, 19], ["the set {\u03c1 s", "TEST", 71, 83], ["the white noise", "PROBLEM", 144, 159], ["fourth central", "ANATOMY_MODIFIER", 337, 351]]], ["Skewness is a measure of asymmetry of the data distribution, whilst kurtosis describes the distribution of observed data in terms of shape or peak.", [["Skewness", "DISEASE", 0, 8], ["peak", "OBSERVATION_MODIFIER", 142, 146]]], ["We use these measures as criteria for choosing the value of r, which can be calculated for m simulation as follows:ReviewMoreover, the coefficient of variation, (CV ), which is defined as the ratio of the standard deviation \u03c3(\u03b6 i ) and \u03b6 i can be calculated mathematically from the following formula:ReviewIn addition, the Spearman correlation \u03c1 s between the eigenvalues \u03b6 i and \u03b6 j (i, j = 1, . . . , L) is also calculated to enhance the results obtained by those measures:Reviewwhere d n = x n \u2212 y n (n = 1, . . . , m) is the difference between x n and y n which are the ranks of \u03b6 i,n and \u03b6 j,n respectively, and \u03b6 i,n is the n-th observation for the i-th eigenvalueReviewAll rights reserved.", [["the Spearman correlation", "TEST", 319, 343], ["the eigenvalues", "TEST", 356, 371], ["Reviewwhere", "TEST", 475, 486], ["the n-th observation", "TEST", 626, 646], ["the i-th", "TEST", 651, 659]]], ["No reuse allowed without permission.Review(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ReviewThe copyright holder for this preprint this version posted May 26, 2020. .", [["med", "ANATOMY", 121, 124]]], ["These measures of difference between the eigenvalues related to the signal and noise components can specify the cut-off point of separability; the number of leading SVD components that are separated from the residual.", [["the signal and noise components", "PROBLEM", 64, 95], ["leading SVD components", "PROBLEM", 157, 179], ["difference", "OBSERVATION_MODIFIER", 18, 28], ["number", "OBSERVATION_MODIFIER", 147, 153], ["leading", "OBSERVATION_MODIFIER", 157, 164], ["SVD", "OBSERVATION", 165, 168], ["residual", "OBSERVATION_MODIFIER", 208, 216]]], ["Thus, the last cut-off point of separability between the signal and noise components obtained by the suggested measures, corresponds to the rank estimation.ReviewThe eigenvalues can be split into two groups by using the above criteria; the first corresponds to the signal and the second to the noise component.", [["separability between the signal and noise components", "PROBLEM", 32, 84], ["the rank estimation", "TEST", 136, 155], ["the above criteria", "TEST", 216, 234], ["separability", "OBSERVATION", 32, 44]]], ["The absolute value of the correlation coefficient is considered; 1 shows that \u03b6 i and \u03b6 j have perfect positive correlation, whilst 0 indicates there is no correlation between them.", [["\u03b6 i", "GENE_OR_GENE_PRODUCT", 78, 81], ["\u03b6 j", "GENE_OR_GENE_PRODUCT", 86, 89], ["absolute", "OBSERVATION_MODIFIER", 4, 12]]], ["The matrix of the absolute values of the Spearman correlation gives a full analysis of the trajectory matrix, and in this analysis each eigenvalue corresponds to an elementary matrix of the SVD.", [["matrix", "CELLULAR_COMPONENT", 4, 10], ["matrix", "CELLULAR_COMPONENT", 102, 108], ["matrix", "OBSERVATION_MODIFIER", 4, 10], ["SVD", "OBSERVATION", 190, 193]]], ["Note that if the absolute value of \u03c1 is close to zero, then the corresponding components are almost orthogonal; however, if it is close to one, then the two components are far from being orthogonal and so it is difficult to separate them.", [["\u03c1", "PROTEIN", 35, 36], ["the absolute value", "TEST", 13, 31]]], ["The results of \u03c1 between the eigenvalues for the white noise are quite large (see [2] ), which helps in the discrimination of the noise part.ReviewOnce r is identified, then the matrices X i can be split into two groups.", [["the white noise", "PROBLEM", 45, 60], ["large", "OBSERVATION_MODIFIER", 71, 76]]], ["Therefore, equation (1) can be written as follows:Reviewwhere S = r i=1 X i is the signal matrix and E = L i=r+1 X i is the noise one.", [["the signal matrix", "TEST", 79, 96], ["E", "TEST", 101, 102]]], ["We then use diagonal averaging to transform matrix S into a new series of size N (see [24] ).AlgorithmThe algorithm consists of two main stages.", [["a new series of size N", "TREATMENT", 58, 80], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Map a one-dimensional time series Y N = (y 1 , . . . , y N ) into multi-dimensional series X 1 , . . . , X K with vectors X i = (y i , . . . , y i+L\u22121 ) T \u2208 R L , where the window length L is an integer; 2 \u2264 L \u2264 N/2, and K = N \u2212 L + 1.", [["N", "CHEMICAL", 57, 58], ["N", "CHEMICAL", 212, 213], ["N", "CHEMICAL", 225, 226], ["Map", "TEST", 0, 3], ["vectors", "TEST", 114, 121], ["length", "TEST", 180, 186], ["an integer", "TEST", 192, 202], ["K", "TEST", 221, 222]]], ["This step gives us the Hankel matrix X = [X 1 , . . . , X K ] = (x ij ) L,K i,j=1 .Algorithm2.", [["the Hankel matrix", "TREATMENT", 19, 36], ["K", "TEST", 58, 59], ["ij", "TEST", 67, 69], ["K i", "TEST", 74, 77], ["j", "TEST", 78, 79]]], ["Compute the matrix A = XX T /tr(XX T ).Decompose matrixis the diagonal matrix of the eigenvalues of A that has the order (1 \u2265 \u03b6 1 \u2265 \u03b6 2 , . . . , \u03b6 L \u2265 0) and 5 All rights reserved.", [["diagonal", "ANATOMY_MODIFIER", 62, 70]]], ["No reuse allowed without permission.Decompose matrix(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Decompose matrixThe copyright holder for this preprint this version posted May 26, 2020. .", [["matrix", "CELLULAR_COMPONENT", 46, 52], ["matrix", "CELLULAR_COMPONENT", 197, 203], ["The copyright holder", "TREATMENT", 203, 223], ["med", "ANATOMY", 131, 134]]], ["P = (P 1 , P 2 , . . . , P L ) is an orthogonal matrix whose columns are the corresponding eigenvectors.Decompose matrix4.", [["matrix", "CELLULAR_COMPONENT", 48, 54], ["matrix4", "GENE_OR_GENE_PRODUCT", 114, 121], ["matrix4", "PROTEIN", 114, 121], ["P", "TEST", 0, 1], ["an orthogonal matrix whose columns", "TREATMENT", 34, 68]]], ["If kurt(\u03b6 c ) is the maximum, select r = c \u2212 1.5.7.", [["\u03b6 c", "GENE_OR_GENE_PRODUCT", 8, 11]]], ["The result of CV splits the eigenvalues in two groups, from \u03b6 1 to \u03b6 c\u22121 which correspond to the signal, and the remainder, which have an almost U shape, correspond to the noise.5.8.", [["CV splits", "OBSERVATION", 14, 23], ["remainder", "OBSERVATION_MODIFIER", 113, 122], ["almost U shape", "OBSERVATION_MODIFIER", 138, 152]]], ["This matrix also splits the eigenvalues into two groups, from \u03b6 1 to \u03b6 r which correspond to the signal, and the remainder, which correspond to the noise.Stage 21.", [["matrix", "CELLULAR_COMPONENT", 5, 11], ["Stage 21", "PROBLEM", 154, 162], ["remainder", "ANATOMY_MODIFIER", 113, 122]]], ["Calculate the approximated signal matrix S, that is S = r i=1 X i , where r is obtained from the first stage, X i = \u221a \u03bb i U i V i T , U i and V i stands for the left and right eigenvectors of the trajectory matrix.Stage 22.", [["left", "ANATOMY", 161, 165], ["matrix", "CELLULAR_COMPONENT", 207, 213], ["the approximated signal matrix S", "TEST", 10, 42], ["U i", "TEST", 134, 137], ["left", "ANATOMY_MODIFIER", 161, 165], ["right", "ANATOMY_MODIFIER", 170, 175], ["eigenvectors", "ANATOMY_MODIFIER", 176, 188], ["trajectory matrix", "OBSERVATION", 196, 213]]], ["By averaging over the diagonals of matrix S, this gives a one dimensional series, which is the approximate signal S.Stage 2The capability of the modified SSA using different synthetic data, including series generated from chaotic map systems with different Signal to Noise ratio (SNR), were presented in [2] .", [["different synthetic data", "TEST", 164, 188], ["chaotic map systems", "TEST", 222, 241], ["Noise ratio", "TEST", 267, 278], ["SNR", "TEST", 280, 283]]], ["This result confirms that the approach works promisingly for any series that is mixed with a low or high noise level.Stage 2Each eigenvalue or singular value contributes to the trajectory matrix decomposition.", [["matrix", "CELLULAR_COMPONENT", 188, 194], ["a low or high noise level", "PROBLEM", 91, 116], ["Stage 2Each eigenvalue", "PROBLEM", 117, 139], ["singular value", "PROBLEM", 143, 157], ["the trajectory matrix decomposition", "PROBLEM", 173, 208], ["singular value", "OBSERVATION", 143, 157], ["trajectory matrix", "OBSERVATION", 177, 194]]], ["We can consider the ratio \u03b6 i \u00d7100 to be the characteristic of matrix H i to Eq.", [["the ratio", "TEST", 16, 25]]], ["Thus, 100 \u00d7 r i=1 \u03b6 i is considered as the characteristic of the optimal approximation of H by matrices of rank r.Stage 2[25]), does not always provide a good separability and correct selection of r, specially for real data.Stage 2It was shown in [2] that the results based on Skew, Kurt, CV , and \u03c1 s are more accurate than those obtained by the w -correlations for small window length, particularly for a data where a linear trend is included in the series.Stage 2Thus, we use the modified SSA, in particular, we use some of those proved criteria on the distribution of \u03b6 i , which given in the previous sections to identify r.", [["sections", "ANATOMY", 606, 614], ["r.", "SPECIES", 627, 629], ["Stage 2It", "PROBLEM", 224, 233], ["Kurt", "TEST", 283, 287], ["CV", "TEST", 289, 291], ["\u03c1 s", "TEST", 298, 301], ["small window length", "PROBLEM", 367, 386], ["a data", "TEST", 405, 411], ["a linear trend", "TEST", 418, 432], ["Stage 2Thus", "PROBLEM", 459, 470]]], ["The results are plausible and reliable.Stage 2We will provide here one synthetic example to show the capability of the approach before applying it to COVID-19 data, for more examples considering different types of series and evaluations with different criteria refer to [2] .Stage 2Simulated data: In the following example, a white noise process t was added to an exponential trend series.Stage 2where t = (1, . . . , N ), N = 42, \u03b1 1 = 10, \u03b1 2 = 0.09, and t is a Gaussian white noise process with variance 1 (see 1).", [["evaluations", "TEST", 225, 236], ["a white noise process", "PROBLEM", 324, 345], ["an exponential trend series", "TEST", 361, 388], ["Stage", "TEST", 389, 394], ["N", "TEST", 423, 424], ["\u03b1", "TEST", 441, 442], ["a Gaussian white noise process", "PROBLEM", 462, 492], ["variance", "TEST", 498, 506]]], ["It is obvious that the number of eigenvalues required to reconstruct the signal for this series is 2, as we have a constant adding to exponential curve, which corresponds to the rank estimation (see [24] .", [["exponential curve", "TEST", 134, 151]]], ["By looking at the w -correlations, and the logarithm of the eigenvalues, we may use only the first component to extract the signal (see Fig. 2 ).Stage 2However, using the suggested measures and criteria, this gives us the correct value of r.", [["r.", "SPECIES", 239, 241]]], ["The maximum value of the kurtosis coefficient is considered as one of the rules and indicators we use for the start of the noise.", [["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["It is clear that the maximum kurtosis coefficients of \u03b6 i is obtained for 7 All rights reserved.", [["clear", "OBSERVATION", 6, 11]]], ["No reuse allowed without permission.Stage 2(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Stage 2The copyright holder for this preprint this version posted May 26, 2020. .", [["med", "ANATOMY", 122, 125]]], ["In addition, the Spearman correlation coefficient between \u03b6 i and \u03b6 i+1 is also calculated.", [["the Spearman correlation", "TEST", 13, 37]]], ["Fig. 5 (left) shows the correlation between \u03b6 i and \u03b6 i+1 .", [["\u03b6 i+1", "GENE_OR_GENE_PRODUCT", 52, 57], ["\u03b6", "PROTEIN", 44, 45], ["left", "ANATOMY_MODIFIER", 8, 12]]], ["For the correlation coefficient, the minimum value of \u03c1 s between \u03b6 c\u22121 and \u03b6 c is used as an another indicator for the cut-off point.", [["\u03b6 c", "GENE_OR_GENE_PRODUCT", 76, 79], ["\u03b6 c\u22121", "PROTEIN", 66, 71], ["\u03b6 c", "PROTEIN", 76, 79], ["the minimum value", "TEST", 33, 50], ["\u03c1 s", "TEST", 54, 57]]], ["Different criteria were used in [2] to evaluate the approach, for example, RMSE and MAE, which confirm that the modified approach can be used as a promising one.Stage 2The correlation matrix also enables us to distinguish and separate the different components from each other.", [["RMSE", "TEST", 75, 79], ["the modified approach", "TREATMENT", 108, 129]]], ["Thus, the correlation matrix of \u03b6 i is identify the separability between the components.", [["components", "OBSERVATION_MODIFIER", 77, 87]]], ["If the absolute value of the correlation coefficient between \u03b6 i 8 All rights reserved.", [["the absolute value", "TEST", 3, 21]]], ["No reuse allowed without permission.Stage 2(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Stage 2The copyright holder for this preprint this version posted May 26, 2020. . and \u03b6 j is small, then the corresponding components are almost orthogonal; however, if the value is large, then the corresponding series are far from being orthogonal and thus they are not neatly separable.", [["\u03b6 j", "GENE_OR_GENE_PRODUCT", 264, 267], ["med", "ANATOMY", 122, 125], ["small", "OBSERVATION_MODIFIER", 271, 276], ["components", "OBSERVATION_MODIFIER", 301, 311], ["almost", "OBSERVATION_MODIFIER", 316, 322], ["orthogonal", "OBSERVATION_MODIFIER", 323, 333], ["large", "OBSERVATION_MODIFIER", 360, 365]]], ["It is clear that the signal can be separated from the noise since the top right pattern from the correlation matrix is related to the white noise process (see Fig. 5 (right)).COVID-19 data analysisThe daily confirmed cases of COVID-19 in Saudi Arabia [32] is used in this research.", [["COVID-19", "CHEMICAL", 226, 234], ["matrix", "CELLULAR_COMPONENT", 109, 115], ["the white noise process", "PROBLEM", 130, 153], ["COVID", "TEST", 175, 180], ["data analysis", "TEST", 184, 197], ["COVID", "TEST", 226, 231], ["clear", "OBSERVATION", 6, 11], ["top", "OBSERVATION_MODIFIER", 70, 73], ["right", "ANATOMY_MODIFIER", 74, 79], ["right", "ANATOMY_MODIFIER", 167, 172]]], ["The number of daily cases series is depicted in Fig. 6 .", [["daily cases series", "TEST", 14, 32]]], ["This does not affect the required number of eigenvalues for the reconstruction stage, this will be discussed in the following part.", [["the reconstruction stage", "TREATMENT", 60, 84]]], ["No reuse allowed without permission.COVID-19 data analysis(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.COVID-19 data analysisThe copyright holder for this preprint this version posted May 26, 2020. .Separability and selection of the componentslet us now start with the first data.", [["COVID", "TEST", 36, 41], ["data analysis", "TEST", 45, 58], ["COVID", "TEST", 193, 198], ["data analysis", "TEST", 202, 215], ["The copyright holder", "TREATMENT", 215, 235], ["med", "ANATOMY", 137, 140]]], ["As we mentioned earlier, since our aim is to extract the signal as a whole, we can choose any value for L, and the goal to find the best choice of r.", [["r.", "SPECIES", 147, 149]]], ["Furthermore, based on our research [2] , we showed that one can use a small window length when analysing exponential series, like the one of COVID-19 series.", [["a small window length", "TREATMENT", 68, 89], ["exponential series", "TEST", 105, 123], ["COVID", "TEST", 141, 146]]], ["The selection of L = 7, provide the best and reasonable results with the required r that will be obtained by the proposed approach.Separability and selection of the componentsTh results based on those measure in extraction the signal for forecasting, give a curve with likely peak.", [["a curve", "TEST", 256, 263], ["L", "ANATOMY_MODIFIER", 17, 18], ["components", "OBSERVATION_MODIFIER", 165, 175]]], ["However, the prediction using many other choices of L and r do not give any end or peak for this pandemic and go up exponentially, and this is impossible as this pandemic will not stay forever.", [["this pandemic", "PROBLEM", 92, 105]]], ["Therefore, the important task now is the selection of the number of eigenvalues r that required for reconstruction and build the model for forecasting.", [["reconstruction", "TREATMENT", 100, 114]]], ["Fig. 7 illustrates the results of the coefficients of skewness and kurtosis for each eigenvalue, and the results of the matrix correlations and correlation between \u03b6 i and \u03b6 i+1 for L = 7.", [["kurtosis", "TEST", 67, 75], ["each eigenvalue", "TEST", 80, 95], ["the matrix correlations", "TEST", 116, 139]]], ["As shown by the results, for the COVID-19 daily series, the maximum values of Skew, Kurt, are observed for \u03b6 c=3 , and the minimum value of \u03c1 s is obtained between \u03b6 c\u22121=2 and \u03b6 c=3 .", [["the COVID", "TEST", 29, 38], ["the maximum values", "TEST", 56, 74], ["the minimum value", "TEST", 119, 136], ["\u03c1 s", "TEST", 140, 143], ["c\u2212", "TEST", 166, 168]]], ["In addition, the matrix of Spearman correlation for \u03b6 i and \u03b6 j (i, j = 1, . . . , 7) split the eigenvalues or the components into two groups; this indicates that the value of r = 2.", [["matrix", "CELLULAR_COMPONENT", 17, 23], ["Spearman correlation", "TEST", 27, 47]]], ["Fig. 8 depicts the the result of the reconstructed series, which is obtained by using L = 7 and eigentriples r = 2.", [["the reconstructed series", "TEST", 33, 57]]], ["The red and the black lines correspond to the reconstructed series and the original series, respectively.", [["lines", "CELL", 22, 27], ["red and the black lines", "CELL_LINE", 4, 27], ["The red and the black lines", "PROBLEM", 0, 27], ["the reconstructed series", "TEST", 42, 66], ["red", "OBSERVATION", 4, 7], ["black lines", "OBSERVATION", 16, 27]]], ["It seems that the reconstructed series has been obtained well.", [["the reconstructed series", "TEST", 14, 38]]], ["No reuse allowed without permission.Separability and selection of the components(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Separability and selection of the componentsThe copyright holder for this preprint this version posted May 26, 2020. . series using the whole data is better than this fitted series.Prediction daily cases of COVID-19 using VSSAAfter obtaining the reconstructed series, the next aim is to predict new data, we will predict values from 13-04-2020 to the end of June 2020.", [["The copyright holder", "TREATMENT", 259, 279], ["the whole data", "TEST", 347, 361], ["this fitted series", "TEST", 377, 395], ["COVID", "TEST", 422, 427], ["the reconstructed series", "TEST", 457, 481], ["med", "ANATOMY", 159, 162], ["components", "OBSERVATION_MODIFIER", 249, 259]]], ["There are two main forecasting methods in SSA, Vector SSA (VSSA) and Recurrent SSA (RSSA).", [["Recurrent SSA (RSSA)", "PROBLEM", 69, 89], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18], ["forecasting", "OBSERVATION_MODIFIER", 19, 30], ["methods", "OBSERVATION", 31, 38], ["SSA", "OBSERVATION_MODIFIER", 42, 45], ["Recurrent", "OBSERVATION_MODIFIER", 69, 78], ["SSA", "OBSERVATION_MODIFIER", 79, 82]]], ["The VSSA forecasting algorithms is the most widely used in SSA [24] .", [["The VSSA forecasting algorithms", "TEST", 0, 31]]], ["Therefore, we use the VSSA algorithm for forecasting in this research as recommended in [13] .Prediction daily cases of COVID-19 using VSSAVector forecasting algorithm: For performing SSA forecasting, the basic requirement is that the series satisfies a linear recurrent formula (LRF).", [["the VSSA algorithm", "TREATMENT", 18, 36], ["COVID", "TEST", 120, 125], ["a linear recurrent formula (LRF", "TREATMENT", 252, 283]]], ["The series Y N = [y 1 , . . . , y N ] satisfies a LRF of order L \u2212 1 if: y t = a 1 y t\u22121 + a 2 y t\u22122 + \u00b7 \u00b7 \u00b7 + a L\u22121 y t\u2212L+1 , t = L + 1, . . . , NPrediction daily cases of COVID-19 using VSSAThe coefficient vector A = a 1 , . . . , a L\u22121 is defined as follows:Prediction daily cases of COVID-19 using VSSAwhere \u03bd 2 = r j=1 \u03c0 2 j , and U \u2207 j is the vector of the first L \u2212 1 components of the 11 All rights reserved.", [["COVID-19", "CHEMICAL", 173, 181], ["COVID-19", "CHEMICAL", 287, 295], ["U \u2207 j", "GENE_OR_GENE_PRODUCT", 336, 341], ["The series", "TEST", 0, 10], ["\u00b7", "TEST", 107, 108], ["L+1", "TEST", 121, 124], ["t", "TEST", 127, 128], ["NPrediction", "TEST", 146, 157], ["COVID", "TEST", 173, 178], ["COVID", "TEST", 287, 292], ["VSSAwhere", "TEST", 302, 311], ["\u2207 j", "ANATOMY", 338, 341], ["vector", "ANATOMY_MODIFIER", 349, 355]]], ["No reuse allowed without permission.Prediction daily cases of COVID-19 using VSSA(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. eigen-vector U j , and \u03c0 j the last component of U j (j = 1, . . . , r).Prediction daily cases of COVID-19 using VSSAConsider the following matrixPrediction daily cases of COVID-19 using VSSAlet us now define the linear operator:Prediction daily cases of COVID-19 using VSSAwhere L r = span{U 1 , . . . , U r } andPrediction daily cases of COVID-19 using VSSAwhere Y is the vector of the last L \u2212 1 elements of Y N .", [["COVID-19", "CHEMICAL", 472, 480], ["COVID-19", "CHEMICAL", 557, 565], ["U j", "GENE_OR_GENE_PRODUCT", 230, 233], ["Y N", "GENE_OR_GENE_PRODUCT", 628, 631], ["L \u2212 1 elements", "DNA", 610, 624], ["COVID", "TEST", 62, 67], ["U j (j", "TREATMENT", 266, 272], ["COVID", "TEST", 315, 320], ["VSSAConsider", "TREATMENT", 330, 342], ["COVID", "TEST", 389, 394], ["COVID", "TEST", 472, 477], ["COVID", "TEST", 557, 562], ["med", "ANATOMY", 160, 163]]], ["The vector Z j is defined as follows:Prediction daily cases of COVID-19 using VSSAwhere the X i are the reconstructed columns of the trajectory matrix of the ith series after grouping and leaving out noise components.", [["vector Z j", "DNA", 4, 14], ["X i", "DNA", 92, 95], ["COVID", "TEST", 63, 68]]], ["Now, by constructing matrix Z = [Z 1 , . . . , Z K+h+L\u22121 ] and performing diagonal averaging, a new series\u0177 1 , . . . ,\u0177 K+h+L\u22121 is obtained, where\u0177 N +1 , . . . ,\u0177 N +h from the h terms of the VSSA forecast.Prediction daily cases of COVID-19 using VSSAAs we discussed above, the best values for reconstruction and forecasting are L = 7 and r = 2.", [["N +h", "CHEMICAL", 165, 169], ["Z", "TEST", 33, 34], ["Z K+h", "TEST", 47, 52], ["performing diagonal averaging", "TEST", 63, 92], ["a new series", "TEST", 94, 106], ["K+h", "TEST", 121, 124], ["COVID", "TEST", 234, 239], ["VSSAAs", "TREATMENT", 249, 255], ["reconstruction", "TEST", 296, 310], ["forecasting", "TEST", 315, 326]]], ["Similar procedures have been done for the new data that updated from 02-03-2020 to 12-05-2020.", [["Similar procedures", "TREATMENT", 0, 18]]], ["No reuse allowed without permission.Prediction daily cases of COVID-19 using VSSA(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Prediction daily cases of COVID-19 using VSSAThe copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111872 doi: medRxiv preprint and used for prediction new data points.", [["COVID", "TEST", 62, 67], ["COVID", "TEST", 242, 247], ["VSSAThe copyright holder", "TREATMENT", 257, 281], ["medRxiv preprint", "TREATMENT", 385, 401], ["med", "ANATOMY", 160, 163]]], ["It is obvious that the reconstructed series is obtained precisely.", [["the reconstructed series", "TEST", 19, 43]]], ["It is obvious that there is no big difference, as the peak by the red curve around May 20 where around beginning of June by the blue curve that used the updated data.", [["big difference", "PROBLEM", 31, 45], ["the updated data", "TEST", 149, 165], ["no", "UNCERTAINTY", 28, 30], ["big", "OBSERVATION_MODIFIER", 31, 34], ["difference", "OBSERVATION", 35, 45]]], ["In addition, and the end of this pandemic will be between mid of June and mid of July.", [["mid", "ANATOMY_MODIFIER", 74, 77]]], ["No reuse allowed without permission.Prediction daily cases of COVID-19 using VSSA(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Prediction daily cases of COVID-19 using VSSAThe copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111872 doi: medRxiv preprintConclusionA modified Singular Spectrum Analysis approach were used in this research for the decomposing and forecasting COVID-19 data in Saudi Arabia.", [["COVID", "TEST", 62, 67], ["COVID", "TEST", 242, 247], ["VSSAThe copyright holder", "TREATMENT", 257, 281], ["medRxiv", "TREATMENT", 385, 392], ["forecasting COVID", "TEST", 509, 526], ["med", "ANATOMY", 160, 163]]], ["The approach was examined in our previous research, and here in analysing COVID-19 data.ConclusionIn the first stage, the first 42 confirmed daily values (02-03 to 12-04-2020) were used and analysed to identify the value of r for separability between noise and the signal.", [["daily values", "TEST", 141, 153]]], ["After obtaining the value of r, which was 2, and extracting the signals, the Vector SSA were used for prediction and determine the pandemic peak.", [["the Vector SSA", "TREATMENT", 73, 87], ["the pandemic peak", "PROBLEM", 127, 144]]], ["We have used the same window length and number of eigenvalues for reconstruction and forecasting.", [["reconstruction", "TREATMENT", 66, 80]]], ["The results of both forecasting scenarios have indicated that the peak will be around end of May and mid of June, and the end of this crises will be between end of June and mid of July.ConclusionAll our results confirm the impressive performance of the modified SSA in analysing COVID-19 data and selecting the value of r for identifying the signal subspace from a noisy time series, and then make a good prediction using Vector SSA method.", [["COVID", "DNA", 279, 284], ["this crises", "PROBLEM", 129, 140], ["Vector SSA method", "TREATMENT", 422, 439]]], ["Note that we have not examined all possible values of window length in this research, and for forecasting we have used only the basic Vector SSA.ConclusionFor future research, we will include more data and considered different window length L that may give a better forecasting.", [["different window length L", "TREATMENT", 217, 242]]], ["In addition, chaotic behaviour in COVID-19 data will be examined as we have some results that show strange patterns, which can be found in chaotic systems.", [["COVID", "DNA", 34, 39], ["COVID", "TEST", 34, 39]]]], "PMC6890989": [["INTRODUCTIONSialic acids (Sia) are a family of nine-carbon monosaccharides expressed mainly in vertebrates that serve as terminal residues of carbohydrate chains on cell membrane glycoproteins and glycolipids, as well as on secreted glycoproteins at all mucosal surfaces (Fig. 1A) (1, 2).", [["cell membrane", "ANATOMY", 165, 178], ["mucosal", "ANATOMY", 254, 261], ["INTRODUCTIONSialic acids", "CHEMICAL", 0, 24], ["Sia", "CHEMICAL", 26, 29], ["INTRODUCTIONSialic acids", "CHEMICAL", 0, 24], ["Sia", "CHEMICAL", 26, 29], ["carbon", "CHEMICAL", 52, 58], ["carbohydrate", "CHEMICAL", 142, 154], ["INTRODUCTIONSialic acids", "SIMPLE_CHEMICAL", 0, 24], ["Sia", "GENE_OR_GENE_PRODUCT", 26, 29], ["cell membrane glycoproteins", "CELLULAR_COMPONENT", 165, 192], ["mucosal surfaces", "TISSUE", 254, 270], ["carbohydrate chains", "PROTEIN", 142, 161], ["cell membrane glycoproteins", "PROTEIN", 165, 192], ["secreted glycoproteins", "PROTEIN", 224, 246], ["nine-carbon monosaccharides", "TREATMENT", 47, 74], ["carbohydrate chains", "TREATMENT", 142, 161], ["cell membrane glycoproteins", "TREATMENT", 165, 192], ["glycolipids", "TREATMENT", 197, 208], ["mucosal surfaces", "ANATOMY", 254, 270]]], ["Sia are key mediators of many cell and tissue functions, where they are bound by cellular receptors such as selectins and siglecs (sialic acid-binding immunoglobulin-type lectins) (3, 4).", [["cell", "ANATOMY", 30, 34], ["tissue", "ANATOMY", 39, 45], ["cellular", "ANATOMY", 81, 89], ["Sia", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 30, 34], ["tissue", "TISSUE", 39, 45], ["cellular", "CELL", 81, 89], ["selectins", "GENE_OR_GENE_PRODUCT", 108, 117], ["siglecs", "GENE_OR_GENE_PRODUCT", 122, 129], ["sialic acid-binding immunoglobulin-type lectins", "GENE_OR_GENE_PRODUCT", 131, 178], ["cellular receptors", "PROTEIN", 81, 99], ["selectins", "PROTEIN", 108, 117], ["siglecs", "PROTEIN", 122, 129], ["sialic acid-binding immunoglobulin-type lectins", "PROTEIN", 131, 178], ["selectins and siglecs (sialic acid-binding immunoglobulin", "TEST", 108, 165], ["many cell", "OBSERVATION", 25, 34]]], ["Their ubiquitous presence on cells, tissues, and mucosal surfaces also make Sia a key point of contact for both commensal microbes and invading pathogens, including viruses, bacteria, and parasites (3).INTRODUCTIONSia are highly diverse since there are more than 50 different chemically distinct variants formed from the basic structure of N-acetylneuraminic acid (Neu5Ac) by the addition of chemical groups at various positions on the pyranose ring or the glycerol side chain.", [["cells", "ANATOMY", 29, 34], ["tissues", "ANATOMY", 36, 43], ["mucosal surfaces", "ANATOMY", 49, 65], ["N-acetylneuraminic acid", "CHEMICAL", 340, 363], ["Neu5Ac", "CHEMICAL", 365, 371], ["pyranose", "CHEMICAL", 436, 444], ["glycerol", "CHEMICAL", 457, 465], ["N-acetylneuraminic acid", "CHEMICAL", 340, 363], ["Neu5Ac", "CHEMICAL", 365, 371], ["pyranose", "CHEMICAL", 436, 444], ["glycerol", "CHEMICAL", 457, 465], ["cells", "CELL", 29, 34], ["tissues", "TISSUE", 36, 43], ["mucosal surfaces", "TISSUE", 49, 65], ["Sia", "GENE_OR_GENE_PRODUCT", 76, 79], ["N-acetylneuraminic acid", "SIMPLE_CHEMICAL", 340, 363], ["Neu5Ac", "SIMPLE_CHEMICAL", 365, 371], ["pyranose", "SIMPLE_CHEMICAL", 436, 444], ["glycerol", "SIMPLE_CHEMICAL", 457, 465], ["glycerol side chain", "PROTEIN", 457, 476], ["both commensal microbes", "PROBLEM", 107, 130], ["invading pathogens", "PROBLEM", 135, 153], ["viruses", "PROBLEM", 165, 172], ["bacteria", "PROBLEM", 174, 182], ["parasites", "PROBLEM", 188, 197], ["50 different chemically distinct variants", "PROBLEM", 263, 304], ["N-acetylneuraminic acid (Neu5Ac", "TREATMENT", 340, 371], ["chemical groups", "TREATMENT", 392, 407], ["the pyranose ring", "TREATMENT", 432, 449], ["the glycerol side chain", "TREATMENT", 453, 476], ["mucosal", "ANATOMY", 49, 56], ["highly", "OBSERVATION_MODIFIER", 222, 228], ["diverse", "OBSERVATION_MODIFIER", 229, 236], ["chemically distinct", "OBSERVATION_MODIFIER", 276, 295], ["variants", "OBSERVATION", 296, 304], ["N-acetylneuraminic acid", "OBSERVATION", 340, 363], ["chemical groups", "OBSERVATION", 392, 407], ["pyranose ring", "OBSERVATION", 436, 449]]], ["These modifications include acetyl, sulfo, methyl, and lactyl groups, among others, which may be present individually or in many combinations (1).", [["acetyl, sulfo, methyl, and", "CHEMICAL", 28, 54], ["lactyl", "CHEMICAL", 55, 61], ["acetyl", "CHEMICAL", 28, 34], ["sulfo", "CHEMICAL", 36, 41], ["methyl", "CHEMICAL", 43, 49], ["lactyl", "CHEMICAL", 55, 61], ["acetyl", "SIMPLE_CHEMICAL", 28, 34], ["sulfo", "SIMPLE_CHEMICAL", 36, 41], ["methyl", "SIMPLE_CHEMICAL", 43, 49], ["lactyl groups", "SIMPLE_CHEMICAL", 55, 68], ["acetyl, sulfo, methyl, and lactyl groups", "TREATMENT", 28, 68]]], ["Since many different enzymes and pathways introduce these modifications, complex mixtures of Sia forms may be present, with significant variation in both the levels and the specific combinations of each modification (1, 2, 5).INTRODUCTIONCommon chemical additions include O-acetyl modifications to the C-4, -7, -8, and/or -9 positions, resulting in a variety of combinations, including Neu4,5Ac, Neu5,9Ac2, and Neu5,7,9Ac3 Sia.", [["O-acetyl", "CHEMICAL", 272, 280], ["O-acetyl", "CHEMICAL", 272, 280], ["Neu4", "CHEMICAL", 386, 390], ["5Ac", "CHEMICAL", 391, 394], ["Neu5", "CHEMICAL", 396, 400], ["9Ac2", "CHEMICAL", 401, 405], ["Neu5", "CHEMICAL", 411, 415], ["Sia", "CHEMICAL", 423, 426], ["Sia", "GENE_OR_GENE_PRODUCT", 93, 96], ["O-acetyl", "SIMPLE_CHEMICAL", 272, 280], ["C-4", "SIMPLE_CHEMICAL", 302, 305], ["-7, -8", "SIMPLE_CHEMICAL", 307, 313], ["Neu4", "GENE_OR_GENE_PRODUCT", 386, 390], ["5Ac", "GENE_OR_GENE_PRODUCT", 391, 394], ["Neu5", "GENE_OR_GENE_PRODUCT", 396, 400], ["9Ac2", "GENE_OR_GENE_PRODUCT", 401, 405], ["Neu5", "GENE_OR_GENE_PRODUCT", 411, 415], ["7,9Ac3 Sia", "GENE_OR_GENE_PRODUCT", 416, 426], ["C-4, -7, -8, and/or -9 positions", "DNA", 302, 334], ["9Ac2", "PROTEIN", 401, 405], ["Neu5", "PROTEIN", 411, 415], ["7,9Ac3 Sia", "PROTEIN", 416, 426], ["many different enzymes", "TEST", 6, 28], ["these modifications", "TREATMENT", 52, 71], ["significant variation in both the levels", "PROBLEM", 124, 164], ["O-acetyl modifications", "TREATMENT", 272, 294], ["Neu4", "TEST", 386, 390], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["variation", "OBSERVATION_MODIFIER", 136, 145]]], ["The addition of O-acetyl modifications (O-Ac) to the C-7 and/or C-9 positions is mediated by the sialate O-acetyltransferase enzyme, Cas1 domain containing 1 (CasD1) (Fig. 1B).", [["O-Ac", "CHEMICAL", 40, 44], ["C-9", "CHEMICAL", 64, 67], ["O-acetyl", "CHEMICAL", 16, 24], ["O-Ac", "CHEMICAL", 40, 44], ["sialate", "CHEMICAL", 97, 104], ["O-acetyl", "SIMPLE_CHEMICAL", 16, 24], ["O-Ac", "SIMPLE_CHEMICAL", 40, 44], ["C-7", "GENE_OR_GENE_PRODUCT", 53, 56], ["C-9", "SIMPLE_CHEMICAL", 64, 67], ["sialate O-acetyltransferase", "GENE_OR_GENE_PRODUCT", 97, 124], ["Cas1 domain containing 1", "GENE_OR_GENE_PRODUCT", 133, 157], ["CasD1", "GENE_OR_GENE_PRODUCT", 159, 164], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 167, 174], ["C-7 and/or C-9 positions", "DNA", 53, 77], ["sialate O-acetyltransferase enzyme", "PROTEIN", 97, 131], ["Cas1 domain containing 1", "PROTEIN", 133, 157], ["CasD1", "PROTEIN", 159, 164], ["Fig. 1B", "PROTEIN", 167, 174], ["O-acetyl modifications", "TREATMENT", 16, 38], ["O-acetyl modifications", "OBSERVATION", 16, 38]]], ["CasD1 appears to add acetyl groups to the C-7 position of Sia, from which it may migrate to the C-8 and C-9 position under physiological conditions, allowing the possible addition of another acetyl group to C-7 (6, 7).", [["CasD1", "CHEMICAL", 0, 5], ["acetyl", "CHEMICAL", 21, 27], ["C-8 and C-9", "CHEMICAL", 96, 107], ["acetyl", "CHEMICAL", 191, 197], ["acetyl", "CHEMICAL", 21, 27], ["Sia", "CHEMICAL", 58, 61], ["acetyl", "CHEMICAL", 191, 197], ["CasD1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Sia", "GENE_OR_GENE_PRODUCT", 58, 61], ["acetyl", "SIMPLE_CHEMICAL", 191, 197], ["C-7", "SIMPLE_CHEMICAL", 207, 210], ["CasD1", "PROTEIN", 0, 5], ["C-7 position", "PROTEIN", 42, 54], ["Sia", "PROTEIN", 58, 61], ["C-8 and C-9 position", "DNA", 96, 116], ["acetyl groups", "TREATMENT", 21, 34], ["another acetyl group", "TREATMENT", 183, 203]]], ["A migrase enzyme has been proposed to aid in the transfer of the acetyl group from C-7 to C-9; however, a specific enzyme has yet to be identified (5, 8, 9).", [["acetyl", "CHEMICAL", 65, 71], ["C-7 to C-9", "CHEMICAL", 83, 93], ["acetyl", "CHEMICAL", 65, 71], ["acetyl", "SIMPLE_CHEMICAL", 65, 71], ["C-7", "SIMPLE_CHEMICAL", 83, 86], ["C-9", "SIMPLE_CHEMICAL", 90, 93], ["migrase enzyme", "PROTEIN", 2, 16], ["A migrase enzyme", "TEST", 0, 16], ["a specific enzyme", "TEST", 104, 121]]], ["CasD1 is localized in the late Golgi compartment, so acetyl modifications are added during the later stages of protein glycosylation.", [["Golgi compartment", "ANATOMY", 31, 48], ["acetyl", "CHEMICAL", 53, 59], ["acetyl", "CHEMICAL", 53, 59], ["CasD1", "GENE_OR_GENE_PRODUCT", 0, 5], ["late", "CELLULAR_COMPONENT", 26, 30], ["Golgi compartment", "CELLULAR_COMPONENT", 31, 48], ["acetyl", "SIMPLE_CHEMICAL", 53, 59], ["CasD1", "PROTEIN", 0, 5], ["acetyl modifications", "TREATMENT", 53, 73], ["protein glycosylation", "TREATMENT", 111, 132], ["late", "OBSERVATION_MODIFIER", 26, 30], ["Golgi compartment", "OBSERVATION", 31, 48], ["acetyl modifications", "OBSERVATION", 53, 73]]], ["The regulatory processes that control the number of acetyl groups added or their positions have not been well defined, although clear differences in expression of 7,9-O-Ac and 9-O-Ac have been reported in mouse and human cells and tissues, in chicken embryos, and in the tissues of some other animals (10, 11).", [["cells", "ANATOMY", 221, 226], ["tissues", "ANATOMY", 231, 238], ["embryos", "ANATOMY", 251, 258], ["tissues", "ANATOMY", 271, 278], ["acetyl", "CHEMICAL", 52, 58], ["7,9-O-Ac", "CHEMICAL", 163, 171], ["9-O-Ac", "CHEMICAL", 176, 182], ["acetyl", "CHEMICAL", 52, 58], ["7,9-O-Ac", "CHEMICAL", 163, 171], ["9-O-Ac", "CHEMICAL", 176, 182], ["acetyl", "SIMPLE_CHEMICAL", 52, 58], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 163, 171], ["9-O-Ac", "SIMPLE_CHEMICAL", 176, 182], ["mouse", "ORGANISM", 205, 210], ["human", "ORGANISM", 215, 220], ["cells", "CELL", 221, 226], ["tissues", "TISSUE", 231, 238], ["chicken", "ORGANISM", 243, 250], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 251, 258], ["tissues", "TISSUE", 271, 278], ["7,9-O-Ac and 9-O-Ac", "DNA", 163, 182], ["mouse and human cells", "CELL_TYPE", 205, 226], ["mouse", "SPECIES", 205, 210], ["human", "SPECIES", 215, 220], ["chicken", "SPECIES", 243, 250], ["mouse", "SPECIES", 205, 210], ["human", "SPECIES", 215, 220], ["chicken", "SPECIES", 243, 250], ["acetyl groups", "TREATMENT", 52, 65], ["Ac", "TEST", 169, 171], ["chicken embryos", "OBSERVATION", 243, 258], ["tissues", "ANATOMY", 271, 278]]], ["CasD1 uses acetyl coenzyme A and likely has a preference for CMP-Neu5Ac as a substrate so that it is less active on CMP-Neu5Gc (7).INTRODUCTIONAt least one sialate O-acetylesterase (SIAE) enzyme regulates the display of 7,9-O- and 9-O-Ac in many cells and tissues (Fig. 1B).", [["cells", "ANATOMY", 246, 251], ["tissues", "ANATOMY", 256, 263], ["CasD1", "CHEMICAL", 0, 5], ["acetyl coenzyme A", "CHEMICAL", 11, 28], ["CMP", "CHEMICAL", 61, 64], ["7,9-O- and 9-O-Ac", "CHEMICAL", 220, 237], ["acetyl coenzyme A", "CHEMICAL", 11, 28], ["Neu5Ac", "CHEMICAL", 65, 71], ["CMP-Neu5Gc", "CHEMICAL", 116, 126], ["sialate", "CHEMICAL", 156, 163], ["7,9-O- and 9-O-Ac", "CHEMICAL", 220, 237], ["CasD1", "SIMPLE_CHEMICAL", 0, 5], ["acetyl coenzyme A", "SIMPLE_CHEMICAL", 11, 28], ["CMP-Neu5Ac", "GENE_OR_GENE_PRODUCT", 61, 71], ["CMP", "SIMPLE_CHEMICAL", 116, 119], ["sialate O-acetylesterase", "GENE_OR_GENE_PRODUCT", 156, 180], ["SIAE", "GENE_OR_GENE_PRODUCT", 182, 186], ["7,9-O", "SIMPLE_CHEMICAL", 220, 225], ["9-O-Ac", "SIMPLE_CHEMICAL", 231, 237], ["cells", "CELL", 246, 251], ["tissues", "TISSUE", 256, 263], ["CasD1", "PROTEIN", 0, 5], ["sialate O-acetylesterase (SIAE) enzyme", "PROTEIN", 156, 194], ["acetyl coenzyme", "TREATMENT", 11, 26], ["CMP-Neu5Ac", "TREATMENT", 61, 71], ["CMP", "TEST", 116, 119], ["Neu5Gc", "TEST", 120, 126], ["enzyme regulates", "TEST", 188, 204], ["less", "OBSERVATION_MODIFIER", 101, 105], ["active", "OBSERVATION_MODIFIER", 106, 112], ["many cells", "ANATOMY", 241, 251], ["tissues", "ANATOMY", 256, 263]]], ["The SIAE gene encodes two isoforms that vary in the presence of a proposed C-terminal localization tag in the lysosomal form (Lse) that is absent from the cytosolic form (Cse) (12).", [["lysosomal", "ANATOMY", 110, 119], ["cytosolic", "ANATOMY", 155, 164], ["C", "CHEMICAL", 75, 76], ["SIAE", "GENE_OR_GENE_PRODUCT", 4, 8], ["lysosomal", "CELLULAR_COMPONENT", 110, 119], ["SIAE gene", "DNA", 4, 13], ["C-terminal localization tag", "PROTEIN", 75, 102], ["lysosomal form", "PROTEIN", 110, 124], ["Lse", "PROTEIN", 126, 129], ["cytosolic form", "PROTEIN", 155, 169], ["a proposed C-terminal localization tag", "PROBLEM", 64, 102], ["terminal", "OBSERVATION_MODIFIER", 77, 85], ["localization tag", "OBSERVATION", 86, 102], ["lysosomal", "ANATOMY", 110, 119]]], ["However, the processes that regulate the expression and activity of these two isoforms remain poorly defined.", [["expression", "OBSERVATION_MODIFIER", 41, 51]]], ["Lse has been found to localize to the Golgi compartment and/or endoplasmic reticulum (ER) and on the surfaces of cells when overexpressed, with the majority being secreted into the supernatant (12).", [["Golgi compartment", "ANATOMY", 38, 55], ["endoplasmic reticulum", "ANATOMY", 63, 84], ["ER", "ANATOMY", 86, 88], ["cells", "ANATOMY", 113, 118], ["supernatant", "ANATOMY", 181, 192], ["Lse", "CHEMICAL", 0, 3], ["Lse", "GENE_OR_GENE_PRODUCT", 0, 3], ["Golgi compartment", "CELLULAR_COMPONENT", 38, 55], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 63, 84], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["cells", "CELL", 113, 118], ["Lse", "PROTEIN", 0, 3], ["ER", "PROTEIN", 86, 88], ["endoplasmic reticulum", "PROBLEM", 63, 84], ["Golgi compartment", "OBSERVATION", 38, 55], ["endoplasmic reticulum", "ANATOMY", 63, 84]]], ["Antibody staining shows that Cse is found diffusely throughout the cytosol, where it is thought to remove 9-O- and 7-O-acetyl groups to recycle the Sia for reuse in glycosylation (12).", [["cytosol", "ANATOMY", 67, 74], ["9-O- and 7-O-acetyl", "CHEMICAL", 106, 125], ["9-O- and 7-O-acetyl", "CHEMICAL", 106, 125], ["Cse", "GENE_OR_GENE_PRODUCT", 29, 32], ["cytosol", "CELLULAR_COMPONENT", 67, 74], ["7-O-acetyl groups", "SIMPLE_CHEMICAL", 115, 132], ["Sia", "GENE_OR_GENE_PRODUCT", 148, 151], ["Cse", "PROTEIN", 29, 32], ["Antibody staining", "TEST", 0, 17], ["Cse", "TEST", 29, 32], ["acetyl groups", "TREATMENT", 119, 132], ["reuse in glycosylation", "TREATMENT", 156, 178]]], ["Despite the reports of distinct protein expression in mouse tissues, bioinformatic analysis of RNA expression in human cells and tissues show mRNA corresponding to the Lse form of SIAE and none responding to the Cse form (13).", [["tissues", "ANATOMY", 60, 67], ["cells", "ANATOMY", 119, 124], ["tissues", "ANATOMY", 129, 136], ["mouse", "ORGANISM", 54, 59], ["tissues", "TISSUE", 60, 67], ["human", "ORGANISM", 113, 118], ["cells", "CELL", 119, 124], ["tissues", "TISSUE", 129, 136], ["SIAE", "GENE_OR_GENE_PRODUCT", 180, 184], ["human cells", "CELL_TYPE", 113, 124], ["mRNA", "RNA", 142, 146], ["Lse form", "PROTEIN", 168, 176], ["SIAE", "PROTEIN", 180, 184], ["mouse", "SPECIES", 54, 59], ["human", "SPECIES", 113, 118], ["mouse", "SPECIES", 54, 59], ["human", "SPECIES", 113, 118], ["distinct protein expression in mouse tissues", "PROBLEM", 23, 67], ["bioinformatic analysis", "TEST", 69, 91], ["RNA expression in human cells and tissues", "PROBLEM", 95, 136], ["mRNA", "TEST", 142, 146], ["protein expression", "OBSERVATION", 32, 50], ["mouse tissues", "OBSERVATION", 54, 67], ["RNA expression", "OBSERVATION", 95, 109]]], ["It is therefore still unclear how these two isoforms are regulated in humans or other animals, whether their expression relates to CasD1, or what controls the levels and locations of 9-O- and 7,9-O-Ac expression.INTRODUCTIONSia O-acetylation and deacetylation play important roles in many different biological processes, particularly in development, cancer, and immunology.", [["cancer", "ANATOMY", 350, 356], ["cancer", "DISEASE", 350, 356], ["9-O- and 7,9-O-Ac", "CHEMICAL", 183, 200], ["humans", "ORGANISM", 70, 76], ["CasD1", "GENE_OR_GENE_PRODUCT", 131, 136], ["7,9-O-Ac", "GENE_OR_GENE_PRODUCT", 192, 200], ["cancer", "CANCER", 350, 356], ["CasD1", "PROTEIN", 131, 136], ["Ac", "DNA", 198, 200], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["INTRODUCTIONSia O-acetylation", "TREATMENT", 212, 241], ["deacetylation", "TREATMENT", 246, 259], ["cancer", "OBSERVATION", 350, 356]]], ["For example, O-acetyl modifications to Sia may alter the binding of host lectins, including siglecs (3, 5, 14).", [["O-acetyl", "CHEMICAL", 13, 21], ["Sia", "CHEMICAL", 39, 42], ["O-acetyl", "CHEMICAL", 13, 21], ["O-acetyl", "SIMPLE_CHEMICAL", 13, 21], ["Sia", "GENE_OR_GENE_PRODUCT", 39, 42], ["lectins", "GENE_OR_GENE_PRODUCT", 73, 80], ["siglecs", "GENE_OR_GENE_PRODUCT", 92, 99], ["O-acetyl modifications", "TREATMENT", 13, 35], ["host lectins", "OBSERVATION_MODIFIER", 68, 80]]], ["Siglecs are regulators of many different cell functions and developmental processes; examples include B- and T cells, where the presence of 9-O-acetyl Sia modulates immune cell activation and differentiation (15).", [["cell", "ANATOMY", 41, 45], ["B- and T cells", "ANATOMY", 102, 116], ["immune cell", "ANATOMY", 165, 176], ["9-O-acetyl", "CHEMICAL", 140, 150], ["9-O-acetyl Sia", "CHEMICAL", 140, 154], ["Siglecs", "GENE_OR_GENE_PRODUCT", 0, 7], ["cell", "CELL", 41, 45], ["B-", "CELL", 102, 104], ["T cells", "CELL", 109, 116], ["9-O-acetyl Sia", "SIMPLE_CHEMICAL", 140, 154], ["immune cell", "CELL", 165, 176], ["Siglecs", "PROTEIN", 0, 7], ["B- and T cells", "CELL_TYPE", 102, 116], ["many different cell functions", "PROBLEM", 26, 55], ["developmental processes", "PROBLEM", 60, 83], ["B- and T cells", "TEST", 102, 116], ["many", "OBSERVATION_MODIFIER", 26, 30], ["different cell functions", "OBSERVATION", 31, 55], ["immune cell activation", "OBSERVATION", 165, 187]]], ["In B cells, negative regulation of B-cell receptor (BCR) activation by siglec CD22 is mediated by binding to Neu5Ac-terminated glycan chains on the BCR, which can be blocked by O-acetyl modifications (16, 17).", [["B cells", "ANATOMY", 3, 10], ["B-cell", "ANATOMY", 35, 41], ["Neu5Ac", "CHEMICAL", 109, 115], ["O-acetyl", "CHEMICAL", 177, 185], ["B cells", "CELL", 3, 10], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 35, 50], ["BCR", "GENE_OR_GENE_PRODUCT", 52, 55], ["siglec CD22", "GENE_OR_GENE_PRODUCT", 71, 82], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 109, 115], ["BCR", "GENE_OR_GENE_PRODUCT", 148, 151], ["O-acetyl", "SIMPLE_CHEMICAL", 177, 185], ["B cells", "CELL_TYPE", 3, 10], ["B-cell receptor", "PROTEIN", 35, 50], ["BCR", "PROTEIN", 52, 55], ["siglec CD22", "PROTEIN", 71, 82], ["BCR", "PROTEIN", 148, 151], ["Neu5Ac", "TEST", 109, 115], ["the BCR", "PROBLEM", 144, 151], ["B cells", "OBSERVATION", 3, 10]]], ["The presence of 9-O-Ac can also reduce the activity of sialidases, including human neuraminidases (18).", [["9-O-Ac", "CHEMICAL", 16, 22], ["9-O-Ac", "CHEMICAL", 16, 22], ["9-O-Ac", "SIMPLE_CHEMICAL", 16, 22], ["sialidases", "GENE_OR_GENE_PRODUCT", 55, 65], ["human", "ORGANISM", 77, 82], ["neuraminidases", "GENE_OR_GENE_PRODUCT", 83, 97], ["sialidases", "PROTEIN", 55, 65], ["human neuraminidases", "PROTEIN", 77, 97], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["the activity of sialidases", "PROBLEM", 39, 65], ["human neuraminidases", "TEST", 77, 97]]], ["Incorrect regulation of 9-O-Ac, 7,9-O-Ac, and SIAE activity has been linked to autoimmune disorders through the development of autoantibodies (17, 19).", [["9-O-Ac", "CHEMICAL", 24, 30], ["7,9-O-Ac", "CHEMICAL", 32, 40], ["autoimmune disorders", "DISEASE", 79, 99], ["9-O-Ac", "CHEMICAL", 24, 30], ["7,9-O-Ac", "CHEMICAL", 32, 40], ["9-O-Ac", "SIMPLE_CHEMICAL", 24, 30], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 32, 40], ["SIAE", "SIMPLE_CHEMICAL", 46, 50], ["SIAE", "DNA", 46, 50], ["autoantibodies", "PROTEIN", 127, 141], ["autoimmune disorders", "PROBLEM", 79, 99], ["autoantibodies", "PROBLEM", 127, 141], ["autoantibodies", "OBSERVATION", 127, 141]]], ["9-O-Ac and 7,9-O-Ac, and their regulation by SIAE also appear to play important roles during early stages of embryonic development, spermatogenesis, and in different forms of cancer, including acute lymphoblastic leukemia, colon cancer, and breast cancer (20\u201323).INTRODUCTIONEffects of different Sia modifications have also been suggested for the binding of pathogens or on the activities of their sialidases (neuraminidases).", [["embryonic", "ANATOMY", 109, 118], ["cancer", "ANATOMY", 175, 181], ["acute lymphoblastic leukemia", "ANATOMY", 193, 221], ["colon cancer", "ANATOMY", 223, 235], ["breast cancer", "ANATOMY", 241, 254], ["9-O-Ac", "CHEMICAL", 0, 6], ["7,9-O-Ac", "CHEMICAL", 11, 19], ["cancer", "DISEASE", 175, 181], ["acute lymphoblastic leukemia", "DISEASE", 193, 221], ["colon cancer", "DISEASE", 223, 235], ["breast cancer", "DISEASE", 241, 254], ["9-O-Ac", "CHEMICAL", 0, 6], ["7,9-O-Ac", "CHEMICAL", 11, 19], ["9-O-Ac", "SIMPLE_CHEMICAL", 0, 6], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 11, 19], ["SIAE", "GENE_OR_GENE_PRODUCT", 45, 49], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 109, 118], ["cancer", "CANCER", 175, 181], ["acute lymphoblastic leukemia", "CANCER", 193, 221], ["colon cancer", "CANCER", 223, 235], ["breast cancer", "CANCER", 241, 254], ["20\u201323", "CANCER", 256, 261], ["Sia", "GENE_OR_GENE_PRODUCT", 296, 299], ["sialidases", "GENE_OR_GENE_PRODUCT", 398, 408], ["neuraminidases", "GENE_OR_GENE_PRODUCT", 410, 424], ["SIAE", "PROTEIN", 45, 49], ["sialidases", "PROTEIN", 398, 408], ["neuraminidases", "PROTEIN", 410, 424], ["Ac", "TREATMENT", 17, 19], ["embryonic development", "PROBLEM", 109, 130], ["cancer", "PROBLEM", 175, 181], ["acute lymphoblastic leukemia", "PROBLEM", 193, 221], ["colon cancer", "PROBLEM", 223, 235], ["breast cancer", "PROBLEM", 241, 254], ["different Sia modifications", "TREATMENT", 286, 313], ["pathogens", "PROBLEM", 358, 367], ["cancer", "OBSERVATION", 175, 181], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["lymphoblastic leukemia", "OBSERVATION", 199, 221], ["colon", "ANATOMY", 223, 228], ["cancer", "OBSERVATION", 229, 235], ["breast", "ANATOMY", 241, 247], ["cancer", "OBSERVATION", 248, 254]]], ["Influenza A virus (IAV), IBV, ICV, and IDV use Sia as their primary receptors for host recognition and cell entry, but with different effects of Sia modification.", [["cell", "ANATOMY", 103, 107], ["Influenza A virus", "DISEASE", 0, 17], ["ICV", "CHEMICAL", 30, 33], ["IDV", "CHEMICAL", 39, 42], ["Influenza A virus", "ORGANISM", 0, 17], ["IAV", "ORGANISM", 19, 22], ["IBV", "ORGANISM", 25, 28], ["Sia", "GENE_OR_GENE_PRODUCT", 47, 50], ["cell", "CELL", 103, 107], ["Sia", "GENE_OR_GENE_PRODUCT", 145, 148], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["IAV", "SPECIES", 19, 22], ["IBV", "SPECIES", 25, 28], ["Influenza", "PROBLEM", 0, 9], ["IBV", "TREATMENT", 25, 28], ["ICV", "TREATMENT", 30, 33], ["cell entry", "TEST", 103, 113], ["Sia modification", "TREATMENT", 145, 161]]], ["IAV and IBV interact with Sia through two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA).", [["surface", "ANATOMY", 42, 49], ["IAV", "ORGANISM", 0, 3], ["IBV", "ORGANISM", 8, 11], ["Sia", "GENE_OR_GENE_PRODUCT", 26, 29], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 65, 78], ["HA", "GENE_OR_GENE_PRODUCT", 80, 82], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 88, 101], ["Sia", "PROTEIN", 26, 29], ["surface glycoproteins", "PROTEIN", 42, 63], ["hemagglutinin", "PROTEIN", 65, 78], ["HA", "PROTEIN", 80, 82], ["neuraminidase", "PROTEIN", 88, 101], ["NA", "PROTEIN", 103, 105], ["IAV", "SPECIES", 0, 3], ["IBV", "SPECIES", 8, 11], ["IAV", "PROBLEM", 0, 3], ["IBV", "TREATMENT", 8, 11], ["Sia through two surface glycoproteins", "TREATMENT", 26, 63], ["hemagglutinin (HA)", "TREATMENT", 65, 83], ["neuraminidase (NA)", "TREATMENT", 88, 106], ["IBV", "OBSERVATION", 8, 11]]], ["For both IAV and IBV, HA binds Sia to initiate the endocytic uptake of the virus by the cell, leading to fusion between the viral envelope and the endosomal membrane at low pH (24, 25).", [["cell", "ANATOMY", 88, 92], ["endosomal membrane", "ANATOMY", 147, 165], ["IAV", "ORGANISM", 9, 12], ["IBV", "ORGANISM", 17, 20], ["Sia", "GENE_OR_GENE_PRODUCT", 31, 34], ["cell", "CELL", 88, 92], ["endosomal membrane", "CELLULAR_COMPONENT", 147, 165], ["Sia", "PROTEIN", 31, 34], ["IAV", "SPECIES", 9, 12], ["IBV", "SPECIES", 17, 20], ["IBV", "PROBLEM", 17, 20], ["HA binds", "PROBLEM", 22, 30], ["the virus", "PROBLEM", 71, 80], ["fusion", "TREATMENT", 105, 111], ["the viral envelope", "PROBLEM", 120, 138], ["IBV", "OBSERVATION", 17, 20], ["endocytic uptake", "OBSERVATION", 51, 67], ["fusion", "OBSERVATION", 105, 111], ["viral envelope", "OBSERVATION", 124, 138], ["endosomal membrane", "OBSERVATION", 147, 165], ["low pH", "OBSERVATION_MODIFIER", 169, 175]]], ["NA is a sialidase which cleaves Sia off glycan chains when it is present in mucus or on the surface of cells, allowing the virus to penetrate to the epithelial cells and also preventing aggregation of newly produced virus after budding (26, 27).", [["mucus", "ANATOMY", 76, 81], ["surface", "ANATOMY", 92, 99], ["cells", "ANATOMY", 103, 108], ["epithelial cells", "ANATOMY", 149, 165], ["NA", "CHEMICAL", 0, 2], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["sialidase", "GENE_OR_GENE_PRODUCT", 8, 17], ["Sia", "GENE_OR_GENE_PRODUCT", 32, 35], ["mucus", "ORGANISM_SUBSTANCE", 76, 81], ["surface", "CELLULAR_COMPONENT", 92, 99], ["cells", "CELL", 103, 108], ["epithelial cells", "CELL", 149, 165], ["sialidase", "PROTEIN", 8, 17], ["epithelial cells", "CELL_TYPE", 149, 165], ["a sialidase", "TREATMENT", 6, 17], ["Sia off glycan chains", "TREATMENT", 32, 53], ["the virus", "PROBLEM", 119, 128], ["aggregation", "PROBLEM", 186, 197], ["newly produced virus", "PROBLEM", 201, 221], ["mucus", "OBSERVATION", 76, 81], ["epithelial cells", "ANATOMY", 149, 165], ["virus", "OBSERVATION", 216, 221]]], ["In contrast to IAV and IBV, ICV and IDV have one surface glycoprotein, the hemagglutinin-esterase fusion protein (HEF), which serves similar purposes to both HA and NA.", [["surface", "ANATOMY", 49, 56], ["ICV", "CHEMICAL", 28, 31], ["IDV", "CHEMICAL", 36, 39], ["NA", "CHEMICAL", 165, 167], ["IAV", "ORGANISM", 15, 18], ["IBV", "ORGANISM", 23, 26], ["ICV", "SIMPLE_CHEMICAL", 28, 31], ["IDV", "SIMPLE_CHEMICAL", 36, 39], ["hemagglutinin-esterase fusion protein", "GENE_OR_GENE_PRODUCT", 75, 112], ["HEF", "GENE_OR_GENE_PRODUCT", 114, 117], ["surface glycoprotein", "PROTEIN", 49, 69], ["hemagglutinin-esterase fusion protein", "PROTEIN", 75, 112], ["HEF", "PROTEIN", 114, 117], ["IAV", "SPECIES", 15, 18], ["IBV", "SPECIES", 23, 26], ["IAV", "PROBLEM", 15, 18], ["IBV", "PROBLEM", 23, 26], ["ICV", "TREATMENT", 28, 31], ["IDV", "TREATMENT", 36, 39], ["one surface glycoprotein", "TREATMENT", 45, 69], ["the hemagglutinin-esterase fusion protein", "TREATMENT", 71, 112]]], ["HEF binds specifically to 9-O-acetyl Sia to initiate uptake of the virus into cells, while the esterase domain removes 9-O-acetyl modifications, releasing the virus from mucus and disassembling virus aggregates after budding (28\u201331).", [["cells", "ANATOMY", 78, 83], ["mucus", "ANATOMY", 170, 175], ["HEF", "CHEMICAL", 0, 3], ["9-O-acetyl Sia", "CHEMICAL", 26, 40], ["9-O-acetyl", "CHEMICAL", 119, 129], ["9-O-acetyl Sia", "CHEMICAL", 26, 40], ["9-O-acetyl", "CHEMICAL", 119, 129], ["HEF", "SIMPLE_CHEMICAL", 0, 3], ["9-O-acetyl Sia", "SIMPLE_CHEMICAL", 26, 40], ["cells", "CELL", 78, 83], ["9-O-acetyl", "SIMPLE_CHEMICAL", 119, 129], ["mucus", "ORGANISM_SUBSTANCE", 170, 175], ["HEF", "PROTEIN", 0, 3], ["esterase domain", "PROTEIN", 95, 110], ["HEF binds", "TEST", 0, 9], ["acetyl Sia", "TREATMENT", 30, 40], ["the virus into cells", "PROBLEM", 63, 83], ["the esterase domain", "TEST", 91, 110], ["acetyl modifications", "TREATMENT", 123, 143], ["the virus", "PROBLEM", 155, 164], ["mucus and disassembling virus aggregates", "PROBLEM", 170, 210]]], ["While the role of O-acetyl modified Sia for ICV and IDV infections are well documented, how these modifications affect IAV is not well characterized.", [["ICV", "CHEMICAL", 44, 47], ["infections", "DISEASE", 56, 66], ["O-acetyl", "CHEMICAL", 18, 26], ["O-acetyl", "SIMPLE_CHEMICAL", 18, 26], ["Sia", "GENE_OR_GENE_PRODUCT", 36, 39], ["IAV", "ORGANISM", 119, 122], ["O-acetyl modified Sia", "TREATMENT", 18, 39], ["ICV and IDV infections", "TREATMENT", 44, 66], ["infections", "OBSERVATION", 56, 66], ["well characterized", "OBSERVATION_MODIFIER", 130, 148]]], ["In addition, although previous preliminary studies have suggested that the presence of 9-O-Ac on cells may be inhibitory for both NA activity and HA binding of IAV (32, 33), the details are unclear.INTRODUCTIONHere, we examine and more closely define the expression and distribution of 9-O-acetyl and 7,9-O-acetyl Sia on cells in culture, define the effects of SIAE and CasD1 on display of these Sia modifications, and perform an initial examination of the effects of these modified Sia on infection by IAV, IBV, ICV, and IDV.", [["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 321, 326], ["9-O-Ac", "CHEMICAL", 87, 93], ["9-O-acetyl", "CHEMICAL", 286, 296], ["7,9-O-acetyl", "CHEMICAL", 301, 313], ["infection", "DISEASE", 490, 499], ["IDV", "CHEMICAL", 522, 525], ["9-O-Ac", "CHEMICAL", 87, 93], ["9-O-acetyl", "CHEMICAL", 286, 296], ["7,9-O-acetyl Sia", "CHEMICAL", 301, 317], ["9-O-Ac", "SIMPLE_CHEMICAL", 87, 93], ["cells", "CELL", 97, 102], ["NA", "SIMPLE_CHEMICAL", 130, 132], ["9-O-acetyl", "SIMPLE_CHEMICAL", 286, 296], ["7,9-O-acetyl Sia", "SIMPLE_CHEMICAL", 301, 317], ["cells", "CELL", 321, 326], ["SIAE", "GENE_OR_GENE_PRODUCT", 361, 365], ["CasD1", "SIMPLE_CHEMICAL", 370, 375], ["Sia", "GENE_OR_GENE_PRODUCT", 396, 399], ["Sia", "GENE_OR_GENE_PRODUCT", 483, 486], ["IAV", "ORGANISM", 503, 506], ["IBV", "ORGANISM", 508, 511], ["SIAE", "PROTEIN", 361, 365], ["IAV", "SPECIES", 503, 506], ["IBV", "SPECIES", 508, 511], ["previous preliminary studies", "TEST", 22, 50], ["Ac on cells", "TREATMENT", 91, 102], ["both NA activity", "PROBLEM", 125, 141], ["HA binding of IAV", "PROBLEM", 146, 163], ["acetyl", "TREATMENT", 290, 296], ["O-acetyl Sia on cells", "TREATMENT", 305, 326], ["culture", "TEST", 330, 337], ["SIAE", "TREATMENT", 361, 365], ["CasD1", "TREATMENT", 370, 375], ["these Sia modifications", "TREATMENT", 390, 413], ["an initial examination", "TEST", 427, 449], ["infection", "PROBLEM", 490, 499], ["IAV", "TREATMENT", 503, 506], ["IBV", "TREATMENT", 508, 511], ["ICV", "TREATMENT", 513, 516], ["IDV", "TREATMENT", 522, 525], ["IAV", "OBSERVATION_MODIFIER", 160, 163], ["infection", "OBSERVATION", 490, 499]]], ["We used CRISPR-Cas9 for gene engineering of the enzymes that add or remove the 9-O- and 7,9-O-acetyl groups from Sia and combine these with the recently developed viral protein-derived probes that specifically recognize modified Sia.", [["9-O- and 7,9-O-acetyl", "CHEMICAL", 79, 100], ["9-O- and 7,9-O-acetyl", "CHEMICAL", 79, 100], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 8, 19], ["7,9-O-acetyl groups", "SIMPLE_CHEMICAL", 88, 107], ["Sia", "SIMPLE_CHEMICAL", 113, 116], ["Sia", "GENE_OR_GENE_PRODUCT", 229, 232], ["CRISPR", "DNA", 8, 14], ["Cas9", "DNA", 15, 19], ["viral protein", "PROTEIN", 163, 176], ["Sia", "PROTEIN", 229, 232], ["CRISPR-Cas9", "TREATMENT", 8, 19], ["the enzymes", "TEST", 44, 55], ["O-acetyl groups", "TREATMENT", 92, 107], ["viral protein", "PROBLEM", 163, 176]]], ["By merging these with high-pressure liquid chromatography (HPLC)-based quantification of the different Sia forms, we provide a more detailed understanding of the expression and localization of these modifications in cells and examine their effects on host-virus interactions as examples.Expression of 7,9-O- and 9-O-acetyl Sia in cells. ::: RESULTSThere is currently only sporadic information about the expression of modified Sia on commonly used cell lines or an understanding of how that compares to the expression in animal tissues.", [["cells", "ANATOMY", 216, 221], ["cells", "ANATOMY", 330, 335], ["cell lines", "ANATOMY", 447, 457], ["tissues", "ANATOMY", 527, 534], ["7,9-O- and 9-O-acetyl", "CHEMICAL", 301, 322], ["7,9-O- and 9-O-acetyl Sia", "CHEMICAL", 301, 326], ["cells", "CELL", 216, 221], ["7,9-O", "SIMPLE_CHEMICAL", 301, 306], ["9-O-acetyl Sia", "SIMPLE_CHEMICAL", 312, 326], ["cells", "CELL", 330, 335], ["Sia", "GENE_OR_GENE_PRODUCT", 426, 429], ["cell lines", "CELL", 447, 457], ["tissues", "TISSUE", 527, 534], ["modified Sia", "PROTEIN", 417, 429], ["cell lines", "CELL_LINE", 447, 457], ["high-pressure liquid chromatography", "TEST", 22, 57], ["HPLC", "TEST", 59, 63], ["these modifications in cells", "TREATMENT", 193, 221], ["host-virus interactions", "TREATMENT", 251, 274], ["Expression", "TEST", 287, 297], ["cell lines", "TREATMENT", 447, 457]]], ["We examined cell lines that are widely used in many experimental systems: A549 human type II alveolar epithelial cells, HEK-293 human kidney derived cells (possibly embryonic adrenal precursor cells [34]), and MDCK canine kidney epithelial cells.", [["cell lines", "ANATOMY", 12, 22], ["A549", "ANATOMY", 74, 78], ["type II alveolar epithelial cells", "ANATOMY", 85, 118], ["HEK-293", "ANATOMY", 120, 127], ["kidney derived cells", "ANATOMY", 134, 154], ["embryonic adrenal precursor cells", "ANATOMY", 165, 198], ["MDCK", "ANATOMY", 210, 214], ["kidney epithelial cells", "ANATOMY", 222, 245], ["cell lines", "CELL", 12, 22], ["A549", "CELL", 74, 78], ["human", "ORGANISM", 79, 84], ["alveolar epithelial cells", "CELL", 93, 118], ["HEK-293 human kidney derived cells", "CELL", 120, 154], ["embryonic adrenal precursor cells [34]", "CELL", 165, 203], ["MDCK canine kidney epithelial cells", "CELL", 210, 245], ["cell lines", "CELL_LINE", 12, 22], ["A549 human type II alveolar epithelial cells", "CELL_LINE", 74, 118], ["HEK-293 human kidney derived cells", "CELL_LINE", 120, 154], ["embryonic adrenal precursor cells", "CELL_TYPE", 165, 198], ["MDCK canine kidney epithelial cells", "CELL_LINE", 210, 245], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 128, 133], ["canine", "SPECIES", 215, 221], ["human", "SPECIES", 79, 84], ["HEK-293", "SPECIES", 120, 127], ["human", "SPECIES", 128, 133], ["canine", "SPECIES", 215, 221], ["cell lines", "TREATMENT", 12, 22], ["A549 human type II alveolar epithelial cells", "TEST", 74, 118], ["HEK", "TEST", 120, 123], ["human kidney derived cells", "TEST", 128, 154], ["embryonic adrenal precursor cells", "PROBLEM", 165, 198], ["MDCK canine kidney epithelial cells", "PROBLEM", 210, 245], ["cell lines", "OBSERVATION", 12, 22], ["alveolar epithelial cells", "OBSERVATION", 93, 118], ["kidney", "ANATOMY", 134, 140], ["adrenal", "ANATOMY", 175, 182], ["precursor cells", "OBSERVATION", 183, 198], ["kidney", "ANATOMY", 222, 228], ["epithelial cells", "OBSERVATION", 229, 245]]], ["In addition, we tested MDCK type I and type II cells that were previously subcloned by others from the ATCC MDCK line (MDCK-NBL2) and which have been extensively characterized (35\u201337).", [["MDCK type I", "ANATOMY", 23, 34], ["type II cells", "ANATOMY", 39, 52], ["ATCC MDCK line", "ANATOMY", 103, 117], ["MDCK-NBL2", "ANATOMY", 119, 128], ["MDCK type I", "CELL", 23, 34], ["type II cells", "CELL", 39, 52], ["ATCC MDCK line", "CELL", 103, 117], ["MDCK-NBL2", "CELL", 119, 128], ["MDCK type I and type II cells", "CELL_LINE", 23, 52], ["ATCC MDCK line", "CELL_LINE", 103, 117], ["MDCK", "CELL_LINE", 119, 123], ["NBL2", "CELL_LINE", 124, 128], ["type II cells", "PROBLEM", 39, 52], ["the ATCC MDCK line", "TEST", 99, 117]]], ["We used probes derived from porcine torovirus (PToV) and bovine coronavirus (BCoV) hemagglutinin-esterase proteins (HE) that were fused to human IgG1 Fc and which had the esterase active site inactivated (HE-Fc).", [["porcine", "ORGANISM", 28, 35], ["torovirus", "GENE_OR_GENE_PRODUCT", 36, 45], ["PToV", "ORGANISM", 47, 51], ["bovine coronavirus", "ORGANISM", 57, 75], ["BCoV) hemagglutinin-esterase proteins", "GENE_OR_GENE_PRODUCT", 77, 114], ["human", "ORGANISM", 139, 144], ["IgG1 Fc", "GENE_OR_GENE_PRODUCT", 145, 152], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 205, 210], ["porcine torovirus (PToV) and bovine coronavirus (BCoV) hemagglutinin-esterase proteins", "PROTEIN", 28, 114], ["HE", "PROTEIN", 116, 118], ["human IgG1 Fc", "PROTEIN", 139, 152], ["esterase active site inactivated (HE-Fc", "PROTEIN", 171, 210], ["porcine", "SPECIES", 28, 35], ["bovine", "SPECIES", 57, 63], ["coronavirus", "SPECIES", 64, 75], ["human", "SPECIES", 139, 144], ["porcine torovirus", "SPECIES", 28, 45], ["PToV", "SPECIES", 47, 51], ["bovine coronavirus", "SPECIES", 57, 75], ["BCoV", "SPECIES", 77, 81], ["human", "SPECIES", 139, 144], ["porcine torovirus (PToV)", "TREATMENT", 28, 52], ["bovine coronavirus (BCoV", "TREATMENT", 57, 81], ["hemagglutinin-esterase proteins", "TREATMENT", 83, 114], ["human IgG1 Fc", "TEST", 139, 152], ["the esterase active site", "PROBLEM", 167, 191]]], ["The PToV HE-Fc probe recognizes 9-O-Ac, while BCoV HE-Fc recognizes primarily 7,9-O-Ac, although with a low affinity for 9-O-Ac (10, 11).", [["9-O-Ac", "CHEMICAL", 32, 38], ["7,9-O-Ac", "CHEMICAL", 78, 86], ["9-O-Ac", "CHEMICAL", 121, 127], ["9-O-Ac", "CHEMICAL", 32, 38], ["7,9-O-Ac", "CHEMICAL", 78, 86], ["9-O-Ac", "CHEMICAL", 121, 127], ["9-O-Ac", "SIMPLE_CHEMICAL", 32, 38], ["BCoV HE-Fc", "SIMPLE_CHEMICAL", 46, 56], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 78, 86], ["9-O-Ac", "SIMPLE_CHEMICAL", 121, 127], ["PToV HE-Fc probe", "DNA", 4, 20], ["BCoV HE-Fc", "PROTEIN", 46, 56], ["a low affinity", "PROBLEM", 102, 116]]], ["As observed by immunofluorescence microscopy, the different forms were evident at variable levels, with between 10 and 70% of the cells of each type showing staining under standard culture conditions (Fig. 2).", [["cells", "ANATOMY", 130, 135], ["cells", "CELL", 130, 135], ["immunofluorescence microscopy", "TEST", 15, 44]]], ["MDCK-NBL2 and MDCK type I cells showed both strong surface and internal staining for 7,9-O- and 9-O-Ac forms, while both were mostly found in intracellular locations in A549 and HEK-293 cells, with an occasional cell showing bright surface staining.", [["MDCK-NBL2", "ANATOMY", 0, 9], ["MDCK type I cells", "ANATOMY", 14, 31], ["surface", "ANATOMY", 51, 58], ["intracellular", "ANATOMY", 142, 155], ["A549", "ANATOMY", 169, 173], ["HEK-293 cells", "ANATOMY", 178, 191], ["cell", "ANATOMY", 212, 216], ["surface", "ANATOMY", 232, 239], ["7,9-O- and 9-O-Ac", "CHEMICAL", 85, 102], ["MDCK-NBL2", "CELL", 0, 9], ["MDCK type I cells", "CELL", 14, 31], ["surface", "CELLULAR_COMPONENT", 51, 58], ["7,9-O", "SIMPLE_CHEMICAL", 85, 90], ["9-O-Ac", "SIMPLE_CHEMICAL", 96, 102], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 142, 155], ["A549", "CELL", 169, 173], ["HEK-293 cells", "CELL", 178, 191], ["cell", "CELL", 212, 216], ["MDCK", "CELL_LINE", 0, 4], ["NBL2", "CELL_LINE", 5, 9], ["MDCK type I cells", "CELL_LINE", 14, 31], ["A549", "CELL_LINE", 169, 173], ["HEK-293 cells", "CELL_LINE", 178, 191], ["HEK-293", "SPECIES", 178, 185], ["MDCK", "TEST", 0, 4], ["MDCK type I cells", "TEST", 14, 31], ["internal staining", "TEST", 63, 80], ["HEK", "TEST", 178, 181], ["an occasional cell", "PROBLEM", 198, 216], ["bright surface staining", "PROBLEM", 225, 248], ["strong", "OBSERVATION_MODIFIER", 44, 50], ["internal", "ANATOMY_MODIFIER", 63, 71], ["staining", "OBSERVATION", 72, 80], ["occasional cell", "OBSERVATION", 201, 216], ["bright", "OBSERVATION_MODIFIER", 225, 231], ["surface", "OBSERVATION_MODIFIER", 232, 239], ["staining", "OBSERVATION", 240, 248]]], ["MDCK type II cells showed staining only for 9-O-Ac and none for 7,9-O-Ac, indicating that these modifications are regulated independently.", [["MDCK type II cells", "ANATOMY", 0, 18], ["9-O-Ac", "CHEMICAL", 44, 50], ["7,9-O-Ac", "CHEMICAL", 64, 72], ["9-O-Ac", "CHEMICAL", 44, 50], ["7,9-O-Ac", "CHEMICAL", 64, 72], ["MDCK type II cells", "CELL", 0, 18], ["9-O-Ac", "SIMPLE_CHEMICAL", 44, 50], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 64, 72], ["MDCK type II cells", "CELL_LINE", 0, 18], ["MDCK type II cells", "TEST", 0, 18], ["staining", "TEST", 26, 34], ["Ac", "TEST", 48, 50]]], ["In HEK-293 and A549 cells, both 7,9-O- and 9-O-Ac appeared to be localized within the Golgi compartment, as confirmed by costaining with the Golgi marker GM130 (Fig. 3).", [["HEK-293", "ANATOMY", 3, 10], ["A549 cells", "ANATOMY", 15, 25], ["Golgi compartment", "ANATOMY", 86, 103], ["Golgi marker GM130", "ANATOMY", 141, 159], ["7,9-O- and 9-O-Ac", "CHEMICAL", 32, 49], ["7,9-O- and 9-O-Ac", "CHEMICAL", 32, 49], ["HEK-293", "CELL", 3, 10], ["A549 cells", "CELL", 15, 25], ["7,9-O", "SIMPLE_CHEMICAL", 32, 37], ["9-O-Ac", "SIMPLE_CHEMICAL", 43, 49], ["Golgi compartment", "CELLULAR_COMPONENT", 86, 103], ["Golgi", "CELLULAR_COMPONENT", 141, 146], ["GM130", "GENE_OR_GENE_PRODUCT", 154, 159], ["HEK-293", "CELL_LINE", 3, 10], ["A549 cells", "CELL_LINE", 15, 25], ["Golgi marker", "PROTEIN", 141, 153], ["GM130", "PROTEIN", 154, 159], ["Fig. 3", "PROTEIN", 161, 167], ["HEK-293", "SPECIES", 3, 10], ["HEK", "TEST", 3, 6], ["A549 cells", "TEST", 15, 25], ["A549 cells", "OBSERVATION", 15, 25], ["Golgi compartment", "OBSERVATION", 86, 103]]], ["Similar localization differences between some cell lines have been seen previously using the ICV HEF as a probe (38).", [["cell lines", "ANATOMY", 46, 56], ["cell lines", "CELL", 46, 56], ["cell lines", "CELL_LINE", 46, 56], ["ICV HEF", "DNA", 93, 100], ["some cell lines", "TREATMENT", 41, 56], ["the ICV HEF", "TREATMENT", 89, 100], ["some", "OBSERVATION_MODIFIER", 41, 45], ["cell lines", "OBSERVATION", 46, 56]]], ["In our studies, there was inherent variability within populations in terms of both level of staining and localization.", [["our studies", "TEST", 3, 14], ["inherent variability within populations", "PROBLEM", 26, 65], ["variability", "OBSERVATION_MODIFIER", 35, 46], ["populations", "OBSERVATION_MODIFIER", 54, 65], ["staining", "OBSERVATION", 92, 100]]], ["For example, in MDCK-NBL2 not all cells were positive for 9-O-Ac, whereas in MDCK type I some cells retained more 9-O-Ac and 7,9-O-Ac internally, while others displayed more of the modified Sia on their surfaces (Fig. 2A).", [["MDCK-NBL2", "ANATOMY", 16, 25], ["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 94, 99], ["9-O-Ac", "CHEMICAL", 58, 64], ["9-O-Ac", "CHEMICAL", 114, 120], ["7,9-O-Ac", "CHEMICAL", 125, 133], ["9-O-Ac", "CHEMICAL", 58, 64], ["9-O-Ac", "CHEMICAL", 114, 120], ["7,9-O-Ac", "CHEMICAL", 125, 133], ["MDCK-NBL2", "CELL", 16, 25], ["cells", "CELL", 34, 39], ["9-O-Ac", "SIMPLE_CHEMICAL", 58, 64], ["MDCK type I", "CELL", 77, 88], ["cells", "CELL", 94, 99], ["9-O-Ac", "SIMPLE_CHEMICAL", 114, 120], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 125, 133], ["Sia", "GENE_OR_GENE_PRODUCT", 190, 193], ["MDCK", "CELL_LINE", 16, 20], ["NBL2", "CELL_LINE", 21, 25], ["MDCK type I", "CELL_LINE", 77, 88], ["MDCK", "TEST", 16, 20], ["all cells", "PROBLEM", 30, 39], ["some cells", "PROBLEM", 89, 99], ["Ac", "TEST", 118, 120]]], ["This heterogeneity was consistent between different passages of each cell line.Expression of 7,9-O- and 9-O-acetyl Sia in cells. ::: RESULTSThe expression levels of those modified Sia variants were also quantified by HPLC analysis using DMB (1,2-diamino-4,5-methylenedioxybenzene) labeling and fluorescence detection (39).", [["cell line", "ANATOMY", 69, 78], ["cells", "ANATOMY", 122, 127], ["7,9-O- and 9-O-acetyl", "CHEMICAL", 93, 114], ["DMB", "CHEMICAL", 237, 240], ["1,2-diamino-4,5-methylenedioxybenzene", "CHEMICAL", 242, 279], ["7,9-O- and 9-O-acetyl Sia", "CHEMICAL", 93, 118], ["DMB (1,2-diamino-4,5-methylenedioxybenzene", "CHEMICAL", 237, 279], ["cell line", "CELL", 69, 78], ["7,9-O", "SIMPLE_CHEMICAL", 93, 98], ["9-O-acetyl Sia", "SIMPLE_CHEMICAL", 104, 118], ["cells", "CELL", 122, 127], ["Sia", "GENE_OR_GENE_PRODUCT", 180, 183], ["DMB", "SIMPLE_CHEMICAL", 237, 240], ["1,2-diamino-4,5-methylenedioxybenzene", "SIMPLE_CHEMICAL", 242, 279], ["cell line", "CELL_LINE", 69, 78], ["Sia variants", "PROTEIN", 180, 192], ["each cell line", "TREATMENT", 64, 78], ["Expression", "TEST", 79, 89], ["HPLC analysis", "TEST", 217, 230], ["DMB", "TEST", 237, 240], ["diamino", "TEST", 246, 253], ["fluorescence detection", "TEST", 294, 316], ["consistent between", "UNCERTAINTY", 23, 41], ["different", "OBSERVATION_MODIFIER", 42, 51], ["passages", "OBSERVATION_MODIFIER", 52, 60], ["cell line", "OBSERVATION", 69, 78]]], ["The cells were treated at 80\u02daC for 3 h in the presence of 2 M acetic acid, and therefore the data likely represent the total Sia present in the cells.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 144, 149], ["acetic acid", "CHEMICAL", 62, 73], ["acetic acid", "CHEMICAL", 62, 73], ["cells", "CELL", 4, 9], ["acetic acid", "SIMPLE_CHEMICAL", 62, 73], ["Sia", "GENE_OR_GENE_PRODUCT", 125, 128], ["cells", "CELL", 144, 149], ["2 M acetic acid", "TREATMENT", 58, 73], ["the data", "TEST", 89, 97], ["cells", "ANATOMY", 144, 149]]], ["Even though some cell lines showed strong staining by the HE-Fc probes, the levels of 9-O-Ac were 1 to 2% of the total collected Sia from all cells, while the levels of 7,9-O-Ac were below the level of detection in all cell lines (Fig. 2 and Table 1; see also Fig. S1 in the supplemental material).", [["cell lines", "ANATOMY", 17, 27], ["cells", "ANATOMY", 142, 147], ["cell lines", "ANATOMY", 219, 229], ["9-O-Ac", "CHEMICAL", 86, 92], ["7,9-O-Ac", "CHEMICAL", 169, 177], ["9-O-Ac", "CHEMICAL", 86, 92], ["7,9-O-Ac", "CHEMICAL", 169, 177], ["cell lines", "CELL", 17, 27], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 58, 63], ["9-O-Ac", "SIMPLE_CHEMICAL", 86, 92], ["Sia", "GENE_OR_GENE_PRODUCT", 129, 132], ["cells", "CELL", 142, 147], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 169, 177], ["cell lines", "CELL", 219, 229], ["S1", "GENE_OR_GENE_PRODUCT", 265, 267], ["cell lines", "CELL_LINE", 17, 27], ["HE-Fc probes", "DNA", 58, 70], ["cell lines", "CELL_LINE", 219, 229], ["S1", "PROTEIN", 265, 267], ["some cell lines", "PROBLEM", 12, 27], ["strong staining", "PROBLEM", 35, 50], ["the HE-Fc probes", "TEST", 54, 70], ["the levels", "TEST", 72, 82], ["Ac", "TEST", 90, 92], ["the levels", "TEST", 155, 165], ["Ac", "TEST", 175, 177], ["all cell lines", "TREATMENT", 215, 229], ["cell lines", "OBSERVATION", 17, 27], ["strong", "OBSERVATION_MODIFIER", 35, 41], ["staining", "OBSERVATION", 42, 50], ["all cell lines", "OBSERVATION", 215, 229]]], ["This includes cells from other species, including cat, mouse, horse, and swine.", [["cells", "ANATOMY", 14, 19], ["horse", "ANATOMY", 62, 67], ["cells", "CELL", 14, 19], ["cat", "ORGANISM", 50, 53], ["mouse", "ORGANISM", 55, 60], ["horse", "ORGANISM", 62, 67], ["swine", "ORGANISM", 73, 78], ["cat", "SPECIES", 50, 53], ["mouse", "SPECIES", 55, 60], ["horse", "SPECIES", 62, 67], ["swine", "SPECIES", 73, 78], ["cat", "SPECIES", 50, 53], ["mouse", "SPECIES", 55, 60], ["swine", "SPECIES", 73, 78], ["other species", "PROBLEM", 25, 38]]], ["Unique among the cells tested, A549 cells are secretory and express significant levels of mucin (including MUC1 and MUC5B) (40).", [["cells", "ANATOMY", 17, 22], ["A549 cells", "ANATOMY", 31, 41], ["cells", "CELL", 17, 22], ["A549 cells", "CELL", 31, 41], ["mucin", "GENE_OR_GENE_PRODUCT", 90, 95], ["MUC1", "GENE_OR_GENE_PRODUCT", 107, 111], ["MUC5B", "GENE_OR_GENE_PRODUCT", 116, 121], ["A549 cells", "CELL_LINE", 31, 41], ["mucin", "PROTEIN", 90, 95], ["MUC1", "PROTEIN", 107, 111], ["MUC5B", "PROTEIN", 116, 121], ["the cells", "TEST", 13, 22], ["A549 cells", "TEST", 31, 41], ["mucin", "TEST", 90, 95], ["MUC1", "TEST", 107, 111], ["MUC5B", "TEST", 116, 121]]], ["Although mucin proteins are not the only secreted protein found in mucus, we chose to focus on them due to their high levels of glycosylation (80% of weight) and proposed importance as a barrier to pathogens (41\u201343).", [["mucus", "ANATOMY", 67, 72], ["mucin", "GENE_OR_GENE_PRODUCT", 9, 14], ["mucus", "ORGANISM_SUBSTANCE", 67, 72], ["mucin proteins", "PROTEIN", 9, 23], ["secreted protein", "PROTEIN", 41, 57], ["mucin proteins", "PROBLEM", 9, 23], ["glycosylation", "TREATMENT", 128, 141]]], ["We found that A549 cells were able to secrete MUC5B into conditioned media (see Fig. S2A in the supplemental material), although we found that the amounts secreted were variable between collections.", [["A549 cells", "ANATOMY", 14, 24], ["A549 cells", "CELL", 14, 24], ["MUC5B", "GENE_OR_GENE_PRODUCT", 46, 51], ["S2A", "GENE_OR_GENE_PRODUCT", 85, 88], ["A549 cells", "CELL_LINE", 14, 24], ["MUC5B", "PROTEIN", 46, 51], ["S2A", "PROTEIN", 85, 88], ["A549 cells", "PROBLEM", 14, 24], ["the amounts secreted", "PROBLEM", 143, 163], ["collections", "PROBLEM", 186, 197], ["A549 cells", "OBSERVATION", 14, 24]]], ["Analysis of conditioned media from A549 cells showed that approximately 2% of Sia was 9-O-Ac on secreted proteins with no 7,9-O-Ac detected, indicating that, at least in these cells, secreted proteins were not enriched for O-acetylated Sia (Fig. S2B).", [["A549 cells", "ANATOMY", 35, 45], ["cells", "ANATOMY", 176, 181], ["9-O-Ac", "CHEMICAL", 86, 92], ["7,9-O-Ac", "CHEMICAL", 122, 130], ["9-O-Ac", "CHEMICAL", 86, 92], ["7,9-O-Ac", "CHEMICAL", 122, 130], ["O", "CHEMICAL", 223, 224], ["A549 cells", "CELL", 35, 45], ["Sia", "GENE_OR_GENE_PRODUCT", 78, 81], ["9-O-Ac", "SIMPLE_CHEMICAL", 86, 92], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 122, 130], ["cells", "CELL", 176, 181], ["O-acetylated Sia", "GENE_OR_GENE_PRODUCT", 223, 239], ["Fig. S2B", "GENE_OR_GENE_PRODUCT", 241, 249], ["A549 cells", "CELL_LINE", 35, 45], ["secreted proteins", "PROTEIN", 96, 113], ["secreted proteins", "PROTEIN", 183, 200], ["O-acetylated Sia", "PROTEIN", 223, 239], ["Fig. S2B", "PROTEIN", 241, 249], ["Analysis of conditioned media", "TEST", 0, 29], ["A549 cells", "TEST", 35, 45], ["Sia", "TEST", 78, 81], ["secreted proteins", "TEST", 96, 113], ["secreted proteins", "TEST", 183, 200]]], ["However, it would be worth examining proteins secreted by primary cells from humans or that are present in different tissues, including mucins, to determine whether the secreted proteins from A549 are representative of respiratory mucus.Expression of 7,9-O- and 9-O-acetyl Sia in cells. ::: RESULTSThe low levels of 9-O- and 7,9-O-Ac detected on HEK-293, A549, and MDCK cells by HPLC could be due to the heterogeneity of the population, since this method measures total Sia for all cells in the population.", [["primary cells", "ANATOMY", 58, 71], ["tissues", "ANATOMY", 117, 124], ["mucins", "ANATOMY", 136, 142], ["A549", "ANATOMY", 192, 196], ["respiratory mucus", "ANATOMY", 219, 236], ["cells", "ANATOMY", 280, 285], ["HEK-293", "ANATOMY", 346, 353], ["A549", "ANATOMY", 355, 359], ["MDCK cells", "ANATOMY", 365, 375], ["cells", "ANATOMY", 482, 487], ["7,9-O- and 9-O-acetyl", "CHEMICAL", 251, 272], ["9-O- and 7,9-O-Ac", "CHEMICAL", 316, 333], ["7,9-O- and 9-O-acetyl Sia", "CHEMICAL", 251, 276], ["9-O- and 7,9-O-Ac", "CHEMICAL", 316, 333], ["cells", "CELL", 66, 71], ["humans", "ORGANISM", 77, 83], ["tissues", "TISSUE", 117, 124], ["mucins", "GENE_OR_GENE_PRODUCT", 136, 142], ["A549", "CELL", 192, 196], ["mucus", "MULTI-TISSUE_STRUCTURE", 231, 236], ["7,9-O", "SIMPLE_CHEMICAL", 251, 256], ["9-O-acetyl Sia", "SIMPLE_CHEMICAL", 262, 276], ["cells", "CELL", 280, 285], ["9-O", "SIMPLE_CHEMICAL", 316, 319], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 325, 333], ["HEK-293", "CELL", 346, 353], ["A549", "CELL", 355, 359], ["MDCK cells", "CELL", 365, 375], ["Sia", "GENE_OR_GENE_PRODUCT", 470, 473], ["cells", "CELL", 482, 487], ["primary cells", "CELL_TYPE", 58, 71], ["secreted proteins", "PROTEIN", 169, 186], ["A549", "CELL_LINE", 192, 196], ["HEK-293", "CELL_LINE", 346, 353], ["A549", "CELL_LINE", 355, 359], ["MDCK cells", "CELL_LINE", 365, 375], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["HEK-293", "SPECIES", 346, 353], ["the secreted proteins", "TEST", 165, 186], ["respiratory mucus", "PROBLEM", 219, 236], ["Expression", "TEST", 237, 247], ["HEK", "TEST", 346, 349], ["A549", "TEST", 355, 359], ["MDCK cells", "TEST", 365, 375], ["HPLC", "TEST", 379, 383], ["the heterogeneity of the population", "PROBLEM", 400, 435], ["this method measures", "TREATMENT", 443, 463], ["respiratory mucus", "OBSERVATION", 219, 236]]], ["However, it is likely that even on cells expressing higher levels of 7,9-O- and 9-O-Ac, these modified Sia make up a small proportion of the total Sia present in the cell or glycocalyx.", [["cells", "ANATOMY", 35, 40], ["cell", "ANATOMY", 166, 170], ["glycocalyx", "ANATOMY", 174, 184], ["7,9-O- and 9-O-Ac", "CHEMICAL", 69, 86], ["7,9-O- and 9-O-Ac", "CHEMICAL", 69, 86], ["cells", "CELL", 35, 40], ["7,9-O", "SIMPLE_CHEMICAL", 69, 74], ["9-O-Ac", "SIMPLE_CHEMICAL", 80, 86], ["Sia", "GENE_OR_GENE_PRODUCT", 103, 106], ["Sia", "GENE_OR_GENE_PRODUCT", 147, 150], ["cell", "CELL", 166, 170], ["glycocalyx", "CELLULAR_COMPONENT", 174, 184], ["is likely", "UNCERTAINTY", 12, 21], ["small", "OBSERVATION_MODIFIER", 117, 122], ["cell", "ANATOMY_MODIFIER", 166, 170], ["glycocalyx", "ANATOMY_MODIFIER", 174, 184]]], ["Previous studies have reported that podoplanin (GP40 in canine cells) is a primary carrier of 9-O-Ac on MDCK cells and therefore acts as the main receptor for ICV (44, 45).", [["cells", "ANATOMY", 63, 68], ["MDCK cells", "ANATOMY", 104, 114], ["9-O-Ac", "CHEMICAL", 94, 100], ["9-O-Ac", "CHEMICAL", 94, 100], ["podoplanin", "GENE_OR_GENE_PRODUCT", 36, 46], ["GP40", "GENE_OR_GENE_PRODUCT", 48, 52], ["canine cells", "CELL", 56, 68], ["9-O-Ac", "SIMPLE_CHEMICAL", 94, 100], ["MDCK cells", "CELL", 104, 114], ["podoplanin", "PROTEIN", 36, 46], ["GP40", "PROTEIN", 48, 52], ["canine cells", "CELL_TYPE", 56, 68], ["MDCK cells", "CELL_LINE", 104, 114], ["canine", "SPECIES", 56, 62], ["Previous studies", "TEST", 0, 16], ["podoplanin (GP40 in canine cells", "TREATMENT", 36, 68], ["MDCK cells", "TREATMENT", 104, 114], ["ICV", "TEST", 159, 162], ["podoplanin", "OBSERVATION", 36, 46]]], ["However, when we costained MDCK cells with an anti-podoplanin antibody and PToV HE-Fc, we saw little correlation between podoplanin and 9-O-Ac staining (Fig. S3).Production of CasD1 knockout and CasD1-overexpressing cells. ::: RESULTSTo better understand the control of expression of 7,9-O- and 9-O-Ac, glycoengineered cell lines were created by manipulating the expression of CasD1 and SIAE genes.", [["MDCK cells", "ANATOMY", 27, 37], ["CasD1-overexpressing cells", "ANATOMY", 195, 221], ["cell lines", "ANATOMY", 319, 329], ["9-O-Ac", "CHEMICAL", 136, 142], ["7,9-O- and 9-O-Ac", "CHEMICAL", 284, 301], ["9-O-Ac", "CHEMICAL", 136, 142], ["7,9-O- and 9-O-Ac", "CHEMICAL", 284, 301], ["MDCK cells", "CELL", 27, 37], ["anti-podoplanin antibody", "GENE_OR_GENE_PRODUCT", 46, 70], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 80, 85], ["podoplanin", "GENE_OR_GENE_PRODUCT", 121, 131], ["9-O-Ac", "GENE_OR_GENE_PRODUCT", 136, 142], ["CasD1", "GENE_OR_GENE_PRODUCT", 176, 181], ["CasD1", "GENE_OR_GENE_PRODUCT", 195, 200], ["cells", "CELL", 216, 221], ["7,9-O", "SIMPLE_CHEMICAL", 284, 289], ["9-O-Ac", "SIMPLE_CHEMICAL", 295, 301], ["cell lines", "CELL", 319, 329], ["CasD1", "GENE_OR_GENE_PRODUCT", 377, 382], ["SIAE", "GENE_OR_GENE_PRODUCT", 387, 391], ["MDCK cells", "CELL_LINE", 27, 37], ["anti-podoplanin antibody", "PROTEIN", 46, 70], ["PToV", "PROTEIN", 75, 79], ["HE", "PROTEIN", 80, 82], ["Fc", "PROTEIN", 83, 85], ["podoplanin", "PROTEIN", 121, 131], ["CasD1", "PROTEIN", 176, 181], ["CasD1-overexpressing cells", "CELL_LINE", 195, 221], ["7,9-O- and 9-O-Ac, glycoengineered cell lines", "CELL_LINE", 284, 329], ["CasD1 and SIAE genes", "DNA", 377, 397], ["an anti-podoplanin antibody", "TEST", 43, 70], ["podoplanin", "TEST", 121, 131], ["overexpressing cells", "PROBLEM", 201, 221], ["Ac", "TREATMENT", 299, 301], ["glycoengineered cell lines", "TREATMENT", 303, 329], ["CasD1 knockout", "OBSERVATION", 176, 190], ["overexpressing cells", "OBSERVATION", 201, 221], ["cell lines", "OBSERVATION", 319, 329]]], ["To do this, we knocked out CasD1 via CRISPR-Cas9 editing or overexpressed CasD1 via transfection of an expression plasmid.", [["plasmid", "ANATOMY", 114, 121], ["CasD1", "GENE_OR_GENE_PRODUCT", 27, 32], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 37, 48], ["CasD1", "GENE_OR_GENE_PRODUCT", 74, 79], ["CasD1", "DNA", 27, 32], ["CRISPR", "DNA", 37, 43], ["CasD1", "DNA", 74, 79], ["expression plasmid", "DNA", 103, 121], ["overexpressed CasD1", "PROBLEM", 60, 79], ["an expression plasmid", "TREATMENT", 100, 121]]], ["Knockout variants of CasD1 (\u0394CasD1) were prepared from MDCK-NBL2, A549, and HEK-293 cells using CRISPR-Cas9 targeting of early exons in the CasD1 gene (Fig. 4A).", [["MDCK-NBL2", "ANATOMY", 55, 64], ["A549", "ANATOMY", 66, 70], ["HEK-293 cells", "ANATOMY", 76, 89], ["CasD1", "GENE_OR_GENE_PRODUCT", 21, 26], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 28, 34], ["MDCK-NBL2", "CELL", 55, 64], ["A549", "CELL", 66, 70], ["HEK-293 cells", "CELL", 76, 89], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 96, 107], ["CasD1", "GENE_OR_GENE_PRODUCT", 140, 145], ["CasD1", "PROTEIN", 21, 26], ["\u0394CasD1", "DNA", 28, 34], ["MDCK", "CELL_LINE", 55, 59], ["NBL2", "CELL_LINE", 60, 64], ["A549", "CELL_LINE", 66, 70], ["HEK-293 cells", "CELL_LINE", 76, 89], ["Cas9", "DNA", 103, 107], ["early exons", "DNA", 121, 132], ["CasD1 gene", "DNA", 140, 150], ["HEK-293", "SPECIES", 76, 83], ["MDCK", "TEST", 55, 59], ["A549", "TEST", 66, 70], ["HEK", "TEST", 76, 79], ["CRISPR", "TEST", 96, 102], ["early exons", "PROBLEM", 121, 132]]], ["\u0394CasD1 clones were confirmed by examining for 7,9-O- and 9-O-Ac display and then by PCR and sequencing of the genomic region surrounding the deletion in modified Sia-negative clones (Fig. 4A).", [["7,9-O- and 9-O-Ac", "CHEMICAL", 46, 63], ["\u0394CasD1 clones", "CELL", 0, 13], ["7,9-O", "SIMPLE_CHEMICAL", 46, 51], ["9-O-Ac", "SIMPLE_CHEMICAL", 57, 63], ["\u0394CasD1 clones", "CELL_LINE", 0, 13], ["genomic region", "DNA", 110, 124], ["modified Sia-negative clones", "CELL_LINE", 153, 181], ["PCR", "TEST", 84, 87], ["the deletion", "PROBLEM", 137, 149]]], ["For all cell types, \u0394CasD1 variants showed loss of both 7,9-O- and 9-O-Ac display when probed with the different specific HE-Fc probes via flow cytometry and immunofluorescence microscopy (Fig. 4B to D).", [["cell", "ANATOMY", 8, 12], ["9-O-Ac", "CHEMICAL", 67, 73], ["7,9-O- and 9-O-Ac", "CHEMICAL", 56, 73], ["cell", "CELL", 8, 12], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 20, 26], ["7,9-O", "SIMPLE_CHEMICAL", 56, 61], ["9-O-Ac", "SIMPLE_CHEMICAL", 67, 73], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 122, 127], ["\u0394CasD1 variants", "CELL_LINE", 20, 35], ["HE-Fc probes", "DNA", 122, 134], ["all cell types", "TEST", 4, 18], ["\u0394CasD1 variants", "TEST", 20, 35], ["loss", "PROBLEM", 43, 47], ["flow cytometry", "TEST", 139, 153], ["immunofluorescence microscopy", "TEST", 158, 187], ["cell types", "OBSERVATION", 8, 18]]], ["This agrees with previous findings that loss of CasD1 leads to loss of both 7,9-O- and 9-O-Ac modifications in haploid HAP1 cells (7).", [["HAP1 cells", "ANATOMY", 119, 129], ["CasD1", "CHEMICAL", 48, 53], ["9-O-Ac", "CHEMICAL", 87, 93], ["7,9-O- and 9-O-Ac", "CHEMICAL", 76, 93], ["CasD1", "GENE_OR_GENE_PRODUCT", 48, 53], ["7,9-O", "SIMPLE_CHEMICAL", 76, 81], ["9-O-Ac", "SIMPLE_CHEMICAL", 87, 93], ["haploid HAP1 cells", "CELL", 111, 129], ["CasD1", "PROTEIN", 48, 53], ["haploid HAP1 cells", "CELL_LINE", 111, 129], ["loss of CasD1", "PROBLEM", 40, 53], ["Ac modifications in haploid HAP1 cells", "PROBLEM", 91, 129], ["HAP1 cells", "OBSERVATION", 119, 129]]], ["HPLC analysis of total Sia showed a significant decrease in 9-O-Ac expression compared to wild-type (WT) cells; however, very low levels (<1%) were still detectable, despite a lack of staining with the HE-Fc probes (Fig. 4E).", [["wild-type (WT) cells", "ANATOMY", 90, 110], ["9-O-Ac", "CHEMICAL", 60, 66], ["9-O-Ac", "CHEMICAL", 60, 66], ["9-O-Ac", "SIMPLE_CHEMICAL", 60, 66], ["WT) cells", "CELL", 101, 110], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 202, 207], ["wild-type (WT) cells", "CELL_TYPE", 90, 110], ["HE-Fc probes", "DNA", 202, 214], ["HPLC analysis", "TEST", 0, 13], ["total Sia", "TEST", 17, 26], ["a significant decrease", "PROBLEM", 34, 56], ["very low levels", "PROBLEM", 121, 136], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["decrease", "OBSERVATION_MODIFIER", 48, 56]]], ["This could be due to exogenous Sia from the fetal bovine serum in the growth media, as is the case for Neu5Gc, which is also detectable at similarly low levels on cells even though the gene for Neu5Gc synthesis, CMAH, is not functional in humans or canines (Fig. S1) (46, 47).Production of CasD1 knockout and CasD1-overexpressing cells. ::: RESULTSDue to the heterogeneity and low expression of 7,9-O- and 9-O-Ac in WT cells, we sought to engineer cells with more homogeneous and higher levels of these modifications.", [["fetal bovine serum", "ANATOMY", 44, 62], ["cells", "ANATOMY", 163, 168], ["CasD1-overexpressing cells", "ANATOMY", 309, 335], ["WT cells", "ANATOMY", 416, 424], ["cells", "ANATOMY", 448, 453], ["9-O-Ac", "CHEMICAL", 406, 412], ["7,9-O- and 9-O-Ac", "CHEMICAL", 395, 412], ["Sia", "GENE_OR_GENE_PRODUCT", 31, 34], ["bovine", "ORGANISM", 50, 56], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 103, 109], ["cells", "CELL", 163, 168], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 194, 200], ["CMAH", "GENE_OR_GENE_PRODUCT", 212, 216], ["humans", "ORGANISM", 239, 245], ["canines", "ORGAN", 249, 256], ["CasD1", "GENE_OR_GENE_PRODUCT", 290, 295], ["CasD1", "GENE_OR_GENE_PRODUCT", 309, 314], ["cells", "CELL", 330, 335], ["7,9-O", "SIMPLE_CHEMICAL", 395, 400], ["9-O-Ac", "SIMPLE_CHEMICAL", 406, 412], ["WT cells", "CELL", 416, 424], ["cells", "CELL", 448, 453], ["Neu5Gc", "PROTEIN", 103, 109], ["Neu5Gc", "PROTEIN", 194, 200], ["CasD1", "PROTEIN", 290, 295], ["CasD1-overexpressing cells", "CELL_LINE", 309, 335], ["7,9-O- and 9-O-Ac", "DNA", 395, 412], ["WT cells", "CELL_TYPE", 416, 424], ["bovine", "SPECIES", 50, 56], ["humans", "SPECIES", 239, 245], ["bovine", "SPECIES", 50, 56], ["humans", "SPECIES", 239, 245], ["exogenous Sia", "PROBLEM", 21, 34], ["the fetal bovine serum", "TEST", 40, 62], ["Neu5Gc", "TEST", 103, 109], ["low levels on cells", "PROBLEM", 149, 168], ["Neu5Gc synthesis", "TEST", 194, 210], ["overexpressing cells", "PROBLEM", 315, 335], ["the heterogeneity", "TEST", 355, 372], ["Ac in WT cells", "TREATMENT", 410, 424], ["these modifications", "TREATMENT", 497, 516], ["could be due to", "UNCERTAINTY", 5, 20], ["exogenous Sia", "OBSERVATION", 21, 34], ["fetal bovine", "OBSERVATION", 44, 56], ["serum", "OBSERVATION_MODIFIER", 57, 62], ["CasD1 knockout", "OBSERVATION", 290, 304], ["overexpressing cells", "OBSERVATION", 315, 335], ["low expression", "OBSERVATION_MODIFIER", 377, 391], ["homogeneous", "OBSERVATION_MODIFIER", 464, 475]]], ["We overexpressed the human CasD1 (CasD1-OX) in the \u0394CasD1 variants of MDCK-NBL2, A549, and HEK-293 cells, expecting that expression of CasD1 under a strong promoter in the \u0394CasD1 background would increase the consistency of the synthesis and display of 9-O- and 7,9-O-acetyl Sia relative to the WT cells.", [["MDCK-NBL2", "ANATOMY", 70, 79], ["A549", "ANATOMY", 81, 85], ["HEK-293 cells", "ANATOMY", 91, 104], ["WT cells", "ANATOMY", 295, 303], ["9-O- and 7,9-O-acetyl", "CHEMICAL", 253, 274], ["9-O- and 7,9-O-acetyl Sia", "CHEMICAL", 253, 278], ["human", "ORGANISM", 21, 26], ["CasD1", "GENE_OR_GENE_PRODUCT", 27, 32], ["CasD1-OX", "GENE_OR_GENE_PRODUCT", 34, 42], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 51, 57], ["MDCK-NBL2", "CELL", 70, 79], ["A549", "CELL", 81, 85], ["HEK-293 cells", "CELL", 91, 104], ["CasD1", "GENE_OR_GENE_PRODUCT", 135, 140], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 172, 178], ["9-O", "SIMPLE_CHEMICAL", 253, 256], ["7,9-O-acetyl Sia", "SIMPLE_CHEMICAL", 262, 278], ["WT cells", "CELL", 295, 303], ["human CasD1", "PROTEIN", 21, 32], ["CasD1", "PROTEIN", 34, 39], ["OX", "PROTEIN", 40, 42], ["\u0394CasD1 variants", "CELL_LINE", 51, 66], ["MDCK", "CELL_LINE", 70, 74], ["NBL2", "CELL_LINE", 75, 79], ["A549", "CELL_LINE", 81, 85], ["HEK-293 cells", "CELL_LINE", 91, 104], ["CasD1", "PROTEIN", 135, 140], ["\u0394CasD1", "DNA", 172, 178], ["WT cells", "CELL_TYPE", 295, 303], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["HEK-293", "SPECIES", 91, 98], ["MDCK", "TEST", 70, 74], ["NBL2", "TEST", 75, 79], ["A549", "TEST", 81, 85], ["HEK", "TEST", 91, 94], ["a strong promoter", "TREATMENT", 147, 164], ["the synthesis", "TEST", 224, 237]]], ["CasD1-OX cells showed significantly higher levels of CasD1 mRNA compared to WT cells, indicating that the CasD1 expression plasmid was being transcribed at high levels (Fig. 4E).", [["CasD1-OX cells", "ANATOMY", 0, 14], ["cells", "ANATOMY", 79, 84], ["CasD1-OX cells", "CELL", 0, 14], ["CasD1", "GENE_OR_GENE_PRODUCT", 53, 58], ["WT cells", "CELL", 76, 84], ["CasD1", "GENE_OR_GENE_PRODUCT", 106, 111], ["CasD1-OX cells", "CELL_LINE", 0, 14], ["CasD1 mRNA", "RNA", 53, 63], ["WT cells", "CELL_TYPE", 76, 84], ["CasD1 expression plasmid", "DNA", 106, 130], ["CasD1-OX cells", "TEST", 0, 14], ["significantly higher levels of CasD1 mRNA", "PROBLEM", 22, 63], ["WT cells", "TEST", 76, 84], ["the CasD1 expression plasmid", "TREATMENT", 102, 130], ["OX cells", "OBSERVATION", 6, 14], ["significantly", "OBSERVATION_MODIFIER", 22, 35], ["higher levels", "OBSERVATION_MODIFIER", 36, 49], ["CasD1 mRNA", "OBSERVATION", 53, 63]]], ["However, only a modest increase in average 9-O- and 7,9-O-Ac expression across the population in HEK-293 cells was seen by flow cytometry, whereas fluorescence microscopy showed heterogeneity of expression in the population (Fig. 4B to D).", [["HEK-293 cells", "ANATOMY", 97, 110], ["9-O", "CHEMICAL", 43, 46], ["9-O- and 7,9-O-Ac", "CHEMICAL", 43, 60], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 52, 60], ["HEK-293 cells", "CELL", 97, 110], ["Ac", "DNA", 58, 60], ["HEK-293 cells", "CELL_LINE", 97, 110], ["a modest increase", "PROBLEM", 14, 31], ["flow cytometry", "TEST", 123, 137], ["fluorescence microscopy", "TEST", 147, 170], ["expression in the population", "PROBLEM", 195, 223], ["modest", "OBSERVATION_MODIFIER", 16, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["expression", "OBSERVATION_MODIFIER", 195, 205]]], ["The transfected MDCK and A549 CasD1-OX cells showed recovery of 9-O- and 7,9-O-Ac synthesis when analyzed by flow cytometry and immunofluorescence microscopy, but the levels were not as high as those seen in WT cells (Fig. 4B to D).", [["MDCK", "ANATOMY", 16, 20], ["A549 CasD1-OX cells", "ANATOMY", 25, 44], ["WT cells", "ANATOMY", 208, 216], ["9-O- and 7,9-O-Ac", "CHEMICAL", 64, 81], ["9-O- and 7,9-O-Ac", "CHEMICAL", 64, 81], ["MDCK", "CELL", 16, 20], ["A549 CasD1-OX cells", "CELL", 25, 44], ["9-O", "SIMPLE_CHEMICAL", 64, 67], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 73, 81], ["WT cells", "CELL", 208, 216], ["MDCK", "CELL_LINE", 16, 20], ["A549 CasD1-OX cells", "CELL_LINE", 25, 44], ["WT cells", "CELL_TYPE", 208, 216], ["The transfected MDCK", "TEST", 0, 20], ["A549 CasD1", "TEST", 25, 35], ["flow cytometry", "TEST", 109, 123], ["immunofluorescence microscopy", "TEST", 128, 157], ["the levels", "TEST", 163, 173]]], ["HPLC analysis confirmed the expression levels for HEK-293, A549, and MDCK cells (Fig. 4F).", [["HEK-293", "ANATOMY", 50, 57], ["A549", "ANATOMY", 59, 63], ["MDCK cells", "ANATOMY", 69, 79], ["HEK-293", "CELL", 50, 57], ["A549", "CELL", 59, 63], ["MDCK cells", "CELL", 69, 79], ["Fig. 4F", "CELL", 81, 88], ["HEK-293", "CELL_LINE", 50, 57], ["A549", "CELL_LINE", 59, 63], ["MDCK cells", "CELL_LINE", 69, 79], ["HEK-293", "SPECIES", 50, 57], ["HPLC analysis", "TEST", 0, 13], ["the expression levels", "TEST", 24, 45], ["HEK", "TEST", 50, 53], ["A549", "TEST", 59, 63], ["MDCK cells", "TEST", 69, 79]]], ["In addition, heterogeneity was still seen in these populations for 9-O-Ac.", [["9-O-Ac.", "CHEMICAL", 67, 74], ["9-O-Ac.", "CHEMICAL", 67, 74], ["9-O-Ac.", "SIMPLE_CHEMICAL", 67, 74], ["heterogeneity", "OBSERVATION", 13, 26]]], ["This suggests that 7,9-O- and 9-O-Ac expression is not directly regulated by the levels of CasD1 gene expression but may be affected by posttranslational regulation of CasD1 activity or removal of the modifications by SIAE or other enzymes.", [["7,9-O- and 9-O-Ac", "CHEMICAL", 19, 36], ["7,9-O- and 9-O-Ac", "CHEMICAL", 19, 36], ["7,9-O", "SIMPLE_CHEMICAL", 19, 24], ["9-O-Ac", "SIMPLE_CHEMICAL", 30, 36], ["CasD1", "GENE_OR_GENE_PRODUCT", 91, 96], ["CasD1", "GENE_OR_GENE_PRODUCT", 168, 173], ["SIAE", "GENE_OR_GENE_PRODUCT", 218, 222], ["CasD1 gene", "DNA", 91, 101], ["CasD1", "PROTEIN", 168, 173], ["SIAE", "PROTEIN", 218, 222], ["enzymes", "PROTEIN", 232, 239], ["CasD1 activity", "TREATMENT", 168, 182], ["removal", "TREATMENT", 186, 193], ["other enzymes", "TEST", 226, 239]]], ["In addition, these modifications are not regulated the same across individual cells, as evidenced by the population heterogeneity.", [["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["the population heterogeneity", "PROBLEM", 101, 129], ["individual cells", "OBSERVATION", 67, 83], ["population", "OBSERVATION_MODIFIER", 105, 115], ["heterogeneity", "OBSERVATION", 116, 129]]], ["SIAE transcripts were consistently expressed in HEK-293 WT, \u0394CasD1, and CasD1-OX cell populations by qPCR analysis, although SIAE mRNA levels in CasD1-OX cells were lower than those seen in WT (Fig. 4E).SIAE knockout cells and display of modified Sia. ::: RESULTSTo determine the role of SIAE activity in regulating 7,9-O- and 9-O-Ac display, SIAE knockout (\u0394SIAE) cells were generated from WT HEK-293 and A549 cells by targeting early exons in the SIAE gene (Fig. 5A).", [["HEK-293", "ANATOMY", 48, 55], ["\u0394CasD1", "ANATOMY", 60, 66], ["CasD1-OX cell", "ANATOMY", 72, 85], ["CasD1-OX cells", "ANATOMY", 145, 159], ["cells", "ANATOMY", 217, 222], ["\u0394SIAE) cells", "ANATOMY", 358, 370], ["HEK-293", "ANATOMY", 394, 401], ["A549 cells", "ANATOMY", 406, 416], ["9-O-Ac", "CHEMICAL", 327, 333], ["7,9-O- and 9-O-Ac", "CHEMICAL", 316, 333], ["SIAE", "GENE_OR_GENE_PRODUCT", 0, 4], ["HEK-293 WT", "CELL", 48, 58], ["\u0394CasD1", "CELL", 60, 66], ["CasD1-OX cell populations", "CELL", 72, 97], ["SIAE", "GENE_OR_GENE_PRODUCT", 125, 129], ["CasD1-OX cells", "CELL", 145, 159], ["cells", "CELL", 217, 222], ["SIAE", "GENE_OR_GENE_PRODUCT", 288, 292], ["7,9-O", "SIMPLE_CHEMICAL", 316, 321], ["9-O-Ac", "SIMPLE_CHEMICAL", 327, 333], ["SIAE", "SIMPLE_CHEMICAL", 343, 347], ["HEK-293", "CELL", 394, 401], ["A549 cells", "CELL", 406, 416], ["SIAE", "GENE_OR_GENE_PRODUCT", 449, 453], ["SIAE transcripts", "RNA", 0, 16], ["HEK-293 WT", "CELL_LINE", 48, 58], ["\u0394CasD1", "CELL_LINE", 60, 66], ["CasD1-OX cell populations", "CELL_LINE", 72, 97], ["SIAE mRNA", "RNA", 125, 134], ["CasD1-OX cells", "CELL_LINE", 145, 159], ["SIAE knockout cells", "CELL_LINE", 203, 222], ["SIAE", "PROTEIN", 288, 292], ["SIAE knockout (\u0394SIAE) cells", "CELL_LINE", 343, 370], ["WT HEK-293", "CELL_LINE", 391, 401], ["A549 cells", "CELL_LINE", 406, 416], ["exons", "DNA", 436, 441], ["SIAE gene", "DNA", 449, 458], ["HEK-293", "SPECIES", 394, 401], ["HEK", "TEST", 48, 51], ["WT", "TEST", 56, 58], ["\u0394CasD1", "TEST", 60, 66], ["CasD1", "TEST", 72, 77], ["qPCR analysis", "TEST", 101, 114], ["SIAE mRNA levels", "TEST", 125, 141], ["CasD1", "TEST", 145, 150], ["OX cells", "TEST", 151, 159], ["SIAE activity", "TEST", 288, 301], ["WT HEK", "TEST", 391, 397], ["A549 cells", "TEST", 406, 416], ["OX cell", "OBSERVATION", 78, 85]]], ["Complete knockout of SIAE was confirmed both by genotyping to show deletions in both alleles and by loss of mRNA by qPCR (Fig. 5A and D).", [["SIAE", "GENE_OR_GENE_PRODUCT", 21, 25], ["SIAE", "DNA", 21, 25], ["mRNA", "RNA", 108, 112], ["deletions in both alleles", "PROBLEM", 67, 92]]], ["\u0394SIAE cells showed a small but significant increase in surface display and a large increase in internal display of 9-O-Ac based on flow cytometry, but they did not appear to show any changes in the surface or internal display of 7,9-O-Ac (Fig. 5B and C).", [["\u0394SIAE cells", "ANATOMY", 0, 11], ["surface", "ANATOMY", 55, 62], ["surface", "ANATOMY", 198, 205], ["9-O-Ac", "CHEMICAL", 115, 121], ["7,9-O-Ac", "CHEMICAL", 229, 237], ["9-O-Ac", "CHEMICAL", 115, 121], ["7,9-O-Ac", "CHEMICAL", 229, 237], ["\u0394SIAE cells", "CELL", 0, 11], ["surface", "CELLULAR_COMPONENT", 55, 62], ["9-O-Ac", "SIMPLE_CHEMICAL", 115, 121], ["surface", "CELLULAR_COMPONENT", 198, 205], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 229, 237], ["C", "SIMPLE_CHEMICAL", 251, 252], ["\u0394SIAE cells", "CELL_LINE", 0, 11], ["\u0394SIAE cells", "TEST", 0, 11], ["significant increase in surface display", "PROBLEM", 31, 70], ["a large increase", "PROBLEM", 75, 91], ["flow cytometry", "TEST", 131, 145], ["internal display", "TEST", 209, 225], ["small", "OBSERVATION_MODIFIER", 21, 26], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["surface", "OBSERVATION_MODIFIER", 55, 62], ["large", "OBSERVATION_MODIFIER", 77, 82], ["increase", "OBSERVATION_MODIFIER", 83, 91]]], ["HPLC analysis also showed a small increase of 9-O-Ac in HEK-293 cells, but no 7,9-O-Ac was detected in either cell line (Fig. 5E).", [["HEK-293 cells", "ANATOMY", 56, 69], ["cell line", "ANATOMY", 110, 119], ["9-O-Ac", "CHEMICAL", 46, 52], ["7,9-O-Ac", "CHEMICAL", 78, 86], ["9-O-Ac", "CHEMICAL", 46, 52], ["7,9-O-Ac", "CHEMICAL", 78, 86], ["9-O-Ac", "SIMPLE_CHEMICAL", 46, 52], ["HEK-293 cells", "CELL", 56, 69], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 78, 86], ["cell line", "CELL", 110, 119], ["Fig. 5E", "CELL", 121, 128], ["HEK-293 cells", "CELL_LINE", 56, 69], ["cell line", "CELL_LINE", 110, 119], ["HEK-293", "SPECIES", 56, 63], ["HPLC analysis", "TEST", 0, 13], ["a small increase", "PROBLEM", 26, 42], ["small", "OBSERVATION_MODIFIER", 28, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["no", "UNCERTAINTY", 75, 77], ["cell line", "OBSERVATION", 110, 119]]], ["When the overexpression CasD1 plasmid was transfected into \u0394SIAE cells (\u0394SIAE+CasD1), the cells showed an increase in both surface and internal 9-O-Ac but no increase in surface or internal display of 7,9-O-Ac by either flow cytometry or immunofluorescence microscopy (Fig. 5B and C).", [["\u0394SIAE cells", "ANATOMY", 59, 70], ["cells", "ANATOMY", 90, 95], ["surface", "ANATOMY", 123, 130], ["surface", "ANATOMY", 170, 177], ["9-O-Ac", "CHEMICAL", 144, 150], ["7,9-O-Ac", "CHEMICAL", 201, 209], ["9-O-Ac", "CHEMICAL", 144, 150], ["7,9-O-Ac", "CHEMICAL", 201, 209], ["CasD1", "GENE_OR_GENE_PRODUCT", 24, 29], ["\u0394SIAE cells", "CELL", 59, 70], ["\u0394SIAE+CasD1", "CELL", 72, 83], ["cells", "CELL", 90, 95], ["surface", "CELLULAR_COMPONENT", 123, 130], ["9-O-Ac", "SIMPLE_CHEMICAL", 144, 150], ["surface", "CELLULAR_COMPONENT", 170, 177], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 201, 209], ["CasD1 plasmid", "DNA", 24, 37], ["\u0394SIAE cells", "CELL_LINE", 59, 70], ["\u0394SIAE", "CELL_LINE", 72, 77], ["CasD1", "CELL_LINE", 78, 83], ["the overexpression CasD1 plasmid", "TREATMENT", 5, 37], ["the cells", "TEST", 86, 95], ["increase in surface", "PROBLEM", 158, 177], ["internal display", "TEST", 181, 197], ["flow cytometry", "TEST", 220, 234], ["immunofluorescence microscopy", "TEST", 238, 267], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["both", "OBSERVATION_MODIFIER", 118, 122], ["surface", "OBSERVATION_MODIFIER", 123, 130], ["no", "UNCERTAINTY", 155, 157], ["increase", "OBSERVATION_MODIFIER", 158, 166]]], ["HPLC confirmed the flow cytometry results by showing a small increase of 9-O-Ac levels in HEK-293 cells, similar to those seen in CasD1-OX (Fig. 5E).", [["HEK-293 cells", "ANATOMY", 90, 103], ["9-O-Ac", "CHEMICAL", 73, 79], ["9-O-Ac", "CHEMICAL", 73, 79], ["9-O-Ac", "SIMPLE_CHEMICAL", 73, 79], ["HEK-293 cells", "CELL", 90, 103], ["CasD1-OX", "GENE_OR_GENE_PRODUCT", 130, 138], ["HEK-293 cells", "CELL_LINE", 90, 103], ["HEK-293", "SPECIES", 90, 97], ["HPLC", "TEST", 0, 4], ["the flow cytometry", "TEST", 15, 33], ["a small increase", "PROBLEM", 53, 69], ["Ac levels", "TEST", 77, 86], ["HEK", "TEST", 90, 93], ["small", "OBSERVATION_MODIFIER", 55, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69]]], ["A549 cells showed a small but nonsignificant increase in 9-O-Ac levels compared to WT by HPLC analysis.", [["A549 cells", "ANATOMY", 0, 10], ["9-O-Ac", "CHEMICAL", 57, 63], ["9-O-Ac", "CHEMICAL", 57, 63], ["A549 cells", "CELL", 0, 10], ["9-O-Ac", "SIMPLE_CHEMICAL", 57, 63], ["A549 cells", "CELL_LINE", 0, 10], ["A549 cells", "TEST", 0, 10], ["nonsignificant increase", "PROBLEM", 30, 53], ["Ac levels", "TEST", 61, 70], ["WT", "TEST", 83, 85], ["HPLC analysis", "TEST", 89, 102], ["small", "OBSERVATION_MODIFIER", 20, 25], ["nonsignificant", "OBSERVATION_MODIFIER", 30, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53]]], ["Interestingly, HEK-293 \u0394SIAE+CasD1 cells grew more slowly than either \u0394SIAE or WT cells (Fig. 5F).", [["HEK-293 \u0394SIAE+CasD1 cells", "ANATOMY", 15, 40], ["\u0394SIAE", "ANATOMY", 70, 75], ["WT cells", "ANATOMY", 79, 87], ["HEK-293", "CHEMICAL", 15, 22], ["HEK-293 \u0394SIAE+CasD1 cells", "CELL", 15, 40], ["WT cells", "CELL", 79, 87], ["HEK-293 \u0394SIAE", "CELL_LINE", 15, 28], ["CasD1 cells", "CELL_LINE", 29, 40], ["\u0394SIAE", "CELL_LINE", 70, 75], ["WT cells", "CELL_LINE", 79, 87], ["HEK", "TEST", 15, 18], ["\u0394SIAE", "TEST", 23, 28], ["CasD1 cells", "TEST", 29, 40], ["WT cells", "PROBLEM", 79, 87]]], ["However, A549 \u0394SIAE+CasD1 showed increased growth rates compared to \u0394SIAE or WT cells, while \u0394SIAE cells had slightly lower growth rates compared to WT.", [["A549", "ANATOMY", 9, 13], ["\u0394SIAE", "ANATOMY", 68, 73], ["cells", "ANATOMY", 80, 85], ["\u0394SIAE cells", "ANATOMY", 93, 104], ["A549 \u0394SIAE", "CELL", 9, 19], ["WT cells", "CELL", 77, 85], ["\u0394SIAE cells", "CELL", 93, 104], ["A549 \u0394SIAE", "CELL_LINE", 9, 19], ["CasD1", "CELL_LINE", 20, 25], ["\u0394SIAE", "CELL_LINE", 68, 73], ["WT cells", "CELL_LINE", 77, 85], ["\u0394SIAE cells", "CELL_LINE", 93, 104], ["A549 \u0394SIAE", "TEST", 9, 19], ["CasD1", "TEST", 20, 25], ["increased growth rates", "PROBLEM", 33, 55], ["WT cells", "PROBLEM", 77, 85], ["\u0394SIAE cells", "PROBLEM", 93, 104], ["slightly lower growth rates", "PROBLEM", 109, 136], ["WT", "TEST", 149, 151], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["growth", "OBSERVATION_MODIFIER", 43, 49], ["slightly", "OBSERVATION_MODIFIER", 109, 117], ["lower growth", "OBSERVATION_MODIFIER", 118, 130]]], ["This suggests that 7,9-O- and 9-O-Ac may affect cell metabolism and growth rates and that these effects may be cell type specific.", [["cell", "ANATOMY", 48, 52], ["cell", "ANATOMY", 111, 115], ["7,9-O- and 9-O-Ac", "CHEMICAL", 19, 36], ["7,9-O- and 9-O-Ac", "CHEMICAL", 19, 36], ["7,9-O", "SIMPLE_CHEMICAL", 19, 24], ["9-O-Ac", "SIMPLE_CHEMICAL", 30, 36], ["cell", "CELL", 48, 52], ["cell", "CELL", 111, 115], ["cell metabolism", "PROBLEM", 48, 63]]], ["Overall, these results show that SIAE regulates levels of 9-O-Ac and 7,9-O-Ac but that knocking out SIAE only leads to small increases in these modifications.", [["SIAE", "CHEMICAL", 33, 37], ["9-O-Ac", "CHEMICAL", 58, 64], ["7,9-O-Ac", "CHEMICAL", 69, 77], ["9-O-Ac", "CHEMICAL", 58, 64], ["7,9-O-Ac", "CHEMICAL", 69, 77], ["SIAE", "SIMPLE_CHEMICAL", 33, 37], ["9-O-Ac", "SIMPLE_CHEMICAL", 58, 64], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 69, 77], ["SIAE", "SIMPLE_CHEMICAL", 100, 104], ["Ac", "DNA", 75, 77], ["SIAE", "PROTEIN", 100, 104], ["SIAE regulates levels", "TEST", 33, 54], ["Ac", "TEST", 62, 64], ["knocking out SIAE", "PROBLEM", 87, 104], ["small increases in these modifications", "PROBLEM", 119, 157], ["small", "OBSERVATION_MODIFIER", 119, 124], ["increases", "OBSERVATION_MODIFIER", 125, 134], ["these modifications", "OBSERVATION", 138, 157]]], ["However, there appear to be mechanisms regulating the surface display of 9-O-Ac and 7,9-O-Ac, since most of the modified Sia were specifically retained in the Golgi compartment on human HEK-293 and A549 cells, in comparison to WT MDCK cells, which appear to display most modified Sia on their surfaces.Effects of 7,9-O-Ac and 9-O-Ac on influenza A, B, C, and D virus infection. ::: RESULTSTo test the effects of 9-O-Ac and 7,9-O-Ac on virus infection, WT, \u0394CasD1, and CasD1-OX HEK-293 cells were inoculated with human H1N1 (A/California/04/2009) and human H3N2 (A/Victoria/361/2011) IAV strains, and we found no significant difference in infection efficiency in any of these cells (Fig. 6A).", [["surface", "ANATOMY", 54, 61], ["Golgi compartment", "ANATOMY", 159, 176], ["HEK-293", "ANATOMY", 186, 193], ["A549 cells", "ANATOMY", 198, 208], ["MDCK cells", "ANATOMY", 230, 240], ["CasD1-OX HEK-293 cells", "ANATOMY", 468, 490], ["cells", "ANATOMY", 675, 680], ["9-O-Ac", "CHEMICAL", 73, 79], ["7,9-O-Ac", "CHEMICAL", 84, 92], ["7,9-O-Ac", "CHEMICAL", 313, 321], ["9-O-Ac", "CHEMICAL", 326, 332], ["infection", "DISEASE", 367, 376], ["9-O-Ac", "CHEMICAL", 412, 418], ["7,9-O-Ac", "CHEMICAL", 423, 431], ["infection", "DISEASE", 638, 647], ["9-O-Ac", "CHEMICAL", 73, 79], ["7,9-O-Ac", "CHEMICAL", 84, 92], ["7,9-O-Ac", "CHEMICAL", 313, 321], ["9-O-Ac", "CHEMICAL", 326, 332], ["9-O-Ac", "CHEMICAL", 412, 418], ["7,9-O-Ac", "CHEMICAL", 423, 431], ["surface", "CELLULAR_COMPONENT", 54, 61], ["9-O-Ac", "SIMPLE_CHEMICAL", 73, 79], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 84, 92], ["Sia", "GENE_OR_GENE_PRODUCT", 121, 124], ["Golgi compartment", "CELLULAR_COMPONENT", 159, 176], ["human", "ORGANISM", 180, 185], ["HEK-293", "CELL", 186, 193], ["A549 cells", "CELL", 198, 208], ["MDCK cells", "CELL", 230, 240], ["Sia", "GENE_OR_GENE_PRODUCT", 280, 283], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 313, 321], ["9-O-Ac", "SIMPLE_CHEMICAL", 326, 332], ["influenza A", "ORGANISM", 336, 347], ["B, C", "ORGANISM", 349, 353], ["D virus", "ORGANISM", 359, 366], ["9-O-Ac", "SIMPLE_CHEMICAL", 412, 418], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 423, 431], ["virus", "ORGANISM", 435, 440], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 456, 462], ["CasD1-OX HEK-293 cells", "CELL", 468, 490], ["human", "ORGANISM", 512, 517], ["H1N1 (A/California/04/2009", "ORGANISM", 518, 544], ["human", "ORGANISM", 550, 555], ["H3N2 (A/Victoria/361/2011", "ORGANISM", 556, 581], ["IAV", "ORGANISM", 583, 586], ["cells", "CELL", 675, 680], ["Sia", "PROTEIN", 121, 124], ["human HEK-293", "CELL_LINE", 180, 193], ["A549 cells", "CELL_LINE", 198, 208], ["WT MDCK cells", "CELL_LINE", 227, 240], ["WT, \u0394CasD1, and CasD1-OX HEK-293 cells", "CELL_LINE", 452, 490], ["human", "SPECIES", 180, 185], ["D virus", "SPECIES", 359, 366], ["human", "SPECIES", 512, 517], ["human", "SPECIES", 550, 555], ["human HEK-293", "SPECIES", 180, 193], ["D virus", "SPECIES", 359, 366], ["human H1N1 (A/California/04/2009", "SPECIES", 512, 544], ["human H3N2 (A/Victoria/361/2011) IAV", "SPECIES", 550, 586], ["Ac", "TEST", 77, 79], ["human HEK", "TEST", 180, 189], ["A549 cells", "TEST", 198, 208], ["WT MDCK cells", "TEST", 227, 240], ["Ac", "TEST", 319, 321], ["influenza", "PROBLEM", 336, 345], ["B, C, and D virus infection", "PROBLEM", 349, 376], ["RESULTSTo test", "TEST", 382, 396], ["Ac", "TEST", 416, 418], ["virus infection", "PROBLEM", 435, 450], ["WT", "TEST", 452, 454], ["\u0394CasD1", "TEST", 456, 462], ["CasD1", "TEST", 468, 473], ["HEK", "TEST", 477, 480], ["cells", "TEST", 485, 490], ["human H1N1", "PROBLEM", 512, 522], ["human H3N2", "PROBLEM", 550, 560], ["A/Victoria", "TEST", 562, 572], ["IAV strains", "PROBLEM", 583, 594], ["significant difference in infection efficiency", "PROBLEM", 612, 658], ["appear to be", "UNCERTAINTY", 15, 27], ["surface", "OBSERVATION_MODIFIER", 54, 61], ["Golgi", "ANATOMY_MODIFIER", 159, 164], ["compartment", "ANATOMY_MODIFIER", 165, 176], ["A549 cells", "OBSERVATION", 198, 208], ["MDCK cells", "OBSERVATION", 230, 240], ["virus infection", "OBSERVATION", 361, 376], ["infection", "OBSERVATION", 441, 450], ["no", "UNCERTAINTY", 609, 611], ["significant", "OBSERVATION_MODIFIER", 612, 623], ["difference", "OBSERVATION", 624, 634], ["infection", "OBSERVATION", 638, 647]]], ["IAV strains, as well as IBV strains B/Colorado/06/2017 and B/Memphis/1/2018, also showed equal infection efficiency on WT MDCK cells compared to \u0394CasD1 and CasD1-OX cells (Fig. 6B and D).", [["MDCK cells", "ANATOMY", 122, 132], ["\u0394CasD1", "ANATOMY", 145, 151], ["CasD1-OX cells", "ANATOMY", 156, 170], ["infection", "DISEASE", 95, 104], ["IAV strains", "ORGANISM", 0, 11], ["IBV strains B/Colorado/06/2017", "ORGANISM", 24, 54], ["B/Memphis/1/2018", "ORGANISM", 59, 75], ["WT MDCK cells", "CELL", 119, 132], ["\u0394CasD1", "CELL", 145, 151], ["CasD1-OX cells", "CELL", 156, 170], ["WT MDCK cells", "CELL_LINE", 119, 132], ["\u0394CasD1", "CELL_LINE", 145, 151], ["CasD1-OX cells", "CELL_LINE", 156, 170], ["IAV", "SPECIES", 0, 3], ["IBV strains B/Colorado/06/2017", "SPECIES", 24, 54], ["B/Memphis/1/2018", "SPECIES", 59, 75], ["IAV strains", "PROBLEM", 0, 11], ["IBV strains", "TEST", 24, 35], ["B/Memphis", "TEST", 59, 68], ["equal infection efficiency", "PROBLEM", 89, 115], ["WT MDCK cells", "PROBLEM", 119, 132], ["\u0394CasD1", "TEST", 145, 151], ["CasD1", "TEST", 156, 161], ["equal", "OBSERVATION_MODIFIER", 89, 94], ["infection", "OBSERVATION", 95, 104]]], ["B/Memphis did show a difference in relative infected cell counts between \u0394CasD1 and CasD1-OX, although B/Colorado did not.", [["cell", "ANATOMY", 53, 57], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["cell", "CELL", 53, 57], ["CasD1-OX", "GENE_OR_GENE_PRODUCT", 84, 92], ["CasD1", "PROTEIN", 84, 89], ["a difference", "PROBLEM", 19, 31], ["relative infected cell counts", "PROBLEM", 35, 64], ["infected cell counts", "OBSERVATION", 44, 64]]], ["However, ICV strains C/Ann Arbor/1/50, C/Taylor/1233/1947, and C/Victoria/1/2011, as well as IDV strains D/bovine/MS/C00020N/2014 and D/swine/OK/1334/2011, showed no infectivity in MDCK \u0394CasD1 cells (Fig. 6C and D).", [["MDCK \u0394CasD1 cells", "ANATOMY", 181, 198], ["ICV strains C/Ann Arbor/1/50", "ORGANISM", 9, 37], ["C/Taylor/1233/1947", "ORGANISM", 39, 57], ["C/Victoria/1/2011", "ORGANISM", 63, 80], ["bovine", "ORGANISM", 107, 113], ["/MS/C00020N/2014", "ORGANISM", 113, 129], ["D/swine/OK/1334/2011", "ORGANISM", 134, 154], ["MDCK \u0394CasD1 cells", "CELL", 181, 198], ["MDCK \u0394CasD1 cells", "CELL_LINE", 181, 198], ["bovine", "SPECIES", 107, 113], ["swine", "SPECIES", 136, 141], ["C/Ann Arbor/1/50, C/Taylor/1233/1947", "SPECIES", 21, 57], ["C/Victoria/1/2011", "SPECIES", 63, 80], ["D/bovine/MS/C00020N/2014 and D/swine/OK/1334/2011", "SPECIES", 105, 154], ["IDV strains D/bovine/MS", "TEST", 93, 116], ["infectivity", "PROBLEM", 166, 177], ["no", "UNCERTAINTY", 163, 165], ["infectivity", "OBSERVATION", 166, 177]]], ["The C/Ann Arbor and C/Victoria recovered a low level of infectivity in the MDCK CasD1-OX cells, whereas the D/bovine and D/swine strains had a higher level of infectivity recovered in the CasD1-OX cells compared to ICV but still were much lower than in WT MDCK cells.", [["MDCK CasD1-OX cells", "ANATOMY", 75, 94], ["CasD1-OX cells", "ANATOMY", 188, 202], ["MDCK cells", "ANATOMY", 256, 266], ["MDCK CasD1-OX cells", "CELL", 75, 94], ["D/bovine", "ORGANISM", 108, 116], ["D/swine strains", "ORGANISM", 121, 136], ["CasD1-OX cells", "CELL", 188, 202], ["WT MDCK cells", "CELL", 253, 266], ["MDCK CasD1", "CELL_LINE", 75, 85], ["OX cells", "CELL_LINE", 86, 94], ["CasD1-OX cells", "CELL_LINE", 188, 202], ["WT MDCK cells", "CELL_LINE", 253, 266], ["bovine", "SPECIES", 110, 116], ["swine", "SPECIES", 123, 128], ["swine", "SPECIES", 123, 128], ["a low level of infectivity", "PROBLEM", 41, 67], ["the MDCK CasD1", "TEST", 71, 85], ["the D/bovine and D/swine strains", "PROBLEM", 104, 136], ["a higher level of infectivity", "PROBLEM", 141, 170], ["the CasD1-OX cells", "TREATMENT", 184, 202], ["ICV", "TEST", 215, 218]]], ["The inability of the ICV and IDV strains to fully recover infectivity may be due to the low surface levels of 9-O-Ac Sia on MDCK CasD1-OX cells.", [["surface", "ANATOMY", 92, 99], ["MDCK CasD1-OX cells", "ANATOMY", 124, 143], ["9-O-Ac", "CHEMICAL", 110, 116], ["9-O-Ac Sia", "SIMPLE_CHEMICAL", 110, 120], ["MDCK CasD1-OX cells", "CELL", 124, 143], ["MDCK CasD1-OX cells", "CELL_LINE", 124, 143], ["the ICV and IDV strains", "TREATMENT", 17, 40], ["the low surface levels", "PROBLEM", 84, 106], ["MDCK CasD1-OX cells", "TREATMENT", 124, 143]]], ["Although the CasD1-OX cells had detectable surface levels of 9-O-Ac, these levels were lower than in WT MDCK cells and could be below the receptor levels required for efficient infection by these viruses.", [["CasD1-OX cells", "ANATOMY", 13, 27], ["surface", "ANATOMY", 43, 50], ["MDCK cells", "ANATOMY", 104, 114], ["9-O-Ac", "CHEMICAL", 61, 67], ["infection", "DISEASE", 177, 186], ["9-O-Ac", "CHEMICAL", 61, 67], ["CasD1-OX cells", "CELL", 13, 27], ["9-O-Ac", "SIMPLE_CHEMICAL", 61, 67], ["MDCK cells", "CELL", 104, 114], ["CasD1-OX cells", "CELL_LINE", 13, 27], ["WT MDCK cells", "CELL_LINE", 101, 114], ["the CasD1-OX cells", "TEST", 9, 27], ["surface levels", "TEST", 43, 57], ["these levels", "TEST", 69, 81], ["the receptor levels", "TEST", 134, 153], ["efficient infection", "PROBLEM", 167, 186], ["these viruses", "PROBLEM", 190, 203], ["surface", "OBSERVATION_MODIFIER", 43, 50], ["infection", "OBSERVATION", 177, 186]]], ["This suggests that ICV and IDV are able to utilize the levels of modified Sia on WT MDCK cells as their primary receptors for binding and infection but cannot infect when they are removed or below a certain necessary threshold.Effects of 7,9-O- or 9-O-acetyl Sia modifications on HA binding and NA activity. ::: RESULTSSince the low levels of 7,9-O- and 9-O-AC on the surfaces of cells did not effect IAV infection in our assays, we sought to determine the effects of these modifications on HA binding and NA cleavage using mouse erythrocytes which have \u223c45% of their total Sia is O-acetylated, primarily 7,9-O- and 9-O-Ac (Fig. 7A).", [["MDCK cells", "ANATOMY", 84, 94], ["cells", "ANATOMY", 380, 385], ["erythrocytes", "ANATOMY", 530, 542], ["ICV", "CHEMICAL", 19, 22], ["infection", "DISEASE", 138, 147], ["7,9-O", "CHEMICAL", 238, 243], ["9-O-acetyl", "CHEMICAL", 248, 258], ["7,9-O- and 9-O-AC", "CHEMICAL", 343, 360], ["IAV infection", "DISEASE", 401, 414], ["NA", "CHEMICAL", 506, 508], ["7,9-O- and 9-O-Ac", "CHEMICAL", 605, 622], ["7,9-O- or 9-O-acetyl Sia", "CHEMICAL", 238, 262], ["7,9-O- and 9-O-AC", "CHEMICAL", 343, 360], ["Sia", "CHEMICAL", 574, 577], ["O", "CHEMICAL", 581, 582], ["7,9-O- and 9-O-Ac", "CHEMICAL", 605, 622], ["ICV", "SIMPLE_CHEMICAL", 19, 22], ["IDV", "SIMPLE_CHEMICAL", 27, 30], ["Sia", "GENE_OR_GENE_PRODUCT", 74, 77], ["MDCK cells", "CELL", 84, 94], ["7,9-O- or 9-O-acetyl Sia", "SIMPLE_CHEMICAL", 238, 262], ["HA", "SIMPLE_CHEMICAL", 280, 282], ["NA", "SIMPLE_CHEMICAL", 295, 297], ["7,9-O", "SIMPLE_CHEMICAL", 343, 348], ["9-O-AC", "SIMPLE_CHEMICAL", 354, 360], ["cells", "CELL", 380, 385], ["IAV", "ORGANISM", 401, 404], ["HA", "SIMPLE_CHEMICAL", 491, 493], ["NA", "SIMPLE_CHEMICAL", 506, 508], ["mouse", "ORGANISM", 524, 529], ["erythrocytes", "CELL", 530, 542], ["Sia", "GENE_OR_GENE_PRODUCT", 574, 577], ["O-acetylated", "SIMPLE_CHEMICAL", 581, 593], ["7,9-O", "SIMPLE_CHEMICAL", 605, 610], ["9-O-Ac", "SIMPLE_CHEMICAL", 616, 622], ["Fig. 7A", "SIMPLE_CHEMICAL", 624, 631], ["WT MDCK cells", "CELL_LINE", 81, 94], ["mouse erythrocytes", "CELL_TYPE", 524, 542], ["mouse", "SPECIES", 524, 529], ["IAV", "SPECIES", 401, 404], ["mouse", "SPECIES", 524, 529], ["ICV", "TREATMENT", 19, 22], ["IDV", "TREATMENT", 27, 30], ["WT MDCK cells", "TREATMENT", 81, 94], ["binding", "PROBLEM", 126, 133], ["infection", "PROBLEM", 138, 147], ["HA binding", "PROBLEM", 280, 290], ["IAV infection", "PROBLEM", 401, 414], ["our assays", "TEST", 418, 428], ["these modifications", "PROBLEM", 468, 487], ["HA binding", "PROBLEM", 491, 501], ["NA cleavage", "TREATMENT", 506, 517], ["mouse erythrocytes", "PROBLEM", 524, 542], ["infection", "OBSERVATION", 138, 147], ["IAV", "OBSERVATION_MODIFIER", 401, 404], ["infection", "OBSERVATION", 405, 414]]], ["Although mouse erythrocytes contain primarily \u03b12,3-linked Sia, they also contain some \u03b12,6-linked Sia that could be bound by human IAV strains (Fig. 7A).", [["erythrocytes", "ANATOMY", 15, 27], ["mouse", "ORGANISM", 9, 14], ["erythrocytes", "CELL", 15, 27], ["Sia", "GENE_OR_GENE_PRODUCT", 58, 61], ["Sia", "GENE_OR_GENE_PRODUCT", 98, 101], ["human", "ORGANISM", 125, 130], ["IAV strains", "ORGANISM", 131, 142], ["Fig. 7A", "ORGANISM", 144, 151], ["mouse erythrocytes", "CELL_TYPE", 9, 27], ["\u03b12,3-linked Sia", "PROTEIN", 46, 61], ["\u03b12,6-linked Sia", "PROTEIN", 86, 101], ["mouse", "SPECIES", 9, 14], ["human", "SPECIES", 125, 130], ["mouse", "SPECIES", 9, 14], ["human IAV", "SPECIES", 125, 134], ["mouse erythrocytes", "TEST", 9, 27]]], ["Mouse erythrocytes were therefore used as a substrate for both binding (hemagglutination) assays and neuraminidase cleavage assays.", [["erythrocytes", "ANATOMY", 6, 18], ["Mouse", "ORGANISM", 0, 5], ["erythrocytes", "CELL", 6, 18], ["Mouse erythrocytes", "CELL_TYPE", 0, 18], ["neuraminidase", "PROTEIN", 101, 114], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse erythrocytes", "PROBLEM", 0, 18], ["a substrate", "TREATMENT", 42, 53], ["hemagglutination) assays", "TEST", 72, 96], ["neuraminidase cleavage assays", "TEST", 101, 130]]], ["The human IAV strains human H1N1 (A/California/04/2009) and human H3N2 (A/Victoria/361/2011) strains were mixed with either untreated mouse erythrocytes or mouse erythrocytes pretreated with esterase active BCV HE-Fc to remove all acetyl modifications (Fig. 7B).", [["erythrocytes", "ANATOMY", 140, 152], ["erythrocytes", "ANATOMY", 162, 174], ["acetyl", "CHEMICAL", 231, 237], ["acetyl", "CHEMICAL", 231, 237], ["human", "ORGANISM", 4, 9], ["IAV strains", "ORGANISM", 10, 21], ["human H1N1 (A/California/04/2009", "ORGANISM", 22, 54], ["human", "ORGANISM", 60, 65], ["H3N2 (A/Victoria/361/2011", "ORGANISM", 66, 91], ["mouse", "ORGANISM", 134, 139], ["erythrocytes", "CELL", 140, 152], ["mouse", "ORGANISM", 156, 161], ["erythrocytes", "CELL", 162, 174], ["BCV", "ORGANISM", 207, 210], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 211, 216], ["acetyl", "SIMPLE_CHEMICAL", 231, 237], ["mouse erythrocytes", "CELL_TYPE", 134, 152], ["mouse erythrocytes", "CELL_TYPE", 156, 174], ["esterase active BCV HE-Fc", "PROTEIN", 191, 216], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 22, 27], ["H1N1", "SPECIES", 28, 32], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 134, 139], ["mouse", "SPECIES", 156, 161], ["human", "SPECIES", 4, 9], ["human H1N1 (A/California/04/2009", "SPECIES", 22, 54], ["human H3N2 (A/Victoria/361/2011)", "SPECIES", 60, 92], ["mouse", "SPECIES", 134, 139], ["mouse", "SPECIES", 156, 161], ["human H3N2", "TREATMENT", 60, 70], ["strains", "PROBLEM", 93, 100], ["untreated mouse erythrocytes", "PROBLEM", 124, 152], ["mouse erythrocytes", "PROBLEM", 156, 174], ["esterase active BCV", "TREATMENT", 191, 210], ["all acetyl modifications", "TREATMENT", 227, 251]]], ["Significantly greater hemagglutination was seen for both viruses on the esterase-treated mouse erythrocytes compared to untreated erythrocytes.", [["erythrocytes", "ANATOMY", 95, 107], ["erythrocytes", "ANATOMY", 130, 142], ["esterase", "GENE_OR_GENE_PRODUCT", 72, 80], ["mouse", "ORGANISM", 89, 94], ["erythrocytes", "CELL", 95, 107], ["erythrocytes", "CELL", 130, 142], ["esterase", "PROTEIN", 72, 80], ["mouse erythrocytes", "CELL_TYPE", 89, 107], ["untreated erythrocytes", "CELL_TYPE", 120, 142], ["mouse", "SPECIES", 89, 94], ["mouse", "SPECIES", 89, 94], ["Significantly greater hemagglutination", "PROBLEM", 0, 38], ["both viruses", "PROBLEM", 52, 64], ["the esterase", "TEST", 68, 80], ["treated mouse erythrocytes", "PROBLEM", 81, 107], ["untreated erythrocytes", "PROBLEM", 120, 142], ["greater", "OBSERVATION_MODIFIER", 14, 21], ["hemagglutination", "OBSERVATION", 22, 38], ["viruses", "OBSERVATION", 57, 64], ["mouse erythrocytes", "OBSERVATION", 89, 107], ["untreated erythrocytes", "OBSERVATION", 120, 142]]], ["It should be noted that the hemagglutination was still quite low, which is likely due to the lower levels of \u03b12,6-linked Sia on mouse erythrocytes.Effects of 7,9-O- or 9-O-acetyl Sia modifications on HA binding and NA activity. ::: RESULTSTo determine the effect of 7,9-O- and 9-O-Ac on NA cleavage, mouse erythrocytes were incubated with soluble NA, in the form of NA-expressing viruslike particles (VLPs) (48).", [["erythrocytes", "ANATOMY", 134, 146], ["erythrocytes", "ANATOMY", 306, 318], ["7,9-O", "CHEMICAL", 158, 163], ["9-O-acetyl", "CHEMICAL", 168, 178], ["7,9-O- and 9-O-Ac", "CHEMICAL", 266, 283], ["NA", "CHEMICAL", 287, 289], ["NA", "CHEMICAL", 347, 349], ["NA", "CHEMICAL", 366, 368], ["7,9-O- or 9-O-acetyl Sia", "CHEMICAL", 158, 182], ["7,9-O- and 9-O-Ac", "CHEMICAL", 266, 283], ["Sia", "GENE_OR_GENE_PRODUCT", 121, 124], ["mouse", "ORGANISM", 128, 133], ["erythrocytes", "CELL", 134, 146], ["7,9-O- or 9-O-acetyl Sia", "SIMPLE_CHEMICAL", 158, 182], ["HA", "SIMPLE_CHEMICAL", 200, 202], ["NA", "SIMPLE_CHEMICAL", 215, 217], ["7,9-O", "SIMPLE_CHEMICAL", 266, 271], ["9-O-Ac", "SIMPLE_CHEMICAL", 277, 283], ["NA", "SIMPLE_CHEMICAL", 287, 289], ["mouse", "ORGANISM", 300, 305], ["erythrocytes", "CELL", 306, 318], ["NA", "SIMPLE_CHEMICAL", 347, 349], ["NA", "SIMPLE_CHEMICAL", 366, 368], ["viruslike particles", "SIMPLE_CHEMICAL", 380, 399], ["VLPs", "ORGANISM", 401, 405], ["\u03b12,6-linked Sia", "PROTEIN", 109, 124], ["mouse erythrocytes", "CELL_TYPE", 128, 146], ["mouse erythrocytes", "CELL_TYPE", 300, 318], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 300, 305], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 300, 305], ["the hemagglutination", "TEST", 24, 44], ["HA binding", "PROBLEM", 200, 210], ["NA cleavage", "TREATMENT", 287, 298], ["mouse erythrocytes", "PROBLEM", 300, 318], ["soluble NA", "TEST", 339, 349], ["NA", "TEST", 366, 368], ["hemagglutination", "OBSERVATION", 28, 44], ["low", "OBSERVATION", 61, 64], ["likely due to", "UNCERTAINTY", 75, 88], ["lower", "ANATOMY_MODIFIER", 93, 98], ["mouse erythrocytes", "OBSERVATION", 128, 146]]], ["Freed Sia was then collected and analyzed using HPLC, and the profile of Sia released by the NA VLPs was compared to Sia composition on mouse erythrocytes released by chemical hydrolysis (Fig. 7C).", [["erythrocytes", "ANATOMY", 142, 154], ["Sia", "GENE_OR_GENE_PRODUCT", 73, 76], ["NA VLPs", "ORGANISM", 93, 100], ["Sia", "GENE_OR_GENE_PRODUCT", 117, 120], ["mouse", "ORGANISM", 136, 141], ["erythrocytes", "CELL", 142, 154], ["mouse erythrocytes", "CELL_TYPE", 136, 154], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 136, 141], ["HPLC", "TEST", 48, 52], ["the NA VLPs", "TREATMENT", 89, 100], ["mouse erythrocytes", "PROBLEM", 136, 154], ["chemical hydrolysis", "OBSERVATION", 167, 186]]], ["The profiles for both N1 and N2 VLPs showed a preferential release of unmodified Neu5Ac compared to modified Sia forms, shown in the increased proportion of this Sia in the N1 and N2 profiles.", [["Neu5Ac", "CHEMICAL", 81, 87], ["N2", "CHEMICAL", 29, 31], ["Neu5Ac", "CHEMICAL", 81, 87], ["Sia", "CHEMICAL", 162, 165], ["N2", "CHEMICAL", 180, 182], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 81, 87], ["Sia", "GENE_OR_GENE_PRODUCT", 109, 112], ["Sia", "GENE_OR_GENE_PRODUCT", 162, 165], ["The profiles", "TEST", 0, 12], ["both N1 and N2 VLPs", "TEST", 17, 36], ["unmodified Neu5Ac", "TREATMENT", 70, 87], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["N2 profiles", "OBSERVATION", 180, 191]]], ["Compared to the chemical release profile, the N1 VLPs did not release any detectable O-acetylated Sia, while the N2 VLPs were able to release 9-O-Ac (Neu5,9Ac2) but released significantly less 7-O- and 8-O-Ac and were unable to release any 7,9-O-Ac (Neu5,7,9Ac3).", [["9-O-Ac", "CHEMICAL", 142, 148], ["8-O-Ac", "CHEMICAL", 202, 208], ["7,9-O-Ac", "CHEMICAL", 240, 248], ["O-acetylated Sia", "CHEMICAL", 85, 101], ["N2", "CHEMICAL", 113, 115], ["9-O-Ac", "CHEMICAL", 142, 148], ["9Ac2", "CHEMICAL", 155, 159], ["7-O- and 8-O-Ac", "CHEMICAL", 193, 208], ["7,9-O-Ac", "CHEMICAL", 240, 248], ["Neu5", "CHEMICAL", 250, 254], ["7,9Ac3", "CHEMICAL", 255, 261], ["Sia", "GENE_OR_GENE_PRODUCT", 98, 101], ["9-O-Ac", "SIMPLE_CHEMICAL", 142, 148], ["Neu5,9Ac2", "SIMPLE_CHEMICAL", 150, 159], ["7-O", "SIMPLE_CHEMICAL", 193, 196], ["8-O-Ac", "SIMPLE_CHEMICAL", 202, 208], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 240, 248], ["Neu5,7,9Ac3", "SIMPLE_CHEMICAL", 250, 261], ["O-acetylated Sia", "PROTEIN", 85, 101], ["the chemical release profile", "TEST", 12, 40], ["the N2 VLPs", "TREATMENT", 109, 120]]], ["Similar to N2 VLPs, commercial NeuA from Arthrobacter ureafaciens, used as an activity control, also had a bias toward unmodified Neu5Ac, with decreased activity against 7-O-, 8-O-, and 7,9-O-Ac.", [["NeuA", "CHEMICAL", 31, 35], ["Arthrobacter ureafaciens", "CHEMICAL", 41, 65], ["Neu5Ac", "CHEMICAL", 130, 136], ["7-O-, 8-O-, and 7,9-O-Ac.", "CHEMICAL", 170, 195], ["N2", "CHEMICAL", 11, 13], ["Neu5Ac", "CHEMICAL", 130, 136], ["7-O-, 8-O-, and 7,9-O-Ac.", "CHEMICAL", 170, 195], ["NeuA", "GENE_OR_GENE_PRODUCT", 31, 35], ["Arthrobacter ureafaciens", "ORGANISM", 41, 65], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 130, 136], ["7-O-, 8-O-", "SIMPLE_CHEMICAL", 170, 180], ["7,9-O-Ac.", "SIMPLE_CHEMICAL", 186, 195], ["NeuA", "PROTEIN", 31, 35], ["Arthrobacter ureafaciens", "SPECIES", 41, 65], ["Arthrobacter ureafaciens", "SPECIES", 41, 65], ["N2 VLPs", "TREATMENT", 11, 18], ["Arthrobacter ureafaciens", "TREATMENT", 41, 65], ["an activity control", "TREATMENT", 75, 94], ["N2 VLPs", "OBSERVATION", 11, 18]]], ["These results indicate that mono O-acetyl modifications, including 7-O-, 8-O-, and 9-O-Ac, reduced the Sia susceptibility to NA cleavage and that diacetyl 7,9-O-Ac was the most resistant to NA cleavage.", [["mono O-acetyl", "CHEMICAL", 28, 41], ["7-O-, 8-O-, and 9-O-Ac", "CHEMICAL", 67, 89], ["NA", "CHEMICAL", 125, 127], ["diacetyl 7,9-O-Ac", "CHEMICAL", 146, 163], ["NA", "CHEMICAL", 190, 192], ["O-acetyl", "CHEMICAL", 33, 41], ["7-O-, 8-O-, and 9-O-Ac", "CHEMICAL", 67, 89], ["diacetyl 7,9-O-Ac", "CHEMICAL", 146, 163], ["mono O-acetyl", "SIMPLE_CHEMICAL", 28, 41], ["7-O-, 8-O-,", "SIMPLE_CHEMICAL", 67, 78], ["9-O-Ac", "SIMPLE_CHEMICAL", 83, 89], ["Sia", "GENE_OR_GENE_PRODUCT", 103, 106], ["NA", "SIMPLE_CHEMICAL", 125, 127], ["diacetyl 7,9-O-Ac", "SIMPLE_CHEMICAL", 146, 163], ["NA", "SIMPLE_CHEMICAL", 190, 192], ["acetyl modifications", "TREATMENT", 35, 55], ["NA cleavage", "TREATMENT", 125, 136], ["diacetyl", "TEST", 146, 154], ["NA cleavage", "TREATMENT", 190, 201]]], ["In addition, there was variability between the ability of the NA VLPs and NeuA to cleave the different Sia forms.", [["NA VLPs", "ORGANISM", 62, 69], ["NeuA", "SIMPLE_CHEMICAL", 74, 78], ["Sia", "GENE_OR_GENE_PRODUCT", 103, 106], ["NA VLPs", "PROTEIN", 62, 69], ["NeuA", "PROTEIN", 74, 78], ["Sia forms", "PROTEIN", 103, 112], ["the NA VLPs", "TREATMENT", 58, 69]]], ["Although the presence of these modified Sia on cells was too low to affect IAV infection, it is likely that higher levels present on erythrocytes, or potentially in secreted proteins in mucus, would inhibit infection or the release of virus.DISCUSSIONBoth 9-O-Ac and 7,9-O-Ac Sia are widely expressed within tissues and on mucosal surfaces of many animals, but with significant variation in the amounts present in different cells, tissues, and animals (10, 11).", [["cells", "ANATOMY", 47, 52], ["erythrocytes", "ANATOMY", 133, 145], ["mucus", "ANATOMY", 186, 191], ["tissues", "ANATOMY", 308, 315], ["mucosal surfaces", "ANATOMY", 323, 339], ["cells", "ANATOMY", 424, 429], ["tissues", "ANATOMY", 431, 438], ["infection", "DISEASE", 79, 88], ["infection", "DISEASE", 207, 216], ["9-O-Ac", "CHEMICAL", 256, 262], ["7,9-O-Ac", "CHEMICAL", 267, 275], ["9-O-Ac", "CHEMICAL", 256, 262], ["Sia", "GENE_OR_GENE_PRODUCT", 40, 43], ["cells", "CELL", 47, 52], ["IAV", "ORGANISM", 75, 78], ["erythrocytes", "CELL", 133, 145], ["mucus", "ORGANISM_SUBSTANCE", 186, 191], ["9-O-Ac", "SIMPLE_CHEMICAL", 256, 262], ["7,9-O-Ac Sia", "SIMPLE_CHEMICAL", 267, 279], ["tissues", "TISSUE", 308, 315], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 323, 339], ["cells", "CELL", 424, 429], ["tissues", "TISSUE", 431, 438], ["erythrocytes", "CELL_TYPE", 133, 145], ["secreted proteins", "PROTEIN", 165, 182], ["Ac Sia", "DNA", 273, 279], ["IAV", "SPECIES", 75, 78], ["these modified Sia on cells", "PROBLEM", 25, 52], ["IAV infection", "PROBLEM", 75, 88], ["higher levels present on erythrocytes", "PROBLEM", 108, 145], ["secreted proteins in mucus", "PROBLEM", 165, 191], ["infection", "PROBLEM", 207, 216], ["the release of virus", "PROBLEM", 220, 240], ["Ac", "TEST", 260, 262], ["significant variation in the amounts", "PROBLEM", 366, 402], ["IAV", "OBSERVATION_MODIFIER", 75, 78], ["infection", "OBSERVATION", 79, 88], ["is likely", "UNCERTAINTY", 93, 102], ["higher", "OBSERVATION_MODIFIER", 108, 114], ["infection", "OBSERVATION", 207, 216], ["many", "OBSERVATION_MODIFIER", 343, 347], ["animals", "OBSERVATION", 348, 355], ["significant", "OBSERVATION_MODIFIER", 366, 377], ["variation", "OBSERVATION_MODIFIER", 378, 387], ["amounts", "OBSERVATION_MODIFIER", 395, 402], ["different cells", "OBSERVATION", 414, 429], ["tissues", "ANATOMY", 431, 438]]], ["These modified Sia are present in secreted mucus on mucosal surfaces, including gastrointestinal and respiratory tissues, where they can potentially control many interactions with both normal flora and pathogens.", [["mucus", "ANATOMY", 43, 48], ["mucosal surfaces", "ANATOMY", 52, 68], ["gastrointestinal", "ANATOMY", 80, 96], ["respiratory tissues", "ANATOMY", 101, 120], ["Sia", "GENE_OR_GENE_PRODUCT", 15, 18], ["mucus", "TISSUE", 43, 48], ["mucosal surfaces", "TISSUE", 52, 68], ["gastrointestinal", "ORGAN", 80, 96], ["respiratory tissues", "TISSUE", 101, 120], ["gastrointestinal and respiratory tissues", "PROBLEM", 80, 120], ["pathogens", "PROBLEM", 202, 211], ["secreted", "OBSERVATION_MODIFIER", 34, 42], ["mucus", "OBSERVATION", 43, 48], ["mucosal surfaces", "OBSERVATION", 52, 68], ["gastrointestinal", "ANATOMY", 80, 96], ["respiratory tissues", "ANATOMY", 101, 120], ["normal flora", "OBSERVATION", 185, 197]]], ["However, there is still little known about the details of their display levels, cell association, and the ways in which their synthesis is regulated either in cells or on mucosal surfaces.", [["cell", "ANATOMY", 80, 84], ["cells", "ANATOMY", 159, 164], ["mucosal surfaces", "ANATOMY", 171, 187], ["cell", "CELL", 80, 84], ["cells", "CELL", 159, 164], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 171, 187], ["mucosal", "ANATOMY", 171, 178], ["surfaces", "ANATOMY_MODIFIER", 179, 187]]], ["While there have been suggestions that 9-O- and 7,9-O-Ac might influence IAV and IBV infection by interfering with HA binding or NA activities, direct evidence for their effects is sparse.", [["9-O- and 7,9-O-Ac", "CHEMICAL", 39, 56], ["infection", "DISEASE", 85, 94], ["9-O- and 7,9-O-Ac", "CHEMICAL", 39, 56], ["9-O", "SIMPLE_CHEMICAL", 39, 42], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 48, 56], ["IAV", "ORGANISM", 73, 76], ["IBV", "ORGANISM", 81, 84], ["IAV", "SPECIES", 73, 76], ["IBV", "SPECIES", 81, 84], ["IAV", "PROBLEM", 73, 76], ["IBV infection", "PROBLEM", 81, 94], ["HA binding", "PROBLEM", 115, 125], ["NA activities", "PROBLEM", 129, 142], ["IAV", "OBSERVATION", 73, 76], ["IBV", "OBSERVATION_MODIFIER", 81, 84], ["infection", "OBSERVATION", 85, 94]]], ["In contrast, ICV and IDV are known to use 9-O-Ac as their primary receptor for cell binding and infection.", [["cell", "ANATOMY", 79, 83], ["ICV", "CHEMICAL", 13, 16], ["IDV", "CHEMICAL", 21, 24], ["9-O-Ac", "CHEMICAL", 42, 48], ["infection", "DISEASE", 96, 105], ["9-O-Ac", "CHEMICAL", 42, 48], ["ICV", "SIMPLE_CHEMICAL", 13, 16], ["IDV", "SIMPLE_CHEMICAL", 21, 24], ["9-O-Ac", "SIMPLE_CHEMICAL", 42, 48], ["cell", "CELL", 79, 83], ["ICV and IDV", "TREATMENT", 13, 24], ["Ac", "TREATMENT", 46, 48], ["cell binding", "PROBLEM", 79, 91], ["infection", "PROBLEM", 96, 105], ["cell binding", "OBSERVATION", 79, 91], ["infection", "OBSERVATION", 96, 105]]], ["Here, we use a number of new tools to define the cell-specific expression of 9-O- and 7,9-O-Ac and provide a preliminary test of their effects on IAV, IBV, ICV, and IDV infection.DISCUSSIONWe confirmed that 9-O- and 7,9-O-Ac are expressed on cells in culture and that expression varies between cell lines, as has been previously reported (38).", [["cell", "ANATOMY", 49, 53], ["cells", "ANATOMY", 242, 247], ["cell lines", "ANATOMY", 294, 304], ["infection", "DISEASE", 169, 178], ["9-O- and 7,9-O-Ac", "CHEMICAL", 207, 224], ["9-O- and 7,9-O-Ac", "CHEMICAL", 77, 94], ["9-O- and 7,9-O-Ac", "CHEMICAL", 207, 224], ["cell", "CELL", 49, 53], ["9-O", "SIMPLE_CHEMICAL", 77, 80], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 86, 94], ["IAV", "ORGANISM", 146, 149], ["IBV", "ORGANISM", 151, 154], ["9-O", "SIMPLE_CHEMICAL", 207, 210], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 216, 224], ["cells", "CELL", 242, 247], ["cell lines", "CELL", 294, 304], ["Ac", "DNA", 222, 224], ["IAV", "SPECIES", 146, 149], ["IBV", "SPECIES", 151, 154], ["a preliminary test", "TEST", 107, 125], ["IAV", "PROBLEM", 146, 149], ["IBV", "TREATMENT", 151, 154], ["ICV", "TREATMENT", 156, 159], ["IDV infection", "PROBLEM", 165, 178], ["culture", "TEST", 251, 258], ["cell lines", "TREATMENT", 294, 304], ["infection", "OBSERVATION", 169, 178], ["cell lines", "OBSERVATION", 294, 304]]], ["However, when present these modified Sia made up only 1 to 2% of the total Sia when analyzed by HPLC.", [["Sia", "GENE_OR_GENE_PRODUCT", 75, 78]]], ["Cells showed distinct population heterogeneity in 7,9-O- and 9-O-Ac display and localization that was observed over many passages examined.", [["Cells", "ANATOMY", 0, 5], ["7,9-O- and 9-O-Ac", "CHEMICAL", 50, 67], ["7,9-O- and 9-O-Ac", "CHEMICAL", 50, 67], ["Cells", "CELL", 0, 5], ["7,9-O", "SIMPLE_CHEMICAL", 50, 55], ["9-O-Ac", "SIMPLE_CHEMICAL", 61, 67], ["Cells", "TEST", 0, 5], ["distinct population heterogeneity", "PROBLEM", 13, 46], ["distinct", "OBSERVATION_MODIFIER", 13, 21], ["population", "OBSERVATION_MODIFIER", 22, 32], ["heterogeneity", "OBSERVATION_MODIFIER", 33, 46]]], ["Previous studies using ICV HEF probes found similar staining patterns on some cell lines and also showed that, after sorting into high and low staining populations, both populations returned to previous levels of heterogeneity within a few passages (11, 38).", [["cell lines", "ANATOMY", 78, 88], ["cell lines", "CELL", 78, 88], ["ICV HEF probes", "DNA", 23, 37], ["cell lines", "CELL_LINE", 78, 88], ["Previous studies", "TEST", 0, 16], ["ICV HEF probes", "TEST", 23, 37], ["some cell lines", "TREATMENT", 73, 88], ["high and low staining populations", "PROBLEM", 130, 163], ["heterogeneity", "PROBLEM", 213, 226], ["some cell lines", "OBSERVATION", 73, 88], ["high", "OBSERVATION_MODIFIER", 130, 134], ["low staining", "OBSERVATION_MODIFIER", 139, 151], ["populations", "OBSERVATION_MODIFIER", 152, 163], ["both", "OBSERVATION_MODIFIER", 165, 169], ["populations", "OBSERVATION_MODIFIER", 170, 181], ["heterogeneity", "OBSERVATION", 213, 226], ["few", "OBSERVATION_MODIFIER", 236, 239], ["passages", "OBSERVATION_MODIFIER", 240, 248]]], ["Here, we saw that the modified Sia are retained in the Golgi compartments of HEK-293 and A549 cells, although an occasional cell displayed these modified Sia on the surface.", [["Golgi compartments", "ANATOMY", 55, 73], ["HEK-293", "ANATOMY", 77, 84], ["A549 cells", "ANATOMY", 89, 99], ["cell", "ANATOMY", 124, 128], ["surface", "ANATOMY", 165, 172], ["Sia", "GENE_OR_GENE_PRODUCT", 31, 34], ["Golgi", "CELLULAR_COMPONENT", 55, 60], ["HEK-293", "CELL", 77, 84], ["A549 cells", "CELL", 89, 99], ["cell", "CELL", 124, 128], ["Sia", "GENE_OR_GENE_PRODUCT", 154, 157], ["surface", "CELLULAR_COMPONENT", 165, 172], ["Sia", "PROTEIN", 31, 34], ["HEK-293", "CELL_LINE", 77, 84], ["A549 cells", "CELL_LINE", 89, 99], ["Sia", "PROTEIN", 154, 157], ["HEK-293", "SPECIES", 77, 84], ["A549 cells", "TEST", 89, 99], ["an occasional cell", "PROBLEM", 110, 128], ["A549 cells", "OBSERVATION", 89, 99], ["occasional cell", "OBSERVATION", 113, 128], ["surface", "OBSERVATION_MODIFIER", 165, 172]]], ["It is not clear why these modified Sia are localized in the Golgi body, although perhaps the modifications could block the onward trafficking of glycoproteins to the cell surface.", [["Golgi body", "ANATOMY", 60, 70], ["cell surface", "ANATOMY", 166, 178], ["Sia", "GENE_OR_GENE_PRODUCT", 35, 38], ["Golgi body", "CELLULAR_COMPONENT", 60, 70], ["cell surface", "CELLULAR_COMPONENT", 166, 178], ["Sia", "PROTEIN", 35, 38], ["glycoproteins", "PROTEIN", 145, 158], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["Golgi body", "OBSERVATION", 60, 70], ["cell", "OBSERVATION_MODIFIER", 166, 170], ["surface", "OBSERVATION_MODIFIER", 171, 178]]], ["In contrast to the human cell lines, MDCK cells showed many cells expressing 7,9-O-Ac and 9-O-Ac on the cell surface, raising the possibility that trafficking could be cell type or species specific.", [["cell lines", "ANATOMY", 25, 35], ["MDCK cells", "ANATOMY", 37, 47], ["cells", "ANATOMY", 60, 65], ["cell surface", "ANATOMY", 104, 116], ["cell", "ANATOMY", 168, 172], ["9-O-Ac", "CHEMICAL", 90, 96], ["7,9-O-Ac", "CHEMICAL", 77, 85], ["9-O-Ac", "CHEMICAL", 90, 96], ["human", "ORGANISM", 19, 24], ["cell lines", "CELL", 25, 35], ["MDCK cells", "CELL", 37, 47], ["cells", "CELL", 60, 65], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 77, 85], ["9-O-Ac", "SIMPLE_CHEMICAL", 90, 96], ["cell surface", "CELLULAR_COMPONENT", 104, 116], ["cell", "CELL", 168, 172], ["human cell lines", "CELL_LINE", 19, 35], ["MDCK cells", "CELL_LINE", 37, 47], ["7,9-O-Ac and 9-O-Ac", "DNA", 77, 96], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["MDCK cells", "TEST", 37, 47], ["many cells", "PROBLEM", 55, 65], ["Ac", "TEST", 83, 85], ["cell type", "PROBLEM", 168, 177], ["human cell lines", "OBSERVATION", 19, 35], ["many cells", "OBSERVATION", 55, 65], ["cell surface", "OBSERVATION_MODIFIER", 104, 116], ["raising the possibility", "UNCERTAINTY", 118, 141], ["could be", "UNCERTAINTY", 159, 167], ["cell type", "OBSERVATION", 168, 177]]], ["A summary of the synthesis and localization of 7,9-O- and 9-O-Ac is shown in Fig. 8.DISCUSSIONTo look more closely at the expression and roles of 7,9-O- and 9-O-Ac modifications and their effects on viral infections, we prepared glycoengineered cell lines that lacked these modifications or that expressed higher levels of CasD1.", [["cell lines", "ANATOMY", 245, 255], ["7,9-O- and 9-O-Ac", "CHEMICAL", 47, 64], ["7,9-O- and 9-O-Ac", "CHEMICAL", 146, 163], ["viral infections", "DISEASE", 199, 215], ["7,9-O- and 9-O-Ac", "CHEMICAL", 47, 64], ["7,9-O- and 9-O-Ac", "CHEMICAL", 146, 163], ["7,9-O", "SIMPLE_CHEMICAL", 47, 52], ["9-O-Ac", "SIMPLE_CHEMICAL", 58, 64], ["7,9-O", "SIMPLE_CHEMICAL", 146, 151], ["9-O-Ac", "SIMPLE_CHEMICAL", 157, 163], ["cell lines", "CELL", 245, 255], ["CasD1", "GENE_OR_GENE_PRODUCT", 323, 328], ["glycoengineered cell lines", "CELL_LINE", 229, 255], ["CasD1", "PROTEIN", 323, 328], ["the synthesis", "TEST", 13, 26], ["localization", "TEST", 31, 43], ["Ac modifications", "TREATMENT", 161, 177], ["viral infections", "PROBLEM", 199, 215], ["glycoengineered cell lines", "TREATMENT", 229, 255], ["cell lines", "OBSERVATION", 245, 255]]], ["A deletion and frameshift in CasD1 completely removed both 9-O- and 7,9-O-Ac expression, confirming this enzyme was responsible for creating both modifications, likely through addition to the C-7 position, from which it migrates to the C-9 position (5, 8, 9).", [["9-O- and 7,9-O-Ac", "CHEMICAL", 59, 76], ["C-9", "CHEMICAL", 236, 239], ["9-O- and 7,9-O-Ac", "CHEMICAL", 59, 76], ["CasD1", "AMINO_ACID", 29, 34], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 68, 76], ["CasD1", "DNA", 29, 34], ["Ac", "DNA", 74, 76], ["C-7 position", "DNA", 192, 204], ["C-9 position", "DNA", 236, 248], ["A deletion and frameshift in CasD1", "PROBLEM", 0, 34], ["this enzyme", "TEST", 100, 111], ["frameshift", "OBSERVATION", 15, 25]]], ["Adding CasD1 back into the cells by plasmid transfection restored modified Sia expression, but none of the cell clones isolated showed universally higher levels of modified Sia synthesis and population heterogeneity was still seen.", [["cells", "ANATOMY", 27, 32], ["plasmid", "ANATOMY", 36, 43], ["cell clones", "ANATOMY", 107, 118], ["CasD1", "CHEMICAL", 7, 12], ["CasD1", "GENE_OR_GENE_PRODUCT", 7, 12], ["cells", "CELL", 27, 32], ["Sia", "GENE_OR_GENE_PRODUCT", 75, 78], ["cell clones", "CELL", 107, 118], ["Sia", "GENE_OR_GENE_PRODUCT", 173, 176], ["CasD1", "PROTEIN", 7, 12], ["Sia", "PROTEIN", 75, 78], ["cell clones", "CELL_LINE", 107, 118], ["CasD1", "TREATMENT", 7, 12], ["plasmid transfection", "TREATMENT", 36, 56], ["the cell clones", "TEST", 103, 118], ["modified Sia synthesis", "PROBLEM", 164, 186], ["population heterogeneity", "PROBLEM", 191, 215], ["population", "OBSERVATION_MODIFIER", 191, 201], ["heterogeneity", "OBSERVATION", 202, 215]]], ["The CasD1-transfected HEK-293 cells showed the greatest increase, whereas for A549 and MDCK cells the expression was similar to or lower than that for WT cells.", [["HEK-293 cells", "ANATOMY", 22, 35], ["A549", "ANATOMY", 78, 82], ["MDCK cells", "ANATOMY", 87, 97], ["cells", "ANATOMY", 154, 159], ["CasD1", "GENE_OR_GENE_PRODUCT", 4, 9], ["HEK-293 cells", "CELL", 22, 35], ["A549", "CELL", 78, 82], ["MDCK cells", "CELL", 87, 97], ["WT cells", "CELL", 151, 159], ["CasD1-transfected HEK-293 cells", "CELL_LINE", 4, 35], ["A549", "CELL_LINE", 78, 82], ["MDCK cells", "CELL_LINE", 87, 97], ["WT cells", "CELL_LINE", 151, 159], ["The CasD1", "TEST", 0, 9], ["transfected HEK", "TEST", 10, 25], ["A549", "TEST", 78, 82], ["MDCK cells", "TEST", 87, 97], ["WT cells", "PROBLEM", 151, 159], ["greatest", "OBSERVATION_MODIFIER", 47, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64]]], ["However, even in the HEK-293 CasD1-OX cells, 9-O-Ac still only accounted for \u223c1.5% of total Sia, and 7,9-O-Ac was not detected.", [["HEK-293 CasD1-OX cells", "ANATOMY", 21, 43], ["9-O-Ac", "CHEMICAL", 45, 51], ["7,9-O-Ac", "CHEMICAL", 101, 109], ["9-O-Ac", "CHEMICAL", 45, 51], ["Sia", "CHEMICAL", 92, 95], ["7,9-O-Ac", "CHEMICAL", 101, 109], ["HEK-293 CasD1-OX cells", "CELL", 21, 43], ["9-O-Ac", "SIMPLE_CHEMICAL", 45, 51], ["Sia", "GENE_OR_GENE_PRODUCT", 92, 95], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 101, 109], ["HEK-293 CasD1", "CELL_LINE", 21, 34], ["OX cells", "CELL_LINE", 35, 43]]], ["This indicates that the levels of these modifications are not only controlled by the expression of CasD1 and could be regulated by other processes.", [["CasD1", "GENE_OR_GENE_PRODUCT", 99, 104], ["CasD1", "PROTEIN", 99, 104]]], ["In addition, there is clearly a differential regulation of 7,9-O-Ac compared to 9-O-Ac, as overexpressing CasD1 did not lead to an increase in 7,9-O-Ac, since it was not detectable by HPLC and there was only very low fluorescence via staining with BCoV HE-Fc.DISCUSSIONOne candidate for control of these modifications is SIAE.", [["7,9-O-Ac", "CHEMICAL", 59, 67], ["9-O-Ac", "CHEMICAL", 80, 86], ["7,9-O-Ac", "CHEMICAL", 143, 151], ["7,9-O-Ac", "CHEMICAL", 59, 67], ["9-O-Ac", "CHEMICAL", 80, 86], ["7,9-O-Ac", "CHEMICAL", 143, 151], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 59, 67], ["9-O-Ac", "SIMPLE_CHEMICAL", 80, 86], ["CasD1", "GENE_OR_GENE_PRODUCT", 106, 111], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 143, 151], ["HPLC", "TEST", 184, 188], ["very low fluorescence", "PROBLEM", 208, 229], ["increase", "OBSERVATION_MODIFIER", 131, 139]]], ["When we knocked SIAE out of HEK-293 and A549 cells, we saw an increase in 9-O-Ac that was still retained in the Golgi compartment, but there was no increase in 7,9-O-Ac.", [["HEK-293", "ANATOMY", 28, 35], ["A549 cells", "ANATOMY", 40, 50], ["Golgi compartment", "ANATOMY", 112, 129], ["9-O-Ac", "CHEMICAL", 74, 80], ["9-O-Ac", "CHEMICAL", 74, 80], ["7,9-O-Ac.", "CHEMICAL", 160, 169], ["HEK-293", "CELL", 28, 35], ["A549 cells", "CELL", 40, 50], ["9-O-Ac", "SIMPLE_CHEMICAL", 74, 80], ["Golgi compartment", "CELLULAR_COMPONENT", 112, 129], ["SIAE", "PROTEIN", 16, 20], ["HEK-293", "CELL_LINE", 28, 35], ["A549 cells", "CELL_LINE", 40, 50], ["HEK-293", "SPECIES", 28, 35], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["Golgi compartment", "OBSERVATION", 112, 129], ["no", "UNCERTAINTY", 145, 147], ["increase", "OBSERVATION_MODIFIER", 148, 156]]], ["Expressing CasD1 from a plasmid in \u0394SIAE HEK-293 and A549 cells resulted in an additional small increase in 9-O-Ac that was still Golgi compartment associated, but with little increase in expression on the cell surface.", [["plasmid", "ANATOMY", 24, 31], ["\u0394SIAE HEK-293", "ANATOMY", 35, 48], ["A549 cells", "ANATOMY", 53, 63], ["Golgi compartment", "ANATOMY", 130, 147], ["cell surface", "ANATOMY", 206, 218], ["9-O-Ac", "CHEMICAL", 108, 114], ["9-O-Ac", "CHEMICAL", 108, 114], ["CasD1", "GENE_OR_GENE_PRODUCT", 11, 16], ["\u0394SIAE HEK-293", "CELL", 35, 48], ["A549 cells", "CELL", 53, 63], ["9-O-Ac", "SIMPLE_CHEMICAL", 108, 114], ["Golgi compartment", "CELLULAR_COMPONENT", 130, 147], ["cell surface", "CELLULAR_COMPONENT", 206, 218], ["CasD1", "PROTEIN", 11, 16], ["plasmid", "DNA", 24, 31], ["\u0394SIAE HEK-293", "CELL_LINE", 35, 48], ["A549 cells", "CELL_LINE", 53, 63], ["9-O-Ac", "DNA", 108, 114], ["HEK-293", "SPECIES", 41, 48], ["a plasmid in \u0394SIAE HEK", "TEST", 22, 44], ["A549 cells", "PROBLEM", 53, 63], ["an additional small increase", "PROBLEM", 76, 104], ["small", "OBSERVATION_MODIFIER", 90, 95], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["Golgi compartment", "OBSERVATION", 130, 147], ["little", "OBSERVATION_MODIFIER", 169, 175], ["increase", "OBSERVATION_MODIFIER", 176, 184], ["expression", "OBSERVATION", 188, 198], ["cell surface", "OBSERVATION", 206, 218]]], ["Similar to the CasD1-OX cells, no increase in 7,9-O-Ac was seen in either \u0394SIAE and \u0394SIAE+CasD1 cell lines by HPLC analysis.", [["CasD1-OX cells", "ANATOMY", 15, 29], ["\u0394SIAE+CasD1 cell lines", "ANATOMY", 84, 106], ["7,9-O-Ac", "CHEMICAL", 46, 54], ["7,9-O-Ac", "CHEMICAL", 46, 54], ["CasD1-OX cells", "CELL", 15, 29], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 46, 54], ["CasD1-OX cells", "CELL_LINE", 15, 29], ["7,9-O-Ac", "DNA", 46, 54], ["\u0394SIAE", "CELL_LINE", 74, 79], ["\u0394SIAE", "CELL_LINE", 84, 89], ["CasD1 cell lines", "CELL_LINE", 90, 106], ["the CasD1-OX cells", "TEST", 11, 29], ["HPLC analysis", "TEST", 110, 123], ["no", "UNCERTAINTY", 31, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["CasD1 cell lines", "OBSERVATION", 90, 106]]], ["Both \u0394SIAE+CasD1 lines had altered growth rates compared to WT cells: HEK-293 \u0394SIAE+CasD1 had delayed growth rates, while A549 \u0394SIAE+CasD1 had increased growth rates.", [["\u0394SIAE+CasD1 lines", "ANATOMY", 5, 22], ["cells", "ANATOMY", 63, 68], ["HEK-293 \u0394SIAE+CasD1", "ANATOMY", 70, 89], ["A549", "ANATOMY", 122, 126], ["cells", "CELL", 63, 68], ["HEK-293 \u0394SIAE", "CELL", 70, 83], ["\u0394SIAE+CasD1 lines", "CELL_LINE", 5, 22], ["WT cells", "CELL_LINE", 60, 68], ["HEK-293 \u0394SIAE", "CELL_LINE", 70, 83], ["CasD1", "CELL_LINE", 84, 89], ["A549 \u0394SIAE", "PROTEIN", 122, 132], ["CasD1", "CELL_LINE", 133, 138], ["altered growth rates", "PROBLEM", 27, 47], ["WT cells", "TEST", 60, 68], ["HEK", "TEST", 70, 73], ["\u0394SIAE", "TEST", 78, 83], ["CasD1", "TEST", 84, 89], ["delayed growth rates", "PROBLEM", 94, 114], ["increased growth rates", "PROBLEM", 143, 165], ["CasD1 lines", "OBSERVATION", 11, 22], ["growth", "OBSERVATION_MODIFIER", 35, 41], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["growth", "OBSERVATION_MODIFIER", 153, 159]]], ["This suggests that dysregulation of SIAE and CasD1 by gene manipulation affects cell metabolism and growth in a cell-type-specific manner, possibly through the buildup of glycoproteins in the Golgi or through dysregulation of the sialic acid recycling pathway.", [["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 112, 116], ["Golgi", "ANATOMY", 192, 197], ["sialic acid", "CHEMICAL", 230, 241], ["sialic acid", "CHEMICAL", 230, 241], ["SIAE", "GENE_OR_GENE_PRODUCT", 36, 40], ["CasD1", "GENE_OR_GENE_PRODUCT", 45, 50], ["cell", "CELL", 80, 84], ["cell", "CELL", 112, 116], ["Golgi", "CELLULAR_COMPONENT", 192, 197], ["sialic acid", "SIMPLE_CHEMICAL", 230, 241], ["SIAE", "PROTEIN", 36, 40], ["CasD1", "PROTEIN", 45, 50], ["glycoproteins", "PROTEIN", 171, 184], ["dysregulation of SIAE", "PROBLEM", 19, 40], ["CasD1", "TREATMENT", 45, 50], ["cell metabolism", "PROBLEM", 80, 95], ["the buildup of glycoproteins", "PROBLEM", 156, 184], ["the sialic acid recycling pathway", "TREATMENT", 226, 259], ["dysregulation", "OBSERVATION", 19, 32], ["cell metabolism", "OBSERVATION", 80, 95], ["growth", "OBSERVATION_MODIFIER", 100, 106], ["glycoproteins", "OBSERVATION", 171, 184]]], ["These effects on cell growth could have implications for cancer and organismal development, since these variant Sia are involved in both these processes (15\u201317, 20\u201323, 49).", [["cell", "ANATOMY", 17, 21], ["cancer", "ANATOMY", 57, 63], ["cancer", "DISEASE", 57, 63], ["cell", "CELL", 17, 21], ["cancer", "CANCER", 57, 63], ["Sia", "GENE_OR_GENE_PRODUCT", 112, 115], ["cell growth", "PROBLEM", 17, 28], ["cancer", "PROBLEM", 57, 63], ["organismal development", "PROBLEM", 68, 90], ["cell growth", "OBSERVATION", 17, 28], ["cancer", "OBSERVATION", 57, 63]]], ["Further research is needed to determine how 7,9-O- and 9-O-Ac expression is regulated, how they are transported within the ER and Golgi bodies, and what roles they play in cell growth.", [["ER", "ANATOMY", 123, 125], ["Golgi bodies", "ANATOMY", 130, 142], ["cell", "ANATOMY", 172, 176], ["7,9-O- and 9-O-Ac", "CHEMICAL", 44, 61], ["7,9-O", "SIMPLE_CHEMICAL", 44, 49], ["9-O-Ac", "SIMPLE_CHEMICAL", 55, 61], ["ER", "GENE_OR_GENE_PRODUCT", 123, 125], ["Golgi bodies", "CELLULAR_COMPONENT", 130, 142], ["cell", "CELL", 172, 176], ["ER", "PROTEIN", 123, 125]]], ["Of particular interest will be disentangling the individual regulation of 7,9-O-Ac expression compared to 9-O-Ac, since there do seem to be differences in how they are regulated in cells in the present study versus previously reported expression in animal tissues (10, 11).DISCUSSIONStudies with two strains of IAV and two strains of IBV showed no differences in infection efficiency in WT HEK-293 or MDCK-NBL2 cells compared to their \u0394CasD1 or CasD1-OX variants.", [["cells", "ANATOMY", 181, 186], ["tissues", "ANATOMY", 256, 263], ["HEK-293", "ANATOMY", 390, 397], ["MDCK-NBL2 cells", "ANATOMY", 401, 416], ["9-O-Ac", "CHEMICAL", 106, 112], ["infection", "DISEASE", 363, 372], ["7,9-O-Ac", "CHEMICAL", 74, 82], ["9-O-Ac", "CHEMICAL", 106, 112], ["7,9-O-Ac", "GENE_OR_GENE_PRODUCT", 74, 82], ["9-O-Ac", "SIMPLE_CHEMICAL", 106, 112], ["cells", "CELL", 181, 186], ["tissues", "TISSUE", 256, 263], ["IAV", "ORGANISM", 311, 314], ["IBV", "ORGANISM", 334, 337], ["HEK-293", "CELL", 390, 397], ["MDCK-NBL2 cells", "CELL", 401, 416], ["\u0394CasD1", "GENE_OR_GENE_PRODUCT", 435, 441], ["CasD1-OX", "GENE_OR_GENE_PRODUCT", 445, 453], ["Ac", "DNA", 80, 82], ["WT HEK-293", "CELL_LINE", 387, 397], ["MDCK-NBL2 cells", "CELL_LINE", 401, 416], ["\u0394CasD1 or CasD1-OX variants", "DNA", 435, 462], ["IAV", "SPECIES", 311, 314], ["IBV", "SPECIES", 334, 337], ["HEK-293", "SPECIES", 390, 397], ["the present study", "TEST", 190, 207], ["IAV", "PROBLEM", 311, 314], ["IBV", "PROBLEM", 334, 337], ["infection efficiency", "PROBLEM", 363, 383], ["WT HEK", "TEST", 387, 393], ["MDCK", "TEST", 401, 405], ["CasD1", "TEST", 445, 450], ["no", "UNCERTAINTY", 345, 347], ["infection", "OBSERVATION", 363, 372], ["OX variants", "OBSERVATION", 451, 462]]], ["This is not surprising, since >95% of the Sia is unacetylated Neu5Ac, which can be utilized by IAV and IBV as a receptor for binding and entry.", [["Neu5Ac", "CHEMICAL", 62, 68], ["Sia", "GENE_OR_GENE_PRODUCT", 42, 45], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 62, 68], ["IAV", "ORGANISM", 95, 98], ["IBV", "ORGANISM", 103, 106], ["IBV", "SPECIES", 103, 106], ["unacetylated Neu5Ac", "TREATMENT", 49, 68], ["IBV", "TREATMENT", 103, 106], ["not surprising", "UNCERTAINTY", 8, 22]]], ["Although the low levels present on cells were not enough to affect either IAV and IBV infection, we did determine that higher levels, such as those found on mouse erythrocytes (\u223c45% O-Ac), were able to block IAV HA binding and decrease IAV NA cleavage efficiency in a strain-dependent manner.", [["cells", "ANATOMY", 35, 40], ["erythrocytes", "ANATOMY", 163, 175], ["IBV infection", "DISEASE", 82, 95], ["NA", "CHEMICAL", 240, 242], ["cells", "CELL", 35, 40], ["IBV", "ORGANISM", 82, 85], ["mouse", "ORGANISM", 157, 162], ["erythrocytes", "CELL", 163, 175], ["O-Ac", "GENE_OR_GENE_PRODUCT", 182, 186], ["mouse erythrocytes", "CELL_TYPE", 157, 175], ["mouse", "SPECIES", 157, 162], ["IAV", "SPECIES", 74, 77], ["IBV", "SPECIES", 82, 85], ["mouse", "SPECIES", 157, 162], ["IAV", "SPECIES", 208, 211], ["IAV", "SPECIES", 236, 239], ["the low levels", "PROBLEM", 9, 23], ["IAV", "PROBLEM", 74, 77], ["IBV infection", "PROBLEM", 82, 95], ["mouse erythrocytes", "TEST", 157, 175], ["\u223c", "TEST", 177, 178], ["IAV HA binding", "PROBLEM", 208, 222], ["decrease IAV NA cleavage efficiency", "PROBLEM", 227, 262], ["low levels", "OBSERVATION_MODIFIER", 13, 23], ["infection", "OBSERVATION", 86, 95], ["decrease", "OBSERVATION_MODIFIER", 227, 235], ["IAV NA", "OBSERVATION", 236, 242], ["cleavage efficiency", "OBSERVATION", 243, 262]]], ["It is possible, therefore, that if higher levels are present on secreted proteins in mucus, they could inhibit infection prior to the virus reaching the cell surface.", [["mucus", "ANATOMY", 85, 90], ["cell surface", "ANATOMY", 153, 165], ["infection", "DISEASE", 111, 120], ["mucus", "ORGANISM_SUBSTANCE", 85, 90], ["cell surface", "CELLULAR_COMPONENT", 153, 165], ["secreted proteins", "PROTEIN", 64, 81], ["higher levels", "PROBLEM", 35, 48], ["secreted proteins in mucus", "PROBLEM", 64, 90], ["infection", "PROBLEM", 111, 120], ["the virus", "PROBLEM", 130, 139], ["infection", "OBSERVATION", 111, 120], ["cell surface", "OBSERVATION", 153, 165]]], ["Further analysis of mucus O-acetylation in IAV hosts would be necessary to determine whether 7,9-O- and 9-O-Ac could contribute to the barrier function of mucus in respiratory tissues (41).DISCUSSIONThe 1 to 2% of 9-O-Ac on the surfaces of WT MDCK-NBL2 cells was sufficient for ICV and IDV binding and entry, and thus cell susceptibility was lost when CasD1 was inactivated.", [["mucus", "ANATOMY", 20, 25], ["mucus", "ANATOMY", 155, 160], ["respiratory tissues", "ANATOMY", 164, 183], ["MDCK-NBL2 cells", "ANATOMY", 243, 258], ["cell", "ANATOMY", 318, 322], ["7,9-O- and 9-O-Ac", "CHEMICAL", 93, 110], ["9-O-Ac", "CHEMICAL", 214, 220], ["7,9-O- and 9-O-Ac", "CHEMICAL", 93, 110], ["9-O-Ac", "CHEMICAL", 214, 220], ["mucus", "GENE_OR_GENE_PRODUCT", 20, 25], ["IAV", "ORGANISM", 43, 46], ["7,9-O", "SIMPLE_CHEMICAL", 93, 98], ["9-O-Ac", "SIMPLE_CHEMICAL", 104, 110], ["mucus", "TISSUE", 155, 160], ["respiratory tissues", "TISSUE", 164, 183], ["9-O-Ac", "SIMPLE_CHEMICAL", 214, 220], ["MDCK-NBL2 cells", "CELL", 243, 258], ["IDV", "SIMPLE_CHEMICAL", 286, 289], ["cell", "CELL", 318, 322], ["CasD1", "GENE_OR_GENE_PRODUCT", 352, 357], ["WT MDCK", "CELL_LINE", 240, 247], ["NBL2 cells", "CELL_LINE", 248, 258], ["CasD1", "PROTEIN", 352, 357], ["IAV", "SPECIES", 43, 46], ["Further analysis", "TEST", 0, 16], ["mucus O-acetylation in IAV hosts", "TREATMENT", 20, 52], ["Ac", "TREATMENT", 108, 110], ["mucus in respiratory tissues", "PROBLEM", 155, 183], ["ICV and IDV binding", "PROBLEM", 278, 297], ["mucus O-acetylation", "OBSERVATION", 20, 39], ["mucus", "OBSERVATION", 155, 160], ["respiratory tissues", "ANATOMY", 164, 183]]], ["Interestingly, there does still seem to be a necessary minimum threshold of 9-O-Ac presence needed for some ICV and IDV strains to infect cells, since the C/Ann Arbor and C/Victoria strains were able to infect some MDCK-CasD1 OX cells at a lower level than WT MDCK cells, whereas the C/Taylor strain was not.", [["cells", "ANATOMY", 138, 143], ["MDCK-CasD1 OX cells", "ANATOMY", 215, 234], ["MDCK cells", "ANATOMY", 260, 270], ["9-O-Ac", "CHEMICAL", 76, 82], ["9-O-Ac", "CHEMICAL", 76, 82], ["9-O-Ac", "SIMPLE_CHEMICAL", 76, 82], ["cells", "CELL", 138, 143], ["C/Ann Arbor", "ORGANISM", 155, 166], ["C/Victoria strains", "ORGANISM", 171, 189], ["MDCK-CasD1 OX cells", "CELL", 215, 234], ["MDCK cells", "CELL", 260, 270], ["C/Taylor strain", "ORGANISM", 284, 299], ["MDCK-CasD1 OX cells", "CELL_LINE", 215, 234], ["WT MDCK cells", "CELL_LINE", 257, 270], ["some ICV and IDV strains", "PROBLEM", 103, 127], ["infect cells", "PROBLEM", 131, 143], ["the C/Ann Arbor and C/Victoria strains", "PROBLEM", 151, 189], ["WT MDCK cells", "TEST", 257, 270], ["the C/Taylor strain", "PROBLEM", 280, 299]]], ["Similarly, IDV also showed lower levels of infectivity in MDCK-CasD1 OX cells compared to WT MDCK cells.", [["MDCK-CasD1 OX cells", "ANATOMY", 58, 77], ["MDCK cells", "ANATOMY", 93, 103], ["IDV", "CHEMICAL", 11, 14], ["IDV", "SIMPLE_CHEMICAL", 11, 14], ["MDCK-CasD1 OX cells", "CELL", 58, 77], ["WT MDCK cells", "CELL", 90, 103], ["MDCK-CasD1 OX cells", "CELL_LINE", 58, 77], ["WT MDCK cells", "CELL_LINE", 90, 103], ["IDV", "TEST", 11, 14], ["lower levels of infectivity", "PROBLEM", 27, 54], ["MDCK", "TEST", 58, 62], ["CasD1 OX cells", "TREATMENT", 63, 77], ["WT MDCK cells", "TEST", 90, 103], ["lower levels", "OBSERVATION_MODIFIER", 27, 39], ["infectivity", "OBSERVATION", 43, 54]]], ["It is likely that similar results would be seen for other viruses that use these modified Sia as a receptor, including human coronaviruses OC43 and HKU1 (50).DISCUSSIONIn summary, we have shown that these modifications are present in different cell lines sourced from different species of animals, but they make up a small minority of the total Sia present.", [["cell lines", "ANATOMY", 244, 254], ["Sia", "GENE_OR_GENE_PRODUCT", 90, 93], ["human", "ORGANISM", 119, 124], ["coronaviruses OC43", "ORGANISM", 125, 143], ["cell lines", "CELL", 244, 254], ["Sia", "GENE_OR_GENE_PRODUCT", 345, 348], ["Sia", "PROTEIN", 90, 93], ["cell lines", "CELL_LINE", 244, 254], ["human", "SPECIES", 119, 124], ["human coronaviruses", "SPECIES", 119, 138], ["other viruses", "PROBLEM", 52, 65], ["human coronaviruses OC43", "TEST", 119, 143], ["HKU1", "TEST", 148, 152], ["different cell lines", "TREATMENT", 234, 254], ["viruses", "OBSERVATION", 58, 65], ["different cell lines", "OBSERVATION", 234, 254], ["small", "OBSERVATION_MODIFIER", 317, 322]]], ["In addition, these modifications vary considerably in their localization and have an inherent heterogeneity within cell populations.", [["cell", "ANATOMY", 115, 119], ["cell populations", "CELL", 115, 131], ["an inherent heterogeneity within cell populations", "PROBLEM", 82, 131], ["inherent", "OBSERVATION_MODIFIER", 85, 93], ["heterogeneity", "OBSERVATION_MODIFIER", 94, 107], ["within cell populations", "OBSERVATION", 108, 131]]], ["While the presence of both 7,9-O- and 9-O-Ac were dependent on the activity of CasD1, the relative proportions, levels of expression, and localization appear to be controlled by more complex mechanisms than simply the expression of CasD1 and SIAE.", [["7,9-O- and 9-O-Ac", "CHEMICAL", 27, 44], ["7,9-O- and 9-O-Ac", "CHEMICAL", 27, 44], ["7,9-O", "SIMPLE_CHEMICAL", 27, 32], ["9-O-Ac", "SIMPLE_CHEMICAL", 38, 44], ["CasD1", "GENE_OR_GENE_PRODUCT", 79, 84], ["CasD1", "GENE_OR_GENE_PRODUCT", 232, 237], ["SIAE", "GENE_OR_GENE_PRODUCT", 242, 246], ["7,9-O- and 9-O-Ac", "DNA", 27, 44], ["CasD1", "PROTEIN", 79, 84], ["CasD1", "PROTEIN", 232, 237], ["SIAE", "PROTEIN", 242, 246]]], ["How this regulated expression affects cell homeostasis is unknown, but it is likely relevant during development, immune responses, and in cancers that show dysregulation of 7,9-O- and 9-O-Ac expression.", [["cell", "ANATOMY", 38, 42], ["cancers", "ANATOMY", 138, 145], ["cancers", "DISEASE", 138, 145], ["7,9-O- and 9-O-Ac", "CHEMICAL", 173, 190], ["cell", "CELL", 38, 42], ["cancers", "CANCER", 138, 145], ["7,9-O", "SIMPLE_CHEMICAL", 173, 178], ["9-O-Ac", "SIMPLE_CHEMICAL", 184, 190], ["Ac", "DNA", 188, 190], ["dysregulation", "TEST", 156, 169], ["cell homeostasis", "OBSERVATION", 38, 54]]], ["For viruses such as ICV and IDV that rely on 9-O-Ac for infection, the low levels seen on cell surfaces are sufficient for infection.", [["cell surfaces", "ANATOMY", 90, 103], ["ICV", "CHEMICAL", 20, 23], ["9-O-Ac", "CHEMICAL", 45, 51], ["infection", "DISEASE", 56, 65], ["infection", "DISEASE", 123, 132], ["9-O-Ac", "CHEMICAL", 45, 51], ["IDV", "SIMPLE_CHEMICAL", 28, 31], ["9-O-Ac", "SIMPLE_CHEMICAL", 45, 51], ["cell", "CELL", 90, 94], ["viruses", "PROBLEM", 4, 11], ["ICV", "PROBLEM", 20, 23], ["IDV", "TREATMENT", 28, 31], ["infection", "PROBLEM", 56, 65], ["the low levels", "PROBLEM", 67, 81], ["cell surfaces", "TREATMENT", 90, 103], ["infection", "PROBLEM", 123, 132], ["viruses", "OBSERVATION", 4, 11], ["infection", "OBSERVATION", 56, 65], ["low levels", "OBSERVATION_MODIFIER", 71, 81], ["sufficient for", "UNCERTAINTY", 108, 122], ["infection", "OBSERVATION", 123, 132]]], ["We found that 7,9-O- and 9-O-Ac do have inhibitory activity on HA binding and NA cleavage when present at higher levels.", [["7,9-O- and 9-O-Ac", "CHEMICAL", 14, 31], ["7,9-O- and 9-O-Ac", "CHEMICAL", 14, 31], ["7,9-O", "SIMPLE_CHEMICAL", 14, 19], ["9-O-Ac", "SIMPLE_CHEMICAL", 25, 31], ["HA", "SIMPLE_CHEMICAL", 63, 65], ["NA", "SIMPLE_CHEMICAL", 78, 80], ["inhibitory activity", "PROBLEM", 40, 59], ["HA binding", "PROBLEM", 63, 73], ["NA cleavage", "PROBLEM", 78, 89]]], ["Although these modifications are present on cell surfaces at levels too low to affect IAV and IBV infection, they are expressed at much higher levels in mucosal tissues and in secreted mucus proteins of many animals, which may provide a more effective barrier (10, 11, 51\u201353).", [["cell surfaces", "ANATOMY", 44, 57], ["mucosal tissues", "ANATOMY", 153, 168], ["mucus", "ANATOMY", 185, 190], ["infection", "DISEASE", 98, 107], ["cell surfaces", "CELLULAR_COMPONENT", 44, 57], ["IAV", "ORGANISM", 86, 89], ["IBV", "ORGANISM", 94, 97], ["mucosal tissues", "TISSUE", 153, 168], ["mucus", "GENE_OR_GENE_PRODUCT", 185, 190], ["mucus proteins", "PROTEIN", 185, 199], ["IAV", "SPECIES", 86, 89], ["IBV", "SPECIES", 94, 97], ["IAV", "PROBLEM", 86, 89], ["IBV infection", "PROBLEM", 94, 107], ["IBV", "OBSERVATION_MODIFIER", 94, 97], ["infection", "OBSERVATION", 98, 107], ["mucosal tissues", "ANATOMY", 153, 168], ["mucus proteins", "OBSERVATION", 185, 199]]], ["We are currently examining these processes for secreted mucus and other sources in different animals.Cells and viruses. ::: MATERIALS AND METHODSHEK-293, A549, MDCK-NBL2, MDCK type I, and MDCK type II cells were grown in Dulbecco modified Eagle medium (DMEM) with 5% fetal bovine serum and 50 \u03bcg/ml gentamicin.", [["mucus", "ANATOMY", 56, 61], ["Cells", "ANATOMY", 101, 106], ["METHODSHEK-293", "ANATOMY", 138, 152], ["A549", "ANATOMY", 154, 158], ["MDCK-NBL2", "ANATOMY", 160, 169], ["MDCK type I", "ANATOMY", 171, 182], ["MDCK type II cells", "ANATOMY", 188, 206], ["fetal bovine serum", "ANATOMY", 267, 285], ["gentamicin", "CHEMICAL", 299, 309], ["gentamicin", "CHEMICAL", 299, 309], ["mucus", "MULTI-TISSUE_STRUCTURE", 56, 61], ["Cells", "CELL", 101, 106], ["METHODSHEK-293", "CELL", 138, 152], ["A549", "CELL", 154, 158], ["MDCK-NBL2", "CELL", 160, 169], ["MDCK type I", "CELL", 171, 182], ["MDCK type II cells", "CELL", 188, 206], ["bovine", "ORGANISM", 273, 279], ["serum", "ORGANISM_SUBSTANCE", 280, 285], ["gentamicin", "SIMPLE_CHEMICAL", 299, 309], ["METHODSHEK-293", "CELL_LINE", 138, 152], ["A549", "CELL_LINE", 154, 158], ["MDCK", "CELL_LINE", 160, 164], ["NBL2", "CELL_LINE", 165, 169], ["MDCK type I", "CELL_LINE", 171, 182], ["MDCK type II cells", "CELL_LINE", 188, 206], ["bovine", "SPECIES", 273, 279], ["bovine", "SPECIES", 273, 279], ["secreted mucus", "PROBLEM", 47, 61], ["viruses", "PROBLEM", 111, 118], ["MATERIALS", "TEST", 124, 133], ["METHODSHEK", "TEST", 138, 148], ["A549", "TEST", 154, 158], ["MDCK", "TEST", 160, 164], ["NBL2", "TEST", 165, 169], ["MDCK type II cells", "PROBLEM", 188, 206], ["5% fetal bovine serum", "TREATMENT", 264, 285], ["gentamicin", "TREATMENT", 299, 309], ["viruses", "OBSERVATION", 111, 118]]], ["HEK-293, A549, and MDCK-NBL2 cells were obtained from the American Type Culture Collection (ATCC).", [["HEK-293", "ANATOMY", 0, 7], ["A549", "ANATOMY", 9, 13], ["MDCK-NBL2 cells", "ANATOMY", 19, 34], ["HEK-293", "CELL", 0, 7], ["A549", "CELL", 9, 13], ["MDCK-NBL2 cells", "CELL", 19, 34], ["HEK-293", "CELL_LINE", 0, 7], ["A549", "CELL_LINE", 9, 13], ["MDCK", "CELL_LINE", 19, 23], ["NBL2 cells", "CELL_LINE", 24, 34], ["HEK", "TEST", 0, 3], ["A549", "TEST", 9, 13], ["MDCK-NBL2 cells", "TEST", 19, 34]]], ["MDCK type I and type II cells were gifts from William Young (University of Kentucky) (35, 37, 54, 55).", [["type II cells", "ANATOMY", 16, 29], ["MDCK type I", "CELL", 0, 11], ["type II cells", "CELL", 16, 29], ["MDCK type I and type II cells", "CELL_LINE", 0, 29], ["type II cells", "PROBLEM", 16, 29]]], ["SiNEC and SiTEC cells were gifts from Stacey Shultz-Cherry (St. Jude Children\u2019s Hospital).", [["SiNEC", "ANATOMY", 0, 5], ["SiTEC cells", "ANATOMY", 10, 21], ["SiNEC", "CELL", 0, 5], ["SiTEC cells", "CELL", 10, 21], ["St. Jude Children", "ORGANISM", 60, 77], ["SiNEC", "CELL_TYPE", 0, 5], ["SiTEC cells", "CELL_LINE", 10, 21], ["Children", "SPECIES", 69, 77]]], ["IAV strains pH1N1 (A/California/04/2009) and Victoria H3N2 (A/Victoria/361/2011) were rescued from reverse genetics plasmids using established protocols (56, 57).", [["IAV strains pH1N1", "ORGANISM", 0, 17], ["A/California/04/2009", "ORGANISM", 19, 39], ["Victoria H3N2", "ORGANISM", 45, 58], ["reverse genetics plasmids", "DNA", 99, 124], ["Victoria H3N2", "SPECIES", 45, 58], ["A/California/04/2009)", "SPECIES", 19, 40], ["Victoria H3N2 (A/Victoria/361/2011)", "SPECIES", 45, 80], ["IAV strains", "PROBLEM", 0, 11], ["H1N1", "PROBLEM", 13, 17]]], ["Rescued viruses were grown to low passage on MDCK-NBL2 cells using infection media containing DMEM, 0.03% bovine serum albumin (BSA), and 1 \u03bcg/ml TPCK (tolylsulfonyl phenylalanyl chloromethyl ketone)-treated trypsin.", [["MDCK-NBL2 cells", "ANATOMY", 45, 60], ["serum", "ANATOMY", 113, 118], ["infection", "DISEASE", 67, 76], ["DMEM", "CHEMICAL", 94, 98], ["BSA", "CHEMICAL", 128, 131], ["TPCK", "CHEMICAL", 146, 150], ["tolylsulfonyl phenylalanyl chloromethyl ketone", "CHEMICAL", 152, 198], ["TPCK", "CHEMICAL", 146, 150], ["tolylsulfonyl phenylalanyl chloromethyl ketone", "CHEMICAL", 152, 198], ["MDCK-NBL2 cells", "CELL", 45, 60], ["bovine", "ORGANISM", 106, 112], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["albumin", "SIMPLE_CHEMICAL", 119, 126], ["BSA", "SIMPLE_CHEMICAL", 128, 131], ["TPCK", "SIMPLE_CHEMICAL", 146, 150], ["tolylsulfonyl phenylalanyl chloromethyl ketone", "SIMPLE_CHEMICAL", 152, 198], ["trypsin", "GENE_OR_GENE_PRODUCT", 208, 215], ["MDCK-NBL2 cells", "CELL_LINE", 45, 60], ["trypsin", "PROTEIN", 208, 215], ["bovine", "SPECIES", 106, 112], ["Rescued viruses", "PROBLEM", 0, 15], ["MDCK", "TEST", 45, 49], ["infection media", "TREATMENT", 67, 82], ["bovine serum albumin", "TEST", 106, 126], ["BSA", "TEST", 128, 131], ["TPCK", "TEST", 146, 150], ["tolylsulfonyl phenylalanyl chloromethyl ketone", "TREATMENT", 152, 198], ["trypsin", "PROBLEM", 208, 215], ["viruses", "OBSERVATION", 8, 15], ["low passage", "OBSERVATION_MODIFIER", 30, 41]]], ["IBV strains B/Colorado/06/2017 and B/Memphis/1/2018, and IDV strains D/bovine/MS/C00020N/2014 and D/swine/OK/1334/2011 were gifts from Richard Webby (St. Jude Children\u2019s Hospital) and were grown in infection media containing DMEM, 0.03% BSA, and 1 \u03bcg/ml TPCK-treated trypsin.", [["infection", "DISEASE", 198, 207], ["DMEM", "CHEMICAL", 225, 229], ["BSA", "CHEMICAL", 237, 240], ["TPCK", "CHEMICAL", 254, 258], ["TPCK", "CHEMICAL", 254, 258], ["IBV strains B/Colorado/06/2017", "ORGANISM", 0, 30], ["B/Memphis/1/2018", "ORGANISM", 35, 51], ["IDV strains D", "ORGANISM", 57, 70], ["bovine", "ORGANISM", 71, 77], ["D/swine", "ORGANISM", 98, 105], ["BSA", "SIMPLE_CHEMICAL", 237, 240], ["TPCK", "SIMPLE_CHEMICAL", 254, 258], ["trypsin", "GENE_OR_GENE_PRODUCT", 267, 274], ["trypsin", "PROTEIN", 267, 274], ["bovine", "SPECIES", 71, 77], ["swine", "SPECIES", 100, 105], ["Children", "SPECIES", 159, 167], ["IBV strains B/Colorado/06/2017", "SPECIES", 0, 30], ["B/Memphis/1/2018", "SPECIES", 35, 51], ["IDV strains D/bovine/MS/C00020N/2014 and D/swine/OK/1334/2011", "SPECIES", 57, 118], ["BSA", "TEST", 237, 240], ["TPCK", "TEST", 254, 258], ["trypsin", "PROBLEM", 267, 274], ["infection", "OBSERVATION", 198, 207]]], ["ICV strains C/Ann Arbor/1/50 and C/Taylor/1233/1947 were gifts from Andrew Pekosz (Johns Hopkins University), and ICV strain C/Victoria/1/2011 was a gift from Richard Webby (St. Jude Children\u2019s Hospital).", [["C/Taylor", "ORGANISM", 33, 41], ["Children", "SPECIES", 183, 191], ["C/Ann Arbor/1/50 and C/Taylor/1233/1947", "SPECIES", 12, 51], ["C/Victoria/1/2011", "SPECIES", 125, 142]]], ["All ICV strains were grown on MDCK-NBL2 cells using infection media containing DMEM, 0.03% BSA, and 5 \u03bcg/ml TPCK-treated trypsin.Immunofluorescence microscopy and flow cytometry. ::: MATERIALS AND METHODSCells were stained using probes derived from viral hemagglutinin-esterase proteins fused to human IgG1 Fc (HE-Fc).", [["MDCK-NBL2 cells", "ANATOMY", 30, 45], ["infection", "DISEASE", 52, 61], ["DMEM", "CHEMICAL", 79, 83], ["BSA", "CHEMICAL", 91, 94], ["TPCK", "CHEMICAL", 108, 112], ["TPCK", "CHEMICAL", 108, 112], ["MDCK-NBL2 cells", "CELL", 30, 45], ["BSA", "SIMPLE_CHEMICAL", 91, 94], ["TPCK", "SIMPLE_CHEMICAL", 108, 112], ["trypsin", "GENE_OR_GENE_PRODUCT", 121, 128], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 255, 277], ["human", "ORGANISM", 296, 301], ["IgG1 Fc", "GENE_OR_GENE_PRODUCT", 302, 309], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 311, 316], ["MDCK-NBL2 cells", "CELL_LINE", 30, 45], ["trypsin", "PROTEIN", 121, 128], ["viral hemagglutinin-esterase proteins", "PROTEIN", 249, 286], ["human IgG1 Fc", "PROTEIN", 296, 309], ["HE", "PROTEIN", 311, 313], ["Fc", "PROTEIN", 314, 316], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 296, 301], ["All ICV strains", "PROBLEM", 0, 15], ["MDCK", "TEST", 30, 34], ["infection media", "TREATMENT", 52, 67], ["BSA", "TEST", 91, 94], ["TPCK", "TEST", 108, 112], ["trypsin", "PROBLEM", 121, 128], ["Immunofluorescence microscopy", "TEST", 129, 158], ["flow cytometry", "TEST", 163, 177], ["METHODSCells", "TREATMENT", 197, 209], ["viral hemagglutinin-esterase proteins", "TREATMENT", 249, 286], ["flow cytometry", "OBSERVATION", 163, 177]]], ["The porcine torovirus strain 4 HE-Fc (PToV HE-Fc) primarily recognizes 9-O-Ac, and the bovine coronavirus Mebus strain HE-Fc (BCoV HE-Fc) recognizes 7,9-O-Ac and shows low levels of binding to 9-O-Ac (10, 11).", [["9-O-Ac", "CHEMICAL", 71, 77], ["7,9-O-Ac", "CHEMICAL", 149, 157], ["9-O-Ac", "CHEMICAL", 193, 199], ["7,9-O-Ac", "CHEMICAL", 149, 157], ["9-O-Ac", "CHEMICAL", 193, 199], ["porcine torovirus strain 4", "ORGANISM", 4, 30], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 31, 36], ["PToV HE-Fc", "GENE_OR_GENE_PRODUCT", 38, 48], ["9-O-Ac", "SIMPLE_CHEMICAL", 71, 77], ["bovine", "ORGANISM", 87, 93], ["coronavirus Mebus", "ORGANISM", 94, 111], ["strain", "ORGANISM", 112, 118], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 119, 124], ["BCoV HE-Fc", "GENE_OR_GENE_PRODUCT", 126, 136], ["7,9-O-Ac", "SIMPLE_CHEMICAL", 149, 157], ["9-O-Ac", "SIMPLE_CHEMICAL", 193, 199], ["Fc", "PROTEIN", 34, 36], ["Fc", "PROTEIN", 46, 48], ["Fc", "PROTEIN", 122, 124], ["Fc", "PROTEIN", 134, 136], ["porcine", "SPECIES", 4, 11], ["bovine", "SPECIES", 87, 93], ["coronavirus", "SPECIES", 94, 105], ["bovine coronavirus", "SPECIES", 87, 105], ["The porcine torovirus strain", "PROBLEM", 0, 28], ["PToV", "TEST", 38, 42], ["the bovine coronavirus Mebus strain", "PROBLEM", 83, 118], ["low levels of binding", "PROBLEM", 168, 189]]], ["For immunofluorescence microscopy, the cells were seeded onto glass coverslips and incubated overnight at 37\u00b0C and 5% CO2.", [["cells", "ANATOMY", 39, 44], ["CO2", "CHEMICAL", 118, 121], ["CO2", "CHEMICAL", 118, 121], ["cells", "CELL", 39, 44], ["CO2", "SIMPLE_CHEMICAL", 118, 121], ["immunofluorescence microscopy", "TEST", 4, 33]]], ["Coverslips were fixed in 4% paraformaldehyde (PFA) for 15 min.", [["paraformaldehyde", "CHEMICAL", 28, 44], ["PFA", "CHEMICAL", 46, 49], ["paraformaldehyde", "SIMPLE_CHEMICAL", 28, 44], ["PFA", "SIMPLE_CHEMICAL", 46, 49], ["Coverslips", "TREATMENT", 0, 10]]], ["Coverslips were incubated with Carbo-Free blocking solution (Vector Laboratories) for 1 h at room temperature, with optional permeabilization with 0.001% Tween 20.", [["Tween 20", "CHEMICAL", 154, 162], ["Carbo-Free blocking solution", "TREATMENT", 31, 59], ["optional permeabilization", "TREATMENT", 116, 141]]], ["For staining, HE-Fc probes were precomplexed with Alexa 488-labeled anti-human IgG antibody for 1 h at 4\u00b0C and then diluted in Carbo-Free blocking solution to a final concentration of 5 \u03bcg/ml HE-Fc and a 1:500 dilution of secondary antibody.", [["Alexa 488", "CHEMICAL", 50, 59], ["Carbo", "CHEMICAL", 127, 132], ["Alexa 488", "CHEMICAL", 50, 59], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 14, 19], ["Alexa 488", "SIMPLE_CHEMICAL", 50, 59], ["C", "SIMPLE_CHEMICAL", 105, 106], ["Carbo", "SIMPLE_CHEMICAL", 127, 132], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 192, 197], ["HE-Fc probes", "DNA", 14, 26], ["Alexa 488-labeled anti-human IgG antibody", "PROTEIN", 50, 91], ["Fc", "PROTEIN", 195, 197], ["secondary antibody", "PROTEIN", 222, 240], ["staining", "TEST", 4, 12], ["Fc probes", "TEST", 17, 26], ["Alexa", "TEST", 50, 55], ["anti-human IgG antibody", "TEST", 68, 91], ["Carbo", "TREATMENT", 127, 132], ["Free blocking solution", "TREATMENT", 133, 155], ["secondary antibody", "PROBLEM", 222, 240], ["secondary antibody", "OBSERVATION", 222, 240]]], ["Cells were stained with HE-Fc/anti-IgG complex for 1 h at room temperature.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 24, 29], ["Fc", "PROTEIN", 27, 29], ["anti", "PROTEIN", 30, 34], ["IgG complex", "PROTEIN", 35, 46], ["Cells", "TEST", 0, 5], ["HE", "TEST", 24, 26], ["Fc", "TEST", 27, 29], ["anti-IgG complex", "TREATMENT", 30, 46]]], ["Coverslips were mounted using Prolong Antifade-Gold with DAPI (4\u2032,6\u2032-diamidino-2-phenylindole; Invitrogen).", [["DAPI", "CHEMICAL", 57, 61], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 63, 93], ["DAPI", "CHEMICAL", 57, 61], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 63, 93], ["DAPI", "SIMPLE_CHEMICAL", 57, 61], ["4\u2032,6\u2032-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 63, 93], ["Invitrogen", "SIMPLE_CHEMICAL", 95, 105], ["DAPI", "TREATMENT", 57, 61], ["diamidino", "TREATMENT", 69, 78], ["phenylindole", "TREATMENT", 81, 93], ["Invitrogen", "TREATMENT", 95, 105]]], ["Cell were imaged using a Nikon TE300 fluorescence microscope.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4]]], ["For flow cytometry, cells were seeded onto nonadherent cell culture dishes and incubated overnight at 37\u00b0C and 5% CO2.", [["cells", "ANATOMY", 20, 25], ["cell culture dishes", "ANATOMY", 55, 74], ["CO2", "CHEMICAL", 114, 117], ["CO2", "CHEMICAL", 114, 117], ["cells", "CELL", 20, 25], ["cell", "CELL", 55, 59], ["CO2", "SIMPLE_CHEMICAL", 114, 117], ["flow cytometry", "TEST", 4, 18], ["nonadherent cell culture", "TEST", 43, 67]]], ["Cells were collected using ice-cold phosphate-buffered saline (PBS; HEK-293 and A549 cells) or Accutase (Sigma, MDCK cells) to retain surface glycans and then fixed in 4% PFA for 15 min.", [["Cells", "ANATOMY", 0, 5], ["HEK-293", "ANATOMY", 68, 75], ["A549 cells", "ANATOMY", 80, 90], ["MDCK cells", "ANATOMY", 112, 122], ["surface", "ANATOMY", 134, 141], ["phosphate", "CHEMICAL", 36, 45], ["phosphate", "CHEMICAL", 36, 45], ["PFA", "CHEMICAL", 171, 174], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 36, 61], ["HEK-293", "CELL", 68, 75], ["A549 cells", "CELL", 80, 90], ["Accutase", "CELL", 95, 103], ["MDCK cells", "CELL", 112, 122], ["PFA", "SIMPLE_CHEMICAL", 171, 174], ["HEK-293", "CELL_LINE", 68, 75], ["A549 cells", "CELL_LINE", 80, 90], ["Accutase (Sigma, MDCK cells", "CELL_LINE", 95, 122], ["Cells", "TEST", 0, 5], ["ice", "TEST", 27, 30], ["cold phosphate", "TREATMENT", 31, 45], ["buffered saline", "TREATMENT", 46, 61], ["PBS", "TEST", 63, 66], ["HEK", "TEST", 68, 71], ["A549 cells", "TEST", 80, 90], ["Accutase (Sigma, MDCK cells", "TEST", 95, 122], ["surface glycans", "TEST", 134, 149]]], ["The cells were blocked as described above.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["HE-Fc probes were prepared as described above with final concentrations of 5 \u03bcg/ml HE-Fc probe and 1:1,200 of anti-IgG.", [["HE-Fc", "GENE_OR_GENE_PRODUCT", 0, 5], ["anti-IgG", "GENE_OR_GENE_PRODUCT", 110, 118], ["HE-Fc probes", "DNA", 0, 12], ["anti-IgG", "PROTEIN", 110, 118], ["Fc probes", "TREATMENT", 3, 12], ["anti-IgG", "TREATMENT", 110, 118]]], ["A Guava EasyCyte Plus flow cytometer (EMD Millipore, Billerica, MA) was used to collect data, followed by analysis using FlowJo software (TreeStar, Ashland, OR).", [["Cyte", "CHEMICAL", 12, 16], ["Cyte", "SPECIES", 12, 16], ["flow cytometer", "TEST", 22, 36], ["EMD Millipore", "TREATMENT", 38, 51], ["flow cytometer", "OBSERVATION", 22, 36]]], ["Statistical analyses were performed using GraphPad Prism software (v8).Cell line mutations and characterization. ::: MATERIALS AND METHODSTwo methods for utilizing CRISPR-Cas9 were used.", [["Cell line", "ANATOMY", 71, 80], ["Cell line", "CELL", 71, 80], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 164, 175], ["CRISPR", "DNA", 164, 170], ["Cas9", "DNA", 171, 175], ["Statistical analyses", "TEST", 0, 20], ["GraphPad Prism software", "TEST", 42, 65], ["Cell line mutations", "TEST", 71, 90], ["METHODSTwo methods", "TREATMENT", 131, 149], ["CRISPR-Cas9", "TREATMENT", 164, 175], ["line mutations", "OBSERVATION", 76, 90]]], ["For A549 and MDCK cells, paired Cas9 plasmids (PX459; Addgene plasmid 62988) targeted adjacent sites in early exons of CasD1, as diagrammed in Fig. 4A.", [["A549", "ANATOMY", 4, 8], ["MDCK cells", "ANATOMY", 13, 23], ["sites", "ANATOMY", 95, 100], ["A549", "CELL", 4, 8], ["MDCK cells", "CELL", 13, 23], ["Cas9", "GENE_OR_GENE_PRODUCT", 32, 36], ["Addgene", "GENE_OR_GENE_PRODUCT", 54, 61], ["CasD1", "GENE_OR_GENE_PRODUCT", 119, 124], ["A549", "CELL_LINE", 4, 8], ["MDCK cells", "CELL_LINE", 13, 23], ["Cas9 plasmids", "DNA", 32, 45], ["PX459", "DNA", 47, 52], ["Addgene plasmid 62988", "DNA", 54, 75], ["early exons", "DNA", 104, 115], ["CasD1", "DNA", 119, 124], ["A549", "PROBLEM", 4, 8], ["paired Cas9 plasmids", "TREATMENT", 25, 45], ["Addgene plasmid", "TREATMENT", 54, 69], ["targeted adjacent sites", "PROBLEM", 77, 100], ["early exons", "OBSERVATION", 104, 115]]], ["Plasmids were transfected using TransIT-X2 (Mirus Bio LLC) (8).", [["X2", "DNA", 40, 42], ["Plasmids", "TREATMENT", 0, 8], ["TransIT-X2 (Mirus Bio LLC", "TREATMENT", 32, 57]]], ["For HEK-293 cells, nickase Cas9 plasmids (PX462; Addgene plasmid 62987) were used instead.", [["HEK-293 cells", "ANATOMY", 4, 17], ["HEK-293 cells", "CELL", 4, 17], ["nickase Cas9", "GENE_OR_GENE_PRODUCT", 19, 31], ["HEK-293 cells", "CELL_LINE", 4, 17], ["nickase Cas9 plasmids", "DNA", 19, 40], ["PX462", "DNA", 42, 47], ["Addgene plasmid 62987", "DNA", 49, 70], ["HEK-293", "SPECIES", 4, 11], ["HEK", "TEST", 4, 7], ["cells", "TEST", 12, 17], ["nickase Cas9 plasmids", "TREATMENT", 19, 40], ["Addgene plasmid", "TREATMENT", 49, 64]]], ["Transfected cells were selected with puromycin, and single cell clones were screened with PToV-P4 HE-Fc to identify nonstaining variants.", [["cells", "ANATOMY", 12, 17], ["cell clones", "ANATOMY", 59, 70], ["puromycin", "CHEMICAL", 37, 46], ["puromycin", "CHEMICAL", 37, 46], ["cells", "CELL", 12, 17], ["puromycin", "SIMPLE_CHEMICAL", 37, 46], ["cell clones", "CELL", 59, 70], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 98, 103], ["single cell clones", "CELL_LINE", 52, 70], ["PToV-P4 HE-Fc", "DNA", 90, 103], ["nonstaining variants", "DNA", 116, 136], ["Transfected cells", "PROBLEM", 0, 17], ["puromycin", "TREATMENT", 37, 46], ["single cell clones", "TREATMENT", 52, 70], ["PToV", "TEST", 90, 94]]], ["Edited sequences were confirmed by PCR amplification of the targeted regions and sequencing the PCR product for each allele.", [["targeted regions", "DNA", 60, 76], ["allele", "DNA", 117, 123], ["Edited sequences", "TEST", 0, 16], ["PCR amplification", "TEST", 35, 52], ["the PCR product", "TEST", 92, 107]]], ["Knockout cell lines were used to prepare overexpression cell lines by transfection of a pcDNA3.1(\u2013) plasmid expressing the complete human CasD1 cDNA open reading frame synthesized by Bio Basic (Markham, Ontario, Canada).", [["cell lines", "ANATOMY", 9, 19], ["cell lines", "ANATOMY", 56, 66], ["cell lines", "CELL", 9, 19], ["cell lines", "CELL", 56, 66], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 88, 94], ["human", "ORGANISM", 132, 137], ["CasD1", "GENE_OR_GENE_PRODUCT", 138, 143], ["Knockout cell lines", "CELL_LINE", 0, 19], ["overexpression cell lines", "CELL_LINE", 41, 66], ["pcDNA3.1(\u2013) plasmid", "DNA", 88, 107], ["human CasD1 cDNA open reading frame", "DNA", 132, 167], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["Knockout cell lines", "TREATMENT", 0, 19], ["overexpression cell lines", "TREATMENT", 41, 66], ["a pcDNA3", "TREATMENT", 86, 94], ["plasmid", "TREATMENT", 100, 107], ["the complete human CasD1 cDNA", "TREATMENT", 119, 148], ["cell lines", "OBSERVATION", 9, 19], ["overexpression cell lines", "OBSERVATION", 41, 66]]], ["Transfected cells were selected with G418, and single-cell clones were screened by staining with PToV-P4 HE-Fc to identify 9-O-Ac positive cell lines.", [["cells", "ANATOMY", 12, 17], ["single-cell clones", "ANATOMY", 47, 65], ["cell lines", "ANATOMY", 139, 149], ["G418", "CHEMICAL", 37, 41], ["cells", "CELL", 12, 17], ["single-cell clones", "CELL", 47, 65], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 105, 110], ["9-O-Ac", "SIMPLE_CHEMICAL", 123, 129], ["cell lines", "CELL", 139, 149], ["single-cell clones", "CELL_LINE", 47, 65], ["PToV", "PROTEIN", 97, 101], ["P4 HE-Fc", "DNA", 102, 110], ["9-O-Ac positive cell lines", "CELL_LINE", 123, 149], ["Transfected cells", "PROBLEM", 0, 17], ["G418", "TREATMENT", 37, 41], ["single-cell clones", "TREATMENT", 47, 65], ["PToV", "TEST", 97, 101], ["Ac positive cell lines", "TREATMENT", 127, 149], ["positive cell lines", "OBSERVATION", 130, 149]]], ["Editing of the SIAE gene followed a protocol for CRISPR-Cas9 similar to that described above, and the gene regions targeted are shown in Fig. 5A.", [["SIAE", "GENE_OR_GENE_PRODUCT", 15, 19], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 49, 60], ["SIAE gene", "DNA", 15, 24], ["CRISPR", "DNA", 49, 55], ["Cas9", "DNA", 56, 60], ["gene regions", "DNA", 102, 114], ["a protocol", "TREATMENT", 34, 44], ["CRISPR-Cas9", "PROBLEM", 49, 60]]], ["After transfection and selection, cells were cloned, and single-cell clones were screened by direct PCR amplification of the target gene region and analysis of the PCR product size for the edited form of both alleles.", [["cells", "ANATOMY", 34, 39], ["single-cell clones", "ANATOMY", 57, 75], ["cells", "CELL", 34, 39], ["single-cell clones", "CELL", 57, 75], ["single-cell clones", "CELL_LINE", 57, 75], ["target gene region", "DNA", 125, 143], ["single-cell clones", "TREATMENT", 57, 75], ["direct PCR amplification", "TEST", 93, 117], ["the PCR", "TEST", 160, 167], ["size", "OBSERVATION_MODIFIER", 176, 180]]], ["Full sequencing of each allele and qPCR were performed to confirm deletion of the gene.Quantification of Sia variants. ::: MATERIALS AND METHODSThe Sia composition of cells were determined by incubating with 2 M acetic acid at 80\u00b0C for 3 h, filtration through a Microcon 10-kDa centrifugal filter (Millipore), and drying in a SpeedVac vacuum concentrator.", [["cells", "ANATOMY", 167, 172], ["acetic acid", "CHEMICAL", 212, 223], ["acetic acid", "CHEMICAL", 212, 223], ["Sia", "GENE_OR_GENE_PRODUCT", 105, 108], ["cells", "CELL", 167, 172], ["acetic acid", "SIMPLE_CHEMICAL", 212, 223], ["allele", "DNA", 24, 30], ["each allele and qPCR", "TEST", 19, 39], ["deletion of the gene", "PROBLEM", 66, 86], ["METHODSThe Sia composition of cells", "TREATMENT", 137, 172], ["2 M acetic acid", "TREATMENT", 208, 223], ["filtration", "TREATMENT", 241, 251], ["a Microcon 10-kDa centrifugal filter (Millipore", "TREATMENT", 260, 307], ["a SpeedVac vacuum concentrator", "TREATMENT", 324, 354], ["Sia variants", "OBSERVATION", 105, 117], ["centrifugal filter", "OBSERVATION", 278, 296], ["vacuum concentrator", "OBSERVATION", 335, 354]]], ["Released Sia were derivatized with DMB (Sigma-Aldrich) for 2.5 h at 50\u00b0C (39).", [["DMB", "CHEMICAL", 35, 38], ["Sigma-Aldrich", "CHEMICAL", 40, 53], ["DMB", "CHEMICAL", 35, 38], ["Sia", "GENE_OR_GENE_PRODUCT", 9, 12], ["DMB", "SIMPLE_CHEMICAL", 35, 38], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 40, 53]]], ["HPLC analysis was performed using a Dionex UltiMate 3000 system with an Acclaim C18 column (Thermo Fisher) under isocratic elution in 7% methanol, 7% acetonitrile, and 86% water.", [["methanol", "CHEMICAL", 137, 145], ["acetonitrile", "CHEMICAL", 150, 162], ["methanol", "CHEMICAL", 137, 145], ["acetonitrile", "CHEMICAL", 150, 162], ["methanol", "SIMPLE_CHEMICAL", 137, 145], ["acetonitrile", "SIMPLE_CHEMICAL", 150, 162], ["HPLC analysis", "TEST", 0, 13], ["an Acclaim C18 column (Thermo Fisher", "TREATMENT", 69, 105], ["isocratic elution", "TREATMENT", 113, 130], ["7% methanol", "TREATMENT", 134, 145], ["7% acetonitrile", "TREATMENT", 147, 162]]], ["Sia standards included bovine submaxillary mucin and commercial standards for Neu5Ac and Neu5Gc (Sigma-Aldrich).", [["submaxillary mucin", "ANATOMY", 30, 48], ["Neu5Ac", "CHEMICAL", 78, 84], ["bovine", "ORGANISM", 23, 29], ["submaxillary mucin", "GENE_OR_GENE_PRODUCT", 30, 48], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 78, 84], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 89, 95], ["bovine", "SPECIES", 23, 29], ["bovine submaxillary mucin", "TREATMENT", 23, 48], ["Neu5Ac and Neu5Gc (Sigma-Aldrich)", "TREATMENT", 78, 111]]], ["Statistical analyses were performed in GraphPad Prism software (v8).Characterization of A549 conditioned media. ::: MATERIALS AND METHODSConditioned medium from A549 cells was prepared by washing a fully confluent flask of cells to remove any serum and allowing the cells to grow in serum-free medium for 5 to 7 days.", [["A549", "ANATOMY", 88, 92], ["A549 cells", "ANATOMY", 161, 171], ["cells", "ANATOMY", 223, 228], ["serum", "ANATOMY", 243, 248], ["cells", "ANATOMY", 266, 271], ["serum", "ANATOMY", 283, 288], ["A549", "CELL", 88, 92], ["A549 cells", "CELL", 161, 171], ["cells", "CELL", 223, 228], ["serum", "ORGANISM_SUBSTANCE", 243, 248], ["cells", "CELL", 266, 271], ["serum", "ORGANISM_SUBSTANCE", 283, 288], ["A549 cells", "CELL_LINE", 161, 171], ["Statistical analyses", "TEST", 0, 20], ["METHODSConditioned medium from A549 cells", "TREATMENT", 130, 171], ["a fully confluent flask of cells", "PROBLEM", 196, 228], ["any serum", "TEST", 239, 248], ["the cells", "TEST", 262, 271], ["serum", "TEST", 283, 288]]], ["The conditioned medium was collected, dialyzed with 3 volumes of PBS, and concentrated using a 30-kDa centrifugal filter (Pall Corporation).", [["PBS", "TREATMENT", 65, 68], ["a 30-kDa centrifugal filter (Pall Corporation", "TREATMENT", 93, 138], ["medium", "OBSERVATION_MODIFIER", 16, 22]]], ["The protein concentration was determined by using a Qubit 4 fluorometer (Invitrogen).", [["The protein concentration", "TEST", 0, 25], ["a Qubit 4 fluorometer (Invitrogen)", "TREATMENT", 50, 84]]], ["To determine Muc5B presence, 2-fold dilutions of conditioned media were compared to purified human Muc5B using a 8% SDS-PAGE gel and probed with an anti-human Muc5B antibody (both purified protein and antibody were gifts from Stefan Ruhl, University of Buffalo).", [["Muc5B", "GENE_OR_GENE_PRODUCT", 13, 18], ["human", "ORGANISM", 93, 98], ["Muc5B", "CELL", 99, 104], ["Muc5B", "GENE_OR_GENE_PRODUCT", 159, 164], ["Muc5B", "PROTEIN", 13, 18], ["purified human Muc5B", "PROTEIN", 84, 104], ["anti-human Muc5B antibody", "PROTEIN", 148, 173], ["purified protein", "PROTEIN", 180, 196], ["antibody", "PROTEIN", 201, 209], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["2-fold dilutions of conditioned media", "TREATMENT", 29, 66], ["a 8% SDS-PAGE gel", "TREATMENT", 111, 128], ["an anti-human Muc5B antibody", "TREATMENT", 145, 173], ["antibody", "TEST", 201, 209]]], ["Conditioned medium was analyzed for total Sia using the HPLC methods listed above.qPCR of SIAE and CasD1 expression. ::: MATERIALS AND METHODSRNA from cells was extracted by using EZNA total RNA kit I (Omega Bio-Tek), and cDNA was synthesized using the SuperScript II reverse transcriptase (Invitrogen) standard protocol with oligo(dT)12-18 primers (Invitrogen).", [["cells", "ANATOMY", 151, 156], ["Sia", "GENE_OR_GENE_PRODUCT", 42, 45], ["SIAE", "GENE_OR_GENE_PRODUCT", 90, 94], ["CasD1", "GENE_OR_GENE_PRODUCT", 99, 104], ["cells", "CELL", 151, 156], ["CasD1", "PROTEIN", 99, 104], ["cDNA", "DNA", 222, 226], ["SuperScript II reverse transcriptase", "PROTEIN", 253, 289], ["oligo(dT)12-18 primers", "DNA", 326, 348], ["total Sia", "TREATMENT", 36, 45], ["the HPLC methods", "TREATMENT", 52, 68], ["EZNA total RNA kit I (Omega Bio-Tek)", "TREATMENT", 180, 216], ["the SuperScript II reverse transcriptase (Invitrogen) standard protocol", "TREATMENT", 249, 320], ["oligo(dT)", "TREATMENT", 326, 335]]], ["CasD1- and SIAE-specific primers were designed using Geneious (Biomatters, Ltd.).", [["CasD1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SIAE", "GENE_OR_GENE_PRODUCT", 11, 15], ["CasD1- and SIAE-specific primers", "DNA", 0, 32], ["CasD1", "TEST", 0, 5]]], ["For CasD1, adequate primers could not be targeted around the CRISPR-Cas9 edit site due to the high G/C content. qPCR was performed on a Applied Biosystems StepOnePlus real-time PCR system using Fast SYBR green (Bio-Rad).", [["SYBR green", "CHEMICAL", 199, 209], ["SYBR green", "CHEMICAL", 199, 209], ["CasD1", "GENE_OR_GENE_PRODUCT", 4, 9], ["G/C", "GENE_OR_GENE_PRODUCT", 99, 102], ["SYBR green", "GENE_OR_GENE_PRODUCT", 199, 209], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 211, 218], ["CasD1", "DNA", 4, 9], ["CRISPR-Cas9 edit site", "DNA", 61, 82], ["Fast SYBR green (Bio-Rad", "PROTEIN", 194, 218], ["CasD1", "TREATMENT", 4, 9], ["adequate primers", "TREATMENT", 11, 27], ["the high G/C content", "PROBLEM", 90, 110], ["qPCR", "TEST", 112, 116], ["PCR system", "TEST", 177, 187], ["Fast SYBR", "TEST", 194, 203]]], ["Data were analyzed using StepOne software (Applied Biosystems, v2.1) and GraphPad Prism statistical analysis software.Virus infection assays. ::: MATERIALS AND METHODSFor infection in HEK-293 cells with IAV, the cells were seeded on coverslips and inoculated with a multiplicity of infection (MOI) of 0.1.", [["HEK-293 cells", "ANATOMY", 184, 197], ["cells", "ANATOMY", 212, 217], ["Virus infection", "DISEASE", 118, 133], ["infection", "DISEASE", 171, 180], ["infection", "DISEASE", 282, 291], ["Virus", "ORGANISM", 118, 123], ["HEK-293 cells", "CELL", 184, 197], ["IAV", "ORGANISM", 203, 206], ["cells", "CELL", 212, 217], ["HEK-293 cells", "CELL_LINE", 184, 197], ["HEK-293", "SPECIES", 184, 191], ["IAV", "SPECIES", 203, 206], ["Virus infection assays", "PROBLEM", 118, 140], ["METHODSFor infection", "PROBLEM", 160, 180], ["IAV", "PROBLEM", 203, 206], ["the cells", "PROBLEM", 208, 217], ["infection", "PROBLEM", 282, 291], ["infection", "OBSERVATION", 124, 133], ["infection", "OBSERVATION", 171, 180], ["multiplicity", "OBSERVATION_MODIFIER", 266, 278], ["infection", "OBSERVATION", 282, 291]]], ["Coverslips of inoculated cells were fixed at 24 h, stained for virus using an anti-NP antibody, and costained with DAPI.", [["cells", "ANATOMY", 25, 30], ["DAPI", "CHEMICAL", 115, 119], ["cells", "CELL", 25, 30], ["DAPI", "SIMPLE_CHEMICAL", 115, 119], ["inoculated cells", "CELL_TYPE", 14, 30], ["anti-NP antibody", "PROTEIN", 78, 94], ["inoculated cells", "PROBLEM", 14, 30], ["virus", "PROBLEM", 63, 68], ["an anti-NP antibody", "TEST", 75, 94], ["DAPI", "TREATMENT", 115, 119], ["inoculated cells", "OBSERVATION", 14, 30]]], ["The percentages of infected cells were determined by imaging coverslips and counting the infected cells per field.", [["cells", "ANATOMY", 28, 33], ["cells", "ANATOMY", 98, 103], ["cells", "CELL", 28, 33], ["cells", "CELL", 98, 103], ["infected cells", "CELL_TYPE", 19, 33], ["infected cells", "CELL_TYPE", 89, 103], ["infected cells", "PROBLEM", 19, 33], ["imaging coverslips", "TEST", 53, 71], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["infected cells", "OBSERVATION", 19, 33], ["infected cells", "OBSERVATION", 89, 103]]], ["Statistical analyses were performed in GraphPad Prism software.", [["Statistical analyses", "TEST", 0, 20]]], ["For infection in MDCK cells with the influenza A, B, C, and D viruses, cells were seeded into 96-well plates and inoculated for 48 h.", [["MDCK cells", "ANATOMY", 17, 27], ["cells", "ANATOMY", 71, 76], ["infection", "DISEASE", 4, 13], ["MDCK cells", "CELL", 17, 27], ["B, C", "CELL", 50, 54], ["D viruses", "ORGANISM", 60, 69], ["cells", "CELL", 71, 76], ["MDCK cells", "CELL_LINE", 17, 27], ["infection", "PROBLEM", 4, 13], ["MDCK cells", "TEST", 17, 27], ["the influenza A", "TEST", 33, 48], ["B, C, and D viruses", "PROBLEM", 50, 69], ["infection", "OBSERVATION", 4, 13]]], ["The cells were then fixed and stained with a mouse anti-influenza A NP antibody, a mouse anti-influenza B NP antibody (Abcam), a polyclonal mouse anti-influenza C antibody (a gift from Peter Palese, Icahn School of Medicine at Mount Sinai), or a polyclonal rabbit anti-influenza D antibody (a gift from Feng Li, South Dakota State University).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["mouse", "ORGANISM", 45, 50], ["anti-influenza A NP", "ORGANISM", 51, 70], ["mouse", "ORGANISM", 83, 88], ["anti-influenza B NP antibody", "ORGANISM", 89, 117], ["Abcam", "GENE_OR_GENE_PRODUCT", 119, 124], ["mouse", "ORGANISM", 140, 145], ["rabbit", "ORGANISM", 257, 263], ["mouse anti-influenza A NP antibody", "PROTEIN", 45, 79], ["mouse anti-influenza B NP antibody", "PROTEIN", 83, 117], ["Abcam", "PROTEIN", 119, 124], ["polyclonal mouse anti-influenza C antibody", "PROTEIN", 129, 171], ["polyclonal rabbit anti-influenza D antibody", "PROTEIN", 246, 289], ["mouse", "SPECIES", 45, 50], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 140, 145], ["rabbit", "SPECIES", 257, 263], ["mouse", "SPECIES", 45, 50], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 140, 145], ["rabbit", "SPECIES", 257, 263], ["a mouse anti-influenza", "TREATMENT", 43, 65], ["A NP antibody", "TEST", 66, 79], ["a mouse anti-influenza B NP antibody", "TEST", 81, 117], ["Abcam", "TEST", 119, 124], ["a polyclonal mouse anti-influenza C antibody", "PROBLEM", 127, 171], ["a polyclonal rabbit anti-influenza D antibody", "PROBLEM", 244, 289]]], ["The cells were imaged using a Nikon TE300 fluorescence microscope.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["Images were analyzed for relative infected cell counts using ImageJ (NIH and LOCI, University of Wisconsin).Mouse erythrocyte hemagglutination and lectin staining. ::: MATERIALS AND METHODSMouse erythrocytes were collected from C57B/6 mice by euthanizing the mice and immediately collecting blood by heart puncture into Alsever\u2019s solution.", [["cell", "ANATOMY", 43, 47], ["erythrocyte", "ANATOMY", 114, 125], ["erythrocytes", "ANATOMY", 195, 207], ["blood", "ANATOMY", 291, 296], ["heart", "ANATOMY", 300, 305], ["cell", "CELL", 43, 47], ["Mouse", "ORGANISM", 108, 113], ["erythrocyte", "CELL", 114, 125], ["lectin", "GENE_OR_GENE_PRODUCT", 147, 153], ["erythrocytes", "CELL", 195, 207], ["C57B/6 mice", "ORGANISM", 228, 239], ["mice", "ORGANISM", 259, 263], ["blood", "ORGANISM_SUBSTANCE", 291, 296], ["heart", "ORGAN", 300, 305], ["lectin", "PROTEIN", 147, 153], ["erythrocytes", "CELL_TYPE", 195, 207], ["Mouse", "SPECIES", 108, 113], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 259, 263], ["Mouse", "SPECIES", 108, 113], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 259, 263], ["Images", "TEST", 0, 6], ["relative infected cell counts", "PROBLEM", 25, 54], ["Mouse erythrocyte hemagglutination", "TEST", 108, 142], ["lectin staining", "PROBLEM", 147, 162], ["METHODSMouse erythrocytes", "TEST", 182, 207], ["heart puncture", "TEST", 300, 314], ["infected cell counts", "OBSERVATION", 34, 54], ["erythrocyte hemagglutination", "OBSERVATION", 114, 142], ["lectin staining", "OBSERVATION", 147, 162], ["heart", "ANATOMY", 300, 305], ["puncture", "OBSERVATION", 306, 314]]], ["Erythrocytes were washed in PBS three times and diluted to 5% (vol/vol) in PBS.", [["Erythrocytes", "ANATOMY", 0, 12], ["Erythrocytes", "CELL", 0, 12], ["Erythrocytes", "CELL_TYPE", 0, 12], ["Erythrocytes", "TEST", 0, 12]]], ["Then, 5% of the mouse erythrocytes were left untreated or treated with 30 \u03bcg/ml BCoV HE-Fc for 18 h at 37\u00b0C, followed by dilution to 0.75% (vol/vol) in PBS for the HA assays.", [["erythrocytes", "ANATOMY", 22, 34], ["mouse", "ORGANISM", 16, 21], ["erythrocytes", "CELL", 22, 34], ["HE-Fc", "GENE_OR_GENE_PRODUCT", 85, 90], ["mouse erythrocytes", "CELL_TYPE", 16, 34], ["Fc", "PROTEIN", 88, 90], ["mouse", "SPECIES", 16, 21], ["mouse", "SPECIES", 16, 21], ["the mouse erythrocytes", "TREATMENT", 12, 34], ["the HA assays", "PROBLEM", 160, 173]]], ["Briefly, HA assays were performed by 2-fold serially diluting virus in duplicate per treatment in a V-bottom 96-well plate.", [["HA assays", "TEST", 9, 18], ["diluting virus", "PROBLEM", 53, 67], ["a V-bottom", "TEST", 98, 108]]], ["Treated or untreated mouse erythrocytes were added to virus and allowed to hemagglutinate at 4\u00b0C to prevent NA cleavage.", [["erythrocytes", "ANATOMY", 27, 39], ["hemagglutinate", "CHEMICAL", 75, 89], ["NA", "CHEMICAL", 108, 110], ["mouse", "ORGANISM", 21, 26], ["erythrocytes", "CELL", 27, 39], ["NA", "SIMPLE_CHEMICAL", 108, 110], ["mouse erythrocytes", "CELL_TYPE", 21, 39], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["untreated mouse erythrocytes", "PROBLEM", 11, 39], ["virus", "TREATMENT", 54, 59], ["hemagglutinate", "TREATMENT", 75, 89], ["NA cleavage", "PROBLEM", 108, 119]]], ["To determine Sia linkage type, 5% washed erythrocytes were blocked for 1 h using 1\u00d7 Carbo Free blocking buffer (Vector Laboratories) and then stained for 1 h with fluoroscein-labeled plant lectins SNA, which binds \u03b12,6-linked Sia, and MAA I, which binds \u03b12,3-linked Sia (Vector Laboratories).", [["erythrocytes", "ANATOMY", 41, 53], ["fluoroscein", "CHEMICAL", 163, 174], ["Carbo", "CHEMICAL", 84, 89], ["fluoroscein", "CHEMICAL", 163, 174], ["erythrocytes", "CELL", 41, 53], ["Carbo", "SIMPLE_CHEMICAL", 84, 89], ["fluoroscein", "SIMPLE_CHEMICAL", 163, 174], ["SNA", "GENE_OR_GENE_PRODUCT", 197, 200], ["Sia", "GENE_OR_GENE_PRODUCT", 226, 229], ["MAA I", "GENE_OR_GENE_PRODUCT", 235, 240], ["Sia", "GENE_OR_GENE_PRODUCT", 266, 269], ["Vector Laboratories", "GENE_OR_GENE_PRODUCT", 271, 290], ["erythrocytes", "CELL_TYPE", 41, 53], ["fluoroscein-labeled plant lectins SNA", "PROTEIN", 163, 200], ["\u03b12,6", "PROTEIN", 214, 218], ["Sia", "PROTEIN", 226, 229], ["MAA I", "PROTEIN", 235, 240], ["\u03b12,3", "PROTEIN", 254, 258], ["Sia", "PROTEIN", 266, 269], ["Vector Laboratories", "PROTEIN", 271, 290], ["Carbo Free blocking buffer", "TREATMENT", 84, 110], ["fluoroscein", "TREATMENT", 163, 174], ["binds", "TEST", 208, 213], ["lectins SNA", "ANATOMY", 189, 200]]], ["Stained erythrocytes were then analyzed using flow cytometry as described above.Generation of NA VLPs and NA cleavage assay. ::: MATERIALS AND METHODSNA sequences were obtained from GenBank (N1, ACP44181; N2, AGC70842).", [["erythrocytes", "ANATOMY", 8, 20], ["NA", "CHEMICAL", 106, 108], ["erythrocytes", "CELL", 8, 20], ["NA VLPs", "GENE_OR_GENE_PRODUCT", 94, 101], ["NA", "SIMPLE_CHEMICAL", 106, 108], ["erythrocytes", "CELL_TYPE", 8, 20], ["METHODSNA sequences", "DNA", 143, 162], ["Stained erythrocytes", "TEST", 0, 20], ["flow cytometry", "TEST", 46, 60], ["NA VLPs", "TREATMENT", 94, 101], ["NA cleavage assay", "TEST", 106, 123], ["METHODSNA sequences", "TEST", 143, 162], ["NA VLPs", "OBSERVATION_MODIFIER", 94, 101]]], ["Sequences were tagged, codon optimized, and ordered through Biomatik in the PcDNA3.1(+) vector.", [["PcDNA3", "GENE_OR_GENE_PRODUCT", 76, 82], ["PcDNA3.1(+) vector", "DNA", 76, 94], ["Sequences", "TEST", 0, 9], ["codon", "TEST", 23, 28], ["Biomatik", "TEST", 60, 68]]], ["To produce VLPs, HEK-293T cells were seeded in 15-cm plates and transfected when 80% confluent.", [["HEK-293T cells", "ANATOMY", 17, 31], ["VLPs", "ORGANISM", 11, 15], ["HEK-293T cells", "CELL", 17, 31], ["HEK-293T cells", "CELL_LINE", 17, 31], ["VLPs", "TEST", 11, 15], ["HEK", "TEST", 17, 20], ["VLPs", "ANATOMY", 11, 15], ["293T cells", "OBSERVATION", 21, 31], ["15-cm", "OBSERVATION_MODIFIER", 47, 52], ["confluent", "OBSERVATION_MODIFIER", 85, 94]]], ["The cells were transfected with 4 \u03bcl of polyethylenimine (Polysciences, catalog no. 23966-2) at 1 mg/ml for every 1 \u03bcg of plasmid DNA stock of in 9 ml of Opti-MEM.", [["cells", "ANATOMY", 4, 9], ["plasmid", "ANATOMY", 122, 129], ["polyethylenimine", "CHEMICAL", 40, 56], ["polyethylenimine", "CHEMICAL", 40, 56], ["cells", "CELL", 4, 9], ["polyethylenimine", "SIMPLE_CHEMICAL", 40, 56], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["polyethylenimine (Polysciences", "TREATMENT", 40, 70], ["plasmid DNA stock", "TREATMENT", 122, 139]]], ["At 8 h posttransfection, 6 ml of prewarmed Opti-MEM was added.", [["prewarmed Opti-MEM", "TREATMENT", 33, 51]]], ["The supernatant was collected at 72 h posttransfection and purified using ultracentrifugation (110,000 \u00d7 g, 1.5 h, 4\u00b0C) through a 20% sucrose cushion.", [["supernatant", "ANATOMY", 4, 15], ["sucrose", "CHEMICAL", 134, 141], ["sucrose", "CHEMICAL", 134, 141], ["ultracentrifugation", "TEST", 74, 93], ["a 20% sucrose cushion", "TREATMENT", 128, 149]]], ["The pellet was resuspended in PBS and stored at 4\u00b0C. To determine NA cleavage on mouse erythrocytes, 5% (vol/vol) mouse erythrocytes in PBS were treated with 1:100 NA VLPs for 4 h at 37\u00b0C. Free Sia were collected and prepared for HPLC analysis as described above.", [["pellet", "ANATOMY", 4, 10], ["erythrocytes", "ANATOMY", 87, 99], ["erythrocytes", "ANATOMY", 120, 132], ["NA", "CHEMICAL", 66, 68], ["NA", "SIMPLE_CHEMICAL", 66, 68], ["mouse", "ORGANISM", 81, 86], ["erythrocytes", "CELL", 87, 99], ["mouse", "ORGANISM", 114, 119], ["erythrocytes", "CELL", 120, 132], ["PBS", "ORGANISM_SUBSTANCE", 136, 139], ["Sia", "GENE_OR_GENE_PRODUCT", 194, 197], ["mouse erythrocytes", "CELL_TYPE", 81, 99], ["mouse erythrocytes", "CELL_TYPE", 114, 132], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 114, 119], ["The pellet", "TREATMENT", 0, 10], ["NA cleavage", "PROBLEM", 66, 77], ["mouse erythrocytes", "TEST", 81, 99], ["5% (vol/vol) mouse erythrocytes in PBS", "TREATMENT", 101, 139], ["1:100 NA VLPs", "TREATMENT", 158, 171], ["HPLC analysis", "TEST", 230, 243], ["pellet", "OBSERVATION", 4, 10]]]]}